NCT ID,Study Title,Conditions,Inclusion Criteria,Exclusion Criteria,Interventions,Study Type,Overall Status
NCT00669227,Intracoronary Stem Cell Therapy in Patients With Acute Myocardial Infarction (SCAMI),"Acute Myocardial Infarction, Coronary Artery Disease","* acute myocardial infarction with time to revascularization \>6 hours from symptom start
* clear target vessel
* large myocardial infarction defined as: proximal vessel occlusion, CK \> 1000 U/L, myocardial scar in magnetic resonance imaging \> 10% of left ventricular muscle mass
* potential prior thrombolysis
* written informed consent","* acute myocardial infarction with revascularization within 6 hours after symptom start
* prior myocardial infarction
* no clear target vessel
* contraindication for magnetic resonance imaging (e.g. pacemaker, ICD)
* severely depressed left ventricular ejection fraction (less than 20% in magnetic resonance imaging)
* prior hematologic disease
* prior chemo therapy
* prior stem cell transplantation
* prior treatment with G-CSF
* known alteration of the bone marrow by alcohol or drugs, e.g. agranulocytosis
* local infection of puncture sites","autologous stem cells, placebo suspension",INTERVENTIONAL,COMPLETED
NCT01459627,"Randomized, Open Label Trial of 6 Months Versus 12 Months DAPT After Drug-Eluting Stent in STEMI","Myocardial Infarction, Cardiovascular Disease","Inclusion Criteria:

STEMI patients between 18-85 years who underwent primary PCI with DES implantation.","enrolment:

* Intolerance to Aspirin, Prasugrel, Ticagrelor, Heparin, Bivalirudin, Zotarolimus or Everolimus.
* Known bleeding diathesis or known coagulopathy.
* Planned elective surgical procedure necessitating interruption of dual antiplatelet therapy during the first 6 months after randomization.
* History of stent thrombosis
* DES in main left coronary artery
* Active bleeding, known bleeding diathesis or known coagulopathy.
* Planned elective surgical procedure necessitating interruption of dual antiplatelet therapy during the first 6 months after randomization.
* Oral anticoagulant therapy with Coumadin derivates
* Malignancies or other comorbidity with a life expectancy of less than one year or that may result in protocol noncompliance
* Pregnancy (present, suspected or planned) or positive pregnancy test (in women with childbearing potential a negative pregnancy test is mandatory)

Exclusion criteria randomization:

* Occurrence of death, myocardial infarction, stent thrombosis and target vessel or lesion revascularization during the first 6 months after inclusion.
* Stroke or bleeding requiring discontinuation of DAPT during the first 6 months after inclusion.
* Oral anticoagulant therapy

Registry

Exclusion criteria

* Intolerance to Prasugrel, Ticagrelor, Bivalirudin.
* Known bleeding diathesis or known coagulopathy

Report Resolute Integrity Exclusion criteria

• See exclusion criteria enrollment DAPT-STEMI protocol","6 months DAPT, 12 months DAPT",INTERVENTIONAL,COMPLETED
NCT00051376,Vascular Interaction With Age in Myocardial Infarction,Myocardial Infarction,"Patients will have suffered their first acute Q-wave MI within 3 to 21 days with creatine kinase levels 3 times normal. All patients will have systolic blood pressure over 100 mmHg and the permission of their attending physician and the ability to give voluntary informed consent. Patients will be excluded if they have had a prior Q-wave infarction, present cardiogenic shock, unstable angina or non-cardiac disease limiting life expectancy to less than 1 year. Other","include significant kidney or liver disease, uncontrolled diabetes, or symptomatic cerebrovascular disease (such as stroke). Patients who have been previously shown to be non-compliant will be asked not to participate.",L-Arginine,INTERVENTIONAL,COMPLETED
NCT04662762,A Nursing Intervention Program to Improve Therapeutic Adherence in Elderly People With Acute Myocardial Infarction,"Medication Adherence, Myocardial Infarction",* Patients with STEMI aged 75 years or older underwent primary percutaneous coronary intervention (PCI),"* Patients who refused to participate in the study
* Patients unable to perform geriatric assessment.
* Patients admitted to nursing homes or social health centres.",Nursing intervention programme,INTERVENTIONAL,COMPLETED
NCT00640991,REsearching Coronary REduction by Appropriately Targeting Euglycemia (RECREATE Pilot Study),"Hyperglycemia, Cardiovascular Diseases, Myocardial Infarction","Both nondiabetic patients and patients with non-insulin-requiring type 2 diabetes mellitus admitted with a suspected AMI are eligible if they meet the following criteria:

* Signs or symptoms of AMI with definite ECG changes, defined as persistent ST-segment elevation (\> or = than 1 mm)in two or more contiguous leads, or new left bundle branch block
* Onset of symptoms within 24 hours before hospital presentation
* Capillary blood glucose level on presentation \> or = 8.0 mmol/L (144 mg/dL)","* Patient with conditions that REQUIRE the administration of insulin, including:

  * Type 1 diabetes mellitus, defined by a documented history of diabetes mellitus before the age of 30
  * Type 2 diabetes mellitus that was treated with insulin prior to AMI presentation
  * Type 2 diabetes mellitus that is known to be very poorly controlled (e.g. admission capillary blood glucose \> 16.0 mmol/L (288 mg/dL)or marked elevation in glucose for which the site investigator plans to treat with insulin therapy)
* A history of severe hypoglycemic episodes (defined as hypoglycemia with symptoms which the patient is unable to reverse without the assistance of another person) within the past two years
* Known or suspected end-stage liver disease (due to the risk of hypoglycemia in the setting of liver dysfunction and consequent impaired regulation of glucose homeostasis)
* Cardiogenic shock on admission (due to the inaccuracy of glucose meter readings)
* Documented pregnancy
* Any concomitant disease (e.g. cancer) that might limit life expectancy to less than 90 days
* Anticipated poor adherence with study treatments or an other factor that might jeopardize 90-day follow-up (e.g. no fixed address, long distance to hospital, etc.)
* Prior enrollment in this trial or current enrollment in another trial of ST-segment elevation myocardial infarction","glulisine insulin, glargine insulin",INTERVENTIONAL,COMPLETED
NCT01504191,Internet-based Cognitive Behavior Therapy After Myocardial Infarction,"Depression, Anxiety, Myocardial Infarction","* Patients younger than 75 years with a recent acute MI (\< 3 months)
* Depression and/or anxiety score of \> 7 on one or both of the HADS subscales (concerns only the intervention, not the reference group)","* Patients that are scheduled for a coronary artery bypass surgery (CABG)
* Unable or unwilling to use computer or Internet
* Difficulties in reading or understanding Swedish
* A life expectancy of less than a year
* Anticipated poor compliance (multi-disease, substance abuse etc.)
* Highly depressed or suicidal (MADRS-score \> 29 or MADRS item 9 \> 3)",Internet-based CBT,INTERVENTIONAL,COMPLETED
NCT01650662,CYCLosporinE A in Reperfused Acute Myocardial Infarction,Acute Myocardial Infarction,"* Male and female patients with large STEMI not older than 6 hours, defined as
* angina pectoris or equivalent symptoms of more than 20 minutes duration within last 6 hours, and
* ST elevation in at least 3 leads in anterior MI and/or a deviation in at least 4 leads in inferior MI,
* TIMI flow 0 or 1 in identified culprit artery
* Intended acute primary PCI
* Age ≥ 18 years
* Ability to understand the nature, scope, and possible consequences of the study participation/legal capacity
* Written informed consent","* Left bundle branch block
* TIMI flow \> 1 in the identified culprit artery
* Treatment with CsA within last 10 days
* Contraindication to CsA or history of allergic reaction to CsA
* Coronary anatomy not suitable for PCI
* Thrombolytic therapy within 24 h. before randomization
* Previous MI
* Previous CABG
* Severe renal or hepatic insufficiency
* Malignant tumor, not curatively treated
* Women with childbearing potential, esp. pregnant or nursing women
* Participation in another clinical or device trial within the previous 30 days",Cyclosporine A,INTERVENTIONAL,COMPLETED
NCT00910962,"A Study to Evaluate the Safety of 12 Weeks of Dosing With GW856553 and Its Effects on Inflammatory Markers, Infarct Size, and Cardiac Function in Subjects With Myocardial Infarction Without ST-segment Elevation",Acute Coronary Syndrome,"* Subjects with a NSTEMI, defined as: symptoms (e.g. chest pain, dyspnea) consistent with acute coronary syndrome, lasting at least 10 minutes, with most recent symptoms occurring within the 24 hours prior to presentation, without persistent ST-segment elevation on admission 12-lead ECG, and with Troponin (T or I) above the upper limit of normal (ULN) for the local institution within 18 hours of presentation.
* Subject able to be randomized within 18 hours of presentation.
* Subjects to be managed with an early invasive strategy, with PCI likely to occur at least 2 hours after the start of dosing \[subjects who do not undergo PCI will not be withdrawn from the study\].
* Male or female subject who is 45 years of age or older.
* A female subject is eligible to participate if she is of: Non-childbearing potential defined as pre-menopausal females with a documented tubal ligation or hysterectomy; or postmenopausal defined as 12 months of spontaneous amenorrhea (in questionable cases a blood sample with simultaneous follicle stimulating hormone (FSH) greater than 40 MlU/ml and estradiol less than 40 pg/ml (less than 140 pmol/L) is confirmatory), or child-bearing potential and agrees to use one of the contraception methods listed in the protocol for the duration of dosing and until the first follow-up visit (approximately 2 weeks post last-dose).
* Negative urine or serum pregnancy test (in women of child-bearing potential only).
* Male subjects must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until the first follow-up visit (approximately 2 weeks post last-dose).
* QTcB or QTcF greater than 530 msec.
* Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.","* History of severe heart failure defined as NYHA class III or IV or those with known severe LV dysfunction \[ejection fraction less than 30%\] regardless of symptomatic status.
* Suspected aortic dissection.
* Severe aortic stenosis or other severe valvular disease.
* Current known life-threatening condition other than vascular disease (e.g. severe chronic airways disease) that may prevent a subject from completing the study.
* Subjects with rheumatoid arthritis, connective tissue disorders and other conditions known to be associated with active chronic or acute inflammation (e.g. inflammatory bowel disease, osteomyelitis, pneumonia, etc.). Intermittent conditions treated with short-term oral antibiotics (e.g. typical URI) or conditions that are not currently exacerbated (e.g. gout with no current flair) may be included.
* History of myopathy or rhabdomyolysis.
* Current or chronic history of liver disease, known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
* Known to be Hepatitis B or Hepatitis C positive.
* Current or anticipated use of systemic steroids (oral or IV). Inhaled, intranasal and topical steroids are allowed. A single prophylactic dose of systemic steroid is allowed at time of PCI for subjects with contrast allergy.
* Current or anticipated use of BCRP substrates with a narrow therapeutic index (e.g. daunorubicin, doxorubicin, topotecan, mitoxantrone).
* Previously diagnosed cancer that has not been in complete remission for at least 5 years. Localized carcinomas of the skin and carcinoma in situ of the cervix that have been resected or ablated for cure are not exclusionary..
* Known alcohol or drug abuse within the past 6 months.
* Previous exposure to GW856553.
* Use of another investigational product within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of IP in the current study.
* Any other subject whom the Investigator deems unsuitable for the study (e.g., due to either medical reasons, laboratory abnormalities, expected study medication non-compliance).
* Unwillingness or inability to follow the procedures outlined in the protocol.
* Previous MI or coronary artery bypass graft (CABG) surgery.
* History of kidney transplant or a history of contrast nephropathy.
* Contraindication to MRI scanning (as assessed by local MRI safety questionnaire) which includes but is not limited to: intracranial aneurysm clips or other metallic objects; history of intra-orbital metal fragments that have not been removed by an MD; pacemakers and non-MR compatible heart valves; inner ear implants; history of claustrophobia in MR.
* Allergy to MRI contrast enhancement agent (gadolinium).
* Estimated creatinine clearance by Cockcroft-Gault formula \< 30 mL/min.","GW856553, GW856553, Placebo",INTERVENTIONAL,COMPLETED
NCT01874262,A Study to Evaluate the Use of Mobile-phone Based Patient Support in Patients Diagnosed With Myocardial Infarction,Myocardial Infarction,"1. Provision of written patient informed consent.
2. Patients must have a smart phone at their disposal and use it on a daily basis.
3. Female or male aged \>18 years, diagnosed with a ST elevation Myocardial Infarction (STEMI) or non ST elevation Myocardial Infarction (NSTEMI) and treated with ticagrelor prior to inclusion into this study and for which the treating physician intend to continue prescribing ticagrelor according to the prescription recommendation.
4. Ability to read, understand and write Swedish.","1. Participation in any clinical trial or device study in the last 30 days excluding prospective/retrospective register based studies that do not require any extra visits in addition to ordinary health care.
2. Patients not suitable for participation based on the investigators judgment for example:

   * Patients on treatment with triple antithrombotic treatment.
   * Patients on treatment with anticoagulantia.
   * Patients accepted/with a plan for thoracic surgery (CABG) or any other elective surgery that cannot be postponed until after study participation.
   * Patients with a life expectancy of less than 12 months.
   * Patients judged to be unable to follow a structured physical activity program.
3. Patients those are pregnant or lactating.
4. Patients involved in the planning and/or conduct of the study (applies to AstraZeneca staff and/or staff at the study site and application developer).","Mobile-phone based patient support, e-diary",INTERVENTIONAL,COMPLETED
NCT00712894,Effects of Different Vasodilators on Coronary No-reflow During primAry percuTaneous Coronary intErvention in Patients With Acute Myocardial Infarction,"Acute Myocardial Infarction, Percutaneous Coronary Intervention","* Clinical diagnosis of acute myocardial infarction
* Vessel TIMI flow \< grade Ⅲ post-PCI","* Heart failure of New York Heart Association (NYHA) class Ⅲ to class Ⅳ
* Sick sinus syndrome
* Atrioventricular block (grade Ⅱ and above)
* SBP ≤ 90mmHg or cardiogenic shock
* Heart Rate ≤60 bpm
* Pregnancy
* Renal or hepatic failure","Diltiazem, Verapamil, Nitroglycerin",INTERVENTIONAL,COMPLETED
NCT02777580,STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction,Myocardial Infarction,"1. Age equal or greater than 60 years
2. Onset of symptoms \< 3 hours prior to randomisation
3. 12-lead ECG indicative of an acute STEMI (ST-elevation will be measured from the J point; scale: 1 mm per 0.1 mV):

   * ≥ 2 mm ST-elevation across 2 contiguous precordial leads (V1-V6) or leads I and aVL for a minimum combined total of ≥ 4 mm ST-elevation or
   * ≥ 2 mm ST-elevation in 2 contiguous inferior leads (II, III, aVF) for a minimum combined total of ≥ 4 mm ST-elevation
4. Informed consent received","1. 1. Expected performance of PCI \< 60 minutes from diagnosis (qualifying ECG) or inability to arrive at the catheterisation laboratory within 3 hours
2. Previous CABG
3. Left bundle branch block or ventricular pacing
4. Patients with cardiogenic shock - Killip Class 4
5. Patients with a body weight \< 55 kg (known or estimated)
6. Uncontrolled hypertension, defined as sustained blood pressure ≥ 180/110 mm Hg (systolic BP ≥ 180 mm Hg and/or diastolic BP ≥ 110 mm Hg) prior to randomisation
7. Known prior stroke or TIA
8. Recent administration of any i.v. or s.c. anticoagulation within 12 hours, including unfractionated heparin, enoxaparin, and/or bivalirudin or current use of oral anticoagulation (i.e. warfarin or a NOACs)
9. Active bleeding or known bleeding disorder/diathesis
10. Known history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) or recent trauma to the head or cranium (i.e. \< 3 months)
11. Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current myocardial infarction)
12. Clinical diagnosis associated with increased risk of bleeding including known active peptic ulceration and/or neoplasm with increased bleeding risk
13. Prolonged cardiopulmonary resuscitation (\> 2 minutes) within the past 2 weeks
14. Known acute pericarditis and/or subacute bacterial endocarditis
15. Known acute pancreatitis or known severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis
16. Dementia
17. Known severe renal insufficiency
18. Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days
19. Known allergic reactions to tenecteplase, clopidogrel, enoxaparin and aspirin
20. Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk if the investigational therapy is initiated.","Tenecteplase, Clopidogrel, Coronary angiography, Primary PCI",INTERVENTIONAL,COMPLETED
NCT02290080,Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers,"Acute Myocardial Infarction (AMI), Acute Coronary Syndrome (ACS), ST Elevation (STEMI) Myocardial Infarction, Ischemic Reperfusion Injury, Non-ST Elevation (NSTEMI) Myocardial Infarction, Angina, Unstable","* symptoms (chest pain, dyspnea) indicating acute myocardial ischemia within the last 6 hours
* ECG changes (ST-segment elevation ≥ 2 mm V1-V4, or ≥ 1 mm in other leads, ST-segment depression \>1 mm in any lead, negative T-wave in leads V2-V6, pathological Q-wave in at least 2 adjacent leads), left bundle branch block

and/or elevated levels of cardiac troponin levels in the emergency department indicating acute myocardial ischemia

* oxygen saturation ≥90% (pulse oximeter)
* age ≥30","* unwillingness to participate
* inability to comprehend given information
* continuous oxygen delivery at home prior to inclusion
* cardiac arrest prior to inclusion",Oxygen,INTERVENTIONAL,COMPLETED
NCT00367991,Effects of Recombinant Human Erythropoietin on Platelet Function in Patients With Acute Myocardial Infarction,Myocardial Infarction,"* Age 21-75 years
* Clinical evidence of acute myocardial infarction (MI) with total or sub-total occlusion on angiogram
* Status post percutaneous revascularization procedure for acute MI with TIMI 3 flow
* Ongoing clinically-indicated treatment with aspirin, thienopyridines","* Hemodynamic instability/shock or severe congestive heart failure
* Time from onset of chest pain to revascularization procedure \> 16 hours
* Use of intravenous thrombolytic agents for treatment of MI
* Known need for additional revascularization procedures","Recombinant human erythropoietin alfa (drug), Placebo",INTERVENTIONAL,COMPLETED
NCT01385631,Ezetimibe In Addition To Atorvastatin Therapy On The Plaque Composition In Patients With Acute Myocardial Infarction.,ST-Segment Elevation Myocardial Infarction,"* ST segment elevation acute myocardial infarction
* 20% \< angiographic diameter stenosis \< 50% on a not previously revascularized native coronary artery
* Statin naïve
* In fertile women: Ongoing contraception with IUD or hormonal contraception.","* Pharmacologic lipid lowering treatment before index hospitalization
* Atrial fibrillation, not well rate-controlled
* Ventricle frequency variation with more than a factor 2 over 1 minute
* Unconscious patients
* History of statin induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins) including Atorvastatin.
* Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception or have a positive serum pregnancy test (a serum-human chorionic gonadotrophin \[Beta-HCG\] analysis)
* History of malignancy (unless a documented disease free period exceeding 5-years is present) with the exception of basal cell or squamous cell carcinoma of the skin. Women with a history of cervical dysplasia would be permitted to enter the study provided they had 3 consecutive clear Papanicolaou (Pap) smears
* Uncontrolled hypothyroidism (TSH \> 1.5xULN)
* Abnormal LFT's
* History of alcohol or drug abuse within the last 5 years (this may affect compliance)
* Current active liver disease (ALT/SGPT \>2xULN or severe hepatic impairment (to protect patient safety as directed on the labels of currently approved statins)
* Unexplained creatine kinase (CK \> 3xULN) (To protect patient safety) (will be increased at baseline because of acute ST segment elevation myocardial infarction a few days before enrolment)
* Serum creatinine \>176mmol/L (2.0mg/dL) (unless the protocol specifically aims to investigate a chronic renal disease population)
* Participation in another investigational drug study less than 4 weeks before enrolment in the study, or according to subjects local ethics committee requirements where a larger period is stipulated (to avoid potential misinterpretation of overlapping adverse events)
* Treatments with cyclosporine
* Treatment with gemfibrozil","Ezetimibe, Placebo",INTERVENTIONAL,COMPLETED
NCT00605631,The Prevention of Myocardial Enlargement and Dilatation Post Myocardial Infarction Study,Post Myocardial Infarction,"* Age 18 or above, or of legal age to give informed consent specific to state and national law
* Willing and capable of providing informed consent, participating in all testing associated with this clinical investigation at an approved clinical investigational center and at the intervals defined by this protocol
* Patient has had a clinically documented anterior myocardial infarction which occurred within the last 14 days
* Measured peak CK \> 2000 mU/mL within 72 hours of MI.
* QRS duration \< 120 ms measured by 12-lead ECG at any time after most recent MI","* Patient has atrial tachyarrhythmia that is permanent (i.e., does not terminate spontaneously and cannot be terminated with medical intervention) or persistent (i.e., can be terminated with medical intervention, but does not terminate spontaneously) at time of enrollment
* Patient is in cardiogenic shock defined by systolic blood pressure \< 90 mmHg and on pressor/inotrope medications at time of potential enrollment
* Patient has 2 or 3 degree heart block at time of potential enrollment
* Patient has undergone or is scheduled for a coronary artery bypass graft procedure, 30 days before or 30 days after date of potential enrollment
* Patient has a known life expectancy of less than 6 months due to non cardiac causes
* Patient has marked renal dysfunction defined as Creatinine \> 2.5 mg/dL at time of enrollment
* Patient enrolled in any concurrent study that may confound the results of the study
* Patient is in class IV heart failure
* Patient is on the heart transplant list
* Patient already has an implanted pacemaker, ICD, or CRT device
* Patient is pregnant or plans to be pregnant during the course of the study
* Both",Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System,INTERVENTIONAL,COMPLETED
NCT00638976,INSTANT: INtegrilin Plus STenting to Avoid Myocardial Necrosis Trial,Cardiovascular Disease,"Inclusion Criteria:

Candidates for this study must meet all of the following criteria:

* Male or female able to understand and sign a witnessed informed consent
* Age ≥ 18 yo
* Patients with stable (CCS 1-4) or unstable angina pectoris (but with the most recent anginal episode occurring \>48 hours before the procedure) or documented silent ischemia
* Stable Hemodynamic conditions (systolic BP \> 100 HR \> 40 \< 100).
* No clinical and ECG changes suggestive of ongoing acute or recent (\<48 hours) myocardial infarction.
* Angiographic evidence of a de novo lesion \> 50% requiring implantation of two DES in overlapping with a total stent length \> 33 mm and reference vessel diameter between 2.5 and 4.0 mm (by visual estimation) in one coronary vessel. Multiple lesions in the same vessels can be included but at least one lesion should require implantation of two DES in overlapping with a total stent length \> 33 mm. The definition of multivessel disease requires an intention to treat at least two lesions (with a least one with the characteristics reported above) in two different major epicardial segments. For example, the presence of a lesion in the left anterior descending artery and in the obtuse marginal or the presence of a lesions in the right postero-lateral branch and in a diagonal branch will qualify as multivessel. The presence of lesions in the left anterior descending artery and in the diagonal branch will not qualify as multivessel. Bifurcation lesions and ostial lesions can be included, but only if at least two DES in overlapping with a total stent length \> 33 mm are implanted in the same branch. When treating diffuse lesion in the same vessel, overlapping stenting is recommended with high pressure (\>14 atm post-dilation) of the overlap zone. There is no maximum stent length to treat one coronary vessel.",":

* Female sex with childbearing potential
* Age \<18 years
* Ongoing or recent episode (\<48 hours) of unstable coronary artery disease (including both ST-elevation and non-ST-elevation acute coronary syndromes)
* Administration of any GP IIb/IIIa inhibitors during the previous 2 weeks
* Serum creatinine \>2.5 mg/dl or with a creatinine clearance \<40mL/min
* Ongoing serious bleeding or bleeding diathesis
* Previous stroke in the last 6 months
* Major surgery within the previous 6 weeks
* Platelet count \<100,000 per mm3
* Ejection Fraction below 30%
* The patient has a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, or sensitivity to contrast which cannot be adequately pre-medicated.
* Hemodynamic instability (systolic blood pressure \< 100 mm Hg; heart rate \< 40 bpm or \>100 bpm; complex ventricular arrhythmias; AV block) requiring balloon counterpulsation or inotropic support.
* The patient is simultaneously participating in another device or drug study. Patient must have completed the follow-up phase of any previous study at least 30 days prior to enrolment in this study.
* Positive clinical history for intracranial neoplasia, AV malformation, aneurysm.
* INR ≥ 2.0 or prothrombin time 1.2 times upper limit of normality
* Clinically manifested reduced liver function
* Programmed surgery within six months

Angiographic Exclusion Criteria:

* DES implantation in a chronic total occlusion or for the treatment of in-stent restenosis.
* Treatment of lesions where the operator feels necessary the usage of rotactional atherectomy
* Vessel size \< 2.25 mm or \> 5 mm (by visual estimation).
* Previous implantation of a bare/DES in the target lesion","eptifibatide, placebo",INTERVENTIONAL,COMPLETED
NCT04970576,Rivaroxaban in Left Ventricular Thrombus,"Acute Coronary Syndrome, Left Ventricular Thrombus","* Patients of acute coronary syndrome with LV thrombus
* Hemodynamically stable
* Willing to participate","* Prior history of cardiomyopathy
* Anticoagulant contraindications
* Prior history of stroke with residual neurological deficit
* Valvular atrial fibrilation
* Pregnancy
* Mentally retarded
* Deranged liver function tests (LFTS)
* Creatinine Clearance \<50 ml","Rivaroxaban, Warfarin",INTERVENTIONAL,COMPLETED
NCT00222573,Efficacy and Safety of Adding Clopidogrel to Aspirin or Use of Metoprolol in Myocardial Infarction,Acute Myocardial Infarction,"* Patients presenting with ST elevation, left bundle branch block or ST depression within 24 hours of the onset of the symptoms of suspected acute MI","* clear indications for, or contraindications to, any of the study treatments",clopidogrel and metoprolol,INTERVENTIONAL,COMPLETED
NCT01208727,Post Cond No Reflow,Myocardial Reperfusion Injury,"* Patients \> 18 years old,
* Male or female,
* Presenting first myocardial infarction, with the beginning of pains \< 12 hours,
* Requiring a revascularisation by primary angioplasty or "" rescue "" (after failure of thrombolysis) on IVA or RCA (not CA).
* Artery guilty with TIMI flow = 0","* cardiac arrest before the angioplasty,
* Cardiogenic shock
* Occlusion of the artery circumflex responsible for the infarction
* Magnetic resonance imaging: contre indication",postconditioning,INTERVENTIONAL,COMPLETED
NCT00421876,GlObal Secondary Prevention strategiEs to Limit Event Recurrence After Myocardial Infarction. GOSPEL Study,Myocardial Infarction,"* Recent myocardial infarction (within 3 months after the index event)
* Standard rehabilitation program of 3-6 weeks performed
* Informed consent (obtained before any study specific procedure)","* Age \> 75 years
* Any condition that in the opinion of the investigator would jeopardize the evaluation of efficacy or be associated with poor adherence to the protocol;
* Presence of any non-cardiac disease (e.g. cancer) that is likely to significantly shorten life expectancy",multifactorial continued educational - behavioural programme,INTERVENTIONAL,COMPLETED
NCT00251576,Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180),Acute Coronary Syndrome,"* A-Phase: Chest pain at rest for 10 minutes, EKG changes or elevated cardiac blood work
* Z-Phase: elevated cholesterol , plus at least one risk factor ( \> 70 years old, diabetes, history of prior heart or blood vessel disease, chest pain with EKG changes, elevation of cardiac lab work or positive cardiac tests , at least 2 heart vessels blocked \[one \>= 75% and one \>= 50%\])","* A-Phase: use of some specific cardiac drugs, high risk bleeding, prior blood clotting disorders
* Z-Phase: elevation in certain cardiac blood tests, no significant heart damage at catheterization, planned cardiac surgery or specific cardiac drugs that lower cholesterol levels, within 6 weeks of enrollment","A-Phase: tirofiban; Z-Phase simvastatin, Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years, Comparator: A-Phase: low molecular weight heparin, unfractionated heparin, Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours, Duration of Treatment: Z-Phase, 2 years.",INTERVENTIONAL,COMPLETED
NCT00684060,Use of Adult Autologous Stem Cells in Treating People 2 to 3 Weeks After Having a Heart Attack (The Late TIME Study),Left Ventricular Dysfunction,"Inclusion criteria

1. Patients at least 21 years of age.
2. Patients with first acute MI and subsequent successful primary percutaneous coronary intervention (PCI) in an artery at least 2.5 mm in diameter occurring two to three weeks before recruitment.
3. No contraindications to undergoing cell therapy procedure within two to three weeks following AMI and PCI.
4. Hemodynamic stability as defined as no requirement for IABP, inotropic or blood pressure supporting medications.
5. Ejection fraction following reperfusion with PCI \<=45% as assessed by echocardiography.
6. Consent to protocol and agree to comply with all follow-up visits and studies.
7. Women of child bearing potential willing to use an active form of birth control.","Patients will be excluded from the study if they meet any of the following conditions:

1. History of sustained ventricular arrhythmias not related to their AMI (evidenced by previous holter monitoring and/or medication history for sustained ventricular arrhythmias in patient's medical chart).
2. Require CABG or PCI due to the presence of residual coronary stenosis \>70% luminal obstruction in the non-infarct related vessel (Additional PCI of non-culprit vessels may be performed prior to enrollment).
3. History of any malignancy within the past five years excluding non-melanoma skin cancer or cervical cancer in-situ.
4. History of chronic anemia (hemoglobin (Hb) \<9.0 mg/dl).
5. History of thrombocytosis (platelets \>500k).
6. History of thrombocytopenia in the absence of recent evidence that platelet counts are normal
7. Known history of elevated INR (PT) or PTT.
8. Life expectancy less than one year.
9. History of untreated alcohol or drug abuse.
10. Currently enrolled in another Investigational drug or device trial
11. Previous CABG.
12. Previous MI resulting in LV dysfunction (LVEF \<55%)
13. History of stroke or transient ischemic attack (TIA) within the past six months.
14. History of severe valvular heart disease (aortic valve area \<1.0 cm2 or \>3+ mitral regurgitation).
15. Pregnancy or breast feeding
16. Subjects with a known history of HIV, or has active hepatitis B, active hepatitis C, or active tuberculosis (TB)
17. Patients with active inflammatory or autoimmune disease on chronic immunosuppressive therapy.
18. Contraindications to cMRI.
19. Previous radiation to the pelvis with white blood cell count (WBC) and platelet counts below hospital specific normal values.
20. Women child bearing potential not willing to practice an active form of birth control.
21. Chronic liver disease that might interfere with survival or treatment with cell therapy.
22. Chronic renal insufficiency as defined by a creatinine ≥2.0 mg/dL or requires chronic dialysis.","Adult stem cells, Placebo",INTERVENTIONAL,COMPLETED
NCT00893360,CArdiosphere-Derived aUtologous Stem CElls to Reverse ventricUlar dySfunction,"Recent Myocardial Infarction, Ventricular Dysfunction","Inclusion Criteria

* Myocardial infarction due to coronary artery atherosclerotic disease. Myocardial infarction will be defined by a rise in serum troponin I to greater than the 99th percentile of the upper limits of normal with at least one of the following:

  * symptoms of ischemia
  * ECG changes indicative of new ischemia (new ST-T changes or new left bundle branch block)
  * development of pathological Q waves on the ECG
  * imaging evidence of new loss of viable myocardium, OR
  * new regional wall motion abnormality.
* An area of regional dysfunction, i.e., hypokinetic, akinetic, or dyskinetic, as assessed by echocardiography, left ventriculography, or MRI.
* History of successful angioplasty and stent placement, with resultant TIMI grade flow ≥ 2, in the artery supplying the infarcted, dysfunctional territory and through which the cells will be infused.
* Left ventricular ejection fraction of ≥ .25 and ≤ .45 as determined by clinically-indicated assessment of cardiac function (echocardiogram, gated blood pool scan, x-ray contrast ventriculography, CT and/or MRI one day or more following successful reperfusion).
* No further revascularization clinically indicated at the time the patient is assessed for participation in the clinical trial. This will be determined by a cardiologist who is not an investigator in the clinical trial. No further revascularization may be indicated by no arteries with significant stenosis, the location, and extent of any stenosis may not be suitable for angioplasty, the distal vessels may not be suitable for placement of bypass grafts, and/or the patient declines angioplasty or bypass surgery.
* Ability to provide informed consent and follow-up with protocol procedures.
* Age \> 18 years.","* Non-cardiovascular disease with expected life expectancy of \< 3 years.
* Contraindications to MRI, including:

  * prior ICD placement
  * estimated glomerular filtration rate \< 50 ml/min
  * known reaction to gadolinium
  * claustrophobia
  * pacemaker
  * ear implant, and cochlear implant.
* History of possible presence of ferromagnetic material including programmable shunt, shrapnel, penile prosthesis, intra-uterine device, bullets, tattoos, artificial limb, blood vessel coil, and tissue expander may require special screening.
* Septal infarction involving the right ventricular endocardium as demonstrated by screening MRI (because its presence might increase the potential risk of septal biopsy and decrease treatment benefit due to decreased viability of injured septal-based stem cells).
* History of cardiac tumor, or cardiac tumor demonstrated on MRI.
* Requirement for chronic immunosuppressive therapy.
* Participation in an on-going protocol studying an experimental drug or device.
* Diagnosis of right ventricular arrhythmogenic dysplasia.
* Patients with occlusion of the infarct-related artery before administration of the study agent.
* Current alcohol abuse.
* Current drug abuse.
* Pregnancy.
* Child-bearing potential without use of effective contraception. Men intending to ""father"" children are also excluded.
* Human Immunodeficiency virus infection.
* Viral hepatitis.
* Uncontrolled diabetes and/or hemoglobin A1C \> 8.5%.
* Abnormal liver function (SGPT \> 3 times the upper reference range) and hematology (hematocrit \< 25%, WBC \< 3000, platelets \< 100,000) studies without a reversible, identifiable cause.
* Ventricular tachycardia or fibrillation not associated with an acute ischemic episode.
* New York Heart Association Class 4 congestive heart failure.
* Canadian Cardiovascular Society Angina Class 3 or 4.
* Evidence of tumor on screening chest/abdominal/pelvic (body) CT scan.
* Symptomatic ventricular tachyarrhythmia complicating the index myocardial infarction.
* Individuals who are not fluent in English.","Autologous stem cell infusion, Autologous stem cell infusion",INTERVENTIONAL,COMPLETED
NCT02976376,The Box: Using Smart Technology to Improve One-year Outcome of Myocardial Infarction Patients,Myocardial Infarction,"* Patient is admitted with acute myocardial infarction
* Patient is able to communicate in English or Dutch at B1 level","* Body Mass Index \> 35 kg x m-2
* Included in another randomized controlled trial
* Patient is \<18 years of age
* Patient is considered an incapacitated adult
* Patient is pregnant
* Patient is unwilling to sign the informed consent form",The Box,INTERVENTIONAL,COMPLETED
NCT02404376,COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial,ST Elevation Acute Myocardial Infarction,"* Men or women ≥18 years of age
* STEMI characterized by 2 mm ST segment elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with minimum of 1 mm concordant ST elevation or 1 mV(millivolt) ST segment elevation in the limb leads (II, III and aVF leads, I, aVL leads) and V4-V6.
* Patients presenting within 6 hours of chest pain.","* Known hypersensitivity to exenatide or any of the excipients
* Known contraindication to CMR imaging such as significant claustrophobia, severe allergy to gadolinium chelate contrast, severe renal insufficiency (defined as estimated glomerular filtration rate \[eGFR\] (epidermal growth factor receptor) \<30 mL/min/1.73 m2), presence of CMRI contraindicated implanted devices (e.g., pacemaker, implanted cardiac defibrillator, cardiac resynchronization therapy device, cochlear implant), embedded metal objects (e.g., shrapnel), or any other contraindication for CMRI.
* Assumed life expectancy \< 1 year e.g. due to non-cardiac disease.
* TIMI flow grade \> 1 at the time of diagnostic coronary angiography. These patients will be excluded from the analysis of infarct size but will be included in the safety analysis.
* Pregnant women
* Patients with loss of consciousness or confused, not able to read the information and to sign the writting consent
* Patients with oro-tracheal intubation
* Patients with cardiogenic shock persisting 48h after reperfusion","Exenatide, Remote Ischemic Conditioning (RIC), Placebo",INTERVENTIONAL,COMPLETED
NCT00734760,An Intervention to Reduce Prehospital Delay to Treatment in Acute Coronary Syndrome,Acute Coronary Syndrome,"* a diagnosis of ischemic heart disease, confirmed by their physician or medical record
* lived independently (i.e., not in an institutional setting).","* complicating serious co-morbidity such as a psychiatric illness or untreated malignancy
* neurological disorder with impaired cognition
* inability to read or understand English.
* major uncorrected hearing loss",education,INTERVENTIONAL,COMPLETED
NCT05536960,Dotatate to Locate Coronary Plaques at High-risk of Myocardial Infarction,"Atheroscleroses, Coronary","* Aged 50 years and older
* Underwent CCTA imaging within 78 weeks from the screening visit
* Either CAD-RADS 4 or higher or 0/1 on CCTA.
* Able to provide written informed consent","* History of chronic kidney disease stage 3b - 5, defined as a CKD-EPI value of \< 45 ml/min/1,73m2.
* CVD events/revascularization in history
* Malignant diseases or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator.
* Chronic or recent (\< 1 month) infections and/or clinical signs of acute infection.
* History of auto-immune diseases.
* Standard contra-indications to 68Ga-Dotatate PET, and CT based on physicians experience and current practices.
* Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
* Elevated liver enzymes (\> 2 ULN of liver transaminases), acute liver failure or known liver disease.",68Ga-Dotatate PET/CT,INTERVENTIONAL,COMPLETED
NCT00187460,Study of the Effectiveness of Report Cards on the Quality of Care for Heart Attack and Heart Failure Patients,"Acute Myocardial Infarction, Congestive Heart Failure","Hospital: Treat \> 30 AMI/CHF cases/patients per year in Ontario

Patient:

* AMI Most responsible diagnosis of acute myocardial infarction(ICD-9 code 410)
* CHF Most responsible diagnosis of heart failure(ICD-9 code 428)","Patient

* AMI Not admitted to an acute care hospital
* AMI Age \< 20 or \> 105 years
* AMI Invalid health card number
* AMI Admitted to non-cardiac surgical service
* AMI Transferred from another acute care facility
* AMI coded as an in-hospital complication
* AMI admission within the past year
* CHF Not admitted to an acute care hospital
* CHF Age \< 20 or \> 105 years
* CHF Invalid health card number
* CHF Admitted to surgical service
* CHF Transferred from another acute care facility
* CHF coded as an in-hospital complication
* CHF admission within the past three years",Publicly released hospital cardiac report cards,INTERVENTIONAL,COMPLETED
NCT02021760,Reduction in Infarct Size by Remote Per-postconditioning in Patients With ST-elevation Myocardial Infarction,"Coronary Artery Disease, Myocardial Infarction","* Patient planned for primary PCI.
* Chest pain indicating myocardial ischemia with a duration \>30 minutes and \< 6 hours prior to randomization.
* ST elevations \>0.1 mV (\>0.2 mV in V2-V3) in \> two contiguous leads in V1-V6.
* Informed consent.","* Previous myocardial infarction based on medical history or Q-wave on ECG in other area
* Left Bundle Branch Block on ECG.
* Previous CABG
* Cardiac arrest
* Any contraindication for CMR.
* Clinical symptoms of claudication
* Treatment with glibenclamide or cyclosporine on admission.
* Any condition that may interfere with the possibility for the patient to comply with or complete the study protocol.",Primary Percutaneous Coronary Intervention,INTERVENTIONAL,COMPLETED
NCT03104062,Effect of Ticagrelor and Clopidogrel on Coronary Microcirculation in Patients With Acute Myocardial Infarction,"Coronary Microvascular Disease, Ticagrelor, Thrombolysis, Microbubble Contrasted Echocardiography","* age from 18 years old to 75 years old.
* Patients with a ST-segment elevation AMI with up to 24 hours duration, documented by ischemic symptoms due to atherosclerosis\> 10 minutes at rest, treated with pharmacological thrombolysis, acetylsalicylic acid (ASA) and Clopidogrel or Ticagrelor.
* Cardiac catheterization performed within 4 (± 2) days of the onset of symptoms, which at the end of coronary angiography showed residual obstruction in the ""culprit"" artery \<50% with TIMI 3 flow regardless of whether or not the percutaneous coronary intervention was performed.","* Previous infarction known from the same wall as the current one
* Any contraindication to the use of Clopidogrel or Ticagrelor
* Need for oral anticoagulation therapy or aspirin doses greater than 100mg per day.
* Concomitant oral or intravenous therapy with strong inhibitors of Cytochrome P450, family 3, subfamily A (CYP3A), Substrates of CYP3A with narrow therapeutic indices or strong inducers of CYP3A
* High risk of bradyarrhythmias
* Dialysis therapy
* Clinically important thrombocytopenia known
* Clinically Significant Anemia
* Pregnancy or lactation
* Contraindications to fibrinolytic therapy","Microbubble Contrasted Echocardiography, Platelet Aggregability, Laboratory",INTERVENTIONAL,COMPLETED
NCT01291329,Intracoronary Human Wharton's Jelly- Derived Mesenchymal Stem Cells (WJ-MSCs) Transfer in Patients With Acute Myocardial Infarction (AMI),ST-Elevation Myocardial Infarction,"1. Patients at least 18 years of age；
2. Patients with 1st acute ST-elevation myocardial infarction (AMI) who undergo successful primary percutaneous coronary intervention (PCI) thrombolysis in myocardial infarction (TIMI) flow grade 3, but have a substantial residual left ventricular regional wall-motion abnormality measured by 2-D echocardiography.
3. No contraindications to undergoing cell-therapy procedure within 1 weeks after AMI and PCI.
4. Hemodynamic stability-defined as no requirement for intra-aortic balloon pump or for inotropic or blood-pressure supporting medications.
5. Consent to protocol and agree to comply with all follow-up visits and studies.","1. Presence of cardiogenic shock ( defined as systolic blood pressure \< 80 mmHg requiring intravenous pressors or intra-aortic balloon counterpulsation);
2. Major bleeding requiring blood transfusion after acute reperfusion treatment;
3. A history of leucopenia;
4. Thrombocytopenia;
5. Hepatic or renal dysfunction;
6. Evidence for malignant diseases;
7. Unwillingness to participate;",intracoronary human umbilical WJ-MSC transfer,INTERVENTIONAL,COMPLETED
NCT05335629,Evaluation of the Effect of SGLT-2 Inhibitors on Cardiac Remodeling in Post Myocardial Infarction Patients,"Myocardial Infarction, Diabetes Mellitus, Type 2, Myocardial Remodeling, Ventricular","1. Female or male aged \>18 and \< 75 years
2. Diabetic post myocardial infarction patients
3. First anterior STEMI with successful TIMI-3 flow
4. STEMI within 12 hrs of onset of chest pain
5. creatine clearance ≥60 mL/min
6. HbA1c between 6.5% and 12.0%","1. Cardiogenic shock on admission
2. Multivessel disease on admission
3. Mechanical complications e.g. mitral regurge on admission
4. Life threatening arrhythmia on admission
5. Hemodynamic instability on admission
6. Diagnosis of Type 1 diabetes mellitus
7. History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time
8. Active urinary infection diagnosed by clinical symptoms of urgency and frequency + lab tests
9. Pregnant or breast-feeding patients
10. Active participation in another clinical study
11. AST or ALT \>3x ULN or Total bilirubin \>2.5 x ULN
12. CrCl \< 60 ml/min (based on the Cockroft-Gault equation)",Dapagliflozin 10Mg Tab,INTERVENTIONAL,COMPLETED
NCT01225562,"Prevention of Cardiovascular Events (eg, Death From Heart or Vascular Disease, Heart Attack, or Stroke) in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin","Myocardial Infarction, Cardiovascular Death, Atherothrombosis, Stroke","* Person who had a heart attack within 1 - 3 years ago and at least one additional risk factor: Age ≥ 65 years old, Diabetes requiring medication, Documented history of 2nd prior MI (\>1 year ago). Angiographic evidence of multivessel CAD, and / or Chronic, non-end stage renal dysfunction.
* Females of child-bearing potential must have a negative pregnancy test at enrollment
* Persons who are currently taking aspirin between 75 and 150 mg once daily","* Persons who are being treated with agents inhibiting blood clotting if the agent cannot be stopped at study start
* Persons who have planned coronary, cerebrovascular, or peripheral arterial Revascularization (invasive surgery) at study start
* Persons with known bleeding disorders
* Persons who need chronic oral anticoagulant therapy or chronic low-molecular-weight heparin
* Persons with a history of ischemic stroke
* Persons with a history of intracranial bleeding at any time, a tumor or blood vessel abnormality in the brain and/or spinal cord at any time, a history of surgery involving the brain or spinal cord within the last 5 years, or a history of bleeding from the gastrointestinal tract (eg, esophagus, stomach, colon, rectum) within the last 6 months or a major surgery within the last 30 days.
* Persons considered to be at risk of bradycardic events unless already treated with a permanent pacemaker
* Persons who have had open heart surgery within the past 5 years, unless the person had a heart attack after the surgery
* Persons with known severe liver disease
* Persons with kidney failure requiring dialysis
* Persons with life expectancy \< 1 year","Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo",INTERVENTIONAL,COMPLETED
NCT01388504,Nitrites in Acute Myocardial Infarction,Acute ST Elevation Myocardial Infarction,"Men aged ≥18 years, women aged ≥55 years, and women \<55years who are sterilised, or have had a hysterectomy or have effective contraception and thus where there is no possibility of them being pregnant; presenting within 12 hours of the onset of chest pain who have ST segment elevation of more than 1mm elevation in limb leads or 2mm elevation in two contiguous chest leads or new left bundle branch block (LBBB) and for whom the clinical decision has been made to treat with primary PCI will be eligible for enrolment. Occlusion of the culprit related artery (TIMI grade 0 or TIMI grade 1) will also be required for inclusion. Eligible patients will be of North European descent.","* Historical or ECG evidence of previous myocardial infarction
* Patients with prior coronary artery bypass grafting (CABG)
* Prior revascularization procedure where this procedure (PCI) was performed in the same territory as the current infarct
* Known or suspected pregnancy
* Contra-indications to MRI
* Patients with cardiac arrest or cardiogenic shock
* Patients with left main coronary occlusion
* Patients with known moderate to severe renal failure (estimated GFR \< 30mls/min), or liver failure
* Patients with prior thrombolysis for this event
* Patients with such Left Main disease which after PCI of their culprit lesion (culprit lesions may be located in the LAD or LCx or RCA) are likely to require CABG within the time course of the study period (6 months).","sodium nitrite, Placebo",INTERVENTIONAL,COMPLETED
NCT01093404,Thrombus Aspiration in Myocardial Infarction,Acute Myocardial Infarction,"* Patients with a diagnosis of ST-segment elevation myocardial infarction
* Correspondence between ECG findings and culprit artery pathoanatomy
* A minimum of 50% stenosis in culprit artery by visual estimate
* Possibility to perform thrombus aspiration","* Need for emergency coronary artery bypass grafting
* Inability to provide informed consent
* Age below 18 years
* Previous randomization in the TASTE trial",Thrombus aspiration,INTERVENTIONAL,COMPLETED
NCT00623272,"Left Ventricular Function Assessment After Acute Myocardial Infarction: Comparison Between Bi-, Three-dimensional and Cardiac Magnetic Resonance",Acute Myocardial Infarction,"* All the patients presenting a first ischemic clinical episode for at least 30 minutes, associated with one known gap will be included in a forward-looking and consecutive way, of at least 0.1mV in at least two peripheral diversions of the same territory or of at least 0.2 mV in at least two precordial diversions of the same territory
* An initial FEVG (measured by echocardiography or ventricular angiography in the daytime of the admittance)","* Age \< 18 years
* Antecedents of IDM
* Contraindications in the MRI (claustrophobia, stimulating and defibrillators heart patient implantable, metal intraocular brightness, allergy in the gadolinium, the severe renal insufficiency with clearance in the creatinine ≤30 mL/min)
* Fibrillation little finger
* Pregnancy.",compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography),INTERVENTIONAL,COMPLETED
NCT02887768,Epicardial Infarct Repair Using CorMatrix®-ECM: Clinical Feasibility Study,"Acute Coronary Syndrome, Heart Failure","* The patient has been diagnosed with an acute STEMI or NSTEMI (confirmed by ST changes on serial ECG, elevated troponin, coronary artery stenosis or occlusion identified by angiography, and a wall motion abnormality identified by angiography or echocardiography)
* The patient is scheduled to undergo coronary artery bypass surgery within 6 weeks of the acute event.
* The patient does not possess any contraindication for CMR.
* The patient is greater then 35-years of age, English speaking, and capable of giving informed consent.
* The patient is geographically accessible and willing to return for all follow-up investigations and clinical visits associated with study.","* The patient is over the age of 75 years.
* The patient has previous MI (other than the qualifying event) and/or has scar or non-viable myocardium identified by CMR in any other LV territory.
* The patient is undergoing other cardiac surgery (i.e. concurrent cardiac valve, or aortic surgery).
* The patient requires emergency surgery (i.e. operative intervention (CABG or ventricular assist device) within 24-hrs of assessment).
* The patient has undergone previous cardiac surgery.
* The patient's postsurgical life expectancy is less than 45 days, in the investigator's opinion.
* The patient is of excessively poor baseline health, health-related quality of life, or physical functioning that would preclude a reasonable expected post-operative recovery.
* The patient has received radiotherapy to the chest wall, is receiving immunosuppressive therapy, or is in any way immunocompromised.
* The patient has a history of malignancy within the past year (other than squamous or basal cell carcinoma, which has been treated without evidence of recurrence).
* The patient has a recent history of drug or alcohol abuse.
* The patient has within 30-days of enrollment or is at anytime during this study participating in any other drug or device study.
* The patient has a known allergy to the CorMatrix-ECM material or any component of the material.
* Absence of non-viable myocardium within the LV on CMR.","Epicardial Infarct Repair with CorMatrix-ECM, Coronary Artery Bypass Grafting Surgery",INTERVENTIONAL,COMPLETED
NCT02382731,Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction,"Myocardial Infarction, Coronary Disease","* Patients aged 18 years and older having a coronary angiography following a myocardial infarction (ST-elevation myocardial infarction or non-ST-elevation myocardial infarction), with evidence of coronary artery disease (\>50% blockage of left main or \>70% blockage of ≥1 major cardiac arteries).
* Discharged from the catheterization centre alive, either home or to a local (non-cardiac) hospital
* Patients must be Ontario residents","* Patients will be excluded if they expire during their hospitalization or if they have cardiogenic shock (Killip Class 4) at the time of their post-MI coronary angiography due to their poor prognosis.(El-Menyar et al., 2012)
* Patients will also be excluded if they require a translator to receive services in English as recorded in the CCN referral form, as it is infeasible to offer the interventions in multiple languages at this stage.
* Patients whose data are not complete and received in time to deliver the first post-procedure intervention will be excluded as they cannot receive the intervention as intended.
* Patients who do not have an Ontario health card number","Usual care + letters, Usual care + letters + automated calls",INTERVENTIONAL,COMPLETED
NCT00275990,AngioJET Thrombectomy and STENTing for Treatment of Acute Myocardial Infarction,Myocardial Infarction,"* Patient age \> 18 years
* ST-segment elevation myocardial infarction
* Angiographically visible thrombus
* Presentation within 6 hours of symptom onset for primary percutaneous coronary intervention
* Patient, or relative or legal guardian,provides written informed consent
* Patient has no childbearing potential or is not pregnant","* Prior administration of thrombolysis for current MI
* Participation in another Study
* Major surgery within past 6 weeks
* History of stroke within 30 days, or any history of hemorrhagic stroke
* Severe hypertension (systolic BP \> 200 mm Hg or diastolic BP \> 110 mm Hg) not controlled on antihypertensive therapy
* Known neutropenia ( \<1000 neutrophils per mm3) or known severe thrombocytopenia (\< 50,000 platelets per mm3)
* Known prior history of renal insufficiency
* Co-morbidities with expected survival \< 1 year
* Patient unwilling to receive blood products","rheolytic thrombectomy with direct stenting, direct stenting",INTERVENTIONAL,COMPLETED
NCT01398384,Effects of Nitric Oxide for Inhalation in Myocardial Infarction Size,Acute Myocardial Infarction,"1. Acute myocardial infarction (defined as an episode of chest pain or related symptom lasting greater than 2 hours but less than 12 hours and electrocardiographic evidence of ST elevation (measured as 0.08 seconds after the J point; sum greater or equal to 0.6 mV in leads I, II, III, AVL, AVF, V1-V6).
2. No evidence of congestive heart failure (no S3 or evidence of pulmonary edema) and normal oxygen saturation on ≤ 2L oxygen by NC.
3. All patients must undergo successful percutaneous coronary intervention for TIMI 0 or 1 coronary flow with resulting TIMI 2 or 3 (residual stenosis less than 30% if stented and less than 50% if opened by balloon angioplasty).
4. Age \> 18 years.
5. Signed EC approved informed consent.","1. Prior myocardial infarction (as determined by patient history and/or ECG), cardiac surgery, or severe pericardial, congenital, cardiomyopathic or valvular heart disease.
2. Requirement for urgent cardiac surgery.
3. Previous CABG or PCI.
4. Left bundle branch block.
5. Unable to tolerate magnetic resonance imaging (including disallowed metallic implants or BMI \> 35) or unable to tolerate gadolinium contrast media, including patients with calculated creatinine clearance less than 60 ml/min/1.73 m2 BSA.
6. Active or recent hemorrhage requiring an invasive procedure for evaluation or transfusion within 6 weeks prior to presentation or hemorrhagic stroke within the 6 weeks prior to presentation.
7. Known or suspected aortic dissection.
8. Prior history of pulmonary disease requiring chronic oxygen therapy.
9. Pregnancy, lactating and woman of childbearing potential.
10. Use of investigational drugs or device within the 30 days prior to enrollment to the study. Investigational uses of approved therapies will be allowed.
11. Medical problem likely to preclude completion of the study.","Nitric Oxide, MI size at 48-72 hours",INTERVENTIONAL,COMPLETED
NCT06877390,Effect of Enhanced External Counterpulsation,"Enhanced External Counterpulsation (EECP), Acute Myocardial Infarction (AMI), Drug-coated Balloon, Cardiac Rehabilitation","* patients with AMI diagnosed based on the universal definition of myocardial infarction criteria
* a single vessel infarcted, and Syntax score ≤22
* patients treated using DCB
* patients without EECP contraindications
* patients aged 18-75 years
* patients who had signed informed consent and were able to cooperate in completing the study","* patients with lower limb deep venous thrombosis and active thrombophlebitis
* patients with moderate to severe valvular heart disease, especially those with aortic insufficiency and/or stenosis
* patients with moderate to severe pulmonary arterial hypertension (mean pulmonary arterial pressure \>50 mmHg)
* patients with aortic, cerebral or dissecting aneurysms
* patients with uncontrolled hypertension (\>180/110 mmHg)
* patients with decompensated heart failure (cardiac function of grade IV)
* patients with arrhythmia that might interfere with the electrocardiographic gating function of the EECP device
* patients with haemorrhagic diseases or obvious bleeding tendencies
* patients with infected lesions in their limbs that may affect EECP
* pregnant women
* patients with ventricular aneurysm and mural thrombus detected through echocardiography","conventional drug and exercise rehabilitation, EECP-based rehabilitation regimen",INTERVENTIONAL,COMPLETED
NCT03416920,A Smartphone-based Application Post-myocardial Infarction to Manage Cardiovascular Disease Risk,Percutaneous Coronary Intervention,"English-speaking PCI: balloon angioplasty, bare-metal stent, or drug-eluting stent at MGH Smartphone or Tablet (iOS or Android)",Recent (within 1mo) illicit substance use or alcohol abuse In-hospital AMI Known pregnancy Dementia or cognitive disability Incarceration,Wellframe,INTERVENTIONAL,COMPLETED
NCT02531165,Platelet Inhibition After Pre-hospital Ticagrelor Using Fentanyl Compared to Morphine in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention,Acute Myocardial Infarction,"* Age \>18-year-old
* STEMI within 12 hours of symptoms' onset eligible for primary PCI with stent implantation.
* Patient able to give written informed consent.","* Contraindication, intolerance or hypersensitivity to Ticagrelor, or any excipients
* Contraindication, intolerance or hypersensitivity to Morphine, Fentanyl, or any excipients
* Active bleeding or bleeding diathesis
* History of intracranial haemorrhage
* Chronic oral anticoagulation treatment
* Previous antiplatelet treatment
* Contraindications to antiplatelet therapy
* Severe renal insufficiency (creatinine clearance \<30 mL/min)
* Severe hepatic dysfunction
* Severe chronic obstructive pulmonary disease
* Periprocedural glycoprotein IIb/IIIa inhibitors administration
* Relevant haematological disease
* Patient who is currently, plans, or has been enrolled in another clinical study involving use of an investigational drug or device within the prior 30 days.
* If female, patient pregnant or breastfeeding.","Fentanyl, Morphine, Ticagrelor, Aspirin, Unfractioned Heparin, Primary PCI",INTERVENTIONAL,COMPLETED
NCT00333320,Positive Effect of Ischemic Postconditioning During Acute Myocardial Infarction,Acute Myocardial Infarction,"* Acute myocardial infarction (\<6 hours)
* Occlusion of a major coronary vessel","* History of previous myocardial infarction
* History of Coronary Artery Bypass Grafting
* Need for Coronary Artery Bypass Grafting
* Stenosis not eligible for angioplasty
* Limited ischemic area
* Cardiogenic shock
* Interventricular septum rupture
* Mitral regurgitation\>2
* Ventricular tachycardia
* Atrioventricular block class II and III","postconditioning, Control group",INTERVENTIONAL,COMPLETED
NCT02013674,The TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis STudy (The TRIDENT Study),"Chronic Ischemic Left Ventricular Dysfunction, Myocardial Infarction","* In order to participate in this study, a patient MUST:

  1. Be ≥ 21 and \< 90 years of age.
  2. Provide written informed consent.
  3. Have a diagnosis of chronic ischemic left ventricular dysfunction secondary to myocardial infarction (MI) as defined by previous myocardial infarction documented by an imaging study demonstrating coronary artery disease with corresponding areas of akinesis, dyskinesis, or severe hypokinesis.
  4. Been treated with appropriate maximal medical therapy for heart failure or post-infarction left ventricular dysfunction. For beta-blockade, the patient must have been on a stable dose of a clinically appropriate beta-blocker for 3 months. For angiotensin-converting enzyme inhibition, the patient must have been on a stable dose of a clinically appropriate agent for 1 month.
  5. Be a candidate for cardiac catheterization within 5 to 10 weeks of screening as determined by doctors.
  6. Have an ejection fraction of less than or equal to 50% by gated blood pool scan, two-dimensional echocardiogram, CT, or left ventriculogram within the prior six months and not in the setting of a recent ischemic event.","* In order to participate in this study, a patient MUST NOT:

  1. Have a baseline glomerular filtration rate ≤ 35 ml/min/1.73m2.
  2. Have a known, serious radiographic contrast allergy.
  3. Have a Mechanical aortic valve or heart constrictive device.
  4. Have a documented presence of aortic stenosis (aortic stenosis graded as 1.5cm2 or less).
  5. Have a documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).
  6. Require coronary artery revascularization. Patients who require or undergo revascularization procedures should undergo these procedures a minimum of 3 months in advance of treatment in this study. In addition, patients who develop a need for revascularization following enrollment will be submitted for this therapy without delay.
  7. Have evidence of a life-threatening arrhythmia in the absence of a defibrillator (non-sustained ventricular tachycardia ≥ 20 consecutive beats or complete second or third degree heart block in the absence of a functioning pacemaker) or Corrected for heart rate (QTc) interval \> 550 ms on screening ECG
  8. Automatic Implantable Cardioverter Defibrillator (AICD) firing in the past 60 days prior to enrollment.
  9. Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/µl or platelet values \< 100,000/µl without another explanation.
  10. Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times the upper limit of normal (ULN).
  11. Have a coagulopathy = (INR \> 1.3) not due to a reversible cause (i.e., Coumadin). Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed to have an INR \< 1.3. Patients who cannot be withdrawn from Coumadin will be excluded from enrollment
  12. Have known allergies to penicillin or streptomycin.
  13. Hypersensitivity to Dimethyl Sulfoxide (DMSO).
  14. Be an organ transplant recipient.
  15. Have a history of organ or cell transplant rejection
  16. Have a clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, melanoma in situ or cervical carcinoma.
  17. Have a non-cardiac condition that limits lifespan to \< 1 year.
  18. Have a history of drug or alcohol abuse within the past 24 months.
  19. Be on chronic therapy with immunosuppressant medication, such as corticosteroids or TNFα antagonists.
  20. Be serum positive for HIV, hepatitis BsAg or viremic hepatitis C.
  21. Be currently participating (or participated within the previous 30 days) in an investigational therapeutic or device trial.
  22. Be a female who is pregnant, nursing, or of childbearing potential while not practicing effective contraceptive methods. Female patients must undergo a blood or urine pregnancy test at screening and within 36 hours prior to injection.",Allogeneic hMSCs,INTERVENTIONAL,COMPLETED
NCT01491074,Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction,Non-ST Elevation Myocardial Infarction,"* NSTEMI (ESC Type 1)
* Age 18-80 years
* Troponin T \>/= 30 ng/ml
* Informed consent to participation","* STEMI
* Known cardiac disease, except coronary disease (cardiomyopathy, heart failure with known EF \< 45%, severe valvular heart disease attending regular follow-up, recent PCI/ACB (\< 3 months))
* Hemodynamic and/or respiratory instability
* Cardiac arrest in acute phase
* Concurrent condition affecting/potentially affecting CRP (infection, malignancy, autoimmune disease)
* Recent major surgery (\< 3 months)
* Recent/concurrent immunosuppressant treatment (\< 2 weeks, except NSAIDs)
* Severe renal failure (eGFR \< 30 ml/min)
* Pregnancy
* Contraindications to any study investigations and/or medication.
* Expected non-adherence to study protocol","Tocilizumab 280 mg, NaCl 0.9% 100 ml",INTERVENTIONAL,COMPLETED
NCT02803931,Assessing the Efficacy of CardiOGoniometry (CGM) to Localise the Culprit Vessel in Mixed Vessel Disease Non-ST elevatIon Myocardial infarcTION (NSTEMI),Acute Coronary Syndrome,"* Patients admitted with NSTEMI.
* Patients who have been consented to undergo coronary angiography +/- PCI as part of their routine care by their clinician.
* Aged 18 or over.
* The patient has been informed of the nature of the study and has provided full written informed consent.","* Patients unable to give informed consent including those with communication difficulties due to poor English.
* Patients with on-going chest pain at rest despite medical therapy
* Patients with haemodynamic instability and / or cardiogenic shock (defined as a sustained blood pressure of \<90mmHg +/- the need for inotropic support)
* Patients with STEMI
* Those unable to perform a good quality CGM: 1) Patients who are SOB at rest; 2) Patients with very frequent ectopic beat; 3) Patients in atrial fibrillation; 4) Patients with a heart rate \>150 beats/min
* Patients with previous coronary artery bypass graft surgery
* Patients who are unable to receive treatment with heparin
* Patients with significant renal impairment (defined as eGFR\<30ml/min)
* Females who are or could be pregnant","Cardiogoniometry, 12-lead ECG",INTERVENTIONAL,COMPLETED
NCT00387231,Comparison of Anti-Ischemic Drug Therapy and Percutaneous Transluminal Angioplasty After Myocardial Infarction,Myocardial Ischemia,"* Recent myocardial infarction within last 3 months
* Documented silent myocardial ischemia (type I)",* Symptomatic myocardial ischemia,"Percutaneous coronary angioplasty/intervention (PCI), Anti-ischemic drug therapy",INTERVENTIONAL,COMPLETED
NCT01203982,Effect of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Carotid Intima-media Thickness (CIMT),"ST-segment Elevation Myocardial Infarction, Subclinical Carotid Atherosclerosis","1. STEMI,
2. no prior treatment with statins and
3. a non significant lesion in one of the two non-culprit coronary arteries. -","1. age below 18 or above 81 years,
2. unconscious patients,
3. serum creatinine \> 176μmol/L,
4. total-cholesterol \> 7.0 mmol/l,
5. hypothyroidism ((TSH \> 1.5 x ULN (upper limit of normal)),
6. current liver disease (ALAT \> 2 x ULN),
7. unexplained creatine kinase \> 3 x ULN,
8. alcohol or drug abuse within the last five years,
9. prior myopathy or serious hypersensitivity reaction caused by statins,
10. women with childbearing potential who were not using chemical or mechanical contraception,
11. pregnant or breastfeeding women,
12. history of malignancy unless a disease-free period of more than five years was present,
13. patients with abnormal lung function test (LFT),
14. participation in another investigational drug study less than four weeks before enrolment in the present study,
15. treatment with cyclosporine or fibrates. -","Rosuvastatin, Rosuvastatin",INTERVENTIONAL,COMPLETED
NCT00162331,CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI,Myocardial Infarction,* Undergoing primary or rescue PCI for acute MI with ECG evidence of a large territory at risk.,"* History of prior MI or CABG surgery, persistent LBBB, Atrial Fibrillation, End stage renal disease, Weight \> 350 lbs.",Technetium Tc99m Sestamibi,INTERVENTIONAL,COMPLETED
NCT01014273,A Trial of Trans-radial Versus Trans-femoral Percutaneous Coronary Intervention (PCI) Access Site Approach in Patients With Unstable Angina or Myocardial Infarction Managed With an Invasive Strategy,"Acute Coronary Syndrome, Percutaneous Coronary Intervention","INCLUSION CRITERIA

1.1 UA/NSTEMI patients

Ischemic symptoms suspected to represent a non-ST segment elevation ACS (unstable angina \[UA\] or non-ST segment elevation myocardial infarction NSTEMI) defined as:

Clinical history consistent with new onset, or a worsening pattern, of characteristic ischemic chest pain occurring at rest or with minimal exercise (lasting longer than 10 minutes) and planned to be managed with an invasive strategy

AND at least one of the following:

1. Electrocardiogram (ECG) changes compatible with new ischemia \[ST depression of at least 1mm or transient ST elevation or ST elevation of less than or equal to 1 mm or T wave inversion greater than 2 mm in at least 2 contiguous leads\].

   or
2. Patients \> 60 years of age with normal ECG are eligible provided there is a high degree of certainty that presenting symptoms are due to myocardial ischemia. Such patients must have documented evidence of previous coronary artery disease (CAD) with at least one of the following:

   * Prior MI requiring hospitalization
   * Prior revascularization procedure (more than 3 months ago)
   * Cardiac catheterization showing significant CAD
   * Positive exercise test
   * Other objective evidence of atherosclerotic vascular disease or
3. Already elevated cardiac enzymes or troponin I or T above the upper limit of normal.

1.2 STEMI patients

1. Presenting with signs or symptoms of acute myocardial infarction lasting at least 20 minutes and planned to be managed with an invasive strategy with intent to perform a percutaneous coronary intervention (PCI) during the index hospitalization.
2. Definite ECG changes compatible with STEMI: persistent ST-elevation (\> 2 mm in two contiguous precordial leads or \> 1 mm in at least two limb leads), or new left bundle branch block, or Q-wave in 2 contiguous leads

   2) Randomized during index hospitalization for acute coronary syndrome 3) Suitable candidate for either radial or femoral artery PCI 4) Intent to perform same-sitting angiography and PCI. 5) Palpable radial artery with documented normal Allen's test 6) Acceptance by operator to use whichever route is assigned by the randomization process 7) Previous experience of the operator with at least 50 cases of radial artery access within the past year 8) Written informed consent","1. Age \< 18 years
   2. Active bleeding or significant increased risk of bleeding, severe hepatic insufficiency, current peptic ulceration, proliferative diabetic retinopathy.
   3. Uncontrolled hypertension
   4. Cardiogenic shock
   5. Prior CABG surgery with use of more than one internal mammary artery
   6. Documented severe peripheral vascular disease precluding a femoral approach
   7. Participation in any study with an investigational drug or device within the previous 30 days
   8. Medical, geographic or social factors making study participation impractical",Percutaneous Coronary Intervention,INTERVENTIONAL,COMPLETED
NCT00334373,Post Conditioning in PCI for Acute ST Elevation Myocardial Infarction,Myocardial Infarction,"* 18 years and over
* ST elevation of \>/= 2mm in 3 consecutive anterior leads or \>/= to 2 mm in leads II, III and AVF with total 8 mm ST shift (ST depression of 1 mm in ant or lat leads)","* Cardiogenic shock or severe heart failure
* Inability to undergo CMR (metallic objects or claustrophobia)
* Previous MI
* TIMI 2-3 flow in target artery
* Collaterals to infarct related artery \> Rentrop grade 1
* Inability to undertake successful PCI at time of angio
* Significant LM disease or requiring CABG during hospital stay
* Inability to proceed with post conditioning within 1 minute of establishing blood flow in culprit artery",Post conditioning,INTERVENTIONAL,COMPLETED
NCT00426231,Culturally-Tailored Approach to Improve Medication Use in Patients With Heart Attacks,"Coronary Arteriosclerosis, Myocardial Infarction","* Admitted to Johns Hopkins Hospital or Johns Hopkins Bayview Medical Center
* Diagnoses of Myocardial Infarction, unstable angina, percutaneous intervention, coronary artery bypass surgery
* One of the following:

  * Less than a high school education (defined as completion of the 12th grade)
  * No insurance for medications with a household income of $50,000. or less
  * Any difficulty in co-pay even with a household income of \>$50,000.","* physician contraindicates statin use
* chronic glucocorticosteroid therapy
* autoimmune disease (i.e. lupus erythematosus)
* current chemotherapy or radiation
* immediate life-threatening comorbidity (i.e. HIV-AIDS, end-stage renal disease, or cancer)
* history of hepatic or renal failure
* myositis with creatine kinase (CK) elevations
* any prior adverse response to statin therapy
* statin allergy
* rhabdomyolysis
* pregnant women","Navigation by a health worker, Information control",INTERVENTIONAL,COMPLETED
NCT00123565,Hexadecasaccharide (SR123781A) in Patients With Unstable Angina or Non-ST-Segment Elevation Myocardial Infarction,Coronary Atherosclerosis,"* A person with a diagnosis of acute coronary syndrome who is scheduled to undergo a PCI within 48 hours.
* A person who is of the legal age of 21, who is mentally competent, and who has signed a written informed consent","* A person with known allergy or any contra-indication to active control.
* A person who has received heparin during more than 48 hours before inclusion in the study.
* A person treated with warfarin (oral anticoagulant).
* A person with current bleeding or recognized increased risk of bleeding or history of intracranial hemorrhage.
* A person who has had a stroke within the last 6 months.
* A person with uncontrolled hypertension despite antihypertensive therapy.
* A person with history of clinically significant reduction in blood platelets or neutrophils (white blood cells).
* A person who has laboratory evidence of significantly reduced renal function or who is dependent on renal dialysis.
* A person who has a coronary bypass performed during the previous month.
* A pregnant or nursing woman or a woman of childbearing potential (before menopause) who does not have a negative pregnancy test and does not use a reliable method of birth control.
* A person who has received any investigational treatment in the preceding month.",Hexadecasaccharide (SR123781A),INTERVENTIONAL,COMPLETED
NCT03058120,Henry Ford Heart Score Randomized Trial: Rapid Discharge of Patients Evaluated for Possible Myocardial Infarction,"Chest Pain, Heart Attack, Coronary Artery Disease","* patients 21 years or older
* patients who presented to the Emergency Department with symptoms suspicious for AMI.
* patients for whom the ED physician's intention to send the patient to the observation unit for stress testing","* Cardiac Troponin I \> 0.04 ng/mL at 0 or 3 hours
* clinical presentation warranting admission
* inability or unwillingness to consent
* trauma as etiology of presenting symptoms.",Deferral of admission for stress test,INTERVENTIONAL,COMPLETED
NCT01747174,REperfusion Facilitated by LOcal Adjunctive Therapy in ST-elevation Myocardial Infarction,ST-elevation Myocardial Infarction (STEMI),"* ≥ 18 years age.
* Informed ASSENT (verbal consent) prior to angiography.
* STEMI ≤ 6 hrs of symptom onset, requiring primary reperfusion by PCI.
* Single-vessel coronary artery disease (non culprit disease ≤70% stenosis at angiography)
* TIMI flow 0/I at angiography.","* Contraindications to: P-PCI \*, CMR\*\*, contrast agents, or study medications: Adenosine\*\*\*, SNP\*\*\*\*, Aspirin, Thienopyridine and Bivalirudin.
* SBP ≤ 90mmHg
* Cardiogenic Shock
* Previous Q wave myocardial infarction
* Culprit lesion not identified or located in a by-pass graft
* Stent thrombosis.
* Left main disease.
* Known severe asthma.
* Known stage 4 or 5 chronic kidney disease (eGFR\<30ml/min).
* Pregnancy.

Notes:

* \* Exclusion criteria for P-PCI (presentation timing, inadequate arterial access etc); patient unable to tolerate ""prolonged"" PCI procedure (in operators' opinion).
* \*\* Absolute contra-indication to CMR (Pacemaker, ICD, intra-cranial metal clips).
* \*\*\* Contraindications to Adenosine (known hypersensitivity to Adenosine, sick sinus syndrome, second or third degree atrio-ventricular block - except in patients with functioning artificial pacemaker, long QT syndrome has been defined as QTc \> 450 ms at baseline). ECG will be undertaken just after the first dose of the study drug and QT/QTc will be recorded and compared to the baseline. If the QTc recorded after the first dose of the study drug exceeds 450ms or there is an increase in the QT/QTc of \> 60 ms from baseline, the second dose will be abandoned and this will be recorded.
* \*\*\*\* Contraindications to SNP (known hypersensitivity to SNP, compensatory hypertension - as may be seen in arteriovenous shunts or coarctation of the aorta, high output failure, congenital optic atrophy or tobacco amblyopia).","IC Adenosine, IC Sodium nitroprusside (SNP), Standard PCI",INTERVENTIONAL,COMPLETED
NCT01896765,Intensive Prevention Program After Myocardial Infarction,"Myocardial Infarction, Prevention Harmful Effects",Hospitalisation due to myocardial infarction (ST-elevation or non-ST-elevation myocardial infarction),"i) Hemodynamically significant valvular heart disease (\> NYHA class II) or inborn cardiac malformations.

ii) Cardiomyopathy associated with hemodynamic obstruction, pregnancy or myocarditis.

iii) Exercise limitations due to clinical conditions not related to CAD. iv) Any major non-cardiac condition that would adversely effect survival during the duration of the study.

v) Patients unlikely to comply to the study treatment and the follow-up visits. vi) Pregnancy (all pre-menopausal females should have a negative serum pregnancy test).

vii) Inability of cooperation with the protocol, including longterm follow-up. viii) Patient refusal or inability to give informed consent. ix) Refusal of the patient's physician regarding trial participation of the patient.

x) Chronic drug or alcohol abuse.","Intensive Prevention Program, Standard medical and interventional therapy",INTERVENTIONAL,COMPLETED
NCT00526474,Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737),"Atherosclerosis, Ischemia, Myocardial Infarction, Cerebrovascular Accident, Peripheral Arterial Disease","Men and women at least 18 years old with evidence or a history of atherosclerosis involving the coronary, cerebral, or peripheral vascular systems by one or more of the following:

* history of myocardial infarction (heart attack)
* history of ischemic stroke (stroke due to a blocked artery)
* history of peripheral arterial disease","* history of intracranial hemorrhage or of central nervous system (CNS) surgery, tumor, or aneurysm
* any bleeding disorder or abnormality
* sustained severe hypertension or valvular heart disease
* current or recent platelet count \<100,000 mm\^3
* planned or ongoing treatment with a blood thinning medication
* pregnancy
* any significant medical or physiological condition or abnormality that could put the subject at increased risk or limit the subject's ability to participate for the duration of the study","Vorapaxar, Placebo",INTERVENTIONAL,COMPLETED
NCT00433966,Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction,Myocardial Infarction,"* Must have clinical symptoms consistent with AMI (e.g., angina or anginal equivalent)lasting \>20 minutes but \<12 hours in duration;
* ST-segment elevation of \>1 mm in \>2 contiguous leads, or (presumably new) left bundle branch block, or true posterior MI with ST depression of \>1 mm in \>2 contiguous anterior leads;
* The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent.","* The patient has a known hypersensitivity or contraindication to any of the following medications:

  * Heparin, pork or pork products
  * Both abciximab and eptifibatide
  * Aspirin
  * Both Clopidogrel and Ticlopidine
  * Bivalirudin
  * Paclitaxel or Taxol
  * The polymer components of the TAXUS™ stent (SIBS)
  * Stainless steel and/or
  * Contrast media;
* Prior administration of thrombolytic therapy, bivalirudin, GP IIb/IIIa inhibitors, low molecular weight heparin or fondaparinux for this admission. Patients receiving prior unfractionated heparin may be enrolled, and treated per randomization;
* Current use of coumadin;
* Systemic (intravenous) Paclitaxel or Taxol use within 12 months;
* Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plans to become pregnant any time after enrollment into this study;
* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or will refuse blood transfusions;
* History of intra-cerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke;
* Stroke or transient ischemic attack within the past 6 months, or any permanent residual neurologic defect;
* Gastrointestinal or genitourinary bleeding within the last 2 months, or major surgery within six weeks;
* Recent history or known current platelet count \<100,000 cells/mm3 or Hgb \<10 g/dL;
* Extensive peripheral vascular disease, such that emergent angiography and intervention in the opinion of the investigator is likely to be difficult or complicated;
* An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first six months post enrollment;
* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance;
* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period;
* Previous enrollment in this trial;
* Patients who underwent coronary stent implantation within the past 30 days.","Bivalirudin, Unfractionated heparin, Bare metal stent, Paclitaxel-eluting stent",INTERVENTIONAL,COMPLETED
NCT00271765,"A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention",Acute Myocardial Infarction,"* Subjects with acute myocardial infarction (as defined in protocol) with onset within 24 hours prior to randomization.
* Scheduled for primary percutaneous coronary intervention within 3 hours of presentation at a hospital participating in this study.
* Males and non-pregnant, non-lactating females.","* Subjects will be required to undergo a full medical review in order to exclude serious medical, or psychological illness prior to inclusion.
* History of a hypersensitivity reaction to more than three drugs or mannitol.
* Participation in any investigational study within 30 days of randomization
* Treatment with certain restricted medications within a specified time prior to participation in the study.",INO-1001,INTERVENTIONAL,COMPLETED
NCT04509674,EMPACT-MI: A Study to Test Whether Empagliflozin Can Lower the Risk of Heart Failure and Death in People Who Had a Heart Attack (Myocardial Infarction),Myocardial Infarction,"1. Of full age of consent (according to local legislation, at least ≥ 18 years) at screening.
2. Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
3. Male or female patients. Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information.
4. Diagnosis of spontaneous Acute Myocardial Infarction (AMI): ST-Elevation Myocardial Infarction (STEMI) or Non-ST Elevation Myocardial Infarction (NSTEMI) with randomisation to occur no later than 14 calendar days after hospital admission. For patients with an in-hospital Myocardial Infarction (MI) as qualifying event, randomization must still occur within 14 days of hospital admission.
5. High risk of HF, defined as EITHER

   1. Symptoms (e.g. dyspnea; decreased exercise tolerance; fatigue), or signs of congestion (e.g. pulmonary rales, crackles or crepitations; elevated jugular venous pressure; congestion on chest X-ray), that require treatment (e.g. augmentation or initiation of oral diuretic therapy; i.v. diuretic therapy; i.v. vasoactive agent; mechanical intervention etc.) at any time during the hospitalization.

      OR
   2. Newly developed Left Ventricular Ejection Fraction (LVEF) \< 45% as measured by echocardiography, ventriculography, cardiac Computer Tomography (CT), Magnetic Resonance Imaging (MRI) or radionuclide imaging during index hospitalisation.
6. In addition at least one of the following risk factors:

   * Age \> 65 years,
   * Newly developed LVEF \< 35%,
   * Prior MI (before index MI) documented in medical records,
   * Estimated Glomerular Filtration Rate (eGFR) \< 60 ml/min/1.73m2 (using Chronic Kidney Disease Epidemiology Collaboration Equation (CKD-EPI) formula based on creatinine from local lab at any time during index hospitalisation),
   * Atrial fibrillation (persistent or permanent ; if paroxysmal, only valid if associated with index MI),
   * Type 2 diabetes mellitus (prior or new diagnosis),
   * N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP) \>1,400 pg/mL for patients in sinus rhythm, \>2,800 pg/mL if atrial fibrillation; Brain Natriuretic Peptide (BNP) \>350 pg/mL for patients in sinus rhythm, \>700 pg/mL if atrial fibrillation, measured at any time during hospitalisation,
   * Uric acid \>7.5 mg/dL (\>446 μmol/L), measured at any time during hospitalisation,
   * Pulmonary Artery Systolic Pressure \[or right ventricular systolic pressure\] \>40 mmHg (non-invasive \[usually obtained from clinically indicated post-MI echocardiography\] or invasive, at any time during hospitalisation),
   * Patient not revascularized (and no planned revascularization) for the index MI (Includes e.g. patients where no angiography is performed, unsuccessful revascularization attempts, diffuse atherosclerosis not amenable for intervention; but does NOT include if revascularization was not performed due to nonobstructive coronary arteries),
   * 3-vessel coronary artery disease at time of index MI,
   * Diagnosis of peripheral artery disease (extracoronary vascular disease, e.g. lower extremity artery disease or carotid artery disease).","1. Diagnosis of chronic Heart Failure (HF) prior to index MI.
2. Systolic blood pressure \< 90 mmHg at randomisation.
3. Cardiogenic shock or use of i.v. inotropes in last 24 hours before randomisation.
4. Coronary Artery Bypass Grafting planned at time of randomisation.
5. Current diagnosis of Takotsubo cardiomyopathy.
6. Any current severe (stenotic or regurgitant) valvular heart disease.
7. eGFR \< 20 ml/min/1.73m2 (using CKD-EPI formula based on most recent creatinine from local lab during index hospitalisation) or on dialysis.
8. Type I diabetes mellitus. Further exclusion criteria apply.","Empagliflozin, Placebo",INTERVENTIONAL,COMPLETED
NCT01502774,Cyclosporine and Prognosis in Acute Myocardial Infarction (MI) Patients,ST Elevation Acute Myocardial Infarction,"Eligibility criteria (for screening before hospital admission):

1. All (male and female) patients, aged over 18, without any legal protection measure,
2. Having a health coverage,
3. Presenting within 12 hours of the onset of chest pain,
4. Who have ST segment elevation ≥0.2 mV in two contiguous leads,
5. For whom the clinical decision was made to treat with percutaneous coronary intervention (PCI).

   And (further inclusion criteria to be confirmed by the admission coronary-angiography):
6. The culprit coronary artery has to be the LAD
7. The LAD artery has to be occluded (TIMI flow grade 0-1) at the time of admission coronary angiography.
8. Preliminary oral informed consent followed by signed informed consent as soon as possible.

Patients undergoing either primary PCI or rescue PCI are eligible for the study. Patients with previous AMI, PCI or coronary artery bypass surgery (CABG) are eligible for the study.","1. Patients with loss of consciousness or confused
2. Patients with cardiogenic shock
3. Patients with the left circumflex or the right coronary artery (RCA) as the culprit artery, or with evidence of coronary collaterals to the risk region
4. Patients with an opened (TIMI \> 1) LAD coronary artery at admission on initial (admission) coronary angiography
5. Patients with 5.2. known hypersensitivity to cyclosporine 5.3. known hypersensitivity to egg, peanut or Soya-bean proteins 5.4. known renal insufficiency (either known creatinin clearance \< 30 ml/min/1.73m² or current medical care for severe renal insufficiency) 5.5. known liver insufficiency 5.6. uncontrolled (treated or untreated) hypertension (\> 180/110 mmHg)
6. Patients treated with any compound containing Hypericum perforatum (St.-John's-worth) or Stiripentol or Aliskiren or Bosentan or Rosuvastatine
7. Female patients currently pregnant or women of childbearing age who were not using contraception (oral diagnosis).
8. Patients with any disorder associated with immunological dysfunction more recently than 6 months prior to presentation 8.2. cancer, lymphoma 8.3. known positive serology for HIV, or hepatitis","Injection of Cyclosporin, Placebo, Echocardiography",INTERVENTIONAL,COMPLETED
NCT00586820,Role of Endothelin in Microvascular Dysfunction Following PCI for NSTEMI,Myocardial Reperfusion Injury,"* Age ≥ 18 years
* Clinical diagnosis of unstable angina or non ST-elevation myocardial infarction, and requiring clinically indicated PCI for the management of non ST elevation acute coronary syndrome.","* Systemic hypotension (systolic \<90 mmHg)
* Heart failure or known ejection fraction \< 30%
* Left main disease
* Culprit lesion is in a saphenous vein graft
* 100% occlusion of the culprit vessel or culprit is an ostial right coronary stenosis
* Currently enrolled in other active cardiovascular investigational studies
* Severe endocrine, hepatic, or renal disorders
* Pregnancy or lactation
* Federal Medical Center inmates
* Inability or unwillingness to provide informed consent","BQ-123, Placebo",INTERVENTIONAL,COMPLETED
NCT02640274,Individual Nurse-led Counselling Programme for Patients Early Discharged After Myocardial Infarction.,"Cardiovascular Diseases, Coronary Disease, Myocardial Infarction","Patients with documented evidence of myocardial infarction during hospitalisation will be considered for inclusion.

* patients over 18 years old
* living at home in the local hospital area after hospital discharge
* able to receive telephone calls, fill in questionnaire and communicate in Norwegian.","* cognitive impaired/dementia
* planning for coronary artery bypass graft surgery","Nurse-led counselling programme, Usual care",INTERVENTIONAL,COMPLETED
NCT00566774,A Randomized Evaluation of First-dollar Coverage for Post-MI Secondary Preventive Therapies,"Myocardial Infarction, Coronary Artery Disease","* discharged alive from hospital after acute MI
* receive health services and prescription drug benefits through Aetna, Inc.","* enrollment in a Health Savings Account (HSA) plan
* age ≥ 65 years of age at the time of hospital discharge
* plan sponsor has opted out of participating in the study
* receive only medical services or pharmacy coverage but not both through Aetna","Full drug coverage, Usual coverage",INTERVENTIONAL,COMPLETED
NCT06615674,Effect of Dapagliflozin Administration on the Apoptosis Levels of Patients with Acute Myocardial Infarction,"Acute Myocardial Infarction (AMI), STEMI - ST Elevation Myocardial Infarction (MI), NSTEMI - Non-ST Segment Elevation Myocardial Infarction (MI)","1. Patients with Acute Myocardial Infarction (STEMI or NSTEMI) according to the Fourth Universal Definition of Myocardial Infarction from the European Society of Cardiology, American College of Cardiology, American Heart Association, and World Heart Federation.
2. Aged 18-75 years
3. Willing to participate in the study and sign informed consent.","1. Patients with cardiogenic shock (SBP ≤ 80 mmHg, cold extremities, urine output \&lt;0.5 ml/kg/hr) \&lt;24 hours before randomization
2. Patients with ketoacidosis (arterial pH \&lt;7.30, serum bicarbonate \&lt;18 mEq/l, positive ketonuria)
3. Patients with impaired renal function with an estimated glomerular filtration rate (eGFR) \&lt;20 ml/min or requiring dialysis
4. Patients with a history of chronic heart failure before the onset of Acute Myocardial Infarction
5. Patients scheduled for coronary artery bypass surgery
6. Patients with type 1 diabetes mellitus
7. Patients with severe valvular disease
8. Patients with sepsis
9. Patients with symptomatic acute urinary tract infection
10. Pregnant patients
11. Patients with severe aortic stenosis or LVOT obstruction","Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia",INTERVENTIONAL,COMPLETED
NCT00768066,The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT),"Stem Cell Transplantation, Ventricular Dysfunction, Left","* Diagnosis of chronic ischemic left ventricular dysfunction secondary to MI.
* Be a candidate for cardiac catheterization.
* Been treated with appropriate maximal medical therapy for heart failure or post-infarction left ventricular dysfunction.
* Ejection fraction less than or equal to 50%.
* Able to perform a metabolic stress test.","* Baseline glomerular filtration rate \< 45 ml/min/1.73m2.
* Presence of a mechanical aortic valve or heart constrictive device.
* Documented presence of aortic stenosis (aortic stenosis graded as ≥+2 equivalent to an orifice area of 1.5cm2 or less).
* Documented presence of moderate to severe aortic insufficiency (echocardiographic assessment of aortic insufficiency graded as ≥+2).
* Evidence of a life-threatening arrhythmia (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete heart block) or QTc interval \> 550 ms on screening ECG. In addition; patients with sustained or a short run of ventricular tachycardia on ECG or 48 hour Ambulatory ECG during the screening period will be removed from the protocol.
* Documented unstable angina.
* AICD firing in the past 60 days prior to the procedure.
* Contra-indication to performance of a magnetic resonance imaging scan.
* Be eligible for or require coronary artery revascularization.
* Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/ul or platelet values \< 100,000/ul without another explanation.
* Have liver dysfunction, as evidenced by enzymes (ALT and AST) greater than three times the ULN.
* Have a coagulopathy condition = (INR \> 1.3) not due to a reversible cause.
* Known, serious radiographic contrast allergy.
* Known allergies to penicillin or streptomycin.
* Organ transplant recipient.
* Clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.
* Non-cardiac condition that limits lifespan to \< 1 year.
* On chronic therapy with immunosuppressant medication.
* Serum positive for HIV, hepatitis BsAg, or non-viremic hepatitis C.
* Female patient who is pregnant, nursing, or of child-bearing potential and not using effective birth control.","Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo",INTERVENTIONAL,COMPLETED
NCT01305226,A Trial Using Double-Bolus THR-100 Versus Streptokinase,Acute Myocardial Infarction,"1. Male or female patients aged 30 to \< 75 years inclusive.
2. Patients presenting within 12 hours with symptoms presumed secondary to an acute myocardial infarction lasting at least 20 minutes and accompanied by ECG evidence of \> 1mm of ST elevation in 2 or more limb leads or \> 2mm in 2 or more contiguous precordial leads or suspected new left bundle branch block will be eligible.
3. Patients must be in the hospital or the emergency department and able to receive the study medication within 12 hours of onset of symptoms.
4. Females of child-bearing age, not using a generally accepted method of contraception must have a negative urine pregnancy test.
5. Written informed consent should be sought from the patient prior to inclusion in the study. If unable to do so, informed verbal consent will be obtained. If neither is possible, a legally acceptable representative (relative) should provide written consent.
6. NB Verbal or written consent should be followed by written informed consent from the patient at the earliest subsequent opportunity.","1. Previous administration of staphylokinase.
2. Active bleeding or known hemorrhagic diathesis.
3. Any history of stroke, transient ischemic attack, dementia, or structural CNS damage e.g. neoplasm, aneurysm, AV malformation.
4. Major surgery or trauma within the past 3 months.
5. Significant hypertension i.e. SBP 180 mm Hg and/or DBP 110 mm Hg at any time from admission to randomization.
6. Current treatment with vitamin K antagonists resulting with an INR \> 1.5.
7. Anticipated difficulty with vascular access.
8. Prolonged (\>10 min) cardiopulmonary resuscitation or cardiogenic shock.
9. Patients who have participated in an investigational drug study within the past 30 days.
10. Pregnancy or lactation, parturition within the previous 30 days.
11. Any serious concomitant systemic or life limiting disorder that would be incompatible with the trial
12. Patients known to have a history of or life limiting malignant disease or HIV.
13. Significant hepatic or renal dysfunction or any other condition which, in the opinion of the Investigator, makes the patient unsuitable for study entry.
14. Previous participation in this trial","THR-100, Streptokinase",INTERVENTIONAL,COMPLETED
NCT02125526,Intra-aortic Balloon Pump in Extensive Myocardial Infarction With Persistent Ischemia,"Acute Myocardial Infarction, Persisting Ischemia, No Reflow","* Acute ST-segment elevation myocardial infarction with summed ST-segment deviation ≥15 mm.
* Insufficient ST-segment resolution (\<50%) on the ECG made 10-30 minutes after the primary PCI in the catheterization laboratory.","* Initial summed ST-segment deviation less than 15 mm
* ST-segment resolution \> 50% on the ECG performed in the catheterization laboratory
* Chest pain onset less than 2 or more than 8 hours before arrival
* Severe aortic valve stenosis/regurgitation
* Aortic abnormalities prohibitive for use of intra aortic balloon pump
* Full blown cardiogenic shock with immediate requirement of left ventricular assist device as judged necessary by the operator
* Inability to provide informed consent
* Pregnancy
* Inability to perform coronary angiography by the femoral approach",Intra-aortic balloon pump,INTERVENTIONAL,COMPLETED
NCT02579031,A Comparison of an Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Stent With a Durable Polymer Everolimus-Eluting Stent for Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention,"Coronary Artery Disease, Acute Coronary Syndrome","Inclusion Criteria:

* Age ≥18 years
* ST-segment elevation acute myocardial infarction
* Primary PCI occurring within 24 hours of symptom onset
* Presence of ≥1 acute infarct artery target vessel with one or more coronary artery stenoses in a native coronary artery from 2.25 to 4.0 mm in diameter that can be covered with one or multiple coronary stents","* Known allergy to aspirin, Ticagrelor, Prasugrel, Clopidogrel, Sirolimus, Everolimus or contrast media
* Planned surgery within 6 months of primary PCI, unless dual antiplatelet therapy could be maintained throughout the peri-surgical period
* Currently participating in another trial before reaching the primary endpoint
* Inability to provide informed consent
* Non-cardiac comorbid conditions with life expectancy of less than 1 year
* Mechanical complication of acute myocardial infarction
* Acute myocardial infarction due to stent thrombosis","Orsiro, Xience",INTERVENTIONAL,COMPLETED
NCT00755131,Effects of Cardiac Rehabilitation on High Mobility Group Box-1 Levels After Acute Myocardial Infarction,Acute Myocardial Infarction,* Acute Myocardial Infarction,"* BMI higher than 30 and lower than 18
* Residual myocardial ischemia
* Severe ventricular arrhythmias
* IIb or III degree atrio-ventricular block
* Valvular disease requiring surgery
* Pericarditis
* Severe renal dysfunction (i.e. creatinine \>2.5 mg/dl)
* Severe concomitant non-cardiac disease such as cancer
* Liver dysfunction (alanine aminotransferase/aspartate aminotransferase level \>1.5 times the upper normal limit)
* Dementia
* Any systemic disease limiting exercise
* Inability to participate in a prospective study for any logistic reason",Exercise-based Cardiac Rehabilitation program,INTERVENTIONAL,COMPLETED
NCT06548282,Efficacy of Acceptance and Commitment Therapy for the Management of Quality of Life in Patients Post Myocardial Infarction,"Psychological Distress, Type D Personality, Medication Adherence, Quality of Life","1. First-time diagnosed, non-hospitalized patients with myocardial infarction (MI).
2. Patients attending follow-up visits at the hospital.
3. Patients experiencing distress.
4. Patients exhibiting features of Type D personality.
5. Patients reporting low levels of:

   * Quality of Life (QoL)
   * Medication adherence
   * Social support
   * Acceptance
   * Psychological flexibility
6. Patients aged 18 years and above.
7. Both genders.
8. Patients who can understand Urdu.
9. Patients who can provide informed consent.","1. Hospitalized patients with myocardial infarction (MI).
2. Patients with myocardial infarction (MI) and other chronic co-morbid diseases, such as:

   * Cancer
   * Cognitive deficits
   * Chronic psychological disorders
3. Patients with silent myocardial infarction.
4. Patients younger than 18 years.",Acceptance and commitment therapy,INTERVENTIONAL,COMPLETED
NCT00384982,Myocardial Stem Cell Administration After Acute Myocardial Infarction (MYSTAR) Study,Myocardial Infarction,"* Patient with a definitive AMI not earlier than 21 days and not later than 42 days before randomization (day 0 is the day of infarction)
* Patients with open IRA without significant stenosis and TIMI flow 3, after successful percutaneous coronary intervention (PCI) of the IRA
* Patients with two- or three-vessel disease might be included after adequate PCI if no significant coronary lesion can be seen in the non-infarct-related major vessels at the time of BM-SCs therapy
* A persistent local new wall motion abnormality related to the recent infarct location.
* Preserved myocardial viability, at least in the part of the recent infarction should be demonstrated by a preserved wall thickness and/or hypokinesia determined by transthoracic echocardiography or contrast ventriculography, and preserved tracer uptake determined by early and late resting Thallium myocardial scintigraphy or FDG-PET.
* Global LVEF between 30 and 45%.
* Written informed consent.","* Previous heart surgery
* Small posterior or inferior AMI
* Previous MI at the same location
* Regional wall motion abnormality outside the area involved in the index AMI
* Ventricular thrombus
* Severe valvular heart disease
* Severe renal, lung and liver disease
* Disease of the hematopoetic system
* Hemoglobin level below 9 mg%
* The patient cannot follow the study protocol
* NYHA functional class IV at baseline
* Postinfarct angina
* Significant coronary stenosis in the IRA requiring repeated PCI at the time of the planned BM-SCs therapy
* Significant coronary lesion in one or more major coronary vessels, requiring revascularization
* Age lower than 18 years",Bone marrow-derived stem cells implantation,INTERVENTIONAL,COMPLETED
NCT00882466,The Effect of Erythropoietin at the Time of Reperfusion in Acute Myocardial Infarction,Acute Myocardial Infarction,"* Acute myocardial infarction \<12hr
* Age \>18yrs
* First myocardial infarction
* culprit lesion : proximal to mid left anterior descending artery
* Baseline coronary flow : TIMI Grade 0\~1","* Patients with previous myocardial infarction
* History of thrombotic complication
* History of cerebral infarction
* Uncontrolled hypertension
* Increased hemoglobin level \>17g/dL
* Patients with mechanical valve
* Cardiogenic shock",human recombinant erythropoietin,INTERVENTIONAL,COMPLETED
NCT04421274,Bone Marrow Mesenchymal Stem Cells Transfer in Patients With ST-segment Elevation Myocardial Infarction,Myocardial Infarction,"* Age\> 18 years old;
* Diagnosed acute ST-elevation myocardial infarction (STEMI)
* STEMI onset \<1 month
* Successful vascular remodeling, blood flow of infarct-related blood vessels recovered to TIMI level 3
* All patients included in the study signed an informed consent form and promised to complete all follow-up plans","* Refractory persistent ventricular tachycardia
* High cardiac block and no pacemaker control
* Liver or renal dysfunction (ALT\>80U/ L, Cr\> 440mmol / L)
* Bleeding disorders, malignant tumors
* Autoimmune disease or any serious fatal disease
* Contraindications for coronary intervention
* Combined with other heart disease: congenital heart Disease (ventricular deficiency, atrial deficient, patent ductus arteriosus and other congenital alformations),primary valvular disease, active myocarditis, pulmonary heart disease,hyperthyroidism, mucous edema heart disease and so on
* Mental illness, no self-awareness, and no precise expression and cooperation","Bone marrow mesenchymal stem cells transfer, Best medical treatment, Percutaneous coronary intervention",INTERVENTIONAL,COMPLETED
NCT01446965,Vest Prevention of Early Sudden Death Trial and VEST Registry,"Myocardial Infarction, Ventricular Dysfunction, Sudden Death, Ventricular Tachycardia, Ventricular Fibrillation","* Patients identified in the hospital or within 7 days after discharge with a diagnosis of an acute MI (STEMI or Non-STEMI)
* LV ejection fraction ≤35% determined at the following time point:

  1. If no PCI within the first 8 hours following the MI: ≥ 8 hours after MI
  2. If acute PCI occurs within 8 hours of MI: ≥8 hours after PCI
  3. If CABG is planned (before or within 7 days of discharge), wait to enroll and then use the most recent assessment at least 48 hours post CABG
* Age ≥ 18 years","* Existing ICD or indication for an ICD at the time of screening
* Existing unipolar pacemakers/leads
* Chronic renal failure requiring hemodialysis after hospital discharge
* Chest circumference too small or too large for LifeVest garment\*
* Participants discharged to an institutional setting with an anticipated stay \> 7 days
* Pregnancy
* Inability to consent
* Any other condition or circumstance that in the judgment of the clinician makes the participant unsuitable for the study.",wearable defibrillator,INTERVENTIONAL,COMPLETED
NCT00856765,Drug-eluting Balloon in Acute Myocardial Infarction,"Coronary Artery Disease, Atherosclerosis, Thrombosis, Acute Myocardial Infarction","* STEMI within 12 hours of onset of complaints
* Candidate for primary PCI with stent-implantation
* Successful thrombus aspiration defined by no angiographic signs of thrombus a the site of plaque rupture and TIMI flow more or equal 1","* Unable to give written informed consent
* Diabetes and Type C- coronary lesion
* Previous PCI or CABG of infarct related vessel
* Left main stenosis more than 50%.
* Triple vessel disease with stenosis more than 50% in 3 epicardial coronary arteries
* Target vessel reference diameter less than 2.5 and more than 4.0 mm
* Target lesion length more than 25 mm
* Intolerance for aspirin or clopidogrel
* Life expectancy less than 12 months
* Women with child bearing potential","Drug eluting balloon, Bare metal stent, Drug eluting stent",INTERVENTIONAL,COMPLETED
NCT00288665,Thrombectomy and Improvement of Left Ventricular Function in AMI,"Acute Myocardial Infarction, Ventricular Remodeling",Inclusion Criteria:- AMI developed \< 12-hr - Reference lumen diameter (RLD) of infarct related artery (IRA) \> 3.0 mm,:- electrical instability- patient is in Killip class 3 or 4 of heart failure- implanted electronic devices are present- all implants held by magnets/fragments/devices,Export catheter (Medtronic),INTERVENTIONAL,COMPLETED
NCT02131220,Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction,"Myocardial Infarction, Percutaneous Coronary Intervention, Thrombolytic Therapy",* ST-segment elevation AMI within 12 hours of symptom onset,"* Contraindications to thrombolysis or PCI
* Patients administered a fibrinolytic agent before PCI
* Patients enrolled in clinical trials","Prourokinase, Tirofiban, normal saline",INTERVENTIONAL,COMPLETED
NCT01093820,Hemoglobin Kinetics in Response to Mircera® in Patients With Acute Myocardial Infarction,Acute Myocardial Infarction,"* Patients (age 18 - 80 years) with acute STEMI undergoing PCI

Main","* Hemoglobin levels \>15g/dL
* history of a myeloproliferative syndrome
* thrombolysis for index infarction
* anticipated additional revascularization within 3 months
* cardiogenic shock",methoxy-polyethyleneglycol epoetin beta,INTERVENTIONAL,COMPLETED
NCT00191282,Hyperglycemia and Cardiovascular Outcomes With Type 2 Diabetes,"Diabetes Mellitus, Type 2, Acute Myocardial Infarction","* Are at least 30 years old
* Have had type 2 diabetes for at least 3 months prior to Visit 1
* Were admitted to the Coronary Care Unit (CCU) within 18 days prior to Visit 1 for an acute MI
* Are capable and willing to do specified study procedures
* Have given informed consent to participate in the study in accordance with local regulations","* Were on one of the following therapies prior to admission to the CCU for the recent MI: a)diet therapy only and have glycosylated hemoglobin (HbA1c) \<1.15 times the upper limit of normal or b) an intensive basal/bolus insulin regimen
* Are using any oral antihyperglycemic medication at the time of Visit 2 and are unwilling to stop the use of such medication for the duration of the study
* Have substantial myocardial damage, which would significantly outweigh the potential benefit of the treatment strategies for diabetes
* Have the most severe form of congestive heart failure
* Have liver disease so severe that it precludes the patient from following and completing the protocol","Insulin lispro, Human insulin isophane suspension (NPH), Insulin glargine, Human insulin isophane suspension, Human insulin 30/70",INTERVENTIONAL,COMPLETED
NCT03498066,Beta Blocker Interruption After Uncomplicated Myocardial Infarction,Myocardial Infarction,"Inclusion criteria

Subjects meeting all of the following criteria will be considered for enrolment into the study:

1. Male or female +/=18 years of age
2. Current treatment with βB whatever the drug or the dose used
3. Prior acute myocardial infarction 6 months or more before randomisation defined either by:

   AβYSS protocol, version 3.0 of 25/05/2021 Page 32 / 65
   * An episode of ST elevation MI with ST segment elevation (STEMI) and/or the presence of Q wave (Type I MI)
   * an episode of Non ST Elevation MI (NSTEMI) with preferably at least one of the followings:

     * i) a documented hypokinetic or akinetic segment on echo or any other imaging technique
     * ii) segmental hypoperfusion Thallium or any other imaging technique
     * iii) segmental aspect of necrosis on MRI
   * An episode of silent MI discovered on ECG or Cardiac Imaging. Importantly = The mention of an MI on a report is enough to be considered as a prior MI and it is not necessary to retrieve the source document and/or documentation of this prior MI .
4. Patient affiliated to Social Security
5. Informed consent obtained in writing at enrolment into the study","* Subjects presenting with any of the following will not be included in the study:

  1. Uncontrolled arterial hypertension according to investigator decision
  2. Prior episode of heart failure in the past two years of follow-up and/or low left ventricular ejection fraction \<40% requiring the use of βB;
  3. New ACS (in the past 6 months) including UA/NSTEMI and STEMI;
  4. Persistent angina or ischemia (\>10% viable myocardium) requiring the use of βB;
  5. Prior episode of ventricular or supraventricular arrhythmia in the past year of follow-up requiring the use of ΒB;
  6. Treatment with other investigational agents or devices within the previous 30 days, or previous enrolment in this trial.
  7. Pregnant Women or breast feeding women
  8. Patient under legal protection (protection of the court, or in curatorship or guardianship).","Beta-blockers withdrawal, Continuation of the Betablockers (βB) treatment",INTERVENTIONAL,COMPLETED
NCT03387826,Low Dose Ticagrelor Versus Low Dose Prasugrel in Patients With Prior Myocardial Infarction,"Myocardial Infarction, Diabetes Mellitus, Coronary Artery Disease, Renal Disease","1. Provision of informed consent prior to any study specific procedures
2. Post-menopausal female (defined as absence of any vaginal bleeding for a year) or male aged \>50 years
3. A spontaneous MI (ST or Non ST segment elevation) 1 to 3 years before enrolment. In addition, at least one of the following high-risk features: age of 65 years or older, diabetes mellitus requiring medication, a second prior spontaneous MI, multivessel coronary artery disease, or non-end stage renal disease (estimated creatinine clearance of \<60 ml per minute).","1. Planned use of a P2Y12 receptor antagonist, dipyridamole, cilostazol, or anticoagulant therapy during the study period;
2. Known allergy, intolerance, hypersensitivity to ticagrelor or prasugrel or any excipients,
3. Active pathological bleeding, severe hepatic impairment, a bleeding disorder or a history of an ischemic stroke or intracranial bleeding, a central nervous system tumor, or an intracranial vascular abnormality;
4. Gastrointestinal bleeding within the previous 6 months or major surgery within the previous 30 days;
5. Concomitant use of potent Cytochrome P450 3A4 (CYP3A4) inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole, grapefruit juice over 1 litre daily), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine).
6. Increased risk of bradycardic events (e.g. known sick sinus syndrome or third degree AV block or previous documented syncope suspected to be due to bradycardia unless treated with a pacemaker).
7. Inability to adhere to the follow-up requirements or any other reason or condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated.","Ticagrelor 60 mg, Prasugrel 5mg",INTERVENTIONAL,COMPLETED
NCT04023266,A Pilot Randomized Controlled Trial of Intravenous N-acetyl Cysteine in STEMI,STEMI,"Patients presenting with STEMI within 3 hours of symptom onset and satisfying all of the following criteria:

1. Patient age ≥ 18 years
2. Have received thrombolysis, with intend to pursue a pharmaco-invasive reperfusion strategy. Onset of chest pain to reperfusion time of \< 3hrs.
3. STEMI involving anterior and/or inferior wall
4. An absence of baseline Q-waves on the initial ECG: The presence of Q waves defined at baseline using the Selvester QRS screening criteria
5. Have a high-risk STEMI ECG defined as:

   * ≥2mm ST-segment elevation in 2 anterior or lateral leads; or
   * ≥2 mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥4 mm","1. Previous myocardial infarction
2. Known to have moderate to severe LV systolic dysfunction (LV EF\< 45%)
3. Known allergy to thrombolytic therapy or NAC
4. Presence of left bundle branch block
5. Cardiogenic shock (defined as systolic blood pressure of \< 90mm Hg, for at least 30 minutes, not responsive to fluid resuscitation)
6. Permanent pacemaker or cardioverter defibrillator implanted previously
7. Patients with contra-indications to thrombolytic therapy
8. Patients with loss of consciousness or confusion
9. Patients with known chronic kidney disease (GFR \< 30ml/min/m2) or on dialysis
10. Current pregnancy
11. Planned therapy with primary PCI",Intravenous N-Acetylcysteine,INTERVENTIONAL,COMPLETED
NCT00648089,EPOMI Study: ErythroPOietin in Myocardial Infarction,Myocardial Infarction,"* ST-Segment elevation myocardial infarction \<6h
* Infarct related artery : proximal circumflex artery , proximal and mid left anterior descending artery, 1st segment of the right coronary artery
* TIMI 0 or 1 before angioplasty
* Successful PCI defined by residual stenosis \< 50% and TIMI 2 or 3 flow grade
* Body weight : \[50-110\] kg
* Informed, written consent","* Age \< 18
* Pregnant, or parturient or breast-feeding women;
* Sexually active women without efficient contraception;
* Inability to fully cooperate with the study protocol
* Pre-treatment with fibrinolysis ;
* Previous Q-wave myocardial infarction or previous aorto-coronary bypass;
* History of deep vein thrombosis or pulmonary embolism;
* Contraindication to aspirin or clopidogrel ;
* Cardiogenic shock ;
* Cardiac resuscitated before angioplasty ;
* Past or active erythropoietin therapy;
* Contraindications to erythropoietin therapy: uncontrolled hypertension, known hypersensitivity to benzoic acid, chronic liver insufficiency, hemoglobin\> 16g / l, thrombocytosis, refractory anemia with excess of blasts;
* Renal insufficiency (creatinine clearance \<30ml/mn.);
* Active Malignancies
* Any contraindications to magnetic resonance imaging: pacemaker and automatic cardiac defibrillator, hearing aid, neurostimulator, infusion pump etc metallic splinters in the eye, ferromagnetic haemostatic clips in the central nervous system cochlear implants, claustrophobia;
* Allergy to gadolinium ;
* Patient refusal / patient not having provided written informed consent.",EPO,INTERVENTIONAL,COMPLETED
NCT02098629,Concomitant Milrinone and Esmolol Treatment in Patients with Acute Myocardial Infarction,Myocardial Reperfusion Injury,"* Men and women, 18 years of age or older, who present within 12 hours after the onset of chest pain, who has ST-segment elevation of more than 0.1 mV in two contiguous leads, and for whom the clinical decision is made to treat with PCI will be eligible for enrollment.","* Patients with cardiac arrest, ventricular fibrillation, cardiogenic shock, previous acute myocardial infarction will not included in the study. Patients with occlusion of the left main will be excluded. Patients with baseline heart rate \<50 beats/min and systolic BP\<90 mmHg and pregnant patients will excluded. Finally, patients who have any disorder that is associated with immunologic dysfunction (e.g., cancer, lymphoma, a positive serologic test for the human immunodeficiency virus, or hepatitis) more recently than 6 months before presentation will be excluded.","Milrinone, Esmolol, Saline Infusion",INTERVENTIONAL,COMPLETED
NCT05705089,Rivaroxaban vErsus Warfarin for Antithrombotic TheRapy in Patients With LeFt Ventricular Thrombus After Acute STEMI,"Left Ventricular Thrombus, ST Segment Elevation Myocardial Infarction","Inclusion criteria

1. Adult patients aged 18-80 years
2. Admission with acute STEMI in past 2 weeks
3. Acute LVT confirmed by non-contrast TTE
4. Willingness to participate and to provide a signed informed consent form","1. History of the mechanical prosthetic heart valve, rheumatic heart disease, and confirmed case of antiphospholipid syndrome
2. Active bleeding
3. Cardiogenic shock defined as persistent hypotension (systolic blood pressure \<90 mm Hg, or requirement of vasopressor to maintain systolic pressure \>90 mm Hg) and clinical signs of hypoperfusion (cold, sweated extremities, oliguria, mental confusion, dizziness, narrow pulse pressure)
4. Acute kidney injury or chronic kidney disease with a glomerular filtration rate \<30 ml/min (calculated based on the Cockcroft-Gault formula)
5. Liver failure (Child-Pugh class C)
6. Other indications for chronic anticoagulation (e.g., AF, VTE, etc.)
7. Sensitivity or intolerance to rivaroxaban/warfarin","Rivaroxaban 15 MG, Warfarin",INTERVENTIONAL,COMPLETED
NCT03400267,The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor,"STEMI, STEMI - ST Elevation Myocardial Infarction","i. age ≥18 years

ii. referred by ambulance paramedics to Isala (Zwolle) or Zuyderland Hospital (Heerlen)

iii. diagnosed in the ambulance with STEMI defined as:

1. ongoing chest pain \>30 minutes and \<12 hours duration and
2. ST-segment elevation \>0.1 milliVolt in at least 2 contiguous leads

iv. ongoing chest pain with a pain score (NRS) ≥4

v. the patient has been informed of the nature of the study, agrees to its provisions and has provided verbal informed consent in the pre-hospital phase followed by written informed consent in hospital","i. presenting with cardiogenic shock; defined as:

1. systolic blood pressure \<90 mmHg and
2. heart rate \>100/min and
3. peripheral oxygen saturation \<90% (without oxygen administration)

ii. patients with a nasogastric tube in situ or requiring a nasogastric tube

iii. patients who already received fentanyl or paracetamol \<2 hours prior to randomization

iv. patients on current treatment with P2Y12 inhibitors (ticagrelor, clopidogrel or prasugrel)

v. allergy to morphine or paracetamol

vi. patients with recent major bleeding complications or contraindication to dual antiplatelet therapy:

1. hypersensitivity to aspirin or ticagrelor
2. current use of (new) oral anticoagulation
3. history of bleeding diathesis or known coagulopathy
4. active bleeding
5. refusal of blood transfusions
6. history of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke
7. known severe liver dysfunction

vii. received any organ transplant or is on a waiting list for any organ transplant

viii. patients undergoing dialysis

ix. pregnant or lactating female

x. patients currently participating in another investigational drug or device study","Paracetamol, Fentanyl",INTERVENTIONAL,COMPLETED
NCT02544594,Clinical Study of Extra-Corporal Life Support in Cardiogenic Shock Complicating Acute Myocardial Infarction,Cardiogenic Shock,"Cardiogenic shock complicating acute myocardial (STEMI or NSTEMI) with

* intended revascularization (PCI or CABG)
* Systolic blood pressure \< 90 mmHg \> 30 min or inotropes required to maintain pressure \> 90 mmHg during systole
* Signs of left heart insufficiency and pulmonary congestion
* Signs of impaired organ perfusion with at least one of the following:

  * Altered mental status
  * Cold, clammy skin
  * Urine output \<30 ml/h
  * Serum lactate \>2mmol/l
* Informed consent","* Resuscitation \> 60 minutes, ischemia \> 10 minutes
* No intrinsic heart action
* Cerebral deficit with fixed dilated pupils
* Mechanical infarction complication
* Onset of shock \> 12 h
* Severe peripheral artery disease
* Aortic regurgitation \> II.°
* Age \> 80 years
* shock of other cause
* Other severe concomitant disease
* participation in another trial",Extra-Corporal Life Support (ECLS),INTERVENTIONAL,COMPLETED
NCT00536562,Cardiac Rehabilitation for TIA Patients,TIA (Transient Ischemic Attack),"* Documented TIA or mild non-disabling stroke within the previous 3 months.
* At least one of the following vascular risk factors: hypertension, ischemic heart disease, diabetes mellitus, dyslipidemia or cigarette smoking","* Inability to speak or understand English or provide informed consent.
* Severe aphasia that renders communication difficult or impossible.
* Modified Rankin Scale score of greater than or equal to 3.
* Mini-Mental Status Examination score of less than or equal to 20.
* Evidence of intracranial hemorrhage confirmed by CT scan or MRI study.
* Anticipated or recent (\<30 days) carotid endarterectomy, angioplasty and/or stenting.
* Resides \>1 hour travel time from London or Ottawa.
* Prior participation in a CCR program.
* Inability to perform expected exercise training of CCR program.
* Evidence of cardioembolic source for TIA/stroke such as atrial fibrillation, valvular disease, septal defect or left ventricular wall motion abnormality.
* Participation in another clinical trial that could interfere with the intervention or outcomes of the current study.",Comprehensive Cardiac Rehabilitation (CR),INTERVENTIONAL,COMPLETED
NCT01043991,"Intracoronary Injection of Epo After Myocardial Infarct ""Intra-CO-EpoMI""",Acute Myocardial Infarct,"* ACS with persistent ST elevation
* First episode
* Symptoms onset \< 12 hours
* Eligible for angioplasty
* Culprit coronary artery occluded (TIMI flow 0-1) at admission, and then adequately reperfused (TIMI flow 2-3) prior to EPO injection","* Cardiogenic shock
* Cardiac arrest
* Currently receiving EPO
* Pregnancy","Darbepoetin alfa, Placebo",INTERVENTIONAL,COMPLETED
NCT02439294,Impact of the Obstructive Sleep Apnea Syndrome (OSAS) on the Ventricular Remodeling After Acute Myocardial Infarction,Recent Acute Myocardial Infarction,"* Provision of informed consent prior to any study specific procedures,
* Adults, men and women aged \< 90 years,
* Hospitalized in Intensive Care Units, MI confirmed by the study of the coronary arteries (coronary angiography) in acute phase (primary coronary angiography) or secondarily (ambulatory IDM IDM initially reperfused by thrombolysis),
* Myocardial infarction defined the criteria normally applied (STEMI: ST segment depression greater than 2 mm in at least 2 contiguous leads or new onset of pain and a left bundle branch block),
* The score of delayed enhancement MRI should be greater than 5 segments of 17 during the first MRI (criterion of severity of AMI),
* The subject must be affiliated to a social security scheme","* Patients for whom CPAP equipment has demonstrated its usefulness regardless of cardiovascular context

  * Patients sleepy (Epworth score\> 13)
  * Road Truckers
* Contraindication to achieve cardiac MRI (primary endpoint):

  * known and crippling claustrophobia,
  * metal clips intracranial, intraocular,
  * presence of an implantable defibrillator
  * presence of a pacemaker
  * history of injury by firearm or shrapnel balance without known projections
  * hypersensitivity to gadolinium products (or history of systemic sclerosis skin) or severe renal impairment with creatinine clearance \<30 ml / min
  * any other known cause of contra-indication.
* Mild infarction (rate of late enhancement MRI in less than or equal to 4 segments of 17 during the first MRI)
* Patient previously treated with CPAP prior MI or already experienced with sleep apnea syndrome.
* SAS whose central part is predominantly (\> 50%)
* General

  * Inability to understand the nature and goals of the study and / or communication difficulties with the investigator
  * No affiliation to a French social security recipient or not such a scheme
  * Major protected by law (guardianship, curators or under judicial protection)
  * deprivation of liberty by judicial or administrative decision
  * Increased likelihood of non compliance to the protocol or abandonment under study
  * History or presence of psychoactive substance abuse
  * pregnancy, become pregnant, or breastfeeding","Without Obstructive Sleep Apnea (syndrome), Mild or moderate Obstructive Sleep Apnea (syndrome), Severe Obstructive Sleep Apnea (syndrome), CPAP",INTERVENTIONAL,COMPLETED
NCT01887080,Effects of Microcurrent in a Cardiovascular Rehabilitation Home-based Program,Acute Myocardial Infarction,"* Individuals admitted to the coronary care unit for acute myocardial infarction for more than one year;
* Individuals of both sexes;
* Ages between 40 and 75 years;
* Heart disease stabilized;
* Motivation to perform physical activity for 8 weeks;
* Cognitive level sufficient to understand the particulars of the study.","* Contraindications of micro-current (pacemaker, osteosynthesis material, tumor areas and open wounds or skin changes in the abdominal region);
* Pregnant at the time, in the preceding 6 months or wishing to become pregnant during the intervention period;
* Neurological, musculoskeletal or respiratory disorders;
* Individuals who are to carry out other therapies.","Exercise, Microcurrent, Cardiovascular Risk Factors",INTERVENTIONAL,COMPLETED
NCT03486080,Study of Dutogliptin in Combination With Filgrastim in Post-Myocardial Infarction,"Acute Myocardial Infarction, Acute Myocardial Ischemia, STEMI - ST Elevation Myocardial Infarction","Inclusion Criteria:

1. 1. Male or female born between 1933 and 2000.
2. Body weight \<96 kg (212 lb).
3. Able to provide written informed consent, including signing and dating the informed consent form (ICF).
4. Diagnosis of STEMI (defined as new ST-segment elevation at the J point of at least 2 continuous leads of \>2 mm \[0.2 mV\] in men or \>1.5 mm \[0.1 mV\] in women in leads V2 and V3 OR \>1 mm in any other contiguous precordial leads or the limb leads \[for both men and women\]) with PCI (bare metal or drug-eluting stent) and Thrombolysis in Myocardial Infarction flow grade 2 or 3 occurring \>2 hours and \<24 hours after symptom onset.
5. LVEF ≤45% obtained by cECHO performed within 36 hours post-stent placement.
6. Receiving standard medical therapy for post-MI treatment, according to local procedures and Principal Investigator discretion
7. Female subjects of childbearing potential must have a negative serum pregnancy test at Screening and an additional negative urine pregnancy test prior to the first dose of IMP unless regulated differently by national legislation.
8. Sexually active female subjects of childbearing potential (i.e., women who are not postmenopausal or who have not had a bilateral oophorectomy, hysterectomy, or tubal ligation) and all male subjects (who have not been surgically sterilized by vasectomy) must agree to use effective contraception during the study.","1. Previous MI prior to Screening.
2. Complex peri/post-MI clinical course, including arrhythmias, cardiogenic shock, pulmonary edema requiring mechanical ventilation, or requirement for vasopressor medications.
3. Significant pre-existing cardiomyopathy with known LVEF ≤45% or moderate to severe mitral or aortic valvular disease.
4. Amyloidosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis.
5. Existing heart transplant.
6. Ventricular tachycardia or fibrillation not associated with an acute ischemic episode.
7. Uncontrolled hypertension (systolic \>180 mmHg or diastolic \>120 mmHg).
8. Treatment with any DPP4 inhibitors (e.g., alogliptin, linagliptin, vildagliptin, saxagliptin, sitagliptin) or G-CSF medication (e.g., filgrastim, lenograstim, pegfilgrastim, lipegfilgrastim) within 4 months prior to Randomization.
9. Contraindication to treatment with filgrastim, including known allergy to filgrastim or other G-CSF medication.
10. Anemia defined as hemoglobin \<9 g/dL prior to Randomization.
11. Thrombocytosis (platelets \>500 k/µL).
12. Known positive serology for hepatitis B, hepatitis C, or human immunodeficiency virus (HIV).
13. Alanine aminotransferase (ALT) concentrations \>3 times the upper limit of normal (ULN) or bilirubin \>2 x ULN prior to Randomization, according to local laboratory assessments.
14. History of cirrhosis and Child-Pugh score B or C.
15. Current fever greater than 101.4 °F (38.6 °C) or recent systemic infection within 2 weeks prior to Randomization.
16. Contraindication to cMRI procedure, including prior implantable cardioverter defibrillator placement, known reaction to gadolinium, claustrophobia, non-MRI-compatible, cochlear implant, morbid obesity, or presence of ferromagnetic material including shunts, shrapnel, penile prostheses, or blood vessel coil.
17. Pregnant, planning to become pregnant, or nursing female subjects.
18. Autoimmune disease requiring immunosuppressive therapy or chronic steroid treatment \>5 mg/day prednisolone or equivalent.
19. Significant renal impairment defined as estimated glomerular filtration rate \<45 mL/min/1.73 m2, using the Chronic Kidney Disease Epidemiology Collaboration equation.
20. Active neoplasm requiring surgery, chemotherapy, or radiation within the prior 12 months (subjects with a history of malignancy who have undergone curative resection or otherwise not requiring treatment for at least 12 months prior to Screening with no detectable recurrence are allowed).
21. Malignant hematological disease, i.e., chronic myeloid leukemia or myelodysplastic syndrome.
22. History of cerebrovascular accident or transient ischemic attack in the past 6 months.
23. History of pneumonia in the last 4 weeks.
24. History of any significant medical or psychiatric disorder that in the opinion of the investigator would make the subject unsuitable for participation in the study.
25. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) or treatment with an investigational biologic drug within 6 weeks prior to randomization.
26. Participation in another concurrent clinical trial involving a therapeutic intervention (participation in observational studies and/or registry studies is permitted).
27. Unable or unwilling to comply with the requirements of the study.
28. Subject and/or an immediate family member is an employee of the investigational site directly affiliated with this study, the sponsor or the contract research organization.
29. Considered by the investigator to be unsuitable to participate in the study for any other reason.
30. Persons who are in an institution as a result of an administrative or judicial order, or soldiers.
31. History of alcohol or drug abuse.","Dutogliptin Tartrate, Filgrastim Injectable Product, Placebos",INTERVENTIONAL,COMPLETED
NCT05987462,The Effect of Green Walking on Myocardial Infarction Patients,"Myocardial Infarction, Quality of Life","* Inclusion criteria were being 18 years of age or older,
* being able to communicate verbally,
* being literate,
* having had MI at least three months ago,
* being followed up as an outpatient with the diagnosis of MI in the cardiology outpatient clinic of X state hospital and Y state hospital,
* achieving the six-minute walk test (6MWT),
* having no obstacle to walking (musculoskeletal problems, joint problems, fracture, neuropathy, chronic severe pain, limb loss)
* volunteering to participate in the study.","* having blood pressure above 140/90 mmHg or below 90/60 mmHg,
* having active chest pain, dyspnea, bradycardia, or tachycardia, a psychiatric diagnosis, visual, hearing,
* cognitive impairment,
* a balance problem,
* using a walker while walking,
* having Parkinson's disease, dementia, or cancer,
* having undergone any surgery that would prevent walking,
* refusing to participate in the study.",Green walking,INTERVENTIONAL,COMPLETED
NCT02108262,A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.,Acute Myocardial Infarction,"* Men or women, at least 18 years of age, with evidence of myocardial necrosis in a clinical setting consistent with a type I (spontaneous) acute myocardial infarction (AMI), in the last week.","* Ongoing hemodynamic instability
* Evidence of hepatobiliary disease
* Evidence of chronic kidney disease (CKD) (Stage III, IV, or V), defined as moderate or severe renal impairment or if subject is receiving dialysis
* Evidence of unstable renal function
* History of acute kidney injury after previous exposure to an intravenous contrast agent.
* Known history of allergies, hypersensitivity or deficiencies to CSL112 or any of its components
* Other severe comorbid condition, concurrent medication, or other issue that renders the subject unsuitable for participation in the study","CSL112, Placebo",INTERVENTIONAL,COMPLETED
NCT00148460,"Trial to Compare the Efficacy and Safety of a Single Bolus of TNK-tPA (Tenecteplase, Metalyse®) With Accelerated Infusion of Rt-PA (Alteplase, Actilyse®) in Asian Patients With Acute Myocardial Infarction",Myocardial Infarction,"1. Age \>= 18 and \<= 75 years.
2. Asian origin.
3. Ischemic discomfort \>= 30 minutes in duration.
4. Onset of acute myocardial infarction (AMI) symptoms within 6 hours prior to randomization.
5. A twelve lead electrocardiogram (ECG) with one of the following:

   * ST segment elevation \>= 0.1 mV in two or more limb leads; or
   * \>= 0.2 mV in two or more contiguous precordial leads indicative of AMI.
6. Ability to give informed consent.","1. Previous coronary artery bypass grafting (CABG) surgery.
2. Cardiogenic shock (e.g. systolic blood pressure \[SBP\] \< 90 mmHg).
3. Systolic blood pressure (SBP) \>= 180 mmHg and/or diastolic blood pressure (DBP) \>= 110 mmHg during current admission on one reliable measurement prior to randomization.
4. Inability to undergo cardiac catheterization.
5. Significant bleeding disorder either at present or within the past 6 months.
6. Major surgery, biopsy of a parenchymal organ, or significant trauma within 3 months.
7. Any minor head trauma and/or any other trauma that occurred after onset of current myocardial infarction.
8. Use of heparin, GPIIb/IIIa antagonists or other anticoagulants within the last 2 weeks.
9. Any known history of stroke or transient ischemic attack or central nervous system structural damage (i.e. neoplasm, aneurysm, intracranial surgery).
10. Prolonged cardiopulmonary resuscitation (\> 10 minutes) within 2 weeks.
11. Pregnancy, lactation or parturition within the previous 30 days. Women of childbearing potential must have had a negative pregnancy test and must have used a medically accepted method of birth control (i.e. uterine device, surgical sterilisation, progestogens alone).
12. Previous treatment with TNK-tPA (tenecteplase).
13. Inability to follow protocol and comply with follow-up.
14. Drug abuse within the last year.
15. Participation in another clinical trial within the previous 30 days.","TNK-tPA, rt-PA",INTERVENTIONAL,COMPLETED
NCT01379248,Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset,Myocardial Infarction,"* ST-elevation myocardial infarction \>12 and \<48 hours after symptom onset
* age 18 to 90 years
* informed consent","* prior fibrinolysis
* severe comorbidities with limited life expectancy
* pregnancy
* patient unable to give informed consent
* participation in another trial
* contraindications for heparin, aspirin or thienopyridines
* contraindications for cardiac magnetic resonance examination","manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)",INTERVENTIONAL,COMPLETED
NCT02666326,Accelerated Rule Out of Myocardial Infarction,Myocardial Infarction,"* Patients which, after telemedical triage, are admitted to a cardiac department in suspicions of myocardial infarction
* A peripheral venous catheter has been inserted prehospitally and blood has drawn from it, before flushing it.","* Age below 18 years
* Patients in which an informed concent can not be obtained (psychiatric disease, dementia, under influence of drugs etc.),
* Suspected STEMI and referral to Primary percutaneous coronary intervention (PPCI), referral to a highly specialized cardiac department for another cardiac reason (e.g ventricular tachycardia, ventricular fibrillation, 3° Atrio-ventricular block.)
* Known central Diabetes insipidus
* Other diagnosis as obvious reason for symptoms at time of admittance (e.g. a new diagnosis of supraventricular tachycardia, pulmonary embolism, aortic dissection) AND no suspicions of ACS","Accelerated, combined biomarker rule-out strategy for MI",INTERVENTIONAL,COMPLETED
NCT02239757,Left vs Right Radial Approach in the Setting of Primary Percutaneous Coronary Intervention for ST-elevation Myocardial Infarction,"Transradial Approach, Primary PCI, ST-segment Elevation Myocardial Infarction",All consecutive patients with ST-segment elevation myocardial infarction within 12 hours of symptom onset for primary PCI.,Patients are excluded if they were in cardiogenic shock.,"Left radial approach, Right radial approach",INTERVENTIONAL,COMPLETED
NCT02958657,Effect of Exercise on Platelet Reactivity After Myocardial Infarction,"Platelet Aggregation, Acute Myocardial Infarction, Exercise Training",* Hospitalization for spontaneous STEMI or non-STEMI in patients older than 18 years.,"* Any condition that contraindicate physical activity;
* Regular exercise training practitioners prior to the ischemic event;
* Planned revascularization in the following 4 months;
* Hospitalization for cardiovascular events in the previous 12 months;
* Ventricular dysfunction, defined as left ventricular ejection fraction (LVEF) \<45% on echocardiography, evaluated by Simpson's method);f) Killip class III and IV;
* High risk of arrhythmia and/or second and third degree atrioventricular block;
* Diabetes mellitus requiring intravenous insulin therapy during hospitalization;
* Important chronic kidney disease, defined by creatinine clearance\<30ml/min/m2 (estimated by MDRD formula);
* Oral anticoagulation;
* Use of NSAIDs and/or dipyridamole;
* Contraindication to dual antiplatelet therapy;
* Serum hemoglobin level \<10 g/dL;
* Use of glycoprotein IIB/IIIA inhibitors in the last 48 hours;
* Terminal illness;
* Liver disease or coagulopathy;
* Refusal to engage in an exercise training program.",Exercise Training,INTERVENTIONAL,COMPLETED
NCT00154466,Study on the Efficacy and Mechanism of Cardiac Rehabilitation for Stem Cell Mobilization and Heart Failure Improvement,Myocardial Infarction,"myocardial infarction with CK more than 3000, status post revascularization therapy, clinical stable with regular follow-up at OPD, NYHA II-III -","sustained ventricular arrhythmia, hypertrophy cardiomyopathy, intolerance to exercise program

-",cardiac rehabilitation,INTERVENTIONAL,COMPLETED
NCT01336348,Facilitation Through Aggrastat By drOpping or Shortening Infusion Line in Patients With ST-segment Elevation Myocardial Infarction Compared to or on Top of PRasugrel Loading dOse,ST Segment Elevation Myocardial Infarction,"* Chest pain for \>30 min with an electrocardiographic ST-segment elevation more than 1 mm in two or more contiguous electrocardiogram (ECG) leads, or with a new left bundle-branch block, and admission either within 12 h of symptom onset or between 12 and 24 h after onset with evidence of continuing ischemia","* Administration of fibrinolytic or any GP IIbIIIa inhibitors for the treatment of current AMI or within 1 month before history of bleeding diathesis
* Known sensitivity to abciximab, to any component of the product or to murine monoclonal antibodies
* Major surgery or trauma within 30 days
* Active bleeding
* Previous stroke in the last six months
* Oral anticoagulant therapy
* Pre-existing thrombocytopenia
* Vasculitis
* Hypertensive retinopathy
* Severe hepatic failure
* Severe renal failure requiring haemodialysis
* Documented allergy/intolerance or contraindication to clopidogrel or inability to assume clopidogrel on a consecutive daily basis for a minimum of 30 days, or to heparin or aspirin
* Uncontrolled hypertension (systolic or diastolic arterial pressure \>180 mmHg or 120, respectively, despite medical therapy)
* Limited life expectancy, e.g. neoplasms, others
* Inability to obtain informed consent","Prasugrel, Tirofiban",INTERVENTIONAL,COMPLETED
NCT01050348,To Investigate the Role of Upstream High Dose Statin in STEMI,Acute Myocardial Infarction,"1. Any patient of 25 to 90 years of age admitted or transferred to Western Pennsylvania Hospital or Allegheny General Hospital with a diagnosis of STEMI undergoing emergent percutaneous intervention (PCI) to the culprit coronary artery. STEMI is defined as greater than 1mm ST segment elevation on electrocardiogram.
2. Elevated cardiac biomarkers (troponin-T \> 0.03ng/ml, CKMB\>5ng/mL, or ck\>170 U/l).","1. Known history of liver disease defined as cirrhosis, alcoholic liver disease, Non alcoholic steatohepatitis, hepatitis or any causes of liver failure.
2. Renal failure with creatinine \>3mg/dL
3. Known history of liver or muscle disease such as rheumatologic myopathies, history of myositis, hepatitis, and hepatic cancer.
4. Cardiovascular arrest and shock.","Atorvastatin calcium, Inactive Placebo",INTERVENTIONAL,COMPLETED
NCT00469248,Aortic Balloon Counterpulastion in Myocardial Infarction Related Shock,"Myocardial Infarction, Cardiogenic Shock","* Acute myocardial infarction
* Cardiogenic shock","* Absent peripheral pulses
* Mechanical complications of myocardial infarction",Intra-aortic balloon pump counterpulsation,INTERVENTIONAL,COMPLETED
NCT02406248,Brilinta Taiwan Post Approval Safety Study,Non ST-elevation Myocardial Infarction,"1. Provision of informed consent prior to any study specific procedures
2. Female or male aged at least 20 years
3. Patient who is considered as ethnic Taiwanese
4. Index event of non-ST elevation myocardial infarction","1. Contraindication or other reason that ticagrelor should not be administered
2. Index event is an acute complication of Percutaneous coronary intervention (PCI)
3. Patient has planned for an urgent coronary artery bypass graft (CABG) within 7 days from the enrolment
4. Oral anticoagulation therapy within 30 days prior to enrolment or cannot be stopped
5. Fibrinolytic therapy in the 24 hours prior to enrolment, or planned fibrinolytic treatment following enrolment","Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)",INTERVENTIONAL,COMPLETED
NCT03234348,MAGnesium-based Bioresorbable Scaffold in ST Segment Elevation Myocardial Infarction,"Acute Coronary Syndrome, ST Segment Elevation Myocardial Infarction, Stent","Clinical:

1. At least 18 years of age.
2. ST-segment elevation Myocardial Infarction documented in an ambulance or in a Cathlab, with ≥2 mm ST segment elevation in at least two contiguous leads, presenting in the Cathlab \<12 hours after the onset of symptoms lasting ≥20 min requiring primary PCI.
3. Target lesion must be a de-novo lesion located in a native vessel.
4. The patient accepts Informed Consent
5. The patient understands and accepts clinical follow-up and angiographic control.

   Angiographic:
6. Vessel size should match available M-BRS scaffold sizes (≥2.75 mm, and ≤3.7 mm by visual assessment).
7. Lesion preparation by either manual thrombectomy or pre-dilatation has been successful, with opening of the vessel and TIMI ≥2 and residual stenosis \<20%.","1. Pregnancy.
2. Known intolerance to aspirin, heparin, stainless steel, sirolimus, and contrast material.
3. Distal vessel occlusion after recanalization
4. STEMI due to stent/scaffold thrombosis
5. Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in sub-optimal m-BRS placement.
6. Fibrinolysis prior to PCI
7. Known thrombocytopenia (PLT\< 100,000/mm3)
8. Active bleeding or coagulopathy or patients at chronic anticoagulation therapy
9. Cardiogenic Shock
10. Significant comorbidities precluding clinical/angiographic FU (as judged by investigators)
11. Major planned surgery that requires discontinuation of dual antiplatelet therapy.
12. Diffuse coronary artery disease that will require CABG
13. Chronic kidney disease with GFR\<30 ml/min",Percutaneous coronary intervention,INTERVENTIONAL,COMPLETED
NCT03048825,Colchicine and Spironolactone in Patients with MI / SYNERGY Stent Registry,"ST Elevation Myocardial Infarction, Non ST Elevation Myocardial Infarction","1. a) Patients with STEMI referred for PCI within 12 hours of symptom onset, have a culprit lesion amenable to stenting, and with planned SYNERGY stent implantation for SYNERGY registry

   OR

   b) Patients with STEMI referred for PCI within 48 hours of symptom onset, not prospectively enrolled in SYNERGY stent registry

   OR

   c) Patients with diagnosis of Non STEMI with ischemic symptoms and either Hs Troponin \> or = 300x ULN or Troponin \> or = 200x ULN who have undergone PCI with one of the following:

   i. LVEF\< or =45% ii. Diabetes iii. Multivessel CAD defined as 50% stenosis in 2nd major epicardial vessel iv. Prior MI v. Age \>60 years
2. Able to be enrolled/randomized within 72 hours of index PCI (however patients should be randomized as soon as possible after PCI)
3. Written informed consent","1. Age ≤18 years
2. Pregnancy, breastfeeding, or women of childbearing potential who are not using an effective method of contraception
3. Any medical, geographic, or social factor making study participation impractical or precluding required follow-up
4. Systolic blood pressure \<90 mm Hg
5. Active diarrhea
6. Known allergy or contraindication to everolimus, the SYNERGY stent or any of its components
7. Unable to receive dual antiplatelet therapy
8. Any contraindication or known intolerance to colchicine or spironolactone
9. Requirement for colchicine or mineralocorticoid antagonist for another indication
10. History of cirrhosis or current severe hepatic disease
11. Current or planned use of any of: cyclosporine, verapamil, HIV protease inhibitors, azole antifungals, or macrolide antibiotics
12. Creatinine clearance \<30 mL/min/1.73 m2
13. Serum Potassium \>5.0 meq/L","Colchicine, Spironolactone, SYNERGY Bioabsorbable Polymer Drug-Eluting Stent, Colchicine-Placebo, Spironolactone-Placebo",INTERVENTIONAL,COMPLETED
NCT03611725,Comparison of Success Rate Between Distal Radial Approach and Radial Approach in STEMI,"Distal Radial Artery Approach, ST Elevation Myocardial Infarction","* Age ≥ 20 years
* ST-segment elevation myocardial infarction
* Palpable unilateral distal radial and radial artery","* Cardiogenic shock
* Thrombolysis before primary percutaneous coronary intervention
* Inability to obtain written informed consent
* Patient with ipsilateral arteriovenous fistula
* Participation in another ongoing clinical trial
* Pregnancy
* Expected lifespan \<12 months

  \* Eligible operator criteria
* Qualified operator who had experienced ≥ 100 cases of distal radial artery puncture","Distal radial artery, Radial artery",INTERVENTIONAL,COMPLETED
NCT01109225,Relation Between Aldosterone and Cardiac Remodeling After Myocardial Infarction,Myocardial Infarction,"* Man or woman hospitalized for a first myocardial infarction with known shift of the segment ST revascularized in acute phase by primary angioplasty and dated less than 4 days
* Patient presenting a stable clinical state
* Patient presenting a regular sinusal cardiac rhythm
* Patient having an age ≥ 18 years","* Counter-indication with examination MRI
* Severe claustrophobia
* Antecedent of over-sensitiveness to gadolinium salts
* Nonischaemic Cardiopathy
* Cardiac surgery planed in the 6 months
* Women into old to procreate without effective contraception","blood sample, MRI, echocardiography, urine sample, pulmonary echography, vascular check, renal echography",INTERVENTIONAL,COMPLETED
NCT00677222,Safety Study of AMI MultiStem® to Treat Heart Attacks,Acute Myocardial Infarction,"* Patients of either sex 18-85 years of age
* Women of childbearing potential or less than 2 years postmenopausal agree to use of adequate contraception during the study
* Patients with the first time diagnosis of ST elevation myocardial infarction
* Acute myocardial infarction (ST elevation in at least two leads \>0.2 mV in V1, V2 or V3 or \>0.1 mV in other leads), treated by one of the following: either
* Acute PCI with stent implantation
* With thrombolysis within 12 hr of symptom onset followed by PCI with stent implantation within 24 hr after Thrombolysis
* Maximal creatine kinase elevation \>400 U/l with significant membrane-bound fraction (\>6%)or troponin \>2X ULN
* Decreasing levels of CK/CK-MB or troponin following reperfusion
* Successful acute PCI/stent implantation (residual stenosis visually \<30% and TIMI flow \>2). Absence of severe disorder of the microcirculation (e.g. pulsatile flow pattern, systolic flow reversal) at the time of administration of the trial therapy
* Significant regional wall motion abnormality in left ventricular angiogram or transthoracic echocardiogram ≤48 hours post PCI
* LVEF between 30 and 45% by LV gram after the primary PCI or transthoracic echocardiogram ≤48 hours post PCI
* Willing and able to comply with the scheduled visits, treatment, laboratory tests and other study related procedures.
* Signed informed consent","* Prior cardiovascular history
* Mechanical complications of the index acute myocardial infarction including but not limited to rupture of the mitral valve with resultant development of mitral regurgitation, rupture of the left ventricular free wall and rupture of the interventricular septum
* Pregnant or lactating
* Known allergy to contrast agents
* Known allergy or religious objections to bovine or porcine products
* History of malignancy of any type except non-melanoma skin cancer
* Presence of major hematological conditions or laboratory abnormalities (low hemoglobin (\<10 gm/dl), - WBC (\<3,000 cells/mm2) or platelet count (\<100,000 cells/mm3))
* Prothrombin time (PT) \> 1x ULN
* Partial thromboplastin time (PTT) \> 1x ULN
* Presence of chronic systemic inflammatory disorders that requires ongoing therapy
* Previous autologous, allogeneic bone marrow or peripheral stem cell transplant
* Prior solid organ transplantation
* Immune system compromise including but not limited to history of human immunodeficiency virus (HIV), hepatitis B (HBV) and hepatitis C (HCV) infection.
* Prior participation in any other study involving investigational pharmacological agents(s), devices or marketed products within 30 days prior to planned AMI MultiStem® administration
* Life expectancy of six months or less
* Current alcohol or substance abuse
* Ongoing systemic infection
* Renal function: Serum creatinine \>2 mg/dL or creatinine clearance ≤50 mL/min
* Hepatic function: Screening ALT and AST ≥3x upper limit of normal for the laboratory or total bilirubin ≥2.0 mg/dL (exception: acceptable if patient is identified with pre existing condition e.g. Gilbert's disease that will contribute to baseline elevations of bilirubin)
* Other serious medical or psychiatric illness that, in the investigator's opinion, would not permit the patient to be managed according to the protocol.",AMI MultiStem®,INTERVENTIONAL,COMPLETED
NCT00232830,The Study to Assess AMI Treated With Balloon Angioplasty.,Coronary Artery Disease,"1. Have prolonged, continuous (lasting at least 20 minutes) chest pain despite administration of nitrates and onset within 12 hours of randomization, and one of the following:

   1. ST segment elevation \>=1mm in standard leads and \>=2mm in 2 or more contiguous precordial leads with reciprocal ST depression
   2. New or presumably new left bundle branch block (LBBB)
2. The culprit lesion must be identified on a de novo native coronary artery and an emergency angioplasty must be possible. The culprit site must be visualized before the stent implantation;","1. Killip class \> 2 upon arrival to the cath-lab;
2. Significant (\>50%) stenosis proximal or distal to the target lesion that might require revascularization or impede inflow or runoff;
3. Evidence of massive thrombus in the infarct related artery distally to the culprit lesion;
4. Documented left ventricular ejection fraction \<=30%;
5. Target lesion is located in an arterial or venous by-pass graft;
6. ECG documented evidence of prior myocardial infarction;
7. Patient who received thrombolytic therapy for the current AMI before enrollment in this study.","drug-eluting stent, bare-metal stent",INTERVENTIONAL,COMPLETED
NCT04347525,The Effect of Culturally Adapted CBT-based Guided Self Help in Depressed Patients With Myocardial Infarction,"Myocardial Infarction, Depression","* Diagnosis of Myocardial Infarction
* Score 8 or more on HADS
* Fulfilling criteria of Major Depressive Disorder using DSM-V","* Participants with use of alcohol or drugs
* Significant cognitive impairment (intellectual disability or dementia)
* Active psychosis
* Participants who have received CBT during the previous 12 months",CaCBT based guided self help using Khushi aur Khatoon Manual,INTERVENTIONAL,COMPLETED
NCT00729430,Effect of High Dose Fish Oil Supplementation After Recent Heart Attack Using Magnetic Resonance Imaging,"Myocardial Infarction, Death, Sudden, Cardiac","* Experienced a heart attack in the 2 to 4 weeks before study entry
* Lives in the greater Boston area or adjacent regions (within a 50-mile radius of Boston)","* Unable to undergo an MRI because of metallic implants (e.g., pacemakers, an implantable cardioverter defibrillator \[AICD\]) at time of study entry
* Active cancer or any other terminal illness with an expected survival rate of less than 6 months after study entry
* Significant kidney dysfunction with a glomerular filtration rate (GFR) of less than 60 mL/min in the 2 weeks before study entry
* Inability to follow study procedures
* Pregnant
* Hemodynamic instability
* Urgent clinical need for a pacemaker or AICD
* Inaccessibility of medical records","Omega-3 Fatty Acids (Fish Oil Supplements), Placebo",INTERVENTIONAL,COMPLETED
NCT04270630,"A Pilot Proof of Concept, Randomized Controlled, Single-Center Study of a Decision Aid Tool for Older Patients Considering LHC as Treatment for NSTEMI",NSTEMI,"* Must be admitted to the hospital, and there must be clinical suspicion for type I NSTEMI
* Must be eligible for non-urgent revascularization
* Must have capacity to consent for the study based on the judgment of the study investigators
* Must speak English","* Does not meet all of the inclusion criteria listed above
* Has significant vision or hearing impairment that prohibits use of the decision aid
* Unable to read
* Has a clinical diagnosis of dementia and/or severe cognitive impairment documented in the electronic medical record",Shared Decision Aid,INTERVENTIONAL,COMPLETED
NCT00212030,Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by a K-ATP,Acute Myocardial Infarction,"1. Age 20-79 years
2. Chest pain of more than 30 min
3. 0.1 mV ST-segment elevation in 2 contiguous ECG leads
4. Admission to hospital within 12 h of symptom onset
5. First episode of AMI
6. Candidates for PCI","1. History of old myocardial infarction
2. Left main coronary artery stenosis
3. Severe liver and/or kidney dysfunction
4. Suspected aortic dissection
5. History of coronary artery bypass graft
6. History of allergic response to drugs
7. Severe hypovolemia
8. Right ventricular infarction","nicorandil, placebo",INTERVENTIONAL,COMPLETED
NCT03728127,Brazilian Cardioprotective Diet and Nuts in Post-acute Myocardial Infarction,"Coronary Artery Disease, Myocardial Infarction",Patients ≥ 40 years with previous AMI (60 to 180 days).,"* Clinical indication of myocardial revascularization surgery (graf /bypass);
* HIV positive in treatment/AIDS;
* Chronic inflammatory diseases;
* Cancer;
* Chemical dependency/alcoholism;
* Chronic use of anti-inflammatories, anticonvulsants and immunosuppressive drugs;
* Pregnancy or lactation;
* Wheelchair users without conditions of anthropometric evaluation;
* Extreme obesity (BMI ≥40kg / m²);
* Use of dietary supplements;
* Rejection/allergy to oilseed consumption;
* Participation in other randomized studies at the time of enrollment.","Brazilian cardioprotective diet, Brazilian cardioprotective diet plus 30g/day of mixed nuts",INTERVENTIONAL,COMPLETED
NCT01160627,Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction,Contrast Induced Nephropathy,* STEMI patients treated with primary PCI,* Cardiogenic shock,"Hydration, Acetylcysteine, Sodium bicarbonate, Combined Acetylcystein and Sodium Bicarbonate",INTERVENTIONAL,COMPLETED
NCT01000727,The Stabilization Of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial,Acute Coronary Syndrome,"* Signed written informed consent.
* Men or women at least 18 years old (in Taiwan, at least 20 years old). Women must be post-menopausal or using a highly effective method for avoidance of pregnancy.
* Hospitalization for acute coronary syndrome (ACS) within 30 days prior to study entry.
* Clinically stable for 24 hours prior to study entry.
* A planned percutaneous coronary intervention (PCI) should be performed prior to study entry, whenever possible.
* At least one of the following:
* At least 60 years old.
* Myocardial infarction prior to the qualifying ACS event.
* Diabetes mellitus requiring treatment with medication.
* Diagnosed mild or moderate reduction in kidney function.
* Cerebrovascular disease (carotid artery disease or ischemic stroke more than 3 months prior to study entry) OR peripheral artery disease.","* ACS symptoms or lab results not believed to be caused by a narrowing or blocked coronary artery.
* No major coronary artery with a blockage of more than 50% (unless all stenoses are successfully treated by PCI).
* Planned coronary artery bypass graft (CABG) surgery, or CABG surgery performed after the qualifying ACS event and prior to study entry.
* Certain types of liver disease.
* Severe reduction in kidney function OR removal of a kidney OR kidney transplant.
* Severe heart failure.
* Blood pressure higher than normal despite lifestyle changes and treatment with medications.
* Any life-threatening disease with a life expectancy of less than 2 years (other than heart disease) that may prevent the subject from completing the study.
* Severe asthma that is poorly controlled with medication.
* Pregnancy (Note: A pregnancy test will be performed on all non-sterile women prior to study entry).
* Previous severe allergic reaction to food, medications, drink, insect stings, etc.
* Drug or alcohol abuse within the past 6 months. Mental/psychological impairment that may prevent the subject from complying with study procedures or understanding the goal and potential risks of participating in the study.
* Certain medications that may interfere with the study medication (these will be identified by the study doctor).
* If both birth parents are at least 50% Japanese, Chinese, or Korean ancestry, must have a blood sample collected for Lp-PLA2 activity. Those with Lp-PLA2 activity less than or equal to 20.0 nmol/min/mL are excluded.
* Previously took darapladib (SB-480848).
* Participation in a study of an investigational medication within the past 30 days.
* Current participation in a study of an investigational device.
* Any other reason the investigator deems the subject should not participate in the study.","Darapladib 160 mg, Placebo, Standard Therapy",INTERVENTIONAL,COMPLETED
NCT02924727,Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI,Acute Myocardial Infarction,"1. Male or female patients ≥ 18 years of age.
2. Diagnosis of spontaneous AMI based on the universal MI definition\* with randomization to occur between 12 hours and 7 days after index event presentation. (\*patients with spontaneous MI event determined to be secondary to another medical condition such as anemia, hypotension, or arrhythmia OR thought to be caused by coronary vasospasm with document normal coronary arteries are not eligible; patients with clinical presentation thought to be related to Takotsubo cardiomyopathy are also not eligible)
3. Evidence of LV systolic dysfunction and/or pulmonary congestion requiring intravenous treatment associated with the index MI event defined as:

   * LVEF ≤40% after index MI presentation and prior to randomization and/or
   * Pulmonary congestion requiring intravenous treatment with diuretics, vasodilators, vasopressors and/or inotropes, during the index hospitalization
4. At least one of the following 8 risk factors:

   * Age ≥ 70 years
   * eGFR \<60 mL/min/1.73 m\^2 based on MDRD formula at screening visit
   * Type I or II diabetes mellitus
   * Documented history of prior MI
   * Atrial fibrillation as noted by ECG, associated with index MI
   * LVEF \<30% associated with index MI
   * Worst Killip class III or IV associated with index MI requiring intravenous treatment
   * STEMI without reperfusion therapy within the first 24 hours after presentation
5. Hemodynamically stable defined as:

   * SBP ≥ 100 mmHg at randomization for patients who received ACEi/ARB during the last 24 hours prior to randomization
   * SBP ≥ 110 mmHg at randomization for patients who did not receive ACEi/ARB during the last 24 hours prior to randomization
   * No IV treatment with diuretics, vasodilators, vasopressors and/or inotropes during the 24 hours prior to randomization

Key","1. Known history of chronic HF prior to randomization
2. Cardiogenic shock within the last 24 hours prior to randomization
3. Persistent clinical HF at the time of randomization
4. Coronary artery bypass graft (CABG) performed or planned for index MI
5. Clinically significant right ventricular MI as index MI
6. Symptomatic hypotension at screening or randomization
7. Patients with a known history of angioedema
8. Stroke or transient ischemic attack within one month prior to randomization
9. Known or suspected bilateral renal artery stenosis
10. Clinically significant obstructive cardiomyopathy
11. Open-heart surgery performed within one month prior to randomization or planned cardiac surgery w/in the 3 months prior to randomization
12. eGFR \< 30 ml/min/1.73 m\^2 as measured by MDRD at screening
13. Serum potassium \> 5.2 mmol /L (or equivalent plasma potassium value) at randomization
14. Known hepatic impairment (as evidenced by total bilirubin \> 3.0 mg/dL or increased ammonia levels, if performed), or history of cirrhosis with evidence of portal hypertension such as esophageal varices
15. Previous use of LCZ696
16. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin) within the past 3 years with a life expectancy of less than 1year.
17. History of hypersensitivity to the study drugs or drugs of similar chemical classes or known intolerance or contraindications to study drugs or drugs of similar chemical classes including ACE inhibitors, ARB or NEP inhibitors
18. Pregnant or nursing women or women of child-bearing potential unless they are using highly effective methods of contraception","LCZ696 (sacubitril/valsartan), Ramipril, Placebo of LCZ696, Placebo of ramipril, Valsartan, Placebo of valsartan",INTERVENTIONAL,COMPLETED
NCT00324766,Levosimendan in Acute Heart Failure Following Acute Myocardial Infarction.,"Myocardial Infarction, Heart Failure, Cardiogenic Shock","* Acute ST-elevation myocardial infarction subject to acute PCI or non-ST elevation myocardial infarction subject to PCI within 72 hours after start of chest pain and:
* Revascularization by PCI,
* Signs of decreased wall-motion in at least 3 of 16 segments of the left ventricle
* Dyspnoea at rest and one of the following:

pulmonary edema, pulmonary congestion,need for CPAP or ventilator, need for IC diuretics or oliguria.

Subgroup of patients in cardiogenic shock: Systolic BP below 90 after 1 hour of volume therapy.","* Age below 20 years
* Heart rate above 120 bpm
* Septic shock
* ARDS
* Creatinine \>450 micromol/l
* Hepatic impairment
* Significant mechanical outlet obstruction
* Allergy against study drug medication
* Anaemia (Hb \<8 g/dl)
* Pregnancy","levosimendan, placebo,",INTERVENTIONAL,COMPLETED
NCT00769366,"Randomized, Controlled Study on Short-term Psychotherapy After Acute Myocardial Infarction",Acute Myocardial Infarction,"* Patients admitted to San Filippo Neri Hospital for AMI and treated with primary or urgent PCI.
* Primary PTCA is performed up to 12 hours after the beginning of chest pain in cases of STEMI, while patients with NSTEMI are enrolled if urgent PTCA is being performed within 48 hours of the onset of chest pain.
* Only patients in whom complete revascularization is achieved are being enrolled in the study.","* Patients with psychiatric disorders or disability, cognitive impairment, or other life-threatening conditions are being excluded from the study.","Psychotherapy, Medical therapy",INTERVENTIONAL,COMPLETED
NCT00435266,Remote Ischemic Preconditioning in Primary PCI,Myocardial Infarction,"1. Acute chest pain or equivalent symptoms during \> 30 minutes.
2. Duration of symptoms \< 12 hours.
3. Cumulated ST elevation \> 2 mm in two contiguous leads.
4. Age ≥ 18 years.
5. Informed consent","1. Previous by-pass surgery.
2. Pulseless femoral artery.
3. Left bundle branch block in ECG (LBBB).
4. Acute MI and/or treatment with thrombolysis within 30 days.
5. Patients treated with cooling or patients who have had cardiac arrest.
6. Diabetic patients
7. Patients with arteriovenous shunts for the purpose of hemodialysis",Remote ischemic preconditioning,INTERVENTIONAL,COMPLETED
NCT01936896,Alpha-1 Anti-Trypsin (AAT) Treatment in Acute Myocardial Infarction,Acute Myocardial Infarction,"* Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and ECG evidence of ST segment elevation (\>1 mm) in 2 or more anatomically contiguous leads that is new or presumably new
* Planned or completed coronary angiogram for potential intervention
* Age\>21","* Inability to give informed consent
* Hemodynamic instability as defined as need for inotropic or vasoactive agents, or need for mechanical support devices (including intra-aortic balloon pump)
* Pregnancy
* Preexisting congestive heart failure (American Heart Association/American College of Cardiology class C-D, New York Heart Association III-IV)
* Preexisting severe left ventricular dysfunction (EF\<20%)
* Preexisting severe valvular heart disease
* Known active infections (acute or chronic)
* Recent (\<14 days) or active use of anti-inflammatory drugs (not including NSAIDs or corticosteroids used for IV dye allergy only)
* Known chronic inflammatory disease (including but not limited to rheumatoid arthritis, systemic lupus erythematosus)
* Known active malignancy of any type, or prior diagnosis in the past 10 years
* Anticipated need for cardiac or major surgery
* Known active cancer (or prior diagnosis of cancer within the past 10 years)
* Known Immunoglobulin A (IgA) deficiency",Alpha 1-Antitrypsin,INTERVENTIONAL,COMPLETED
NCT03760796,"Myocardial Infarction, COmbined-device, Recovery Enhancement Study","Acute Myocardial Infarction, Coronary Artery Disease, Acute Coronary Syndrome, Myocardial Infarction","Corrie Health Digital Platform group

Inclusion Criteria:

* Admitted for acute myocardial infarction (STEMI or Type 1 NSTEMI)
* 18 years or older
* English-speaking
* Own any type of smartphone",":

* Visual, hearing, or motor impairment which precludes the use of the intervention
* Inability to participate due to severity of illness (e.g., intubated and on sedation in the setting of cardiogenic shock). If patients are deemed clinically unstable and unable to participate at the time of initial screening, the research team member returns at a later date to determine whether this status has changed.

Historical Standard of Care Comparison group

Inclusion Criteria:

* Admitted for acute myocardial infarction (STEMI or NSTEMI)
* 18 years or older
* English-speaking

Exclusion Criteria:

* None",Corrie Health Digital Platform,INTERVENTIONAL,COMPLETED
NCT00175058,Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II),Myocardial Infarction,"INCLUSION CRITERIA

Candidates for this study must meet ALL of the following criteria:

Pre-PCI:

1. Patient must be \>= 18 years of age
2. AMI must be anterior
3. Patient is experiencing clinical symptoms consistent with anterior AMI of \< 6 hour duration from time of symptom onset until admission to the emergency room
4. Complete medical history, history of AMI, previous coronary interventions, list of medications given within last 24 hours
5. 12-lead qualifying ECG criteria: Anterior infarction (ST-segment elevation \> 1 mm in two or more contiguous leads between V1 and V4 or new left bundle branch block (LBBB) with documentation of LAD system culprit lesion)
6. Patient provides written, Informed Consent
7. Patient and his/her physician agree to all required follow-up procedures and visits
8. Women of childbearing potential who have a negative pregnancy test (applies to female patients only)

   ANGIOGRAPHIC INCLUSION CRITERIA: These are evaluated after the subject has provided signed Informed Consent but prior to randomization:
9. Based on coronary anatomy, PCI is indicated for culprit lesion with anticipated use of an Intra-Coronary Stent
10. TIMI 0, I, or II flow is present on the initial angiographic injection of the infarct-related artery
11. Successful angioplasty as documented by \< 50% diameter residual angiographic stenosis within and associated with the culprit lesion and ³ TIMI II flow and no major complications such as perforation or shock
12. Documented time of reperfusion is \< 6 hours from the documented time of symptom onset","Candidates will be excluded from this study if ANY of the following conditions apply:

    Pre-PCI:
13. Patients with ventricular pseudoaneurysm, VSD, or papillary muscle rupture.
14. Absolute contraindications to anticoagulant therapy, including hemorrhagic diathesis or thrombocytopenia
15. Systemic Arterial pO2 is \< 80 mmHg with supplemental oxygen
16. Placement of an intra-aortic balloon pump (IABP)
17. Patient has had coronary bypass surgery during the 30 day period preceding PCI
18. Severe known cardiac valvular stenosis or insufficiency, pericardial disease, or non-ischemic cardiomyopathy
19. Patients requiring cardiopulmonary resuscitation for \> 10 minutes
20. Cardiogenic shock (SBP \< 80 mm Hg for more than 30 minutes unresponsive to fluids or requiring intravenous pressors or placement of an IABP)
21. Expected survival of less than 6 months due to non-cardiac condition
22. Current participation in other investigational device or drug trials that have not finished the primary efficacy endpoint follow-up parameters
23. Patient has had a hemorrhagic stroke during the 6 month period preceding PCI
24. Physician discretion regarding unacceptability for enrollment

    ANGIOGRAPHIC EXCLUSION CRITERIA: These are evaluated after the subject has provided signed Informed Consent but prior to randomization:
25. Any proximal coronary diameter stenosis \> 40 % that would restrict native flow with the Tracker-38 infusion catheter in place
26. Infarct-related vessels that are either saphenous vein grafts and/or small second order coronary vessels that do not supply significant areas of myocardium
27. Presence of a non-stented coronary dissection upon completion of the PCI procedure
28. Unprotected left main diameter stenosis \> 60%
29. Severe target vessel calcification or tortuosity
30. Multi - vessel disease that in the judgment of the investigator is best treated with emergent or urgent CABG or additional PCI within 30 days
31. In the investigator's opinion, the target vessel is unsuitable for either placing the infusion catheter or treatment with PCI",AO Therapy (aqueous oxygen),INTERVENTIONAL,COMPLETED
NCT00882635,The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study,Acute Myocardial Infarction,"1. Age equal or greater than 18 years
2. Onset of symptoms of STEMI \< 3 hours prior to randomisation
3. 12-lead ECG (ST elevation will be measured from the J point) indicative of an acute STEMI: \>2 mm ST elevation across 2 contiguous precordial leads (best 2 of V1-V6) or leads I, AVL for a minimum combined total of \>4 mm ST elevation,or \>3 mm ST elevation in 2 contiguous inferior leads (best 2 of II, III, AVF) for a minimum combined total of \> 6 mm ST elevation.
4. Informed consent received","1. PCI (1st balloon inflation) expected to commence \< 60 minutes from diagnosis (qualifying ECG) or inability to arrive at the cardiac catheterization laboratory (1st balloon inflation) within 3 hours after randomisation.
2. Anticipated or obvious problem with vascular access.
3. Previous CABG
4. Left bundle branch block or ventricular pacing.
5. Patients with cardiogenic shock - Killip Class 4
6. Patients with a body weight \< 55 kg (known or estimated)
7. Uncontrolled hypertension, defined as blood pressure measurement \> 180/110 mm Hg (systolic BP \> 180 mm Hg and/or diastolic BP \> 110 mm Hg) confirmed on repeat measures (2 documented measurements at any time) prior to randomization.
8. Known use oral anticoagulants (warfarin or coumadin) or GP IIb/IIIa antagonists within the preceding 7 days or recent administration of any IV or SC anticoagulation within 12 hours including: unfractionated heparin, enoxaparin, and/or bivalirudin.
9. Active bleeding, known bleeding diathesis/disorder including thrombocytopenia or clinical diagnosis associated with increased risk of bleeding including: known active peptic ulceration and/or neoplasm with increased bleeding risk.
10. Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current AMI)
11. Any history of central nervous system abnormality (i.e. neoplasm, aneurysm, intracranial or spinal surgery) or recent trauma to the head or cranium (i.e \<3 months)
12. Any known history of haemorrhagic stroke or stroke of unknown origin
13. Ischaemic stroke or transient ischaemic attack (TIA) in the preceding 6 months
14. Prolonged or traumatic cardiopulmonary resuscitation (\> 10 minutes) within the past 2 weeks
15. Known acute pericarditis and/or subacute bacterial endocarditis
16. Known acute pancreatitis or known severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (oesophageal varices) and active hepatitis
17. Chronic dialysis or known renal insufficiency (prior S-creatinine \>2.5 mg% (\>220 µmol/l) for men and \>2.0 mg% (\>175 µmol/l)) for women
18. Pregnancy or lactation or parturition within the previous 30 days; women of childbearing potential must be using a medically accepted method of birth control
19. Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days
20. Known hypersensitivity to tenecteplase, alteplase, ASA, clopidogrel, enoxaparin, or to any of the excipients or to the contrast media used in angiography Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk if the investigational therapy is initiated","enoxaparin, Unfractionated heparin",INTERVENTIONAL,COMPLETED
NCT01012544,Platelet Reactivity in Stent Thrombosis Patients,Coronary Artery Stent Thrombosis,* Patients with a history of a stent thrombosis in the period 2004-2008.,"* Persistent acute ST-segment elevation
* Successful revascularization during the qualifying hospitalization, prior to study entry
* Acute pulmonary edema, hypotension, or evidence of cardiogenic shock
* Clinically significant liver disease
* End stage kidney disease requiring dialysis
* Use at study entry of drugs that are strong inhibitors of cytochrome P450 3A4 and CYP3A5 (i.e. clarithromycin, erythromycin, itraconazole, ketoconazole)
* Contraindications to antithrombotic/antiplatelet therapy
* Failed coronary intervention in the previous 2 weeks
* Malignancies
* Increased risk of bleeding (previous stroke in the past months, active bleeding or bleeding diathesis, recent trauma or major surgery in the last month, suspected aortic dissection, oral anticoagulation therapy with coumarin derivate within 7 days, recent use of GPIIb/IIIa inhibitors within 14 days, severe uncontrolled hypertension \>180 mmHg unresponsive to therapy)
* Relevant hematologic deviations (haemoglobin \<100g/L (6,2 mmol/L) or hematocrit \<34%, platelet count \<100 x 109 /L or platelet count \> 600 x 109/L)
* Known allergy to clopidogrel
* Pregnancy (present or suspected)
* uncontrolled hypertension at time of randomization",Clopidogrel,INTERVENTIONAL,COMPLETED
NCT00356044,Arterial Access for Coronary Intervention in Myocardial Infarction,"Myocardial Infarction, Angioplasty, Transluminal, Percutaneous Coronary, Myocardial Reperfusion","* Patients with ST elevation acute myocardial infarction referred for primary,facilitated or of rescue coronary angioplasty in the first 12 hours since the start of the symptoms.","* Patients in cardiogenic shock were excluded following operator criteria.
* Previous coronary surgery with mammary artery graft
* Coronary artery intervention in the previous month
* Absolute or relative contraindication for access via the radial artery route:Radial pulse absent or weak, abnormal Allen test,anatomy known to impede the use of the radial route or hemodialysis or advanced chronic renal insufficiency (creatinine \>3 mg/dl).
* Patients with absolute or relative contraindication for the use of the femoral route.
* Absence of informed consent from the patient",Coronary angioplasty,INTERVENTIONAL,COMPLETED
NCT02976467,"A Double-blind Study to Investigate Efficacy, Safety and Tolerability of BAY 1142524 in Patients After Acute Myocardial Infarction With Left-ventricular Dysfunction",Myocardial Infarction,"* Patients with first ST elevation myocardial infarction (STEMI) treated with primary percutaneous intervention (PCI) or thrombolysis within 24 hours after symptom onset
* Diagnosis of STEMI requires the presence of the following three criteria:

  * Typical clinical symptoms such as chest pain, shortness of breath for more than 20 minutes related to the myocardial infarction
  * New ST elevation indicating myocardial infarction
  * Significant elevation in troponin T or I with at least one value above the 99th percentile upper reference limit (URL) and/or elevation creatine kinase (CK) and creatine kinase MB (6-10% of total CK)
* At the screening period, on day 5 to 9 after MI, patients have to have a LVEF ≤ 45% and an infarct size \>10% LV mass (as measured by LGE-MRI, central-blinded evaluation)","* Contraindication to perform contrast-enhanced cardiac MRI
* LVEF \< 20%
* History of heart failure or LVEF \< 50% before occurrence of the first STEMI
* Infarct size \> 45% (g/g; LV mass) between 5 and 9 days after myocardial infarction
* NYHA (New York Heart Association) class IV at randomization
* Any planned cardiac intervention after baseline MRI or any other planned operations
* Non-ischemic causes for cardiomyopathy
* Diagnosis of atrial fibrillation
* Systolic blood pressure \< 100 mm Hg or \> 180 mm Hg; diastolic blood pressure \< 50 mm Hg or \>110 mm Hg, heart rate \< 50 or \>100 beat/minute; mean of triplicate values at randomization
* Clinically relevant hepatic dysfunction","Fulacimstat (BAY1142524), Placebo",INTERVENTIONAL,COMPLETED
NCT00627744,Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction,"Myocardial Infarction, Unstable Angina Pectoris, Diabetes Mellitus, Impaired Glucose Tolerance","Inclusion Criteria:

1. Patients diagnosed with an acute myocardial infarction or unstable angina pectoris according to the joint ESC and ACC recommendations \[58\].
2. Classification of impaired glucose tolerance (IGT) or type 2 diabetes (T2DM) by means of an oral glucose tolerance test (OGTT) according to WHO \[59\].
3. Patients who have signed a written informed consent consistent with ICH-GCP guidelines and local legislations prior to participation in the trial.",":

1. No informed consent.
2. \<18 years old.
3. Previous known type 2 diabetes.
4. Admission plasma glucose \>12 mmol/L.
5. Impaired renal function (S-creatinine ≥ 130 μmol/L or need of renal dialysis).
6. BMI\>30.
7. Known Type 1 diabetes, GAD positive or C-peptide\<0.30.
8. Patients with severe concomitant disease (i.e. malignancy, liver failure).
9. Patients who at discharge are planned for Coronary Artery Bypass Grafting or percutaneous coronary intervention.
10. Congestive heart failure (NYHA III-IV).
11. Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception.
12. Patients who, in the opinion of the investigator, will have difficulties to comply with the protocol (examples: alcohol or drug abuse, psychiatric disorder, resident outside of the catchment area).",Sitagliptin,INTERVENTIONAL,COMPLETED
NCT00573144,Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction,Acute Myocardial Infarction,"Inclusion criteria:

* Patients with acute ST elevation myocardial infarction with \> or = 2 mm ST elevation in one or any combination of anterior leads, with successful revascularization (TIMI grade 3 flow) of the lesion within 24 hours of symptoms and consented within 24 hours of procedure.",":

* Cardiogenic shock or hypotension, Systolic BP\< 90 mmHg or overt Congestive Heart Failure (CHF)
* Previous history of MI (Myocardial Infarction)
* Previous ECG suggesting previous MI
* Known Ejection Fraction (EF) \< 30%
* Atrial fibrillation
* Previously known significant valvular disease (Grade III, IV), cardiomyopathy and congenital heart disease.
* Hemoglobin \<10 mg/dL
* Pregnant women/nursing mothers
* Participants still menstruating and have not been surgically sterilized must have a negative pregnancy test prior to participating in this study.
* Unable to undergo cardiac MRI (Magnetic Resonance Imaging).
* Contraindications to MRI include pacemaker or defibrillator, pregnant women, atrial fibrillation or other arrhythmia, cerebral aneurysm clips or severe claustrophobia.","Nesiritide, Placebo",INTERVENTIONAL,COMPLETED
NCT00886444,Comparative Evaluation of Various Combinable Magnetic Resonance (CMR) Pulse-sequences for Macrophage Imaging Using Ferucarbotran,Acute Myocardial Infarction,* acute myocardial infarction (STEMI or NSTEMI),* contraindication to CMR or Magnevist® or Resovist®,Ferucarbotran (Resovist),INTERVENTIONAL,COMPLETED
NCT03759067,Method of Clopidogrel Pre-treatment Undergoing Conventional Coronary Angiogram in Angina Patients,"Angina, Stable","* Written informed consent and, stable angina pectoris and, at least 1 ischemic evidence below

  1. Treadmil test positive
  2. ST-T change in resting ECG or 24-hour ECG
  3. Regional wall motion abnormality in Echocardiography or cardiac MRI
  4. Myocardial ischemia at MIBI scan
  5. moderate to severe stenosis at coronary CT angiography
  6. chest pain or dyspnea","* AST or ALT \> 3 times upper normal limits
* Serum creatinine \> 2.0 mg/dL
* chronic malaborption status (disorder or operation)
* planned surgery within 1 year
* pregnancy or breast-feeding patients
* life expectancy \< 1 year","clopidogrel 75mg, Clopidogrel 300 mg, clopidogrel 600mg",INTERVENTIONAL,COMPLETED
NCT01800201,Automated Hovering to Improve Medication Adherence Among Myocardial Infarction Patients (Heartstrong),"Patients With Principal or Secondary Diagnosis Code of Intrntl Classification of Diseases, 9th Revision, (ICD-9-CM) 410 (Except When 5th Digit Was 2)","* Patients admitted to hospitals throughout New Jersey or at the University of Pennsylvania Health System who are discharged (or scheduled to be discharged) to their homes with a principal or secondary diagnosis code of International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 410 (except when the fifth digit was 2)
* a length of stay of 1 to 180 days
* Aged 18 to 80 years
* Be discharged to home
* Prescribed at least 2 of these 4 medication categories (statin, aspirin, beta-blocker, anti-platelet)","* cannot give consent
* have a markedly shortened life expectancy (diagnosis of metastatic cancer, end-stage renal disease on dialysis, or dementia)","Electronic Pill Bottle, Incentives, Social Influence",INTERVENTIONAL,COMPLETED
NCT00662467,Warfarin After Anterior ST-Elevation Myocardial Infarction,Myocardial Infarction,"* Anterior STEMI
* An ejection fraction less than 40% as per initial LV angiography or echocardiogram
* Randomization possible within hospital admission if anticoagulated with no interruption \> 24 hours
* Patient able and willing to give informed consent to participate in this trial","* history of intracranial hemorrhage
* history of GI bleed last 6 months
* hemoglobin \< 90 g/L
* platelet count \< 100 x 10exp9/L
* ischemic stroke last 30 days
* intracranial tumor or aneurysm
* significant pericardial effusion
* severe renal failure (creatinine \> 250 mmol/L).","aspirin + clopidogrel, aspirin + clopidogrel + warfarin",INTERVENTIONAL,COMPLETED
NCT01642667,Pharmacoinvasive Therapy With Prourokinase,ST-segment Elevation Myocardial Infarction (STEMI),"* age 75 years or younger, symptom onset 6 h or less before randomization, intention to undertake primary PCI, ST-segment elevation of 2 mm or more in two anterior leads or of 1 mm or more in two inferior leads if they had ST-segment elevation, or new left bundle-branch block.","* expected arrival at the catheterization laboratory less than 1 h or more than 3 h after randomization, anticipated problems with vascular access, previous enrollment to other studies, and the usual contraindications to thrombolytic therapy.","Prourokinase, Placebo",INTERVENTIONAL,COMPLETED
NCT00507468,Autologous Bone Marrow Transplanted Via Transendocardial Catheter to Chronic Myocardial Infarct Border Zone,"Ventricular Dysfunction, Myocardial Infarction","* Must be 18 years of age or older
* Able to give informed consent
* Must have documentation of prior myocardial infarction with left ventricular ejection fraction of less than 40 percent at baseline
* Must be a candidate for percutaneous heart catheterization
* Must have identifiable area of transmural scar within the left ventricle","* Be a candidate for concurrent ventricular surgical restoration, AICD placement or valvular surgery
* Clinical evidence of infection
* Other complicating cardiovascular abnormalities
* Clinically significant electrocardiographic abnormalities
* Active malignancy
* Recent history or drug or alcohol abuse
* Pregnancy, planned or current
* Artificial aortic valve
* Ejection fraction less than 30 percent at baseline
* Myocardial infarction in the past 4 weeks",Transendocaridal Transplantation of Autologous Bone Marrow,INTERVENTIONAL,COMPLETED
NCT02158468,Effect of Conditioning on Myocardial Damage in STEMI,ST-elevation Myocardial Infarction,ST-elevation myocardial infarction \<12 hours,"* Age ≤ 18 years
* Patients presenting with pregnancy
* Thrombolysis \<12 hours
* Patients without informed consent
* Participation in another trial.","Combined intrahospital pre- and postconditioning, Postconditioning",INTERVENTIONAL,COMPLETED
NCT05350969,Study to Assess Efficacy and Safety of CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction,"Myocardial Infarction, Acute, Heart Failure, Left Sided","Main 

1. Male or female patients, aged ≥ 30 to ≤ 80 years at the date of signing informed consent which is defined as the beginning of the Screening Period.
2. Spontaneous acute mycardial infarction (AMI) (type I) based on the universal MI definition with randomization to occur no later than 14 days after index event diagnosis.
3. Patient with a LVEF ≤ 45% as measured by ECHO after MI diagnosis (STEMI or NSTEMI).
4. Patient with previous MI events in history can be included.
5. Patient with body weight of ≤ 120 kg.
6. N-terminal pro B-type natriuretic peptide level ≥ 125 pg/ml and \< 8000 pg/ml at screening.
7. Patient with STEMI/NSTEMI who underwent percutaneous coronary intervention for this event.","1. A woman of childbearing potential (WOCBP).
2. Patient with HF of non-ischemic origin; e.g., myocarditis, alcoholic cardiomyopathy.
3. Patient with New York Heart Association (NYHA) class IV at screening or randomization.
4. Patient has any planned cardiac intervention (angiogram without angioplasty is acceptable) or any other planned surgery after the Screening Period.
5. Patient has severe valvular heart disease.
6. Patient has systolic BP \< 90 mmHg or \> 180 mmHg, diastolic BP \< 50 mmHg or \> 110 mmHg, and/or heart rate \< 50 or \> 100 beats/minute at screening or randomization.
7. Patient with an estimated glomerular filtration rate \< 30 mL/min/1.73 m2 or on dialysis.
8. Patient with hepatic insufficiency classified as Child-Pugh B or C.
9. Patient has medical history of disease(s) affecting the blood-brain-barrier, e.g., stroke within 6 months or multiple sclerosis.
10. Patient has medical history of bleeding disorders or has thrombocytopenia (platelets \< 100,000/μL).
11. Patient has poorly controlled diabetes as determined by the Investigator.
12. Patient has a history or presence of any of the following cardiac conditions: known structural cardiac abnormalities beyond HF, family history of long QT syndrome, cardiac syncope, or recurrent, idiopathic syncope.
13. Any clinically significant abnormalities, at the discretion of the Investigator, in rhythm, conduction, or morphology of resting ECG that pose an additional safety risk to patients.
14. Patient with active ""severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)"" infection confirmed as per the local testing guidelines at screening.
15. Patient is not to be enrolled into the study if they received any prohibited therapy within 3 months of screening.","CDR132L, Placebo to CDR132L",INTERVENTIONAL,COMPLETED
NCT02890589,Strut Coverage With SYNERGY Stents and Bioresorbable Vascular Scaffold in Acute Myocardial Infarction,Acute Coronary Syndrome,"* Acute coronary syndrome with ST-elevation,
* One culprit lesion eligible for percutaneous coronary intervention (PCI) with stent implantation,
* Reference vessel measuring 2.5 mm to 3.75 mm per visual estimation, without extreme vessel tortuosity,
* thrombolysis in myocardial infarction (TIMI) 3 flow before stent deployment in the target vessel,
* Patient with at least 1 lesion eligible for planned PCI next to the culprit lesion,
* Patient affiliated to the French national health care system,
* Patient agreed to participate after full information on the study (signature of an informed consent).","* Acute coronary syndrome with ST-elevation,
* One culprit lesion eligible for percutaneous coronary intervention (PCI) with stent implantation,
* Reference vessel measuring 2.5 mm to 3.75 mm per visual estimation, without extreme vessel tortuosity,
* TIMI 3 flow before stent deployment in the target vessel,
* Patient with at least 1 lesion eligible for planned PCI next to the culprit lesion,
* Patient affiliated to the French national health care system,
* Patient agreed to participate after full information on the study (signature of an informed consent).","SYNERGY stent, ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)",INTERVENTIONAL,COMPLETED
NCT00863629,Tight Glycemic Control Increases Cardiac Stem Cells During Acute Myocardial Infarction,"Myocardial Infarction, Oxidative Stress, Glycemic Control","* evidence of AMI within the last 8 h (troponin-I \>2.50 µg/l together with either typical symptoms of angina or electrographic criteria of ST-segment modification)
* first uncomplicated AMI
* the need for CABG","* previous AMI
* inflammatory disorders
* malignancy
* renal diseases infections",Insulin,INTERVENTIONAL,COMPLETED
NCT02151929,Bioresorbable Vascular Scaffold in Patients With Myocardial Infarction,ST Elevation Acute Myocardial Infarction,"1. chest pain for more than 30 minutes;
2. ST-segment elevation of 1 mm or more in 2 or more contiguous electrocardiograph leads or with presumably new left bundle-branch block","1. Active internal bleeding or a history of bleeding diathesis within the previous 30 days;
2. Contraindication to dual antiplatelet therapy for 12 months;
3. Known allergy to everolimus;
4. A history of stroke within 30 days or any history of hemorrhagic stroke;
5. History, symptoms, or findings suggestive of aortic dissection;
6. High-likelihood of death within BVS resorbtion time;
7. Cardiogenic shock;
8. Infarct artery reference diameter, \<2.0 mm or \>3.7 mm (i.e. not suitable for currently available BVS sizes);
9. Pregnancy;
10. Participation in other trials","Bioresorbable vascular scaffold, Everolimus eluting stent",INTERVENTIONAL,COMPLETED
NCT03092089,Sonothrombolysis in Patients With STEMI,ST-segment Elevation Myocardial Infarction,"Patients presenting with STEMI within 6 hours of symptom onset and:

1. Are expected to receive reperfusion therapy with primary PCI
2. Have a high-risk STEMI ECG defined as:

   * ≥2mm ST-segment elevation in 2 anterior or lateral leads; or
   * ≥2 mm ST-segment elevation in 2 inferior leads coupled with ST segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥4mm
3. Age ≥30 years.
4. Adequate apical and/or parasternal images by echocardiography","1. Isolated inferior STEMI without anterior ST-segment depression
2. Previous coronary bypass surgery
3. Cardiogenic shock
4. Known or suspected hypersensitivity to ultrasound contrast agent used for the study
5. Life expectancy of less than two months or terminally ill.
6. Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors, anticoagulants, or aspirin
7. Known large right to left intracardiac shunts.","Definity, (Lipid Microspheres) Intravenous Suspension, Myocardial Contrast Echocardiography, Repurfusion therapy with PPCI",INTERVENTIONAL,COMPLETED
NCT00766740,Long Term Clinical Efficacy of Thrombectomy Devices in Acute ST Elevation Myocardial Infarction,Acute Myocardial Infarction,"Inclusion criteria for selected studies who entered this pooled analysis were:

* Comparison of PCI with Thrombectomy with Standard PCI in patients with STEMI
* Randomized treatment allocation","was:

* Equivocal treatment allocation process

About the clinical and angiographic inclusion and exclusion criteria they were different for each single randomized trial that entered this pooled analysis.","thrombectomy devices, angioplasty",INTERVENTIONAL,COMPLETED
NCT03067844,Vascular Effects of Alirocumab in Acute MI-Patients,"Coronary Vessel, Coronary Circulation, Atheroma; Myocardial","* Male or female, age ≥18 years at screening;
* Acute myocardial infarction: acute ST-segment elevation myocardial infarction (STEMI) with pain onset within ≤24h, or non-ST segment elevation myocardial infarction (NSTEMI), with at least one coronary segment (culprit lesion) requiring PCI;
* LDL-C ≥70 mg/dL (≥1.8 mmol/L) assessed prior to, or during PCI in patients who have been receiving any stable statin regimen within ≥ 4 weeks prior to enrollment; OR LDL-C ≥125 mg/dL (≥3.2 mmol/L) in patients who are statin-naïve or have not been on stable statin regimen for ≥ 4 weeks prior to enrollment;
* At least two major native coronary arteries (""target vessels"") each meeting the following criteria for intracoronary imaging immediately following the qualifying PCI procedure: Angiographic evidence of \<50% reduction in lumen diameter by angiographic visual estimation;
* Target vessel deemed to be accessible to imaging catheters and suitable for intracoronary imaging in the proximal (50mm) segment (""target segment"");
* Target vessel may not be a bypass (saphenous vein or arterial) graft or a bypassed native vessel;
* Target vessel must not have undergone previous PCI within the target segment;
* Target vessel is not candidate for intervention at the time of qualifying PCI or over the following 6 months in the judgment of the Investigator;
* Hemodynamic stability allowing the repetitive administration of nitroglycerine;
* Ability to understand the requirements of the study and to provide informed consent;
* Willingness to undergo follow-up intracoronary imaging.","* Left-main disease, defined as ≥50% reduction in lumen diameter of the left main coronary artery by angiographic visual estimation;
* Three-vessel disease, defined as ≥70% reduction in lumen diameter of three major epicardial coronary arteries by angiographic visual estimation or in major branches of one or more of these arteries, irrespective of the localization (proximal 50mm or more distal localization) of the obstructive lesions;
* History of coronary artery bypass surgery;
* ""Thrombolysis In Myocardial Infarction"" (TIMI) flow \<2 of the infarct-related artery after PCI;
* Unstable clinical status (hemodynamic or electrical instability);
* Significant coronary calcification or tortuosity deemed to preclude IVUS, NIRS and OCT evaluation;
* Uncontrolled cardiac arrhythmia, defined as recurrent and symptomatic ventricular tachycardia or atrial fibrillation with rapid ventricular response not controlled by medications in the past 3 months prior to screening;
* Severe renal dysfunction, defined by estimated glomerular filtration rate \<30 ml/min/1.73m2;
* Active liver disease or hepatic dysfunction;
* Known intolerance to rosuvastatin OR known statin intolerance;
* Known allergy to contrast medium, heparin, aspirin, ticagrelor or prasugrel;
* Known sensitivity to any substances to be administered, including known statin intolerance;
* Patients who previously received alirocumab or other PCSK9 inhibitor;
* Patient who received cholesterol ester transfer protein inhibitors in the past 12 months prior to screening;
* Treatment with systemic steroids or systemic cyclosporine in the past 3 months;
* Known active infection or major hematologic, metabolic, or endocrine dysfunction in the judgment of the Investigator;
* Planned surgery within 12 months;
* Patients who will not be available for study-required visits in the judgment of the Investigator;
* Current enrollment in another investigational device or drug study;
* History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer;
* Estimated life expectancy less than 1 year;
* Female of childbearing potential (age \<50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy.",Alirocumab,INTERVENTIONAL,COMPLETED
NCT01625104,Randomized Trial of a Quality Improvement Intervention to Decrease D2B Time in Primary PCI for AMI,STEMI,"* Acute ST segment myocardial infarction, non transfer patients, with symptom onset to balloon time less than or equal to 24 hours.","* Patients transferred from one facility to another,
* non ST segment myocardial infarction patients.","Non Intervention, Agressive Intervention Process Improvement Strategies",INTERVENTIONAL,COMPLETED
NCT00712101,Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction,ST-elevation Myocardial Infarction,"1. Clinical symptoms:

   * Angina pectoris \< 12 hours and
   * Persistent angina \> 30 minutes
2. ECG-criteria for ST-elevation myocardial infarction in 12-lead ECG:

   * ST-segment elevation \> 1mm in ≥ 2 extremity leads and/or
   * ST-segment elevation \> 2mm in ≥ 2 adjacent precordial leads
3. Informed consent","1. No informed consent
2. Pregnancy
3. Known allergy to abciximab, ASA or heparin
4. Active peptic ulcus ventriculi or duodeni
5. Active, non-superficial bleeding
6. History of major surgery (including intracranial or intraspinal) \<4 weeks
7. active internal bleeding
8. Cerebrovascular complications \< 2 years
9. Known coagulation defect or thrombocytopenia
10. Arteriovenous malformations or aneurysm
11. Severe liver insufficiency, renal insufficiency requiring dialysis
12. Uncontrolled hypertension, hypertensive retinopathy
13. Vaskulitis
14. Thrombolysis \< 12 h
15. Participation in another trial","abciximab intracoronary, abciximab intravenously",INTERVENTIONAL,COMPLETED
NCT03571269,EROSION III: OCT- vs Angio-based Reperfusion Strategy for STEMI,ST-segment Elevation Myocardial Infarction,"1. 18 years old ≤ age ≤ 80 years old;
2. Patients with STEMI\<12h;
3. The target lesion is located in a native coronary artery;
4. The residual diameter stenosis (DS) is ≤70% on angiogram and thrombolysis in myocardial infarction (TIMI) flow grade is 3 after thrombus aspiration or not;
5. Written informed consent.","1. Patients who are breastfeeding or pregnant or planning to pregnant during the study period;
2. Patients with a history of heart failure;
3. Hemodynamic instability;
4. Target lesion such as: left main coronary artery; three-vessel disease; ostial lesion (defined as within 3mm of the left main coronary artery or aorto-ostium); tortuous lesion; angular lesion;
5. Subjects with contraindication of contrast medium;
6. There are contraindications to aspirin or clopidogrel;
7. Severe hepatic and renal insufficiency (ALT or AST \>3x upper limits of normal, creatinine\>2.0 mg/dL or end-stage renal disease);
8. Patients with bleeding tendency such as peptic ulcer, bleeding or coagulation disorders;
9. AMI is caused by surgery, trauma, gastrointestinal bleeding, PCI, or its complications;
10. AMI occurs in patients who have been hospitalized for other reasons;
11. Patients who were considered with poor compliance and could not complete the study as required judged by the investigators;
12. Patient with life expectancy ≤24 months;
13. Patients with heart transplantation;
14. Patients with definite diagnosis of tumors;
15. Patients who are currently enrolled in other clinical trial (except other subjects in this project) which has not reached its primary endpoint;
16. Patients who are not suitable for the current study judged by the investigators.",Optical coherence tomography-guided reperfusion strategy,INTERVENTIONAL,COMPLETED
NCT01898546,Ischemic Postconditioning on Microvascular Obstruction in Reperfused Myocardial Infarction,Myocardial Infarction,"* Patients of age ≥ 18 years admitted to two university hospitals for a first STEMI within the first 12 h of chest pain onset, with ST-segment elevation of \>0.1 mV in at least 2 contiguous leads and for whom the clinical decision to treat with percutaneous coronary intervention is made.","* Documented history of previous infarction
* Primary percutaneous revascularization not attempted
* Severe clinical or hemodynamic deterioration
* Left main stem disease
* Thrombolysis In Myocardial Infarction (TIMI) 2-3
* Rentrop collateral flow grade ≥1 upon patient arrival
* Death, re-infarction, cardiac surgery or severe clinical deterioration before CMR study
* Patients who denied participation in the registry
* Any contraindications to CMR","Primary angioplasty, Postconditioning",INTERVENTIONAL,COMPLETED
NCT00755469,Post-conditioning to Reduce Infarct Size,Myocardial Infarction,"* Age ≥ 18 \< 80
* Able to give informed consent
* 100% occlusion of a major epicardial vessel with TIMI 0 Flow","* Significant collateral blood flow to the distal vasculature of the occluded vessel.
* Previous CABG
* Previous q-wave myocardial infarction in the same territory",Post-conditioning,INTERVENTIONAL,COMPLETED
NCT01841944,Omega-3 Fatty Acids in Elderly Patients With Acute Myocardial Infarction,"Myocardial Infarction, Heart Failure, Myocardial Revascularization, Atrial Fibrillation",* Patients with acute myocardial infarction discharged from hospital alive,"* Being part of another randomized trial
* Documented intolerance for omega-3 fatty acids
* Additional disease state that is thought to be incompatible with compliance to the study drugs
* Additional disease state thought to reduce survival for the follow-up time of 2 years","Pikasol, Corn oil",INTERVENTIONAL,COMPLETED
NCT00310544,Depiction of Delayed Enhancement in Patients With Documented Myocardial Infarction,Myocardial Infarction,* At least 8 weeks post-documented myocardial infarction (heart attack),"* History of radiation therapy to the chest
* Clinically unstable
* Any contraindication for MRI","Magnevist (Gadopentetate dimeglumine, BAY86-4882), Magnevist (Gadopentetate dimeglumine, BAY86-4882)",INTERVENTIONAL,COMPLETED
NCT02322944,China PEACE II: Quality Improvement for Acute Myocardial Infarction,Acute Myocardial Infarction,* Patients with STEMI who arrive at the hospital within 12 hours from the symptoms onset.,"* Received reperfusionthrombolytic therapy before the index hospitalization;
* AMI occurring during hospitalization;
* Chest trauma resulting in secondary acute myocardial infarction.","Quality improvement strategies and tools, Process optimization",INTERVENTIONAL,COMPLETED
NCT00077792,Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25),"Myocardial Infarction, Acute ST-Segment Elevation","INCLUSION CRITERIA:

Patients with ST-segment elevation acute myocardial infarction meeting all of the following criteria:

* Male or non-pregnant female greater than or equal to 18 years of age (depending on local regulations, minimal age can vary between 18 and 21 years)
* Onset of prolonged (greater than or equal to 20 min) ischemic symptoms at rest less than or equal to 6 hours prior to randomization
* ST-segment elevation of 0.1 mV in 2 or more limb leads, or 0.2 mV in two (2) or more contiguous precordial leads, or left bundle-branch block
* Planned reperfusion therapy with streptokinase, tenecteplase, alteplase or reteplase
* Written informed consent will be obtained",":

Cardiovascular

* Evidence of cardiogenic shock at randomization
* Acute pericarditis
* History or symptoms suggestive of aortic dissection
* MI precipitated by obvious provoking factors such as arrhythmia, infection, severe anemia, hyperthyroidism, cocaine, or amphetamine

Hemorrhagic Risk

* Any minor head trauma or any other trauma occurring after the index acute myocardial infarction
* Active or recent (\< 3 months) bleeding including gastrointestinal bleeding, known presence of occult blood in the stool, or gross hematuria.
* Any history of bleeding diathesis, coagulopathy, platelet disorder, or thrombocytopenia
* Any single reliable recording of systolic blood pressure \>180 mm Hg and/or diastolic blood pressure \>110 mm Hg prior to randomization
* Any history of stroke or transient ischemic attack; any history of hemorrhagic cerebrovascular disease
* Any known structural damage or other pathologic process involving the central nervous system
* Any head trauma within 6 months prior to randomization
* Major surgery (including CABG), any ophthalmologic surgery, or non-cutaneous biopsy, or substantial trauma within 3 months prior to randomization
* Traumatic or prolonged cardiopulmonary resuscitation (\> 2 minutes) within 2 weeks prior to randomization
* Puncture of a non-compressible vessel (artery or vein) within the 24 hours prior to randomization
* Acute peptic ulcer disease within 3 months prior to randomization

Prior or Concomitant Pharmacologic Therapy

* Administration of abciximab (ReoPro), within the previous 7 days or eptifibatide (Integrilin), or tirofiban (Aggrastat) within the previous 24 hours prior to randomization
* Current therapy with oral anticoagulants, or an International Normalized Ratio of \>1.5
* Administration of a low molecular weight heparin within 8 hours prior to randomization.
* Known hypersensitivity to low molecular weight heparins, unfractionated heparin or heparin-like products; allergy to pork or pork products
* Known hypersensitivity and/or contra-indication(s) to fibrinolytic drugs (streptokinase, tenecteplase, alteplase and reteplase)

General

* Known platelet count \<100,000 cells/microL or history of heparin-induced thrombocytopenia
* Known clinically significant anemia (Hemoglobin \<10 g/dL which is \< 6.2 mmol/L)
* Known renal insufficiency with serum creatinine \>220 mmol/L (2.5 mg/dL) for men and \>175 mmol/L (2.0 mg/dL) for women when assessed prior to baseline examination.
* Advanced neoplastic or other life-threatening disease with a life expectancy of \<12 months
* Pregnancy or parturition within the last 90 days or currently breast feeding
* Women of childbearing potential except if post-menopausal, surgically sterile or using accepted method(s) of birth control or having a negative pregnancy test.
* Treatment with other investigational agents in the last 30 days before study entry or previous enrollment in ExTRACT-TIMI 25
* History of drug or alcohol abuse
* Mental condition rendering the patient unable to understand the nature, scope, and possible consequences of the study
* Any patient unlikely to comply with protocol, e.g., uncooperative attitude, inability to return for follow-up visits, and who are unlikely to complete the study",Enoxaparin sodium (XRP4563),INTERVENTIONAL,COMPLETED
NCT02584192,Efficacy of Early Home-based Cardiac Rehabilitation Program for Patients After Acute Myocardial Infarction,Acute Myocardial Infarction,"* Being aged 18-65 years with a confirmed AMI diagnosis
* Being suitable for the CR program
* Undergoing PCI at the entry","* Known ischemic heart disease, heart valvular lesions, intra-ventricular conduction disturbances, malignant arrhythmia, cardiac shock, and poor echocardiographic conditions to take STE examination","entailing an early home-based CR program, enter the usual care program",INTERVENTIONAL,COMPLETED
NCT04610892,Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction,Coronary Heart Disease (CHD),"1. Participant must provide informed consent before any study specific activities are performed, must be able and willing to meet all requirements for randomization within 42 days after signing the full ICF, and must adhere to the schedules of activities.
2. Women must be ≥ 40 years of age at the time of signing the ICF. Men must be ≥ 21 years of age at the time of signing the ICF.
3. Participant must:

   1. be 30 to 365 days after presumed type-1 (ie, due to plaque rupture or erosion) MI (either STEMI or NSTEMI) at the time of enrollment.
   2. have persistent inflammation, defined as hs CRP ≥ 1 mg/L, as measured centrally at screening Visit 1.
4. Participant must have body mass index within the range 18 to 40 kg/m2 inclusive.
5. For female participants, the participant must not be pregnant or lactating and must be of non-childbearing potential, confirmed at screening Visit 1 by one of the following:

   1. Postmenopausal, defined as amenorrhea for ≥ 12 months following cessation of all exogenous hormonal treatments, and with luteinizing hormone and follicle stimulating hormone levels in the postmenopausal range.
   2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy. Tubal ligation is not considered as irreversible surgical sterilization.
6. Participant must have an evaluable, pre-randomization CTA with quantifiable, non calcified plaque.","1. History of any clinically important disease or disorder which, in the opinion of the investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
2. Percutaneous coronary intervention or diagnostic angiogram planned after screening. Eligible participants who have a diagnostic angiogram performed in the absence of undergoing a new PCI may continue screening after the diagnostic angiogram has been performed or may be rescreened.
3. History of or planned coronary artery bypass grafting.
4. Documented episode of post-MI pericarditis in the 3 months before enrollment.
5. Ongoing New York Heart Association Class IV HF.
6. Increased risk of bleeding

   1. Patients with history or presence of any bleeding disorder.
   2. Signs of ongoing bleeding at screening (eg, identified macroscopic bleeding, low hemoglobin presumed to be caused by bleeding) or high risk for major bleeding in accordance with the Investigator's assessment.
   3. Need for chronic therapeutic anticoagulation therapy anticipated to be required throughout the course of the study (short-term treatment with prophylactic doses of heparin/low molecular weight heparin are allowed).
   4. Known severe liver disease.
7. History or presence of any of the following:

   1. Ongoing infection or febrile illness that in the opinion of the investigator may be the cause of elevated hs-CRP on screening.
   2. Ongoing atrial fibrillation or flutter.
   3. Cancer within 5 years before randomization, with the exception of non melanoma skin cancer.
   4. Alcohol or substance abuse within 6 months before randomization, as judged by the investigator.
   5. Known history of hypersensitivity reactions to other biologics, to human IgG preparations, or to any component of MEDI6570, or ongoing severe allergy as judged by the investigator.
   6. Patients with active positive results on screening for serum hepatitis B surface antigen, hepatitis C antibody, or HIV.
8. Any clinically important abnormalities in clinical chemistry, hematology, coagulation parameters, as judged by the investigator.
9. BP values at screening:

   1. Systolic BP \< 90 mmHg or \> 180 mmHg.
   2. Diastolic BP \> 100 mmHg.
   3. Participants who are excluded based on elevated BP may be rescreened following adequate treatment.
10. Participants with any of the following contraindications to CTA:

    1. eGFR \< 50 mL/min/1.73 m2 by the Chronic Kidney Disease Epidemiology Collaboration equation, or end stage renal disease treated with kidney transplant or renal replacement therapy.
    2. Allergy to iodinated contrast.
    3. History of contrast-induced nephropathy.
    4. Contraindication to nitroglycerin.
    5. Rapid heart rate that is uncontrolled by medical therapy.
    6. Inability to hold breath for at least 6 seconds.
11. Receipt of any investigational device or therapy within 6 months or 5 half lives before screening (whichever is longer).

    This criterion does NOT apply for inactive, non replicating COVID-19 vaccines approved by Health Authorities or under emergency use authorization.
12. Planned participation in an additional investigational study of an intervention or biologic before the end of the follow-up period. Participation in observational studies or studies without investigational drugs or devices is allowed.
13. Participants who are legally institutionalized.
14. An employee or close relative of an employee of the sponsor, the CRO, or the study site, regardless of the employee or close relative's role.","MEDI6570, Placebo",INTERVENTIONAL,COMPLETED
NCT02943369,Cangrelor Following Ticagrelor Loading vs Ticagrelor Loading Alone in STEMI,STEMI,* Consecutive P2Y12 inhibitor-naive STEMI patients with pain onset\<12 hours admitted for primary PCI.,"* a history of stroke/transient ischemic attack
* bleeding diathesis
* chronic oral anticoagulation treatment
* contraindications to anti platelet therapy
* PCI or coronary artery bypass grafting \<3 months
* platelet count \<100 000/μL
* hematocrit \<30%
* creatinine clearance \<30 mL/min
* severe hepatic dysfunction
* use of strong CYP3A inhibitors or inducers
* increased risk of bradycardia
* severe chronic obstructive pulmonary disease
* periprocedural IIb/IIIa inhibitor administration.","Ticagrelor 180 mg loading dose, Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min",INTERVENTIONAL,COMPLETED
NCT00611169,The Effects of Facilitated Percutaeous Coronary Intervention in Acute Myocardial Infarction,Acute Myocardial Infarction,"* presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset
* ST-segment elevation more than 1 mm in two or more contiguous leads or presumably a new-onset left bundle branch blockage","* hemodynamic instability
* history of MI
* old age \> 80years
* Patients with bleeding diathesis (coagulopathy, thrombocytopenia or platelet dysfunction, Gastrointestinal or genitourinary bleeding within the prior 3 months)",tirofiban,INTERVENTIONAL,COMPLETED
NCT02978040,"Randomized Comparison of Cangrelor, Tirofiban and Prasugrel in Patients With STEMI Referred for Primary PCI.","Coronary Artery Disease, STEMI - ST Elevation Myocardial Infarction","* Age greater than 18 years old
* ST-segment elevation myocardial infarction
* Referred for primary PCI either within 12 h of symptom onset or between 12 and 24 h after onset with evidence of continuing ischemia","* Unconsciousness
* Other conditions that make the patient incapable receiving integer loading dose of prasugrel
* Any contraindication and/or known hypersensitivity or allergy to aspirin, prasugrel, intravenous unfractionated heparin, cangrelor, tirofiban
* Any contraindication to primary PCI
* Administration of glycoprotein IIb/IIIa inhibitors (GPI) or P2Y12-inhibitors or cangrelor \< 7 days
* Chronic dialysis
* Recent (\< 15 days) or current major bleeding
* Recent (\< 15 days) major surgery
* Administration of fibrinolytics \< 30 days
* Current use or indication to oral anticoagulant
* Previous stroke or transient ischemic attack (TIA)
* Inability to follow the procedures of the study (language problems, psychological disorders, dementia) or comorbidities associated with less than 6 months survival (active malignancies drug or alcohol abuse, etc.)
* Women who are pregnant or breast feeding or with potential to become pregnant during the course of the study (age \< 55 years and last menstruation within the last 12 months) and did not undergo tubal ligation, ovariectomy or hysterectomy
* Participation in another study with investigational drug within the 30 days preceding and during the present study
* Enrolment of the investigator, his/her family members, employees and other dependent persons","Cangrelor, Tirofiban, Prasugrel",INTERVENTIONAL,COMPLETED
NCT04183140,Comparison of Radial and Ulnar Artery Intervention in Patients With ST Elevated Myocardial Infarction,ST Elevated Myocardial Infarction,"* patients over 18 years of age
* admitted for primary percutaneous intervention
* either of these two routes has not been used in the last week
* a sufficient pulse at both routes","* cardiogenic shock
* stent thrombosis
* the use of either of these two arteries in the last 1 week
* either of these arteries can not be pulsed or very weak pulsed",primary percutaneous coronary intervention,INTERVENTIONAL,COMPLETED
NCT00209144,Phase 1 Study of Potential Anti-Inflammatory Effects of Glucose Control During Acute Myocardial Infarction.,Acute Myocardial Infarction,Patients to be treated with percutaneous coronary intervention for myocardial infarction.,MI \> 6 hrs duration Thrombolytic therapy (within last 2 days) Recent inflammatory/infectious illness (last 2 weeks) Pregnancy Renal insufficiency (Cr \> 2.0) Type I Diabetes Mellitus Initial BG \>110 but \<140 Enrollment in another research study,Intensive insulin therapy,INTERVENTIONAL,COMPLETED
NCT02808767,Comparison of Prasugrel and Ticagrelor in the Treatment of Acute Myocardial Infarction,"Myocardial Infarction, Angioplasty, Balloon, Coronary, Platelet Aggregation Inhibitors","1. Acute myocardial infarction (\> 1mm ST elevation in at least 2 related leads or ST depression \> 2mm in 3 leads or new BBB) with an indication to emergent (within 120 minut from admission to the PCI center) coronary angiography and PCI,
2. Signed informed consent.","1. History of stroke,
2. Serious bleeding within last 6 months,
3. Indication to an oral anticoagulation (e.g. atrial fibrillation, artificial valve, thromboembolism etc...)
4. Use of ≥ 300 mg of clopidogrel or another antiplatelet agent (except of aspirin and lower dose of clopidogrel) before randomization,
5. Low body weight (\<60 kg) in an older patient (\>75 years of age),
6. Moderate or severe liver dysfunction,
7. Ongoing therapy with a strong CYP3A4 inhibitor (e.g. ketoconazole, clarythromycine, nefazodone, ritonavir, atazanavit),
8. Hypersensitivity to prasugrel or ticagrelor.","Prasugrel, Ticagrelor",INTERVENTIONAL,COMPLETED
NCT06882044,The Effect of a Mobile Application in Patients With Acute Myocardial Infarction,"Acute Myocardial Infarction (AMI), Mobile Health Technology (mHealth), Quality of Lifte, Treatment Adherence, Self Care","* Patients who had ST-segment elevation acute myocardial infarction and underwent primary percutaneous coronary intervention,
* Above the age of 18,
* Have a smart phone,
* Have internet access,
* Have orientation to place, time, and situation,
* Have no problems with vision, hearing, or speech,
* Have minimal literacy,
* Patients who volunteer to participate in the study","* Patients who want to leave the study,
* Patients who do not come to their doctor's check-ups regularly.",mHealth,INTERVENTIONAL,COMPLETED
NCT00966563,Mangafodipir as an Adjunct to Percutaneous Coronary Intervention,Myocardial Infarction,"1. Males 40-80 and females 50-80 years with first severe coronary attack
2. Chest pain up to 6 hours.
3. T segment elevation (≥ 0.2 mV in two neighbouring anterior and inferior wall leads.
4. Decided for treatment by primary PCI.
5. TIMI grade 0 flow in the occluded LAD or RCA artery
6. Written informed consent.","1. Previous coronary artery bypass operation.
2. Previous AMI.
3. Chest pain more than 6 hours.
4. Angina within 48 hours before admission.
5. Cardiac arrest and cardiogenic shock.
6. Occlusion of the left main stem, circumflex and right coronary arteries at angiography.
7. Known hypersensitivity to mangafodipir (as contrast agent for MRI).
8. Received mangafodipir ≤ 5 weeks before admission
9. History of prior serious allergic or pseudo-allergic reaction
10. Severely reduced liver or renal function
11. Any other serious illness or medical condition
12. Fertile females
13. Phaeochromocytoma","Mangafodipir, Placebo",INTERVENTIONAL,COMPLETED
NCT03340948,The Mindfulness Intervention as Myocardial Infarction Rehabilitation Additive (MIMIRA) Study,"Coronary Artery Disease, Depressive Symptoms","1. Recent (within 12 month) first time coronary artery event; defined as a diagnosis of myocardial infarction or unstable angina pectoris addressed with either percutaneous coronary intervention (PCI) or coronary artery by-pass graft surgery (CABG).
2. Depressive symptoms above a score of 8 on the questionnaire centre for epidemiological studies depression scale (CES-D).
3. Interest for participation in MBSR.","1. Major depression or other serious psychiatric illness (such as psychosis or ongoing life crisis).
2. Severe comorbidities, such as cancer, severe cognitive impairment and alcohol or drug abuse.
3. Practical hindrances for participation in MBSR.",Mindfulness Based Stress Reduction (MBSR),INTERVENTIONAL,COMPLETED
NCT04665648,Clinical Efficacy and SAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention,"ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention","* 18-80 years;
* acute ST-segment elevation myocardial infarction within 12 hours of symptom onset;","* systolic blood pressure\<100mmHg;
* cardiac shock;
* aortic dissection;
* history of myocardial infarction or percutaneous coronary intervention or coronary artery bypass grafting (\<6 month);
* history of the treatment of nicorandil (\<6 month);
* history of intravenous nitrates before percutaneous coronary intervention;
* contraindicated or intolerable to nicorandil;
* pregnant or lactation period;
* patients with an estimated survival time of less than 1 year.","Nicorandil, Placebo",INTERVENTIONAL,COMPLETED
NCT02048696,Effect of Exercise Training on Left Ventricular Function in Patients Post Myocardial Infarction,"Myocardial Infarction, Heart Failure, Coronary Artery Disease","* Acute myocardial infarction
* Complete revascularization: no residual major epicardial coronary artery coronary stenosis ≥ 70%; no residual left main coronary stenosis ≥ 40%.
* Stage A-C heart failure, New York Heart Association class I-III.
* Stable dose of medications during the 4 weeks prior to enrolment.
* Able to perform a maximal cardiopulmonary stress test.
* Capacity and willingness to provide sign informed consent.","* Pregnant
* Coronary artery bypass surgery: patients post coronary artery bypass graft exhibit wall motion abnormalities that may interfere with speckle tracking analysis.
* Incomplete revascularization with major epicardial coronary artery (left anterior descending, circumflex, or right coronary) stenosis ≥ 70%.
* Myocardial necrosis in the absence of significant flow limiting coronary artery stenosis or thrombosis, with the exception of documented STEMI and successful thrombolytic therapy resulting on no significant residual epicardial coronary artery stenosis.
* Significant valvular disease that is greater than moderate in severity
* History of non-ischemic cardiomyopathy (dilated, restrictive, infiltrative cardiomyopathy, hypertrophic, LV non compaction, or Takotsubo cardiomyopathy)
* Significant resting ECG abnormalities that preclude accurate speckle tracking.
* Paced rhythm.
* left bundle branch block
* Atrial arrhythmias (ex. persistent/permanent atrial fibrillation, atrial flutter).
* Frequent ventricular ectopics
* Significant ventricular arrhythmias (non-sustained ventricular tachycardia or syncope).
* New York Heart Association class IIIb - IV symptoms.
* Severe LV systolic dysfunction (Ejection fraction ≤ 30%)
* Active decompensated heart failure with orthopnea or paroxysmal nocturnal dyspnea.
* Uncontrolled resting arterial hypertension \> 180/110 mmHg.
* More than moderate systemic disease
* Chronic inflammation or infection.
* Any contraindication to exercise training or any condition limiting ability to partake in adequate exercise stress testing or training (peripheral artery disease, articular, neurologic, or psychiatric pathology)",Secondary prevention and cardiac rehabilitation clinic,INTERVENTIONAL,COMPLETED
NCT02868216,Management of Anger in Patients With Acute Myocardial Infarction (MAPAMI),Myocardial Infarction,acute st elevation myocardial infarction,"* dementia, cognitive dysfunction,
* bypass surgery previous or during the study periods living from more 200 Km from hospital",anger management training,INTERVENTIONAL,COMPLETED
NCT02324348,Efficacy and Safety Study of Deferred Stenting in Patients With STEMI,ST-segment Elevation Myocardial Infarction,"* 18 years of age or older
* more than 30 minutes of duration of typical chest pain
* 1mm or more of ST elevation on 2 or more continuous leads
* chest pain within 12 hours
* Thrombolysis In Myocardial Infarction (TIMI) flow 0, Ⅰ or Ⅱ before procedure
* TIMI Ⅲ flow after balloon angioplasty, intracoronary abciximab infusion, or thrombus aspiration
* accepted informed consent","* cardiogenic shock
* previous history of myocardiac infarction, or coronary artery bypass graft
* rescue percutaneous coronary intervention after fibrinolysis
* life expectancy \< 1 year
* left main disease (included if left main lesion is not infarct related artery)
* contraindication to cardiac MRI
* STEMI due to stent thrombosis
* anticipated risk of acute closure when assigned as deferred stenting group in the condition major dissection (type C\~F) has occurred during procedure achieving TIMI flow involving balloon angioplasty","Deferred coronary stenting, Immediate coronary stenting",INTERVENTIONAL,COMPLETED
NCT03070496,Multicenter Cohort of STEMI Patients,STEMI - ST Elevation Myocardial Infarction,"* Age \> 18 years old
* Diagnosis of STEMI defined by ST segment elevation ≥ 0.2 mV in 2 contiguous leads on a 12-lead ECG.
* Primary Percutaneous coronary intervention (PCI)","* Diagnosis of STEMI not confirmed by angiography
* Refusal to participate in the study or to sign the consent
* Impossibility to give information to the subject about the study
* Lack of medical social coverage
* Obvious contraindication to magnetic resonance imaging (claustrophobia, pacemaker, defibrillator, renal insufficiency, known allergy to a contrast agent)
* Deprivation of civil rights
* participating to another interventional study","Blood sampling, ECG, MRI, Quality of life questionnaire",INTERVENTIONAL,COMPLETED
NCT03404063,Cardiovascular Clinical Project to Evaluate the Regenerative Capacity of CardioCell in Patients With Acute Myocardial Infarction (AMI),Myocardial Infarction,"* Acute myocardial infarction successfully treated by infarct related artery (IRA) successful revascularization
* Male and female patients, aged 18-80 years
* Large myocardial injury as demonstrated by LVEF ≤45% and/or infarct size (IS) ≥10% of the LV muscle on cMRI 2-5 days after pPCI
* Signed informed consent","* Pacemaker or other contraindications to cardiac MRI
* Malignancy
* Moderate or severe immunodeficiency
* Acute or chronic bacterial or viral infectious disease
* Soft tissue disease or local infection in a place of required artery puncture
* Pregnancy or breastfeeding
* Any objective or subjective reason for inability to attend follow-up visits
* Females of childbearing potential, who does not want to use a highly effective method of contraception
* Females of childbearing potential who does not have a menstrual period confirmed and a negative highly sensitive urine or serum pregnancy test
* Participation in any other clinical research study that has not reached the primary efficacy endpoint or otherwise would interfere with the patient's participation in this project
* Life expectancy \< 1 year
* Any concurrent disease or condition that, in the opinion of the investigator, would make the patient unsuitable for participation in the project","Cardiac Drug, Placebos",INTERVENTIONAL,COMPLETED
NCT01323296,Ferumoxytol for Magnetic Resonance Imaging of Myocardial Infarction,Myocardial Infarction,"* Presentation with myocardial infarction (either 'ST-elevation' myocardial infarction or 'non-ST-elevation' myocardial infarction
* Troponin I ≥ 10 IU/mL at 12 hours after the onset of chest pain
* Age 18 - 80 years inclusive","* Known critical (≥95%) left main stem coronary artery disease
* Continued symptoms of angina at rest or minimal exertion
* Atrial fibrillation
* Symptomatic heart failure; Killip Class ≥2.
* Hepatic failure (Childs-Pugh grade B or C) or renal failure (estimated glomerular filtration rate \<25 mL/min)
* Contraindication to magnetic resonance imaging
* Past history of systemic iron overload/haemochromatosis
* Patients with known allergy to dextran- or iron-containing compounds",Ferumoxytol,INTERVENTIONAL,COMPLETED
NCT03893435,The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction,Acute Myocardial Infarction,* Post-AMI patients who underwent successful PPCI and LVEF ≤40%.,"* Post-AMI patients who underwent successful PPCI and LVEF \>40%.
* History of hypersensitivity or allergy to any of the study drugs, as well as known or suspected contraindications to the study drugs.
* Symptomatic hypotension and/or an SBP \< 100 mmHg.
* Estimated GFR \< 30 mL/min/1.73m2 as measured by the simplified MDRD formula or serum potassium \> 5.2 mmol/L.",Sacubitril / Valsartan Oral Tablet [Entresto],INTERVENTIONAL,COMPLETED
NCT01870258,Myocardial Infarction Prediction,"Myocardial Infarction, Artificial Neural Network",* patient with chest pain refered to ER with nondiagnostic ECG,"* 1) Absence of a history of myocardial infarction
* 2) Absence of bundle branch block, Wolf-Parkinson-White abnormality, ventricular hypertrophy or previous ECG signs of myocardial infarction,
* 3) Absence of a history of percutaneous coronary surgery or coronary artery bypass grafting,
* 4) Absence of ECG abnormalities attributable to drugs such as digoxin or tricyclic antidepressants.",ANN prediction of myocardial infarction,INTERVENTIONAL,COMPLETED
NCT05649696,Prolonged Clinical Follow-up of OPTIMA-5,ST-segment Elevation Myocardial Infarction (STEMI),"Arm 1 and 2 inclusion and exclusion criteria



1. Age 18-75 years, weight ≥45 kg;
2. Diagnosed as STEMI (meeting the following two criteria simultaneously):

   i. Ischemic chest pain lasts ≥30 minutes; ii. Electrocardiogram indicates that ST-segment elevation ≥2 mm in 2 or more contiguous precordial leads or ≥1 mm in 2 or more peripheral leads;
3. Time from onset of persistent chest pain to randomization \<12 hours;
4. Primary PCI expected to be performed within 120 minutes.","1. Cardiogenic shock;
2. Active bleeding or at high risk of bleeding (including grade Ⅲ or Ⅳ retinopathy or retinal gastrointestinal or urinary tract hemorrhage within the past 1 month);
3. Ischemic stroke or TIA in the past 6 months;
4. History of hemorrhagic stroke;
5. Platelet count \<100×109/L or hemoglobin \<100 g/L;
6. Known intracranial aneurysm;
7. Severe trauma, surgery or head injury within 1 month;
8. Suspected aortic dissection or infective endocarditis;
9. Recent puncture with difficult hemostasis by compression (eg, visceral biopsy, compartment puncture);
10. Currently taking anticoagulants;
11. Poorly controlled hypertension ( ≥180/110 mmHg);
12. Hepatic or renal impairment (glutamic-pyruvic transaminase, glutamic oxalacetic transaminase, or γ -glutamyl transferase \>2.5 times upper limit of normal value; creatinine \>1.5 times upper limit of normal value);
13. Known allergy to r-SAK;
14. Pregnancy, lactation, or planning for pregnancy;
15. History of myocardial infarction or CABG;
16. Having taken antiplatelet drugs other than aspirin and ticagrelor, such as clopidogrel, prasugrel or cilostazol after the symptom onset;
17. Patients with other conditions that made them unsuitable to be recruited at the discretion of the investigators.

Arm 3 inclusion and exclusion criteria Inclusion criteria

1. Age ≥18, ≤75 years old, weight ≥45kg, gender is not limited；
2. Taking maintenance dose of aspirin and ticagrelor for more than 3 days, or taking loading dose of aspirin (300mg) and ticagrelor (180mg);
3. Inpatients with suspected coronary atherosclerotic heart disease scheduled for coronary angiography or interventional therapy.

Exclusion criteria

1. Patients who had received r-SAK thrombolytic therapy before;
2. Previous diagnosis of Staphylococcus aureus infection;
3. Patients who were participating in other clinical trials;
4. Other patients considered unsuitable for inclusion by the investigators.","Recombinant Staphylokinase, Normal Saline",INTERVENTIONAL,COMPLETED
NCT00157768,IRIS : Use of Implantable Defibrillator in High-risk Patients Early After Acute Myocardial Infarction,Acute Myocardial Infarction,"* acute myocardial infarction (5-31 days)
* fulfill requirement I and/or II :

  * I first ECG heart rate \>= 90 bpm (within day 1-2 post MI) and LVEF \<= 40 % (within day 5-31 post-MI)
  * II \>= 1 episode of non-sustained ventricular tachycardia \>= 150 bpm (on Holter, within 5-31 days post-MI)","* Patients with ventricular arrhythmia, requiring clinical therapy, before the index infarction or more than 48 h later
* Patients with therapy refractory heart failure (NYHA IV)
* Myocardial infarction older than 31 days
* First-ECG not available or was recorded more than 48 h after the symptom onset.
* Patients with indication for CABG operation before inclusion
* Patients with cerebral organic psycho syndrome
* Secondary diseases which clearly limit life expectancy
* Patient with right sided artificial heart valve
* Patients with poor compliance
* Patients who are participating in another study
* Unstable clinical condition
* Pregnancy
* No consent from patient",Implantable cardioverter defibrillator,INTERVENTIONAL,COMPLETED
NCT01176968,Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction,Myocardial Infarction,* Subjects must have experienced a myocardial infarction (STEMI) within the previous 24 hours confirmed by symptoms and ECG.,"* Subjects with a known low ejection fraction of less than 40% or any previous history of heart failure.
* Subjects treated with eplerenone or other aldosterone antagonists within the past 1 month.
* The subject has uncontrolled hypotension (SBP\<90mmHg).
* Subjects with eGFR ≤30ml/min (based on admission serum creatinine and the MDRD formula) or serum creatinine ≥220µmol/L.","Eplerenone, Placebo",INTERVENTIONAL,COMPLETED
NCT05498844,Adherence to Nutritional Treatment Following MI Using Telemedicine Treatment (ADNUT),"Cardiovascular Diseases, Acute MI","* Patients within one month from hospital discharge for PTCA/MI,
* Patients with cardiac risk 1-2
* Patients capable of conducting a conversation using Zoom software
* Patients speaking either Hebrew or English","* Patients with a prognosis of one year or less due to comorbidity
* Patients with renal failure or patients with hemodynamic instability
* Patients who were already participating in a remote cardiac rehabilitation program
* Patients with hearing or vision impairments are prevented from reasonable participation in an online call (zoom) or patients
* Patients who do not have access to a computer/smartphone.",Medical Nutrition Therapy (counselling),INTERVENTIONAL,COMPLETED
NCT06822244,The Effect of Pranayama Exercise,"Pranayama, Exercise, Anxiety, Death, Sleep","Voluntary participation in the study

Age ≥18 years

Diagnosed with AMI

Cognitive ability to perform pranayama exercises

Ability to comprehend and respond to survey questions

No communication impairments","* having respiratory diseases
* low saturation \<95","Pranayama exercise, normal breathing",INTERVENTIONAL,COMPLETED
NCT01149044,A Trial of Routine Aspiration Thrombectomy With Percutaneous Coronary Intervention (PCI) Versus PCI Alone in Patients With ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Primary PCI,"Acute Coronary Syndrome, ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention","1. Patients presenting with:

   * Symptoms of myocardial ischemia lasting for ≥ 30 minutes AND
   * Definite ECG changes indicating STEMI: ST elevation of greater than 0.1 mV in two contiguous limb leads or 0.2 mV in two contiguous precordial leads
2. Referred for primary PCI
3. Randomized within 12 hours of symptoms onset and prior to diagnostic angiography
4. Informed consent","1. Age ≤ 18 years
2. Prior coronary artery bypass surgery (CABG)
3. Life expectancy less than six months due to non-cardiac condition
4. Treatment with fibrinolytic therapy for qualifying index STEMI event",Percutaneous Coronary Intervention with or without manual aspiration thrombectomy,INTERVENTIONAL,COMPLETED
NCT03930589,Remote Ischemic Conditioning in STEMI to Decrease Infarct Size,"STEMI, CAD","Patients presenting with STEMI within 6 hours of symptom onset and:

1. Are expected to receive reperfusion therapy with either fibrinolysis or primary PCI.
2. Documented informed consent (verbal)","1. Cardiogenic shock
2. History of anatomical deformity or vascular complication that limit ability to conduct remote ischemic preconditioning","Remote Ischemic conditioning, Standard of care",INTERVENTIONAL,COMPLETED
NCT01594489,Aminophylline and Contrast Induced Nephropathy in Acute Myocardial Infarction,Acute Kidney Injury,* Consecutive patients with AMI candidates for primary PCI presenting within 12 h of symptom onset with ST-segment elevation of more than 1 mm in at least two contiguous leads of the electrocardiogram,"* contrast medium administration within the previous 10 days,
* end-stage renal failure requiring dialysis,
* refusal to give informed consent","Aminophylline, Hydration plus N-acetylcisteine",INTERVENTIONAL,COMPLETED
NCT01004289,POSTconditioning During Coronary Angioplasty in Acute Myocardial Infarction Study,Myocardial Reperfusion Injury,"* clinical evidence of myocardial infarction defined by the presence of ischemic chest pain lasting more than 30 minutes, with a time interval from the onset of symptoms less than 6 hours before hospital admission, associated with typical ST-segment elevation on the 12-lead ECG
* angiographic-detected culprit lesion with stenosis diameter \>70% and TIMI flow grade \<=1","* previous acute myocardial infarction
* previous myocardial revascularization (angioplasty or coronary bypass)
* previous heart valve replacement
* previous heart transplant
* clinical instability precluding the suitability of the study
* cardiogenic shock or persistent hypotension (systolic blood pressure \<100 mmHg)
* rescue angioplasty after thrombolytic therapy
* evidence of coronary collaterals (Rentrop grade\>0) in the risk area
* advanced atrioventricular block
* significant bradycardia
* absence of sinus rhythm
* inability to lay flat (due to severe cardiac heart failure/respiratory insufficiency)
* history or clinical evidence of bronchospastic lung disease
* pregnancy
* known existence of a life-threatening disease with a life expectancy \<6 months
* inability to give informed consent
* any contraindication to undergo cardiac-MRI, such as implanted metallic objects (cardiac pacemakers and/or implantable cardioverter defibrillator, implanted insulin pumps or any other type of electronic devices, cerebral clips, aneurysm clips) or any other contraindication to cardiac-MRI (such as claustrophobia)","Postconditioning, Primary angioplasty and stenting without additional intervention",INTERVENTIONAL,COMPLETED
NCT01559467,The Supplementary Role of Non-invasive Imaging to Routine Clinical Practice in Suspected Non-ST-elevation Myocardial Infarction,"Chest Pain, Myocardial Infarction, Acute Coronary Syndrome, Coronary Artery Disease, Myocardial Ischemia","* Prolonged symptoms suspected of cardiac origin (angina pectoris or angina equivalent), and presentation on the cardiac emergency department \<24 hours after symptom onset

  * Increased levels of high-sensitive Troponin-T (\>14ng/L)
  * Age \>18 years and \<85 years
  * Willing and capable to give written informed consent
  * Written informed consent","* Ongoing severe ischemia requiring immediate invasive coronary angiography
* Shock (mean arterial pressure \< 60 mmHg) or severe heart failure (Killip Class ≥ III)
* ST-elevation myocardial infarction (ST-elevation in 2 contiguous leads: ≥0.2mV in men or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other leads or new left bundle branch block)
* Chest pain highly suggestive of non-cardiac origin:

  * Acute aortic dissection
  * Acute pulmonary embolism (high risk patient defined as Wells score \>6)
  * Musculoskeletal or gastro-intestinal pain
  * Other (pneumothorax, pneumonia, rib fracture, etc.)
* Previously known coronary artery disease, defined as:

  * Any non-invasive diagnostic imaging test positive for coronary artery disease
  * Coronary stenosis \>50% on any previous invasive coronary angiography or computed tomography angiography
  * Documented previous myocardial infarction
  * Documented previous coronary artery revascularization
  * Known cardiomyopathy
* Pregnancy
* Life threatening arrhythmia on the cardiac emergency department or prior to presentation
* Tachycardia (≥100/bpm)
* Atrial fibrillation
* Angina pectoris secondary to anemia (\<5.6 mmol/L), untreated hyperthyroidism, aortic valve stenosis (aortic valve area ≤ 1.5 cm2), or severe hypertension (\>200/110 mmHg)
* Life expectancy \<1 year (malignancy, etc.)
* Contraindications to cardiovascular magnetic resonance imaging: metallic implant (vascular clip, neuro-stimulator, cochlear implant), pacemaker or implantable cardiac defibrillator, claustrophobia","Cardiovascular Magnetic Resonance Imaging, Computed Tomography Angiography",INTERVENTIONAL,COMPLETED
NCT05340946,Comparison of the Effect of Two Anaesthesia Methods in Preventing Perioperative Myocardial Infarcation in Patients With Cardiac Risk Undergoing Total Knee Arthroplasty,Myocardial Ischaemia,"* presence and/or risk for coronary artery disease (CAD) as well as planned lower extremity surgery was considered. Presence of CAD was ascertained by history of myocardial infarction and diagnosis of typical angina or atypical angina with a positive stress test \& ECG finding. Risk for CAD included age (\> 65 years old), hypertension, smoking habit, blood cholesterol (\>240 mg/dL), and diabetes.","* 1) severe impairment of left ventricular function (ejection fraction \< 40 %). 2) renal failure requiring hemodialysis. 3) known allergies to the drugs used in the present study. 4) contraindications to regional blocks (localized infection, and use of an antiplatelet drug within 3 days before the surgery). 5) unusual blood coagulation tests.","general anaesthesia, spinal anaesthesia",INTERVENTIONAL,COMPLETED
NCT02672267,A Study of Allogeneic Low Oxygen Mesenchymal Bone Marrow Cells in Subjects With Myocardial Infarction,Myocardial Infarction,"1. Males and females 18-85 years of age.
2. First Acute Myocardial Infarction (STEMI, non STEMI) within 7 days of study enrollment. Myocardial infarction is defined as ECG, Lab and CMR evidences.
3. Subject had successful revascularization within 12 hours of symptoms as evidenced by residual stenosis \< 30% and TIMI antegrade flow II or III in the culprit vessel. Revascularization may include one of the following:

   * PCI angioplasty/stenting placement
   * Thrombolytic therapy
4. Life expectancy greater than 12 months.
5. Ability to understand and provide signed informed consent, or have a designated legal guardian or spouse legally able and willing to make such decisions on the subject's behalf.
6. Reasonable expectation that subject will receive standard post myocardial infarction care, unless contraindicated, including medications: • Anticoagulation (e.g. aspirin, clopidogrel, ticlopidine, prasugrel, etc.), beta-blockers, ace inhibitors, and statin agents, as tolerated.
7. Attend all scheduled safety follow-up visits.","1. Hemodynamic instability as demonstrated by any of the following:

   * Requirement of intra-aortic balloon pump of left ventricular assist device.
   * Need for inotropic support (e.g. dopamine and/or dobutamine) for more than 36 hours for the maintenance of mean arterial blood pressure ≥60 mmHg.
2. History of cancer within the past 5 years, with the exception of localized basal or squamous cell carcinoma.
3. Clinically-significant hematologic, hepatic, or renal impairment within 24 hours of study procedure as determined by screening clinical laboratory tests. Severe chronic anemia or hematocrit ≤24%. Liver function tests (total bilirubin at 3 times upper limit of normal, or creatinine level ≥3mg/dL).
4. Presence of any other clinically-significant medical condition, psychiatric condition, or laboratory abnormality, that in the judgment of the Investigator or Sponsor for which participation in the study would pose a safety risk to the subject.
5. Participation in another study with an investigational drug or device within 3 months prior to stem cell administration.
6. History within the past year of drug or alcohol abuse.
7. Females known to be pregnant, lactating or having a positive pregnancy test (will be tested during screening) or planning to become pregnant during the study.
8. Inability to comply with the conditions of the protocol.
9. Presence of a transplanted tissue or organ or left ventricular assist device (LVAD) (or the expectation of the same within the next 12 months).
10. Planned Automatic Implantable Cardiac Defibrillator (AICD) or CRT within the next 12 months.
11. Need for chronic intermittent inotropic therapy.
12. Active myocarditis or early postpartum cardiomyopathy (within the first twelve months of delivery).
13. Porphyria.
14. Allergy to sodium citrate or any ""caine"" type of local anesthetic.
15. Subject scheduled for hospice care.
16. Clinically relevant abnormal findings in the clinical history, physical examination, ECG (e.g. life threatening arrhythmias, including QTc interval of ≥550 ms) or laboratory tests at the screening assessment that would interfere with the objectives of the study or that would, in the Investigator's opinion, preclude safe completion of the study.
17. Abnormal findings could include: known HIV infection or other immunodeficiency state, chronic active viral infection (such as hepatitis B or C), acute systemic infections (defined as subjects undergoing treatment with antibiotics), gastrointestinal tract bleeding, or any severe or acute concomitant illness or injury.
18. Any other medical, social, or geographical factor that would make it unlikely that the subject could comply with study procedures (e.g., alcohol abuse, lack of permanent residence, severe depression, disorientation, distant location, or a history of noncompliance).","Stem cells, Placebo",INTERVENTIONAL,COMPLETED
NCT04202172,Functional Assessment of the Infart-related Artery With Bioactive and Polymer-free Coronary Stents (The FUNCOMBO Trial),"Endothelial Dysfunction, Coronary Microvascular Disease, Myocardial Infarction","* STEMI \< 12 hours undergoing primary PCI.
* ST-segment elevation of \> 1mm in \> 2 contiguous leads, or (presumably new) left bundle branch block, or true posterior MI with ST depression of \>1mm in \>2 contiguous anterior leads.
* Presence of at least one acute infarct artery target vessel with one or more de-novo coronary artery stenosis in a native coronary artery within 2.75 - 3.75 mm reference vessel diameter and \< 24 mm length (visually estimated).","* Inability to provide informed consent
* Female of childbearing potential (age \<50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy
* Known intolerance to aspirin, heparin, PLLA, everolimus, contrast material
* Cardiogenic Shock
* Unprotected left main coronary artery stenosis
* Distal occlusion of target vessel
* Acute myocardial infarction secondary to stent thrombosis
* Mechanical complications of acute myocardial infarction
* Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in sub-optimal imaging or excessive risk of complication in the follow-up procedure
* Active bleeding or coagulopathy or patients at chronic anticoagulation therapy
* Chronic renal dysfunction with creatinine clearance \< 45 ml/minm2
* Subject is currently participating in another clinical trial that has not yet completed its primary endpoint",Stent implantation in the infart-related artery in patients with ST elevation myocardial infarction,INTERVENTIONAL,COMPLETED
NCT01216995,Safety and Efficacy of Adipose Derived Regenerative Cells (ADRCs) Delivered Via the Intracoronary Route in the Treatment of Patients With ST-elevation Acute Myocardial Infarction (AMI),Acute Myocardial Infarction,"Key 

* ST-segment Elevation Myocardial Infarction (STEMI) Criteria:
* Ischemic symptoms AND
* ECG:
* Development of pathologic Q waves on the ECG; or
* ECG changes indicative of severe ischemia (ST segment elevation and/or depression); or
* New left bundle branch block; AND
* Creatine Phosphokinase Isoenzyme (MB Form) \> 100 IU/L, or troponin \>5x the upper limit of normal between admission and randomization
* Successful revascularization of the culprit lesion in a major epicardial vessel

Key","* More than 24 hours between PCI and start of liposuction
* Prior myocardial infarction, cardiomyopathy, or a history of congestive heart failure
* Pacemaker, ICD, or any other contra-indication for MRI
* Patients with increased bleeding risk
* Cardiogenic shock present post-index PCI","Dose A, Placebo",INTERVENTIONAL,COMPLETED
NCT01991795,A Study Comparing Cardiovascular Effects of Ticagrelor Versus Placebo in Patients With Type 2 Diabetes Mellitus,"Diabetes Mellitus, Type 2","Men or women ≥50 years of age with type 2 diabetes mellitus on treatment with a glucose lowering medication since at least 6 months, and either documented coronary artery occlusive disease or previous revascularization of a coronary artery.

Key","History of myocardial infarction or any stroke; planned treatment with agents inhibiting blood clotting; planned use of ASA/Aspirin at doses above 150 mg daily; planned coronary, cerebrovascular, or peripheral arterial revascularization; patients with known bleeding disorders and patients who need chronic oral anticoagulant therapy or chronic low-molecular-weight heparin; history of intracranial bleeding at any time, or a history of bleeding from the gastrointestinal tract within the last 6 months or a major surgery within the last 30 days; patients with known severe liver disease or with kidney failure requiring dialysis","Ticagrelor 60 mg, Ticagrelor placebo",INTERVENTIONAL,COMPLETED
NCT01977755,Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction,Focus of Study is STEMI,"* Age ≥ 18 years
* ST-segment elevation myocardial infarction
* Acute onset of chest pain of \< 12 hours duration","* Pregnancy
* Known prior Myocardial Infarction in same area as present STEMI, known hypertrophic or dilated cardiomyopathy, or prior hospital admission for heart failure
* Contraindication for cardiac MRI
* Inability to understand information or provide informed consent","danegaptide, Placebo",INTERVENTIONAL,COMPLETED
NCT00604695,A Safety/Efficacy Study of Intra-coronary Tenecteplase During Balloon Angioplasty to Treat Heart Attacks,Acute Myocardial Infarction,"* Subjects (men or women) at least 18 years and less than 75 years of age and
* Ischemic discomfort ≥20 minutes and ≤6 hours of duration and
* ST elevation ≥1mm (≥0.1mV) in two contiguous limb leads OR ≥2mm (≥0.2mV) in two contiguous precordial leads and
* Occluded infarct-related artery (TIMI Flow Grade 0 or 1) at the time of coronary angiography and
* Planned primary PCI within 2 hours of hospital presentation and
* Planned or concomitant use of aspirin, clopidogrel, unfractionated heparin, and Glycoprotein IIb/IIIa inhibition with intent to stent the infarct-related artery and
* Informed consent able to be obtained","CLINICAL

* Age ≥75 years
* Maximal systolic blood pressure \<80 mmHg AFTER initial fluid and/or pressor resuscitation.
* Uncontrolled hypertension (SBP \>180 OR DBP \>110) at time of enrollment.
* Cardiac arrest or arrhythmia requiring chest compressions or cardiopulmonary resuscitation.
* Known pregnancy.

BIOCHEMICAL

* Known thrombocytopenia (platelet count \<100,000)
* Known severe renal insufficiency (creatinine \>4.0 mg/dL).

INCREASED BLEEDING RISK

* Active internal bleeding
* Recent (\<3 months) gastrointestinal hemorrhage
* Recent intracranial or intraspinal surgery, trauma, major surgery, or biopsy of a parenchymal organ (\< 1 month)
* Known coagulopathy, platelet disorder, or history of thrombocytopenia
* Current warfarin therapy
* Known neoplasm
* Any known history of transient ischemic attack, cerebrovascular accident, or active intracranial pathology including arteriovenous malformation or aneurysm

MEDICATIONS

* Administration of a fibrinolytic agent within 72 hours
* Known allergy or contraindication to fibrinolytics OR aspirin OR heparin OR clopidogrel

ANGIOGRAPHIC

* Left Main Coronary artery culprit lesion
* Ostial culprit lesion (ostium of LAD, LCX, or RCA).
* Lesion in non-native coronary artery (e.g. saphenous vein graft, arterial conduit graft)
* Subjects requiring urgent coronary artery bypass grafting","Tenecteplase, Sterile Saline",INTERVENTIONAL,COMPLETED
NCT05128981,Internet-delivered Cognitive Behavioral Therapy Following Myocardial Infarction,"Myocardial Infarction, Cardiac Anxiety, CBT, Exposure",( - )MI ≥ 6 months before assessment ( - )Age 18-75 years endorsed cardiac anxiety that leads to significant distress or interferes with daily life (Cardiac Anxiety Questionnaire (CAQ); score ≥20) ( - ) On optimal medical treatment ( - )Able to read and write in Swedish.,"( - ) heart failure with severe systolic dysfunction (ejection fraction ≤ 35%) ( - ) significant valvular disease ( - ) planned coronary artery bypass surgery or other invasive therapy ( - ) other severe medical illness ( - )any medical restriction to physical exercise ( - )severe psychiatric disorder, severe depression, or risk of suicide ( - )alcohol dependency",MI-CBT,INTERVENTIONAL,COMPLETED
NCT00286312,Myocardial Infarction Size Reduction With Atorvastatin,"Myocardial Infarction, Reperfusion Injury",* Consecutive patients (aged \> 18 years) who are to undergo a primary PCI for a first acute ST elevation myocardial infarction will be asked to participate in this study.,"* Previous myocardial infarction
* Previous coronary artery bypass grafting (CABG)
* Cardiac rhythm is other than normal sinus rhythm.
* Electrical instability.
* The patient is in Killip class 3 or 4 of heart failure.
* Need for intra aortic balloon counterpulsation therapy
* The patient is unable to hold his/her breath for up to 20 seconds due to age or concomitant illness.
* Implanted electronic devices are present: pacemakers, internal defibrillators, ECG-registration devices, neurostimulators, implanted drug infusion devices, cochlear implants etc.
* Previous vascular surgery: aneurysm clip, carotid artery vascular clamp, aortic clips, or venous umbrella
* Prosthesis (orbital/penile, etc.)
* Spinal/intra-ventricular shunts.
* Swan-Ganz catheter; transdermal delivery systems.
* Metal fragments: eye, head, ear, skin.
* Implants held by magnets.
* Known allergy to MR contrast media
* Prior use of statins
* No PCI performed
* No recanalisation achieved",Atorvastatin,INTERVENTIONAL,COMPLETED
NCT03625869,Pressure-controlled Intermittent Coronary Sinus Occlusion (PiCSO) in Acute Myocardial Infarction,"STEMI, Anterior MI","Inclusion Criteria:

1. Age ≥18 years old
2. Culprit lesion in proximal or mid LAD
3. Pre-PCI TIMI flow 0 or 1.
4. Symptoms onset time consistent with myocardial ischemia (e.g. persistent chest pain, shortness of breath, nausea/vomiting, fatigue, palpitations or syncope) ≤ 12 h.
5. ECG evidence of acute anterior myocardial infarction with ST-elevation ≥ 2 mm (0.2 mV) in 2 or more contiguous anterior precordial ECG leads (one of which should be V2, V3, or V4) in men or ≥ 1.5 mm (0.15 mV) in women
6. Patient is deemed eligible for primary PCI
7. STEMI patients: consent as per approved national ethical committee specific requirements prior to the procedure.",":

1. Implants or foreign bodies in the coronary sinus
2. Known allergy to polyurethanes, PET or stainless steel
3. Known pregnancy and breastfeeding
4. Pericardial effusion (cardiac tamponade)
5. Central hemodynamically relevant left/right shunt
6. Previous MI or CABG
7. History of stroke, TIA or reversible ischemic neurological deficit within last 6 months
8. Known coagulopathy
9. Need for circulatory support or pre-procedural ventilation
10. Patients with cardio-pulmonary resuscitated (CPR) cardiac arrest for more than 5 minutes
11. Patient not suitable for femoral vein access
12. Contraindication to cardiac magnetic resonance imaging (CMR), e.g. claustrophobia, foreign body implants incompatible with CMR, gadolinium intolerance.
13. Active participation in another drug or device investigational study
14. Known severe kidney disease or on hemodialysis
15. Unconscious on presentation
16. Patients under judicial protection, legal guardianship or curatorship",PiCSO,INTERVENTIONAL,COMPLETED
NCT03156816,COlchicine for Left VEntricular Remodeling Treatment in Acute Myocardial Infarction,Myocardial Infarction,"* All patients, aged over 18 and \<80 years,
* Presenting within 12 hours of chest pain onset,
* With ST segment elevation ≥ 0.2 mV in two contiguous leads or new onset of left bundle branch block,
* Referral for primary percutaneous coronary intervention (PPCI).
* Preliminary oral informed consent followed by signed informed consent as soon as possible
* With an initially occluded coronary artery (TIMI angiographic flow of the culprit coronary artery ≤1)","* Patients with any legal protection measure,
* Patients without any health coverage,
* Patients with loss of consciousness or confused
* Patients with a history of prior myocardial infarction
* Patients with cardiogenic shock as defined by a systolic blood pressure \<90 mmHg, despite 30 minutes of fluid challenge or requiring intravenous vasoactive agents (dobutamine, noradrenaline, adrenaline)
* Patient with severe liver or known renal dysfunction (known GFR≤30 ml/min)
* Patient with known history of severe drug intolerance to colchicine
* Female patients currently pregnant or women of childbearing age not using contraception (oral diagnosis)
* Patients with any obvious contraindication to magnetic resonance imaging (claustrophobia, pace maker, defibrillator....)
* Patients treated by macrolides or pristinamycin
* Chronic treatment with COLCHICINE (Mediterranean familial fever mainly)
* Patient with lactose intolerance
* Patient with swallowing disorders","Colchicine group (experimental arm), Placebo group (control arm)",INTERVENTIONAL,COMPLETED
NCT04824716,Analysis of the Efficacy of Cardiac Ischemic Postconditioning With New Clinical End-points Using Novel Biomarkers,Acute Myocardial Infarction With ST Elevation,"1. Subject must be \>18 years of age
2. Myocardial infarction with elevated ST
3. Chest pain onset less than 12 hours before PCI
4. concordant ST elevation (\>0,1 mV) in at least 2 ECG leads
5. Occluded main proximal or middle main coronary ('Thrombolysis In Myocardial Infarction' flow grade: 0) diagnosed with coronarography
6. Coronary opened by PCI (TIMI 2 flow grade)
7. Awake, conscious, co-operating patient, who is able to retain his breath for 10 sec
8. Signed Patient Information Leaflet and Patient Informed Consent Form","1. Cardiogenic shock
2. Previous myocardial infarction in the area of the occluded coronary artery
3. Occluded coronary with visible collateral branches
4. Lack of co-operation
5. Current left or right bundle branch block (LBBB)
6. Malignant ventricle arrhythmia or atrial fibrillation
7. Killip class \> 2
8. Known renal failure","Postconditioning, Percutaneous coronary intervention",INTERVENTIONAL,COMPLETED
NCT01950416,Ticagrelor vs High Dose Clopidogrel in Patients With ST Elevation Myocardial Infarction Post Fibrinolysis,"ST Elevation Myocardial Infarction, Fibrinolysis, P2Y12 Inhibitor","1. Age 18-85 years old
2. Patients with STEMI, having undergone fibrinolytic therapy in the previous 3 to 48 hours
3. Presenting HPR (≥208 PRU) post 300mg clopidogrel loading dose ( assessment immediately before coronary angiography)
4. Informed consent obtained in writing","* Pregnancy
* Breastfeeding
* Inability to give informed consent
* Cardiogenic shock
* Major periprocedural complications (death, stent thrombosis, vessel perforation, arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents, respiratory failure requiring intubation, vascular injury (arteriovenous shunt, retroperitoneal bleeding), major bleeding (need for bood transfusion or drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding)
* Known hypersensitivity to ticagrelor or clopidogrel
* History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 3 months.
* Other bleeding diathesis, or considered by investigator to be at high risk for bleeding
* Any previous history of stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).
* Thombocytopenia (\<100.000 / μL) at randomization
* Anaemia (Hct \<30%) at randomization
* Polycytaemia (Hct \> 52%) at randomization
* Periprocedural IIb/IIIa inhibitors administration
* Per os anticoagulants
* Recent (\< 6 weeks) major surgery or trauma, including GABG.
* Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
* Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin /rifampicin, phenytoin, carbamazepine).
* Increased risk of bradycardiac events.
* Dialysis required.
* Severe uncontrolled chronic obstructive pulmonary disease
* Known severe hepatic impairement","Ticagrelor 180mg loading dose and 90mg bid maintenance dose, Clopidogrel 600mg loading dose and 150mg maintenance dose",INTERVENTIONAL,COMPLETED
NCT00215124,A Phase I - II Safety Study of Filgrastim (Neupogen) to Improve Left Ventricular Function After Severe Acute Myocardial Infarction,Acute Myocardial Infarction,Acute Myocardial Infarction within 6 hours of symptoms,-,Filgrastim,INTERVENTIONAL,COMPLETED
NCT03335839,"Adjunctive, Low-dose TPA in Primary PCI for STEMI","Myocardial Infarction, Percutaneous Coronary Intervention","1. Patients with STEMI undergoing primary PCI and,
2. ECG changes indicating large territory STEMI (defined as ≥2mm ST-segment elevation in 2 contiguous anterior precordial leads; or ≥2mm ST-segment elevation in 2 inferior leads coupled with ST-segment depression in 2 contiguous anterior leads for a total ST-segment deviation of ≥8mm) and,
3. Randomization within 6 to 12 hours of symptom onset and,
4. Large thrombus burden with angiographic TIMI Thrombus Grade ≥3 after guidewire crossing.","1. Active internal bleeding or high risk of bleeding or any prior intracranial bleeding.
2. Any other absolute or relative contraindication to fibrinolytic therapy.
3. Administration of a fibrinolytic ≤24hrs prior to randomization.
4. Cardiogenic shock on presentation.
5. Left bundle branch block (excluded because the ECG cannot be evaluated for ST segment resolution, an outcome of the study).
6. Planned upfront use of a glycoprotein IIb/IIIa inhibitor.
7. Any medical, geographic, or social factor making study participation impractical or precluding 1 month follow-up.","tissue plasminogen activator, Saline",INTERVENTIONAL,COMPLETED
NCT00313339,Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction,"Myocardial Infarction, Coronary Artery Disease","* Age 18 - 75 years.
* Acute ST elevation myocardial infarction meeting ACC/AHA criteria, with symptoms of chest pain within 3 days of admission. Criteria include (ST elevation \> 1mm in limb leads or 2 mm in two or more precordial leads and increased levels of troponin, CPK MB or both)
* NYHA heart failure class of I, II or III","* Patients who are not candidates for percutaneous intervention, conscious sedation, MRI, SPECT imaging or mini-bone marrow harvest
* History of sustained chest pain unrelieved by nitrates, occurring 4 or more days before revascularization.
* Patients who fail to re-perfuse the infarct related coronary artery or have successful stent placement",Intra-coronary infusion,INTERVENTIONAL,COMPLETED
NCT02823886,Inflammatory Response in Myocardial Infarction Evaluated by MRI and Biomarkers,Myocardial Infarction,"* All patients, aged over 18, without any legal protection measure,
* Having a health coverage,
* Presenting within 12 hours of the onset of chest pain,
* Who have ST segment elevation ≥0.2 millivolt (mV) in two contiguous leads,
* For whom the clinical decision was made to treat with percutaneous coronary intervention (PCI).
* he culprit coronary artery has to be the left anterior descending (LAD) or the right coronary (RC)
* The LAD or RC artery has to be occluded (TIMI flow grade 0-1) at the time of admission coronary angiography.
* Preliminary oral informed consent followed by signed informed consent as soon as possible
* Final TIMI ≥ 2","* Female patients currently pregnant or women of childbearing age who were not using contraception (oral diagnosis).
* Patients with cardiogenic shock
* Patient in Cardiac arrest
* History of Myocardial Infarction
* Contre-indication to MRI : claustrophobia, pacemaker or cardiac defibrillator , eye metal body allergy to gadolinium
* Patient with Atrial Fibrillation.
* Patients with loss of consciousness or (Glasgow \<14)
* known renal insufficiency (either known creatinin clearance \< 30 ml/min/1.73m² or current medical care for severe renal insufficiency)
* Patients with any disorder associated with immunological dysfunction
* Adult with legal protection measure","MRI at D7, Blood samples",INTERVENTIONAL,COMPLETED
NCT01438086,Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack,"Heart Failure, Myocardial Infarction","* Age 18 - 75
* Presents within 2-12 hours of at least 30 minutes of myocardial ischemic pain
* ECG evidence of myocardial infarction
* Undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction
* Left ventricular ejection fraction during PCI of 40% or less
* TIMI flow grade 3 in the infarct-related artery following reperfusion and stenting","* History of prior myocardial infarction
* Prior history of heart failure, left ventricular dysfunction or cardiomyopathy
* Active or suspected neoplasia
* Known impaired liver function
* Cardiogenic shock
* Estimated glomerular filtration rate \< 45 ml/min/1.73m2
* History of hypoglycaemia requiring hospitalisation
* History of primary insulin-like growth factor-1 deficiency or growth hormone disorders
* Contraindication to cardiac magnetic resonance imaging
* Pregnancy or nursing mothers
* Known allergy to study drug or any of its inactive ingredients
* Treatment with another investigational agent within 30 days of enrolment
* Subjects unable or unwilling to comply with follow-up requirements of study
* Subjects unable to provide written informed consent","mecasermin, mecasermin, 0.9% sodium chloride injection",INTERVENTIONAL,COMPLETED
NCT04441086,Emotion Regulation Intervention to Sustain Physical Activity in Rural-dwelling Women and Men After Myocardial Infarction,"Cardiac Event, Emotions","Inclusion Criteria:

1. First time major cardiac event as documented in medical record;
2. enrolled in cardiac rehabilitation phase II program;
3. living independently; and
4. at least mild symptoms of depression and/or anxiety (determined by standardized measure cutpoints).",":

1. does not speak English;
2. major Axis 1 psychiatric diagnosis (e.g. schizophrenia);
3. terminal cancer; and
4. legally blind","eMotion, Healthy Living Active Control",INTERVENTIONAL,COMPLETED
NCT03005886,The Effect of Periodontal Therapy in Chronic Periodontitis Patients With and Without Acute Myocardial Infarction,"Myocardial Infarction, Chronic Periodontitis","* None of the patients had received periodontal treatment during the past 6 months and none had received antibiotic medication during the past 3 months.
* AMI+CP and CP groups were regarded as suitable for the study if they were affected by CP and had at least 16 teeth, including at least four molars in different quadrants at least two periodontal pocket at least 5mm in depth, with a minimum of 2mm attachment loss.
* Patients, who met the AMI diagnostic criteria, with or without persistent ST-segment elevation","* Patients with neoplasias, liver cirrhosis, HIV infection, chronic renal failure, hypo or hyperparathyroidism, diabetes mellitus, chronic inflammatory diseases (rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and Chron's Disease","Periodontal examination, GCF sampling, phase I therapy",INTERVENTIONAL,COMPLETED
NCT04934735,Case-management Rehabilitation Intervention in Facilitating Return to Work After Myocardial Infarction,"Case Manager, Myocardial Infarction, Sick Leave, Return to Work","* Sex/Gender: Both males and females
* Age limits: Minimum Age: 25 years old; Maximum age: 57 years old
* Clinical diagnosis: Patients after acute myocardial infarction
* Occupational status: Patients that have been working before the myocardial infarction
* HMO membership: Members in Maccabi Healthcare Service (HMO in Israel)
* Sampling Method: A consecutive participant sampling took place. Each patient who fulfilled the study terms was invited to participate in the study","* Age over 57 years old or less than 25 years old
* Clinical diagnosis: Patients who had not sustained acute myocardial infarction
* Occupational status: Not working 6 months prior to the acute myocardial infarction
* HMO membership: Non-members of Maccabi Healthcare Service (HMO in Israel).
* Consent to participate: Patients who have not agreed to participate in the study",Rehabilitation program group,INTERVENTIONAL,COMPLETED
NCT02768935,Macrophage Phenotype in Type 2 Diabetics After Myocardial Infarction and the Potential Role of miRNAs Secreted,"DIABETES, MYOCARD INFARCTUS","* Male Patients (to avoid the influence of estrogen hormones known to influence the M1 / M2 balance)
* Age: greater than 65 years (allowing homogeneity of the study population vis-à-vis the effect of age on differentiation M1 / M2)
* Patients hospitalized for a heart attack (chest pain, characteristic ECG changes, increased troponin levels (\> 0.06 ng / ml))
* BMI between 19 and 30 (to avoid interference of obesity per se)
* Signed informed consent
* Affiliation to a social security scheme

Additional inclusion criterion for the group of diabetic subjects:

HbA1c of less than 2 months between 6 and 10% (to avoid confounding effects of anti-diabetic drugs).","* Patients treated with anti-inflammatory agents (nonsteroidal anti-inflammatory drugs in the long term, corticosteroids, steroids, immunomodulators or immunosuppressants)
* Patients with acute inflammatory condition (in particular infectious)
* Patients with chronic inflammatory diseases (eg rheumatoid arthritis)
* Vulnerable Patients (convicts, under guardianship)",blood sample,INTERVENTIONAL,COMPLETED
NCT00979758,Strengthening Transplantation Effects of Bone Marrow Mononuclear Cells With Atorvastatin in Myocardial Infarction,"Myocardial Infarction, Stem Cell Transplantation, Angioplasty, Transluminal, Percutaneous Coronary","1. Patients with coronary disease undergoing PCI.
2. At most 2 months since last episode of ST-elevation myocardial infarction.
3. Left ventricular ejection fraction \>=20% \<=45% based on coronary angiography or echocardiography.","Any one of the following exclusion criteria is sufficient to disqualify a patient from the study.

1. Patients with non-ST-elevation myocardial infarction.
2. Patients with normal left ventricular function.
3. Patients with mechanical complications of myocardial infarction.
4. Patients with a malignant tumor.
5. Patients with infection disease.
6. Less than 6 months since last episode of stroke.
7. Patients with hematological disease (leukemia, myeloproliferative disease, or myelodysplastic syndromes).
8. AST (GOT) exceeding 100 IU/L or ALT (GPT) exceeding 100 IU/L.
9. Leukocytes less than 4,000/µL or exceeding 10,000/µL.
10. Platelets less than 100,000/µL.
11. Hemoglobin less than 10 g/dL.
12. Pregnant or nursing patients, those who may be pregnant, or those who plan on becoming pregnant before the end of the study period.
13. Any other reason that the Clinical Supervisors or Clinical Researchers may have for considering a case unsuitable for the study.",Atorvastatin and mononuclear cells transplantation,INTERVENTIONAL,COMPLETED
NCT01226563,IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction,"Acute Myocardial Infarction, Congestive Heart Failure, ST-Elevation Myocardial Infarction","Inclusion criteria:

Subjects must meet all of the following inclusion criteria to participate in this trial:

1. The subject is ≥ 18 years of age.
2. The subject has given informed consent.
3. The subject has experienced a large STEMI defined by the following criteria:

   Peak cardiac enzyme value within 48 hours of symptom onset as follows:
   * Creatine kinase MB fraction (CK-MB) \> 30 x the upper limit of normal OR
   * Troponin I \> 200 x upper limit of normal OR
   * Troponin T \> 60 x the upper limit of normal

   AND at least 1 of the following 3 criteria:
   * Delayed presentation with PCI \> 6 hours from onset of symptoms
   * Significant new Q waves in ≥ 2 anterior leads or anterior ST segment elevation of at least 3 mm persistent at 24 hours after PCI
   * New onset of CHF (Killip class 3-4) or cardiogenic shock persistent at 24 hours after PCI

   AND at least 1 of the following 2 criteria:
   * MI ≥ 20% by Single Photon Emission Computed Tomography scan (SPECT) or cardiac Magnetic Resonance Imaging (MRI) with defect in the appropriate distribution
   * Ejection fraction ≤ 35% with wall motion abnormality in the appropriate distribution at baseline imaging assessment
4. The subject has had successful PCI with stent within 48 hours of symptom onset, and residual stenosis less than 20% in the infarct related artery and greater than or equal to thrombolysis in myocardial infarction (TIMI) 2 flow. Subjects undergoing rescue PCI after thrombolysis or delayed presentation with ongoing ischemia may be enrolled.
5. For Germany only: Patients determined to have Killip class 4 at time of device deployment are not eligible for randomization.
6. For Germany only: If SPECT is used for determination of MI size in order to meet inclusion criteria, the SPECT must have been previously performed as part of standard clinical care. SPECT is not to be performed solely to qualify a patient for this study in Germany.",":

Subjects will be excluded from participating in this trial if ANY of the following exclusion criteria are met:

1. Any subject with cardiogenic shock requiring mechanical ventilation or mechanical support at the time of deployment. Subject must be off mechanical support prior to deployment.
2. Need for urgent coronary artery bypass graft (CABG)
3. Clinically significant valvular heart disease with planned surgical correction or transcatheter aortic valve implantation (TAVI)
4. Uncontrolled ventricular arrhythmias
5. Renal insufficiency with a calculated creatinine clearance of less than 30 mL/ minute. See Appendix A for determining estimated creatinine clearance.
6. Clinically significant hepatic insufficiency
7. Inadequate imaging windows (defined as the inability to visualize the endocardial border of at least 16 of the 17 segments in both the apical four chambers and apical two chamber views without foreshortening) or arrhythmia that would preclude adequate 3D imaging on transthoracic echocardiography at the local baseline echo assessment
8. Non-ambulatory prior to the index MI
9. The subject has participated in another trial of an investigational agent within 30 days prior to randomization.
10. Subject has received resorbable stent as part of PCI.
11. The subject is pregnant or breastfeeding. Women of child-bearing potential will have a negative urine pregnancy test prior to randomization.
12. Any other concurrent condition that, in the opinion of the investigator, would prevent completion of the clinical trial, including inability to comply with follow up requirements.
13. For Germany only: In the investigator's opinion, the patient is not expected to survive ≥12 months.
14. For Germany only: 24 hours prior to device deployment, the patient has a serum calcium level greater than the upper limit of normal as determined by the local laboratory.","IK-5001, Saline Solution",INTERVENTIONAL,COMPLETED
NCT00808717,Efficacy of High Dose atorvaSTATIN Loading Before Primary Percutaneous Coronary Intervention in ST Elevation Myocardial Infarction (STATIN STEMI),"Myocardial Infarction, Angioplasty, Percutaneous Coronary","1. The patient must be at least 18 years and 80 years of age.
2. The patient had the symptoms of acute myocardial infarction within 12 hours with ST segment elevation of more than 1 mm in at least two contiguous leads of EKG or new onset LBBB.
3. The patient or guardian agrees to the study protocol and provides informed, written consent.","1. Patients to whom PCI can not be undergone within 12 hours from receiving the study drug
2. Cardiogenic shock or symptomatic hypotension or sitting SBP \< 95 mmHg
3. The history of major surgery, trauma, retinal hemorrhage, significant gastrointestinal or genitourinary bleeding within recent 6 weeks; history of cerebrovascular attack within two years, or cerebrovascular attack with a significant residual neurological deficit
4. History of cerebrovascular attack within two years, or cerebrovascular attack with a significant residual neurological deficit
5. Severe or malignant hypertension (= sitting SBP \> 180 mmHg and/or sitting DBP \> 105 mmHg)
6. The history or diagnosis of vasculitis; renal insufficiency (the level of serum creatinine is two times higher than the upper limit of normal of each center)
7. The patients who might die of other disease than cardiac disease during the trial.",Atorvastatin,INTERVENTIONAL,COMPLETED
NCT00652717,Study To Assess The Efficacy Of A Cholesterol Lowering Drug On Top Of Statins In Patients After Myocardial Infarction (MI)(0653A-150),Cardiovascular Disorder,* Patients; Post Acute Coronary Syndrome,-,"Ezetimibe, simvastatin",INTERVENTIONAL,COMPLETED
NCT03470441,A Study of Acute Myocardial Infarction Using FDY-5301,"Acute Myocardial Infarction, STEMI","1. 18-80 year old male subjects
2. 18 to 80 year old female subjects who are not of child-bearing potential.
3. Accepted for Primary PCI with diagnosis of first STEMI, based on clinical and ECG criteria (ST-elevation at the J-point in two contiguous leads with the cut-off points: ≥0.2 millivolt (mV) in men or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other leads), within 12 hours of symptom onset.

Written informed consent prior to study participation (either by the subject or a legally authorized representative of the subject)","1. Previous myocardial infarction
2. Left bundle branch block (LBBB)
3. Previous coronary artery bypass graft surgery (CABG)
4. Major hemodynamic instability or uncontrolled ventricular arrhythmias
5. Known contraindication to CMR
6. Patients with known thyroid disease
7. Subjects with past or current renal impairment requiring dialysis
8. Pregnant or females of child bearing potential
9. Body weight \> 120 kg or Body Mass Index (BMI) \> 35 kg/m2
10. Use of investigational drugs or devices within 30 days prior to enrollment into the study.
11. Life expectancy of less than 1 year due to non-cardiac pathology
12. Any clinically significant abnormality identified at the time of screening that in the judgment of the Investigator or any sub-Investigator would preclude safe completion of the study","FDY-5301, Placebo",INTERVENTIONAL,COMPLETED
NCT02934217,Does Cyclosporine ImpRove Clinical oUtcome in ST Elevation Myocardial Infarction Patients at 3 Years of Follow-up. CIRCUS II Study,ST Elevation Acute Myocardial Infarction,"* All (male and female) patients, aged over 18, without any legal protection measure,
* Having a health coverage,
* Presenting within 12 hours of the onset of chest pain,
* Who have ST segment elevation ≥0.2 mV in two contiguous leads,
* For whom the clinical decision was made to treat with percutaneous coronary intervention (PCI).

And (further inclusion criteria to be confirmed by the admission coronary-angiography):

* The culprit coronary artery has to be the LAD
* The LAD artery has to be occluded (TIMI flow grade 0-1) at the time of admission coronary angiography.
* Preliminary oral informed consent followed by signed informed consent as soon as possible.

Patients undergoing either primary PCI or rescue PCI are eligible for the study. Patients with previous AMI, PCI or coronary artery bypass surgery (CABG) are eligible for the study.","* Patients with loss of consciousness or confused
* Patients with cardiogenic shock
* Patients with the left circumflex or the right coronary artery (RCA) as the culprit artery, or with evidence of coronary collaterals to the risk region
* Patients with an opened (TIMI \> 1) LAD coronary artery at admission on initial (admission) coronary angiography
* Patients with 1. known hypersensitivity to cyclosporine 2. known hypersensitivity to egg, peanut or Soya-bean proteins 3. known renal insufficiency (either known creatinin clearance \< 30 ml/min/1.73m² or current medical care for severe renal insufficiency) 4. known liver insufficiency 5. uncontrolled (treated or untreated) hypertension (\> 180/110 mmHg)
* Patients treated with any compound containing Hypericum perforatum (St.-John's-worth) or Stiripentol or Aliskiren or Bosentan or Rosuvastatine
* Female patients currently pregnant or women of childbearing age who were not using contraception (oral diagnosis).
* Patients with any disorder associated with immunological dysfunction more recently than 6 months prior to presentation 1. cancer, lymphoma 2. known positive serology for HIV, or hepatitis","Injection of Cyclosporin, Placebo, Echocardiography",INTERVENTIONAL,COMPLETED
NCT05984134,Efficacy and Safety Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction,Acute Myocardial Infarction,"1. The subjects or their guardians voluntarily participate in the experiment and sign the informed consent;
2. Age ≥18 years old and ≤75 years old, gender is not limited;
3. STEMI patients with proximal or/and middle occlusion of a single left anterior descending artery (TIMI grade 0-1) and PCI;
4. No coronary collateral (Rentrop grade 0);
5. meet one of the following conditions:

   * The total myocardial ischemia time before PCI was \< 6 hours, and the TIMI grade after PCI was \< 3
   * 6 hours ≤ Total myocardial ischemia time before PCI ≤24 hours Note: Total myocardial ischemia time =PCI wire passage time - start time of chest pain
6. All subjects (male and female) must agree to use appropriate contraceptive methods (hormonal or barrier methods, abstinence) during study participation and up to 6 months of the last dosing, and women of childbearing age must test negative for pregnancy before dosing.","1. Patients with a history of myocardial infarction who have received acute coronary thrombolysis, interventional therapy, or bypass surgery; A clear diagnosis of acute heart failure (Killip grade ≥III);
2. Severe arrhythmias that cannot be corrected;
3. Aortic dissection;
4. Severe liver and kidney dysfunction or severe consumption;
5. History of major surgery or hemorrhagic stroke within six months;
6. Previous history of malignant tumors;
7. Hypertensive patients with systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg after active antihypertensive treatment;
8. Clinically significant allergic reaction history, especially mannitol, drugs, protein preparations, biological products;
9. Patients who participated in other clinical studies within 3 months prior to screening;
10. Can not perform CMR examination;
11. Other conditions deemed unsuitable for inclusion by the investigators (for example, those whose coronary arteries other than the left anterior descending branch were judged by the investigators to require elective revascularization therapy at the same time or within 1 month).","NL005 Middle Dose, NL005 High Dose, Placebo",INTERVENTIONAL,COMPLETED
NCT00372216,CIPAMI-Study: Clopidogrel Administered Prehospital to Improve Primary PCI in Patients With Acute Myocardial Infarction,Myocardial Infarction,"* Acute STEMI \<= 6 hrs.
* Planned percutaneous coronary intervention
* Age \>= 18 years
* Ability to understand the natures, scope, and possible consequences of the study / legal capacity
* Informed consent","* Thrombolytic therapy within 24 hours before randomization
* Effective oral or intravenous anticoagulation (INR\>2, or PTT\>2xcontrol)
* Known hemorrhagic diathesis
* Stroke or TIA within 3 months
* Evidence of an active gastrointestinal or urogenital bleeding
* Major surgery (including CABG) within 6 weeks
* Contraindication to Clopidogrel
* Severe renal or hepatic insufficiency
* Contraindication to coronary angiography
* Planned administration of a GP IIb/IIIa-Inhibitor before angiography
* Pregnant or nursing (lactating) women
* Women with childbearing potential
* Patients currently (within the last 10 days) treated with clopidogrel or ticlopidine
* Participation in another clinical or device trial within the previous 30 days",Clopidogrel (Iscover/Plavix),INTERVENTIONAL,COMPLETED
NCT00128024,Effects of Early Statin Treatment After Acute Myocardial Infarction (AMI) in Japanese Patients,Myocardial Infarction,"* Clinical diagnosis of acute myocardial infarction
* Serum total cholesterol levels on admission ranges ≥180 mg/dL and \<240 mg/dL","* Age \< 18 years
* Time from symptom onset to admission \> 96 hours
* Use of lipid-lowering agents within the previous 3 months
* Known familial dyslipidemia
* Severe renal failure
* Known hepatic disease
* Signs and symptoms of severe heart failure (Killip class III or IV)
* A scheduled PCI or coronary artery bypass grafting (CABG)
* A history of previous PCI (within 6 months) or CABG (within 3 months)
* The presence of malignant disease
* The presence of allergy to statins.",lipid-lowering treatment,INTERVENTIONAL,COMPLETED
NCT02341534,BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Myocardial Infarction,"Myocardial Infarction, Myocardial Infarction, Acute, Myocardial Infarction Old","* Patient has a history of MI according to guidelines
* CHA2DS2-VASc-Score ≥ 4 in men / ≥ 5 in women
* LVEF \> 35 % as estimated within 6 months before enrollment but after conclusion of AMI treatment
* Patient accepts activation of Home Monitoring®
* Patient is able to understand the nature of the clinical study and has provided written informed consent","* Patients with hemorrhagic diathesis
* Permanent oral anticoagulation treatment for atrial fibrillation
* Indication for chronic renal dialysis
* Pacemaker or ICD implanted or indication for implantation
* Parkinson's disease
* Life expectancy \< 1 year
* Participation in another interventional clinical Investigation
* Age \< 18 years
* Woman who are pregnant or breast feeding",BioMonitor,INTERVENTIONAL,COMPLETED
NCT01107886,Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications,Type 2 Diabetes Mellitus,"* Patients with type 2 diabetes mellitus
* HbA1c ≥6.5%. (based on the last measured and documented laboratory measurement within 6 months)
* High risk for CV events -Established cardiovascular disease and/or multiple risk factors","* Current or previous (within 6 months) treatment with DPP4 inhibitors and/or GLP-1 mimetics
* Acute vascular event \<2months prior to randomisation","Saxagliptin, Placebo",INTERVENTIONAL,COMPLETED
NCT01761786,Cost-effectiveness of Genotype Guided Treatment With Antiplatelet Drugs in STEMI Patients: Optimization of Treatment (POPular Genetics),"Myocardial Infarction, STEMI","* more than 21 years of age with symptoms of acute myocardial infarction of more than 30 minutes but less than 12 hours
* performed primary PCI with stenting for STEMI","* unable to give informed consent or have a life expectancy of less than one year
* active malignancy with increase in bleeding risk, in the investigator's opinion
* women who are known to be pregnant or who have given birth within the past 90 days or who are breastfeeding
* having received thrombolytic therapy within the previous 24 hours or oral anticoagulants during the previous 7 days
* severe renal function impairment needing dialysis
* confirmed or persistent severe hypertension (Systolic Blood Pressure (SBP) \> 180 mmHg and/or Diastolic Blood Pressure (DBP) \>110 mmHg) at randomization
* contraindication to anticoagulation or at increased bleeding risk, at the investigator's opinion
* cardiogenic shock (SBP ≤ 80mmHg for \>30 mins) or Intra-Aortic Balloon Pump (IABP) placed
* history of major surgery, severe trauma, fracture or organ biopsy within 90 days prior to randomisation
* clinically significant out of range values for platelet count or haemoglobin level at screening, in the investigator's opinion.",CYP2C19 genotyping,INTERVENTIONAL,COMPLETED
NCT00235339,Effect of Standard Care Rehabilitation Versus Interval Treadmill Training After Myocardial Infarction,Myocardial Infarction,* Myocardial infarction 2-12 weeks ago,"* Heart failure
* limitations to walking on a treadmill
* failure to reach a maximal pre-test(\> NYHA class II)
* uncontrolled hypertension
* COPD
* pregnancy
* kidney failure (creatinin \> 140)
* drug abuse
* left ventricle EF \< 30%","Exercise training, Exercise training",INTERVENTIONAL,COMPLETED
NCT00251134,OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction,Myocardial Infarction,"* Myocardial infarction 3-14 days before randomisation (STEMI and NSTEMI)
* Ability to take Ω-3-FAE or olive oil without risk
* Informed consent","* Premenopausal women who are not surgically sterile, who are pregnant or nursing, who are of child-bearing potential and are not practising acceptable means of birth control (pregnancy testing required before randomisation)
* Known hypersensitivity to study medication
* Dislike of fish oil
* Haemorrhagic diathesis
* Unwillingness to discontinue other medications containing fish oil
* Legal incapacity
* History of drug or alcohol abuse within 6 months
* Any investigational therapy within one month of signing informed consent form","Zodin (drug), Olive oil (placebo)",INTERVENTIONAL,COMPLETED
NCT01327534,Early Thienopyridine Treatment to Improve Primary PCI in Patients With Acute MI,"Myocardial Infarction, STEMI","* Age ≥ 18 years and \< 75 years
* Acute STEMI ≤ 12 h defined as 1. Angina or equivalent symptoms \> 30 min and 2. ST elevation ≥ 2 leads (≥ 2 mm precordial leads, ≥ 1 mm limb leads) or ST depression ≥ 1 mm precordial leads in posterior MI
* planned percutaneous coronary intervention
* legal capacity
* informed consent
* first medical contact in the prehospital setting or in a non-PCI hospital (this criterion was changed by a protocol amendment in autumn 2012 to ""first medical contact in the prehospital setting, in a non-PCI hospital, or in a PCI-hospital, if the expected time until the start of the scheduled PCI is at least 20 minutes"")","* Age ≥ 75 years
* Body weight \< 60 kg
* Thrombolytic therapy within 24 hours before randomization
* Oral anticoagulation
* Known hemorrhagic diathesis
* History of Stroke or TIA
* Cardiogenic shock
* Evidence of an active gastrointestinal or urogenital bleeding
* Major surgery within 6 weeks
* Contraindication to prasugrel or clopidogrel
* Severe renal or hepatic insufficiency
* Contraindication to coronary angiography
* Planned administration of a GP IIb/IIIa-Inhibitor before angiography
* Pregnant or nursing (lactating) women
* Patients currently (within the last 10 days) treated with clopidogrel, prasugrel, ticlopidine, or ticagrelor
* Uncontrollable hypertension (blood pressure ≥ 200/110 mmHg in repeated measurements)
* Treatment with NSAIDs
* Participation in another clinical or device trial within the previous 30 days
* First medical contact in a PCI-hospital (this criterion was changed by a protocol amendment in autumn 2012 to ""Expected time between administration of loading dose and start of PCI is \< 20 minutes"")","Prasugrel, Clopidogrel",INTERVENTIONAL,COMPLETED
NCT02835534,The Efficacy and Safety of rhTNK-tPA in Comparison With Alteplase(Rt-PA) as Fibrinolytic Therapy of Acute STEMI,Acute ST Elevation Myocardial Infarction,"1. Diagnosis of acute STEMI（meet with both conditions）:

   * Ischemic chest pain ≥30mins in duration
   * ST elevation ≥0.1 mV in two or more limb ECG leads or ≥0.2 mV in two or more contiguous precordial leads
2. Onset of continuous ischemic symptoms of STEMI ≤6 hours prior to randomisation
3. Anticipated Delay to Performing Primary PCI \>60mins，or time from hospital arrival to to balloon inflation \>90mins
4. Signed Informed consent received prior to participation the study","1. Non-ST-segment-elevation myocardial infarction or unstable angina
2. Reinfacrtion
3. Cardiacgenic shock
4. Suspected aortic dissection
5. New left bundle branch block in ECG
6. Absolute and relative contraindications for Fibrinolytic Therapy in STEMI(referred from 2015 China STEMI Management Guideline）：

   * Severe uncontrolled hypertension (unresponsive to emergency Therapy,BPs \> 180 mmHg and/or BPd \> 110 mmHg)
   * Any prior ICH,stroke with unknown cause, Ischemic stroke within 3 months
   * Known structural cerebral vascular lesion, malignant intracranial neoplasm
   * Active bleeding, or bleeding diathesis, active peptic ulcer
   * Significant closed-head or facial trauma within 3 months
   * Intracranial or intraspinal surgery within 2 months
   * Recent internal bleeding within 4 weeks
   * Major surgery within 3 weeks, or Traumatic
   * Prolonged cardiopulmonary resuscitation (\>10 minutes)
   * Noncompressible vascular punctures within 2 weeks
   * Current use of anticoagulant therapy
7. Current or with a history of significant diseases：

   * Damage to the central nervous system
   * Severe renal or hepatic dysfunction, blood system diseases,
   * Present with cardiac rupture evidence
   * Acute pericarditis,Subacute bacterial endocarditis, Septic thrombophlebitis or occluded AV cannula at seriously infected site
   * Malignancy
   * High likelihood of left heart thrombus, e.g., mitral stenosis with atrial fibrillation
   * Diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions
   * History of PCI or coronary artery bypass graft（CABG）within 1 month
8. Administration of fibrinlytic therapy prior to participation
9. Weight below 50 kg
10. Known current histroy of fall-down accident
11. Any other unfavourable conditions for participation：

    * Known participation in other clinical trials
    * Known to allergic to rhTNK-tPA or tPA or relevant vehicle
    * Pregnancy or lactation
    * Mental disorder
    * Present with any unsuitable conditions for participation or completion of the study at the discretion of their treating physician","rhTNK-tPA, alteplase",INTERVENTIONAL,COMPLETED
NCT00363324,Bone Marrow Cells in Myocardial Infarction,Acute Myocardial Infarction,* Acute ST-elevation myocardial infarction treated with thrombolytic therapy,"* Indication for rescue PCI, severe clinical heart failure, age \<18 years",intracoronary injection of bone marrow cells,INTERVENTIONAL,COMPLETED
NCT00260416,Primary Angioplasty for Acute Myocardial Infarction in Patients With Symptom Duration Above 12 Hours,Acute Myocardial Infarction,"* Acute myocardial infarction with ST-segment elevation;
* Symptom duration 12 hours to 72 hours.","* Age below 18 years;
* Bleeding disorders or anaemia or low levels of thrombocytes;
* Thrombolysis used during the present admission;
* Expected survival less than 1 year due to other diseases;
* Previous acute myocardial infarction or coronary by-pass surgery;
* Major operation within last 30 days;
* Heamorrhaghic stroke within last 3 months.",Primary angioplasty with stent and abciximab,INTERVENTIONAL,COMPLETED
NCT01325116,Delayed Educational Reminders in Acute Myocardial Infarction (MI),"Acute Myocardial Infarction, STEMI","* Admitted with STEMI to a hospital in LHIN IV, coronary angiogram with and without PCI at Hamilton General Hospital during hospital admission",* Non-english speaking,Educational Reminder,INTERVENTIONAL,COMPLETED
NCT01340716,Effects of Tai Chi Chuan in Patients After Recent Acute Myocardial Infarction,Acute Myocardial Infarction,"* Recent acute myocardial infarction
* Age 45 and 75 years.
* admission until 20 days after hospital discharge
* With physical conditions for a cardiac rehabilitation program with exercise.","* Unstable angina
* Severe congestive heart failure
* Severe lung disease
* Altered response of blood pressure to stress","Tai Chi Chuan exercise, stretching exercise",INTERVENTIONAL,COMPLETED
NCT00264316,Bone Marrow-Derived Stem Cell Transfer in Acute Myocardial Infarctions,Myocardial Infarction,"* patients with acute myocardial infarction with cumulative ST-segment elevation \>=6mm, successful epicardial reperfusion after PCI and significant LV dysfunction","* patients presenting within 2 hours of symptom onset (no dilution of any treatment effect from aborted infarctions)
* patients with prior coronary artery bypass grafting, pulmonary edema, cardiogenic shock or significant co-morbidities",bone marrow-derived stem cell transfer,INTERVENTIONAL,COMPLETED
NCT01087996,The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study),Stem Cell Transplantation,"* Diagnosis of chronic ischemic left ventricular dysfunction secondary to MI.
* Be a candidate for cardiac catheterization.
* Been treated with appropriate maximal medical therapy for heart failure or post-infarction left ventricular dysfunction.
* Ejection fraction between 20% and 50%.
* Able to perform a metabolic stress test.","* Baseline glomerular filtration rate \<50 ml/min/1.73m2.
* Presence of a mechanical aortic valve or heart constrictive device.
* Documented presence of aortic stenosis (aortic stenosis graded as ≥+2 equivalent to an orifice area of 1.5cm2 or less).
* Documented presence of moderate to severe aortic insufficiency (echocardio- graphic assessment of aortic insufficiency graded as ≥+2).
* Evidence of a life-threatening arrhythmia (nonsustained ventricular tachycardia ≥20 consecutive beats or complete heart block) or QTc interval \>550 ms on screening ECG. In addition; patients with sustained or a short run of ventricular tachycardia on ECG or 48 hour Ambulatory ECG during the screening period will be removed from the protocol.
* Documented unstable angina.
* AICD firing in the past 60 days prior to the procedure.
* Be eligible for or require coronary artery revascularization.
* Have a hematologic abnormality as evidenced by hematocrit \< 25%, white blood cell \< 2,500/ul or platelet values \< 100,000/ul without another explanation.
* Have liver dysfunction, as evidenced by enzymes (ALT and AST) greater than three times the ULN.
* Have a coagulopathy condition = (INR \> 1.3) not due to a reversible cause.
* Known, serious radiographic contrast allergy.
* Known allergies to penicillin or streptomycin.
* Organ transplant recipient.
* Clinical history of malignancy within 5 years (i.e., patients with prior malignancy must be disease free for 5 years), except curatively-treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma.
* Non-cardiac condition that limits lifespan to \< 1 year.
* On chronic therapy with immunosuppressant medication.
* Serum positive for HIV, hepatitis BsAg, or hepatitis C.
* Female patient who is pregnant, nursing, or of child-bearing potential and not using effective birth control.","Auto-hMSCs, Allo-hMSCs",INTERVENTIONAL,COMPLETED
NCT02291796,Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction,Acute Myocardial Infarction,"* Patients \>18 years of age who were admitted to the Cardiovascular Intensive Care Unit of the Cardiology Hospital, National Medical Center, Century XXI (Mexico City) and diagnosed with ST segment elevation ACS and hyperfibrinogenemia within 72 h of symptom onset","* Patients with known bezafibrate allergy,
* previous fibrate treatments,
* patients with cardiogenic shock,
* hepatic failure,
* renal failure,
* history of neoplastic disease,
* chronic inflammatory disease or active infectious process,
* anti-inflammatory or immunosuppressive therapies,
* fibrinolysis with streptokinase and
* patients with triglyceride concentrations \>150 mg/dl",Bezafibrate,INTERVENTIONAL,COMPLETED
NCT02783963,Optical Coherence Tomography in Patients With Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease,Myocardial Infarction,"* Evidence of myocardial infarction: elevation of troponin to above the laboratory upper limit of normal (ULN) or new ST segment elevation of ≥1mm on 2 contiguous ECG leads or new left bundle branch block
* Symptoms of ischaemia (chest pain or anginal equivalent symptoms at rest or new onset exertional anginal equivalent symptoms with concomitant ST-segment depression, T wave inversion or transient ST-segment elevation)
* Delivery of an informed consent and compliance with study protocol
* Age ≥ 18 years","* Prior diagnosis of obstructive CAD (including history of percutaneous coronary intervention or coronary artery bypass grafting)
* Stenosis \>50% of any coronary vessel on invasive angiography
* Contraindication to OCT in the opinion of the treating physician
* Use of vasospastic agents
* Alternate causes of myocardial injury/ischaemia (severe anaemia, hypertensive crisis, acute heart failure, cardiac trauma, pulmonary embolism, etc.)
* Severe renal failure (eGFR\<30)
* Pregnancy",OCT and CMR imaging,INTERVENTIONAL,COMPLETED
NCT01153334,Efficacy of Early Intensive ROsuvastatin Therapy in Patients With ST-segment Elevation Myocardial Infarction Undergoing PrimARY Percutaneous Coronary Intervention (the ROSEMARY Trial),ST-segment Elevation AMI,"1. Patient had the symptoms of acute myocardial infarction within 12 hours with ST-segment elevation of more than 1 mm in at least two contiguous leads of EKG or new onset LBBB.
2. Male or female over 20 years of age
3. Signed written informed consent to participate in the study","1. Congestive heart failure (NYHA Class III or IV) or LVEF \<35%.
2. Clinically significant heart disease requiring CABG, cardiac transplantation, surgical repair and/or replacement during the course of the study.
3. Previous MI or CABG
4. Known serious or hypersensitivity reactions to statin, antiplatelet agents (aspirin or clopidogrel), or heparin.
5. Known familial hypercholesterolemia
6. Known skeletal muscle disease
7. Known active liver disease such as hepatitis or liver cirrhosis (except for fatty liver)
8. Renal failure (Cr \>2.0 mg/dL)
9. Secondary causes of hyperlipoproteinemia: uncontrolled primary hypothyroidism, and/or nephrotic syndrome
10. Non-cardiac comorbidity with a life expectation \< 1 year
11. Contraindications to CMRI (eg, implanted pacemaker or cardiac defibrillator, claustrophobia, etc.)
12. Pregnant or lactating women or women of childbearing potential
13. Participation in any investigational drug or device study within 30 days prior to study entry","Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)",INTERVENTIONAL,COMPLETED
NCT01958034,Bilberry as a Dietary Supplement After Myocardial Infarction (The BEAR SMART Trial),Myocardial Infarction,"Inclusion Criteria:

* Patients with a diagnosis of STEMI as defined by chest pain suggestive for myocardial ischemia for at least 30 minutes before hospital admission, time from onset of symptoms of less than 24 hours, and an ECG with new ST-segment elevation in two or more contiguous leads of ≥0.2 mV in leads V2-V3 and/or ≥0.1 mV in other leads or a probable new-onset left bundle branch block.
* Patients with a diagnosis of non-STEMI as defined by a combination of; onset of symptoms such as central chest pain or an aggravated angina pectoris, with or without an ECG change with ST-segment lowering or an inverted T-wave, and at least two values with levels of troponin-T or troponin-I above the established margin of an MI.",":

* Need for emergency coronary artery bypass grafting
* Inability to provide informed consent
* Age below 18 years
* Previous randomization in the BEAR SMART trial
* A daily intake, or the intent to start a daily intake of bilberries in some form (fresh berries, bilberry powder, bilberrysoup etc)

Exclusion Criteria:

* Need for emergency coronary artery bypass grafting
* Inability to provide informed consent
* Age below 18 years
* Previous randomization in the BEAR SMART trial
* A daily intake, or the intent to start a daily intake of bilberries in some form (fresh berries, bilberry powder, bilberrysoup etc)",Bilberry extract,INTERVENTIONAL,COMPLETED
NCT04304534,Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack,Acute Myocardial Infarction,"* Participants must be 45 years of age or older, at the time of signing the informed consent
* Acute myocardial infarction (excluding MI associated with PCI or CABG revascularization procedures) with:

  * clinical symptoms of acute myocardial infarction AND
  * elevated biomarkers of myocardial necrosis (creatine kinase-muscle and brain isoenzyme \[CK-MB\] or cardiac troponins) AND
  * at least one of the following risk factors need to be fulfilled:

    * Age ≥ 65 years
    * Prior MI (before the index AMI event)
    * Prior peripheral arterial disease
    * Diabetes Mellitus
    * Prior coronary artery bypass grafting (CABG) AND
  * initial angiography and revascularization procedures, either PCI or CABG, as treatment for the index event performed before randomization. (Note: a planned, staged PCI procedure can be performed after randomization)
* Plan for dual antiplatelet therapy (ASA + P2Y12 inhibitor) after hospital discharge for the index AMI
* Randomization during hospitalization for the index AMI event and latest within 5 days of hospital admission
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent has to be signed before any study-specific procedure.","* Hemodynamically significant ventricular arrhythmias or cardiogenic shock at time of randomization
* Active bleeding; known bleeding disorder, history of major bleeding (intracranial, retroperitoneal, intraocular) or clinically significant gastrointestinal bleeding within last 6 months of randomization
* Planned use or requirement of full dose and long term anticoagulation therapy during study conduct.","BAY2433334, BAY2433334 matching placebo",INTERVENTIONAL,COMPLETED
NCT02164695,Remote Ischemic Perconditioning in Patients With ST-segment Elevation Myocardial Infarction,ST-segment Elevation Myocardial Infarction,"* Age \>19 years
* Presenting within 12 hours of symptom onset
* \>20 min of chest pain
* ST-elevation myocardial infarction defined as ST-segment elevation (\>0.1 mV) in at least 2 contiguous precordial leads","* Previous myocardial infarction
* Presence of chronic total occlusion
* Evidence of retrograde filling by collaterals at coronary angiography (Rentrop 2 or 3 collateral flow)
* Severe multi-vessel coronary artery disease to require further interventions before follow-up CMR
* Cardiac arrest before randomization
* Arrhythmias requiring external electric shock before randomization
* Unwillingness to participate
* External electric shock for cardioversion within first 3 days
* Cardiac surgery within first 3 days","PPCI plus RIPC, PPCI only",INTERVENTIONAL,COMPLETED
NCT01484795,Noninvasive Ventilation in Acute Myocardial Infarction,Acute Myocardial Infarction,"* acute myocardial infarction with Killip I classification, hemodynamic stability, between 24 and 72 hours post event;
* agreement to participate in the study, according written informed consent;
* 45 to 80 years old age.","* unstable angina;
* systolic blood pressure \< 80 mmHg;
* patients who presented ST elevation \> 2 mm or with second-degree atrioventricular block;
* presence of pacemaker.","BILEVEL (Respironics), Continuos positive airway pressure (Respironics)",INTERVENTIONAL,COMPLETED
NCT00237614,Contrast Nephropathy Prevention With N-Acetylcysteine in Acute Myocardial Infarction,"Contrast-Induced Nephropathy, Acute Myocardial Infarction",Consecutive patients admitted to the Coronary Care Unit for ST-segment elevation acute myocardial infarction undergoing primary angioplasty. Patients were included if they presented within 12 hours (18 hours for acute myocardial infarction complicated by cardiogenic shock) from the onset of symptoms. -,"Patients in chronic peritoneal or hemodialytic treatment and those with known allergy to N-acetylcysteine.

-",intravenous and oral N-acetylcysteine,INTERVENTIONAL,COMPLETED
NCT01911910,Heart Attack Prevention Programme for You (HAPPY) London,Cardiovascular Disease,"* Subjects will be enrolled following an informed consent. The subject will be able to understand and comply with protocol requirements, instructions and protocol-stated restrictions
* Subjects will be between 40 and 74 years of age
* Subjects will have unrestricted access to the Internet
* Subjects will be sufficiently fluent in English language.
* Subjects will have an estimated intermediate to high risk for CV events based on the web-based pre-screening tool (www.happylondon.info), which is based on the nonlaboratory Framingham risk score (\>10% 10 year cardiovascular risk)","* History of stroke or transient ischaemic attack (TIA)
* Cardiac sounding chest pain requiring further investigations
* Current life threatening conditions other than vascular disease (e.g. very severe chronic airways disease, HIV positive, life-threatening arrhythmias) that may prevent a subject from completing the study
* Only for subgroup undergoing cardiac contrast-enhanced magnetic resonance studies: Any contraindication to a contrast-enhanced magnetic resonance study, such as known allergies to gadolinium-based contrast agents, severe claustrophobia, pacemakers, defibrillators, etc",Electronic coaching plus standard care,INTERVENTIONAL,COMPLETED
NCT00487812,Low-Dose Dobutamine Tc-99m-Mibi Gated SPECT to Predict Left Ventricular Remodelling in Patients Reperfused in the Acute Phase of MI,"Ischemic Heart Disease, Myocardial Infarction","* Acute myocardial infarction,
* Successful coronary angioplasty in the acute phase,
* Absence of heart failure in the acute phase","* acute heart failure in the acute phase
* severe ventricular arrhythmias
* contra indications for MRI imaging",Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging,INTERVENTIONAL,COMPLETED
NCT01612312,Thrombus Aspiration in ThrOmbus Containing culpRiT Lesions in Non-ST-Elevation Myocardial Infarction (TATORT-NSTEMI),Non-ST-elevation Myocardial Infarction,"* ischemic symptoms such as angina pectoris \>20 minutes
* occurrence of last symptoms \<72 h before randomization
* cardiac troponin T or I levels above the 99th percentile
* culprit lesion containing thrombus (TIMI-thrombus grade 2-5 within the lesion) and intended early PCI","* cardiogenic shock
* STEMI
* no identifiable culprit lesion or a TIMI-thrombus grade \<2
* coronary morphology ineligible for thrombectomy (e.g. very tortuous vessels, severe calcification)
* indication for acute bypass surgery
* age \<18 and \>90 years
* contraindications for treatment with heparin, aspirin or thienopyridines
* pregnancy
* current participation in another clinical study
* co-morbidity with limited life expectancy \<6 months
* contraindications to CMR at study entry","Thrombectomy, Standard percutaneous coronary intervention",INTERVENTIONAL,COMPLETED
NCT00639912,Effects of Hydration to Prevent Contrast Induced Nephropathy in PCI for ST-elevation Myocardial Infarction.,Contrast Induced Nephropathy,"* Age \> 18 years of years
* Chest pain lasting at least 30 minutes, non responsive to nitrates, associated to ST elevation of at least 0.2 mV on surface ECG in two or more contiguous leads or to new left bundle branch block.
* Informed consent","* Chronic hemodialytic or peritoneal treatment
* Coronary anatomy unsuitable for PCI
* Need of emergency coronary artery by-pass grafting
* Post-anoxic coma
* Pregnancy","sodium chloride, sodium chloride, sodium bicarbonate, sodium bicarbonate",INTERVENTIONAL,COMPLETED
NCT01327846,Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events),Atherosclerosis,"Main Study 

* Written informed consent
* Male, or Female of non-child-bearing potential
* Age ≥ 18 years.
* Spontaneous MI at least 30 days before randomization. hsCRP ≥ 2 mg/L

Substudy 1 Inclusion:

* All Inclusion from Main Study
* Acquisition of evaluable baseline MRI images of bilateral carotid arteries by the imaging core laboratory

Substudy 2 Inclusion:

* All inclusion from Main Study
* T2D at baseline per Main protocol criteria and be on a stable anti-hyperglycemic medication for at least 4 weeks prior to the baseline OGTT test
* Willing to have the OGTT assessment started before 10 am

Main Study","* Pregnant or nursing (lactating) women
* Women of child-bearing potential
* Any of the following concomitant diseases
* Planned coronary revascularization (PCI or CABG)
* Major non-cardiac surgical or endoscopic procedure within past 6 months
* Multi-vessel CABG surgery within the past 3 years
* Symptomatic patients with Class IV heart failure (HF) (New York Heart Association \[NYHA\].
* Uncontrolled hypertension
* Uncontrolled diabetes
* History or evidence of active tuberculosis (TB) infection Substudy 1 Exclusion
* All Main exclusion
* Patients with prior history of carotid angioplasty, stenting, or carotid atherectomy
* Patients with contraindications to MRI examination (brain aneurysm clip, implanted neural stimulator, implanted cardiac pacemaker, pacemaker wires or defibrillator, prosthetic heart valves, cochlear implant, ocular foreign body or other implanted body, tattoos, implanted insulin pump, metal shrapnel or bullet)
* Patients prone to claustrophobia or known anxiety disorders
* BMI \> 40 kg/m2 Substudy 2 Exclusion
* This sub-study does not have any additional exclusion criteria.","Canakinumab, Placebo, Standard of care",INTERVENTIONAL,COMPLETED
NCT00833612,Counterpulsation Reduces Infarct Size Pre-PCI for AMI,Acute Myocardial Infarction (AMI),"* Able to understand and sign an ICF
* ≥ 18 and ≤ 90 years of age
* General good health, in the opinion of the investigator
* ST elevation of 2mm in 2 contiguous anterior leads or ≥ 4mm total in anterior leads
* Scheduled for PCI \< 6 hours from onset of symptoms of MI","* Known contraindication to MRI
* Prior thrombolytic therapy during the index event
* Known history of MI
* Known severe aortic insufficiency
* Known aortic aneurysm
* Known severe calcific aorta-iliac disease or peripheral vascular disease
* Experiencing cardiac shock
* Known end-stage renal disease
* Weight \>400 lbs. or height \<4 ft.",Counterpulsation with IAB,INTERVENTIONAL,COMPLETED
NCT00440895,A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI,"Myocardial Infarction, Ischemia","* Patient with acute myocardial infarction eligible for rescue PCI within 24 hrs of symptoms.
* Failed thrombolysis (defined as less than 50% reduction of ST-elevation at 90 min ECG in the lead with previous maximal ST-segment elevation).
* Patient \> 18 years old.
* Patient and treating interventional cardiologist agree for randomization.
* Patient will be informed of the randomization process and will sign an informed consent.
* Diagnostic and therapeutic intervention performed through transradial/transulnar approach.
* The culprit lesion in a native coronary artery can identified and is suitable for immediate angioplasty and stent implantation.","* Age \> 75 years old
* Body weight \< 65 kg
* Concurrent participation in other investigational study
* Intolerance or allergy to ASA, clopidogrel or ticlopidine precluding treatment for 12 months
* Any significant blood dyscrasia, diathesis or INR \> 2.0.
* Any clinical contraindication to abciximab administration i.e. known structural intracranial lesion, thrombocytopenia (\< 100,000), hemoglobin level \< 10 g/dl
* Patient has received more than one dose of thrombolytic within 24 hours of symptoms
* Previous treatment with glycoproteins IIb-IIIa inhibitors within 30 days
* Perceived increased risk of intracranial or severe bleeding i.e. previous stroke/TIA, alteration of consciousness, recent trauma or major surgery.
* Uncontrolled high blood pressure i.e. systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 100 mmHg.
* Life expectancy less than 6 months owing to non-cardiac cause
* Evident cardiogenic shock",Abciximab,INTERVENTIONAL,COMPLETED
NCT01575795,"Standard (180mg) Versus Double (360mg) Loading Dose of Ticagrelor in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)",ST-elevation Myocardial Infarction,"Inclusion Criteria:

1. Age ≥ 18 years old
2. Patients with STEMI (onset of pain \< 12 hours) with indication for primary PCI
3. Antiplatelet naïve or presenting HTPR (≥ 208 PRU) immediately before primary percutaneous coronary intervention
4. Informed consent obtained in writing","* Pregnancy
* Breastfeeding
* Inability to give informed consent or high likelihood of being unavailable until the Day 5
* Cardiogenic shock
* Major periprocedural complications (death, stent thrombosis, vessel perforation, arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents, respiratory failure requiring intubation, vascular injury (arteriovenous shunt, retroperitoneal bleeding), major bleeding (need for bood transfusion or drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding).
* Unsuccessful PCI (residual stenosis \> 30% or flow \< ΤΙΜΙ 3)
* Known hypersensitivity to ticagrelor
* History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 3 months.
* Other bleeding diathesis, or considered by investigator to be at high risk for bleeding
* Any previous history of stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).
* Thrombocytopenia (\< 100.000/μL) at randomization
* Anaemia (Hct \< 30%) at randomization
* Polycytaemia (Hct \> 52%) at randomization
* Periprocedural IIb/IIIa inhibitors administration
* Thrombolysis administration
* Recent (\< 6 weeks) major surgery or trauma, including GABG.
* Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
* Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin/rifampicin, phenytoin, carbamazepine).
* Increased risk of bradycardiac events.
* Dialysis required.
* Severe uncontrolled chronic obstructive pulmonary disease
* Known severe hepatic impairment","Ticagrelor, Ticagrelor",INTERVENTIONAL,COMPLETED
NCT05043610,MSCs for Prevention of MI-induced HF,"Myocardial Infarction, Acute, Myocardial Infarction First, Myocardial Infarction, Anterior Wall, Cardiac Remodeling, Ventricular, STEMI, Regenerative Medicine, Heart Failure","* Age 18-65 years
* Either gender
* First myocardial infarction in the preceding 3 to 7 days
* Post-acute myocardial infarction left ventricular ejection fraction \< 40%
* Negative pregnancy test (for women of reproductive age)
* Written informed consent","* A history of any prior cardiac conditions (valvular, ischemic, or congenital disorders)
* Regional wall motion abnormalities outside the region of the infarction
* LV dysfunction due to other etiologies like non-ischemic cardiomyopathy, anthracycline use, or ethanol abuse (\> 6 oz./day regularly)
* Poor echocardiography window
* Active infection, malignancy, or autoimmune disease","Umbilical Cord-Derived Wharton's Jelly Mesenchymal Stem Cells (WJ-MSCs), Conventional Treatment",INTERVENTIONAL,COMPLETED
NCT03579914,Effect of Intravenous Metoprolol Combining RIC on Myocardial Protection in STEMI Patients,"Anterior Myocardial Infarction, Heart Failure","1. ages 18 to 80 years;
2. presenting within 12 h of symptoms onset, with anterior STEMI and planned for pPCI; anterior STEMI was defined as the occurrence of \>20 min of chest pain and ST-segment elevation (\>2 mm) in at least 2 contiguous precordial leads;
3. sign informed consent;","1. systolic blood pressure \< 110mmHg;
2. cardiogenic shock or with heart failure symptoms, Killip III\~IV;
3. allergic history of metoprolol;
4. history of asthma or the need for bronchodilators;
5. PR interval \> 240ms, II\~III atrioventricular block；
6. heart rate \< 60 beats/min;
7. unable to consent;
8. pregnancy and lactation women;
9. life expectancy for diseases (i.e. cancer) \< 1 year.","intravenous Placebo, Metoprolol Injectable Product, Romote Ischemic Conditioning (RIC), Metoprolol & RIC",INTERVENTIONAL,COMPLETED
NCT01528514,Effects of CUrcuminoids on Coronary Artery byPass graftIng-related myocarDial Infarction Study,Coronary Artery Bypass Grafting,Patients undergoing CABG without valve surgery,"* emergency cardiac surgery
* any increase in CK-MB above upper limit of normal range (ULN) at the time of randomization
* patients with cholestatic jaundice (total bilirubin \> 2-fold ULN)
* severe liver disease (AST or ALT \> 3-fold ULN)","Curcuminoids, Placebo",INTERVENTIONAL,COMPLETED
NCT01531114,PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus,ST-Elevation Myocardial Infarction,"* Diabetic patients
* acute coronary syndrome
* patients underwent to primary PCI
* naïve for platelet P2Y12 receptor inhibition therapy","* history of bleeding diathesis
* chronic oral anticoagulation treatment
* contraindications to antiplatelet therapy
* PCI or coronary artery bypass grafting (CABG) \< 3 months
* hemodynamic instability
* platelet count \< 100,000/μl
* hematocrit \< 30%
* creatinine clearance \< 25 ml/min
* Patients with a history of stroke
* contraindication for prasugrel administration
* patients weighing \< 60 kg
* patients treated with morphine
* \> 75 years of age.","ticagrelor, prasugrel",INTERVENTIONAL,COMPLETED
NCT00623623,STREAM-Strategic Reperfusion (With Tenecteplase and Antithrombotic Treatment) Early After Myocardial Infarction,Myocardial Infarction,"Inclusion criteria:

1. Age equal or greater than 18 years
2. Onset of symptoms \< 3 hours prior to randomisation 3.12-lead ECG indicative of an acute STEMI

4.Informed consent received",":

Medical history, procedures, medication administration or the presence of factors that would in general predispose to bleeding events and/or the inability to evaluate the study primary endpoint","primary PCI, enoxaparin, catheterisation, tenecteplase, clopidogrel",INTERVENTIONAL,COMPLETED
NCT04838808,Rivaroxaban in Type 2 Myocardial Infarctions,Type II Myocardial Infarction,"1. Participant age ≥ 65years or \>45 years and an additional risk factor (smoking, diabetes mellitus, hypertension, dyslipidemia or known atherosclerotic disease)
2. Rise in troponin level, with one troponin value above the 99th percentile of the upper limit of normal deemed to be due to a type 2 myocardial infarction by the attending team within the past 30 days
3. Alive at the time of hospital discharge","1. Current use of anticoagulation
2. Current use of dual antiplatelet therapy
3. Advanced kidney disease (eGFR \<15ml/min)
4. Previous hemorrhagic stroke at any time or embolic stroke within the past year
5. Previous life-threatening bleeding event
6. Life expectancy less than one year
7. Anticoagulation recommended conditions - atrial fibrillation, pulmonary embolism, deep vein thrombosis, mechanical heart valves, rheumatic mitral valve disease, left ventricular thrombosis
8. Surgery in the previous 30 days
9. Inability to provide informed consent in English
10. Pregnancy, breastfeeding or child bearing potential","Rivaroxaban 2.5 MG [Xarelto], Placebo",INTERVENTIONAL,COMPLETED
NCT01807208,PLATFORM to Maximize Patient Knowledge of Health Goals After Acute Myocardial Infarction,Acute Myocardial Infarction,"1. Patients with either ST-elevation MI (STEMI) or non-ST-elevation MI (NSTEMI) who are on antiplatelet therapy at the time of enrollment.
2. English language literacy and
3. Able to provide written informed consent.","1. Patients less than 18 years of age.
2. Patients who are unable or unwilling to comply with the protocol or not expected to complete the study period, including its follow-up requirements
3. Life expectancy less than 6 months or discharged on hospice care.
4. Patients without at least 1 scheduled outpatient follow-up visit inside the Duke University Affiliated Physicians network.
5. Patients who receive a coronary artery bypass grafting (CABG) during the eligible enrollment hospitalization.
6. Active chronic inflammatory conditions (e.g., inflammatory bowel disease, lupus, rheumatoid arthritis)",Educational Tool,INTERVENTIONAL,COMPLETED
NCT05023681,The OPTIMA-5 Trail,Acute Myocardial Infarction,"1. Age ≥ 18, ≦75 years old, weight ≥45kg, gender is not limited.
2. Diagnosis of acute ST-segment elevation myocardial infarction (both of the following) (A) Ischemic chest pain lasting more than 30 minutes; (B) Ecg indicates ST-segment elevation ≥ 0.1mV in 2 or more limb leads, or ST-segment elevation ≥ 0.2mV in 2 or more adjacent chest leads;
3. Time from onset of persistent ischemic chest pain to randomization ≤12 hours;
4. Coronary angiography and/or PCI are expected to be performed within 2 hours of r-SAK thrombolysis.","1. Non-ST-segment elevation myocardial infarction;
2. STEMI with cardiogenic shock;
3. active bleeding or bleeding tendency, including Ⅲ, Ⅳ period history of retinopathy, retinal hemorrhage, gastrointestinal tract and urinary tract hemorrhage (1 month), ischemic stroke happened over the past 6 months, transient ischemic attack (TIA) happened over the past 6 weeks, hemorrhagic stroke in the past, unexplained platelet count \< 100 x 109 / L or Hemoglobin \<100g/L;
4. Having a history of central nervous system trauma or known intracranial aneurysm;
5. Recent (within 1 month) severe trauma, surgery or head injury;
6. Suspected aortic dissection, infective endocarditis;
7. Recent history of puncture which difficult hemostasis by compression (visceral biopsy, compartment puncture);
8. Long-term use and/or current use of anticoagulant drugs;
9. Hypertension not well controlled ≥180/110mmHg;
10. Having severe hepatic and renal impairment (ALT, AST, γ-GT \> 2.5 times the upper limit of normal value; Cr \> 1.5 times upper normal);
11. Known allergies to r-SAK;
12. Pregnant, breastfeeding or planned pregnancy women and male patients with family planning;
13. Patients who have participated in other clinical trials in the past 3 months;
14. Having a history of myocardial infarction or CABG;
15. Having taken antiplatelet drugs after pain onset, such as clopidogrel, prasugrel, cilostazol etc;
16. Other reasons that patients considered unsuitable for inclusion by researchers.","Recombinant Staphylokinase, normal saline",INTERVENTIONAL,COMPLETED
NCT01454323,Intracoronary Infusion of Bone Marrow Mononuclear Cells in Patients With Previous Myocardial Infarction.,Chronic Myocardial Ischemia,"1. Aged between 18 and 80 years.
2. Patients diagnosed with Chronic anterior myocardial infarction (more than 6 months from the acute episode) with symptoms and / or signs of heart failure.
3. Left ventricular ejection fraction (LVEF)\<45% and distensibility changes.
4. Complete revascularization performed at least 6 months before infusion cells.","1. Patients in active waiting list for heart transplantation..
2. Treatable patients with resynchronization.
3. Patients over 80 years
4. Coexistence of other serious systemic diseases.
5. Active infection, HIV, Hepatitis B or Hepatitis C.
6. Patients with malignant or pre-malignant tumours.
7. Coexistence of any haematological disease.
8. Pregnant women, in breastfeeding period, or in childbearing potential age who are not using effective contraception.
9. Patients who are currently participating or have completed their participation in a clinical trial in a period of less than three months.",Bone marrow mononuclear cells,INTERVENTIONAL,COMPLETED
NCT00048308,Effect of Pexelizumab on All-Cause Mortality and Myocardial Infarction in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardio-Pulmonary Bypass,"Cardio-pulmonary Bypass, Coronary Artery Bypass Graft","INCLUSION CRITERIA:

The study population will be drawn from patients undergoing CABG or CABG plus valve surgery using a bypass pump. In addition, they must meet all of the following criteria:

* be at least 18 years of age;
* have one or more of the following risk factors:
* diabetes mellitus;
* prior CABG;
* the need for urgent intervention, defined according to the American College of Cardiology/ American Heart Association (ACC/AHA) guidelines as being patients who are required to stay in the hospital, but may be scheduled and operated on within a normal scheduling routine, excluding patients who have had a MI within 48 hours of CABG;
* female;
* history of a neurologic event (cerebrovascular accident, transient ischemic attack or carotid endarterectomy);
* history of congestive heart failure (New York Heart Association \[NYHA\]Class III or IV);
* history of 2 myocardial infarctions, or a myocardial infarction that occurred greater than 48 hours but less than four (4) weeks prior to CABG;
* provide Informed Consent.",":

A patient will be ineligible for study entry if he/she meets any of the following exclusion criteria:

* has planned aortic dissection repair and/or requires aortic root reconstruction;
* requires salvage intervention as defined by the ACC/AHA guidelines as being ongoing cardiopulmonary resuscitation on the way to the operating room;
* has current cardiogenic shock, acute left ventricular rupture, acute septal rupture or acute papillary muscle rupture;
* has uncontrolled diabetes, defined as a documented plasma blood glucose value \> 400 mg/dl (22.2 mmol/L) within three (3) days before surgery;
* has a history of renal failure and a serum creatinine value greater than 3.0 mg/dl;
* has a history of chronic hepatic failure and/or hepatic cirrhosis;
* has a history of malignancy, excepting basal cell carcinoma and malignancies in remission (greater than 2 years);
* has any active bacterial or other infection which is clinically significant, in the opinion of the investigator (e.g. evaluate the evidence based on WBC, temperature, cultures, etc. as appropriate for the patient);
* has any serious medical condition which, in the opinion of the investigator is likely to alter the patient's course of recovery or the evaluation of the study medication's safety;
* has a history of alcohol or drug abuse within the past year;
* has a known or suspected hereditary complement deficiency;
* has participated in any other investigational drug study or was exposed to an investigational agent or device within 30 days of randomization;
* is receiving, or is planning to receive, any other investigational drug or device, or will participate in any other research study during the trial;
* is pregnant or breast-feeding.",pexelizumab,INTERVENTIONAL,COMPLETED
NCT01787110,An Efficacy and Outcome Study of Supplemental Oxygen Treatment in Patients With Suspected Myocardial Infarction,"Acute Coronary Syndrome, Non-ST Elevation (NSTEMI) Myocardial Infarction, Acute ST Segment Elevation Myocardial Infarction, Angina, Unstable","* symptoms (chest pain, dyspnea) indicating acute myocardial ischemia within the last 6 hours
* ECG changes (ST-segment elevation ≥ 2 mm V1-V4, or ≥ 1 mm in other leads, ST-segment depression \>1 mm in any lead, negative T-wave in leads V2-V6, pathological Q-wave in at least 2 adjacent leads), left bundle branch block

and/or elevated levels of cardiac troponin levels in the ED

indicating acute myocardial ischemia

* oxygen saturation ≥90% (pulse oximeter)
* age ≥30","* unwillingness to participate
* inability to comprehend given information
* continuous oxygen delivery at home prior to inclusion
* cardiac arrest prior to inclusion",Oxygen,INTERVENTIONAL,COMPLETED
NCT00316381,Stem Cell Therapy to Improve Myocardial Function in Patients With Acute Myocardial Infarction,Myocardial Infarction,"* Acute myocardial infarction treated successfully with primary coronary angioplasty
* Left ventricular ejection fraction less than 40%
* Informed consent granted","* Presence of significant coronary stenoses in non-infarct related artery requiring revascularization
* Cardiogenic shock
* Previous myocardial infarction
* Age \< 18 years and \> 75 years
* Pregnancy
* Neoplasm
* Contraindications for MRI",Autologous bone marrow-derived stem cells,INTERVENTIONAL,COMPLETED
NCT01696110,BivaliRudin in Acute Myocardial Infarction vs Glycoprotein IIb/IIIa and Heparin :a Randomised Controlled Trial.,"Acute Myocardial Infarction, Percutaneous Coronary Intervention","1. Age 18 to 80 years old
2. Planned emergency PCI for acute myocardial infarction (STEMI or NSTEMI) Symptom onset within 12h for STEMI (or within 24 h for patients have unrelieved chest pain, continuous ST elevation or new developed LBBB) Symptom onset within 72h for NSTEMI
3. Avoid to undergoing revascularization for non-culprit vessels within 30 days after index procedure.
4. Provide written informed consent.","1. Unsuitable for PCI; treatment by thrombolysis within 72 hours of acute ST-elevation myocardial infarction; left main coronary artery disease; cardiogenic shock.
2. Any anticoagulant agents were used 48 h before randomization.
3. Active bleeding or bleeding constitution, bleeding tendency, including the recent retina or vitreous hemorrhage (1 months), GI or urinary tract hemorrhage (3 months), cerebral hemorrhage (6 months) or cerebral infarction history (3 months), etc.;
4. Other disease may lead to vascular lesions and secondary bleeding factors (such as active gastric ulcer, active ulcerative colitis, intracranial aneurysm, etc.),
5. Deep puncture or major surgery (including eye or brain surgery) within 1 month.
6. Suspicious aortic dissection, pericarditis and subacute bacterial endocarditis.
7. Untreated or uncontrolled hypertension \> 180/110 mmHg.
8. Hemoglobin \< 100 g/L or platelet count \< 100 \* 109 / L.
9. Elevated AST, ALT level higher than three times of the normal upper limit.
10. severe renal insufficiency (eGFR \< 30 mL/min / 1.73 m2).
11. Heparin induced thrombocytopenia.
12. Known allergy to the study drugs and instruments (UFH, bivalirudin, aspirin and clopidogrel, stainless steel, contrast agents, etc.), or those allergic constitution.
13. Pregnancy or lactation.
14. Researchers think that doesn't fit to participate in this study.","Bivalirudin, heparin, heparin plus tirofiban",INTERVENTIONAL,COMPLETED
NCT04664881,Home Telemonitoring In Patients After Myocardial Infarction,"Myocardial Infarction, Heart Attack","* Acute myocardial infarction, both STEMI and non-STEMI.
* Able to use the home ECG telemonitoring.
* Must have smartphone device with home wi-fi/mobile internet which allows for 24/7 ability to transmit ECG.
* Caring family member who will be able to help/perform the ECG in case the patient won't be able to do it.","* No ability to use the device at home/unable to comply with the device instructions
* No smartphone device or home wi-fi/mobile internet which prevent 24/7 ability to transmit ECG
* Cannot download the smartheart app
* No support in home environment
* Out of hospital cardiac arrest: secondary to a non-shockable rhythm, unrelated to an acute coronary syndrome, or with any level of neurologic damage.
* Resident of nursing home or acute care facility
* Uninterpretable ECG at discharge - left bundle branch block (LBBB), pacemaker or implantable cardioverter defibrillator (ICD) with pacing dependence.
* Patients who are planned for staged PCI after the index hospitalization",SmartHeart Device,INTERVENTIONAL,COMPLETED
NCT00821210,Obstructive Sleep Apnea and Acute Myocardial Infarction and the Role of Continuous Positive Airway Pressure (CPAP)Treatment,"Sleep Apnea, Obstructive, Acute Myocardial Infarction","1. First-time AMI
2. s/p revascularization (successful primary PTCA for ischemia-related artery)
3. Killip I","1. Refuse to participate
2. Require mechanical ventilation
3. Having active neurologic event, severe obstructive airway disease and active infection, active malignancy
4. Need sedative drug or narcotics during the study period within 3 days of PSG
5. Participates other study at the same time","Sham CPAP, CPAP of optimal pressure",INTERVENTIONAL,COMPLETED
NCT00121446,Which Therapy for Acute Heart Attacks? (The WEST Study),Myocardial Infarction,"* Male or non-pregnant female patients aged \>18 years
* Patients with symptoms presumed secondary to STEMI lasting at least 20 minutes and accompanied by ECG evidence \>2 mm of ST elevation in 2 or more contiguous precordial leads or in 2 or more limb leads;or \> 1mm ST elevation in 2 or more limb leads coupled with \>1 mm ST depression in 2 or more contiguous precordial leads such that the total ST deviation is \>4 mm; or presumed new left bundle branch block
* Earliest point of care and randomisation must be within 6 hours of onset of symptoms as defined in previous criteria
* Females of child-bearing age, not using a generally accepted method of contraception must have a negative urine pregnancy test
* Written informed consent prior to randomisation of study","* PCI expected to commence within \< 60 minutes from identification of suitable candidate
* Inability to have angiography/PCI within 3 hrs from randomisation
* Active bleeding or known hemorrhagic diathesis
* Any history of stroke, transient ischemic attack, dementia or structural CNS damage e.g. neoplasm, aneurysm, AV malformation
* Major surgery or trauma within the past 3 months
* Previous Coronary Artery Bypass Graft (CABG)
* Use of abciximab (ReoPro) or other GP IIb/IIIa antagonists within the preceding 7 days
* Any minor head trauma and/or any other trauma occurring after onset of the current myocardial infarction
* Significant hypertension (i.e. SBP \> 180 mm HG and/or DBP \> 110mm HG) at any time from presentation (earliest point of care) to randomisation
* Current treatment with vitamin K antagonist (warfarin) resulting with an INR \> 1.5
* Anticipated difficulty obtaining vascular access
* Prolonged (\>10 min) cardiopulmonary resuscitation or cardiogenic shock
* Patients who have participated in an investigational drug study within 7 days prior to randomisation
* Known renal insufficiency (prior creatinine \>2.5 mg% for men and \>2.0 mg% for women)
* Treatment with standard unfractionated heparin (heparin sodium) \>5000 IU or a therapeutic dose of any low molecular weight heparin, within 6 hours prior to randomisation
* Known thrombocytopenia (prior platelet count below 100 000/ul)
* Known sensitivity to TNKase, clopidogrel, heparin, low molecular weight heparin or abciximab
* Pregnancy or lactation, parturition within the previous 30 days
* Any serious concomitant systemic or life limiting disorder that would be incompatible with the trial
* Inability to follow protocol and comply with follow-up requirements","tenecteplase, enoxaparin, clopidogrel, percutaneous coronary intervention",INTERVENTIONAL,COMPLETED
NCT05711810,Medicine-induced Cardiac Hemodialysis on COVID-19,"Severe Acute Respiratory Syndrome-related Coronavirus, Renal Dialysis, Vaccines, Myocarditis Allergic, Infection Viral","* No mRNA vaccinated poisoning have been included currently, but scientific evidence suggest the methods of vaccination are irrelevant to the conditions. It is theorized that the more advanced the vaccine production technology, the deeper the poisoning.","* healthy individuals with no myocarditis or unvaccinated without infection by SARS-CoV series
* persons with diabetes (Paxlovid and PrEP treatments can be applied according to availability)","Nifedipine 30 MG, Kangzhu BPCB0A-3A, Low Mobility, Enalapril Maleate 10Mg Tab, Lansoprazole 30Mg Ec Cap, Metoprolol Succinate, Coenzyme Q10, d-alpha tocopherol acetate, Omega-3, Duloxetine Hydrochloride 20 MG Oral Capsule, Delayed Release, Superoxide Dismutase",INTERVENTIONAL,COMPLETED
NCT04289012,HELicobacter Pylori Screening in Patients With Acute Myocardial Infarction Pilot Study,"STEMI - ST Elevation Myocardial Infarction, NSTEMI - Non-ST Segment Elevation MI",* Type 1 myocardial infarction (both STEMI and NSTEMI),"* Only concerning UBT (Patients after gastric surgery, with acute gastrointestinal bleeding, suspected gastric infection, or known atrophic gastritis).",Helicobacter Pylori screening by UBT,INTERVENTIONAL,COMPLETED
NCT03005158,High-Sensitivity Cardiac Troponin On Presentation to Rule Out Myocardial Infarction,"Acute Coronary Syndrome, Myocardial Infarction","* All consecutive patients with suspected acute coronary syndrome
* High-sensitivity cardiac troponin I measured as part of routine clinical care","* Patients who are not resident in Scotland
* Patients with ST-segment elevation myocardial infarction
* Patients presenting to hospital in cardiac arrest
* Patients with presentation high-sensitivity cardiac troponin I concentrations greater than sex-specific 99th centile thresholds","Validation Phase, Randomization Phase, Implementation Phase",INTERVENTIONAL,COMPLETED
NCT02603835,Evaluation of Intracoronary Hyperoxemic Oxygen Therapy in Anterior Acute Myocardial Infarction Patients (IC-HOT),Anterior Wall Acute Myocardial Infarction,"GENERAL INCLUSION CRITERIA: Candidates for this study must meet ALL of the following criteria:

Pre-PCI:

1. The subject must be ≥18 and ≤80 years of age.
2. AMI must be anterior (ST-segment elevation \>1 mm in two or more contiguous leads between V1 and V4 or new left bundle branch block).
3. Subject is experiencing clinical symptoms consistent with anterior AMI of ≤6 hour duration from time of symptom onset until admission to the emergency room.
4. The subject or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided and signed written informed consent, approved by the appropriate Institutional Review Board (IRB).
5. Subject and his/her physician agree to all required follow-up procedures and visits.

   ANGIOGRAPHIC INCLUSION CRITERIA: These are evaluated after the subject has provided signed informed consent but prior to enrollment:
6. Based on coronary anatomy, PCI is indicated for revascularization of the culprit lesion(s) with use of a commercially available coronary stent (bare metal or drug-eluting, at operator discretion) in the LAD.
7. The primary stented infarct-related lesion(s) must be in the proximal and/or mid-LAD coronary artery (other lesions in the LAD target vessel, including diagonal branches, may be treated if clinically indicated).
8. Baseline (pre-PCI) TIMI flow grade 0, 1, 2, or 3 flow in the LAD.
9. Successful angioplasty as documented by \<50% diameter residual angiographic stenosis within all treated culprit lesions with TIMI 2 or 3 flow and no major complications such as perforation or shock.
10. Expected ability to place the SSO2 delivery catheter in the coronary ostium of the left main coronary system to deliver SSO2 Therapy with stable, coaxial alignment.

GENERAL",":

Pre-PCI:

1. Prior CABG surgery.
2. Prior myocardial infarction, or known prior systolic dysfunction (known ejection fraction \<40% by any prior measure or regional wall motion abnormalities; this criterion does not include left ventricular dysfunction induced by the acute MI).
3. Thrombolytic therapy administered for this STEMI.
4. An elective surgical procedure is planned that would necessitate interruption of anti-platelet agents during the first 30 days post-enrollment.
5. Subjects who previously underwent coronary stent implantation and in whom coronary angiography demonstrates stent thrombosis to be the cause of the anterior AMI.
6. Subjects who have previously undergone an angioplasty or stenting procedure in the left anterior descending coronary artery.
7. Subjects with ventricular pseudoaneurysm, VSD, or severe mitral valve regurgitation (with or without papillary muscle rupture).
8. Any contraindication to MRI imaging. This will include any of the following exclusions:

   * Cardiac pacemaker or implantable defibrillator;
   * Non-MRI compatible aneurysm clip;
   * Neural Stimulator (i.e., TENS unit);
   * Any implanted or magnetically activated device (insulin pump);
   * Any type of non-MRI compatible ear implant;
   * Metal shavings in the orbits;
   * Any metallic foreign body, shrapnel, or bullet in a location which the physician feels would present a risk to the subject;
   * Any history indicating contraindication to MRI, including claustrophobia or allergy to gadolinium;
   * Inability to follow breath hold instructions or to maintain a breath hold for \>15 seconds; and
   * Known hypersensitivity or contraindication to gadolinium contrast.
9. Known impaired renal function (creatinine clearance \<30 ml/min/1.73 m2
10. Known platelet count \<100,000 cells/mm by the MDRD formula) or on dialysis. 3 or \>700,000 cells/mm3
11. Subject has active bleeding or a history of bleeding diathesis or coagulopathy (including heparin induced thrombocytopenia), or refusal to receive blood transfusions if necessary. or a known Hgb \<10 g/dL.
12. History of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke.
13. Stroke or transient ischemic attack within the past six (6) months, or any permanent neurological defect.
14. Gastrointestinal or genitourinary bleeding within the last two (2) months, or any major surgery (including CABG) within six weeks of enrollment.
15. Subject has received any organ transplant or is on a waiting list for any organ transplant.
16. Subject has other medical illness (e.g., cancer, dementia) or known history of substance abuse (alcohol, cocaine, heroin, etc.) that may cause non-compliance with the protocol, confound the data interpretation, or is associated with limited life expectancy of less than one year.
17. Subject has a known hypersensitivity or contraindication to unfractionated heparin, abciximab, aspirin, bivalirudin, cangrelor, clopidogrel, ticlopidine, prasugrel, or ticagrelor that cannot be adequately premeditated.
18. Current use of warfarin, dabigatran, or factor Xa inhibitors, or known intent to administer these agents after the primary PCI.
19. Subjects presenting with or developing in the cath lab prior to completion of the primary PCI procedure any of the following conditions: cardiogenic shock (SBP \<80 mmHg for \>30 minutes), or requiring IV pressors or emergent placement of an intra-aortic balloon pump (IABP), Impella, or other hemodynamic support for hypotension treatment, or cardiopulmonary resuscitation for \>10 minutes, or ventricular fibrillation or tachycardia requiring cardioversion or defibrillation.
20. Severe known cardiac valvular stenosis or insufficiency, pericardial disease, or non-ischemic cardiomyopathy.
21. Any significant medical or social condition which in the investigator's opinion may interfere with the subject's participation in the study or ability to comply with follow-up procedures, including MRI (e.g. alcoholism, dementia, lives far from the research center, etc.).
22. Current participation in other investigational device or drug trials that have not finished the primary endpoint follow-up period.
23. Previous enrollment in this study.

    ANGIOGRAPHIC EXCLUSION CRITERIA: These are evaluated after the subject has provided signed Informed Consent but prior to enrollment:
24. Anticipated inability to achieve a stable coaxial position in the left main coronary artery with the SSO2 delivery catheter.
25. Treatment during the index procedure of any lesion in either the left main, LCX (including the ramus), and/or RCA.
26. Post-index procedure planned intervention within 30 days (i.e., PCI of non-target lesions in any vessel, or CABG). Note: Planned revascularization (PCI or bypass) of a non-target lesion \>30 days following the index procedure is allowed.
27. Anterior MI is due to thrombosis within or adjacent to a previously implanted stent.
28. Left ventriculography demonstrates severe mitral regurgitation, a ventricular septal defect, or a pseudoaneurysm.
29. Any left main coronary artery stenosis \>20%.
30. Any untreated LAD or diagonal branch lesion is present with diameter stenosis \> 50% in a vessel with reference vessel diameter \> 2.0 mm (visually estimated), or for which PCI will be required before the MRI study.
31. Presence of a non-stented coronary dissection with NHLBI grade \>B upon completion of the PCI procedure.",SSO2 Therapy,INTERVENTIONAL,COMPLETED
NCT05415735,Stress Management and Resiliency Training Following Acute Myocardial Infarction,"Heart Attack, Cardiovascular Diseases","* Concurrently enrolled in an observational study of patients who have had an acute myocardial infarction
* Score on PSS-10 of 14 or greater during screening
* Willing and able to access the internet to participate in the online SMART Program","* Poorly controlled physical or mental health condition that would likely interfere with the ability to participate in SMART or ability to undergo PET scan
* Current daily practice of meditation of 10 minutes or more per day",Stress Management and Resiliency Training Program,INTERVENTIONAL,COMPLETED
NCT02425358,Timing for Bone Marrow Mononuclear Cells After Acute Myocardial Infarction,Myocardial Infarction,"* a history of first acute ST-elevation myocardial infarction
* treatment with successful PCI two to twelve hours after symptom onset
* LVEF less than 50% on angiography immediately after emergency PCI or rescue PCI","* previous Q-wave myocardial infarction
* cardiogenic shock
* severe coexisting conditions such as acute and chronic heart failure, malignant
* arrhythmia, renal failure and severe bleeding that interfered with the ability of the
* patient to comply with the protocol","BMC therapy within 24 hours, BMC therapy within 3-7 days, BMC therapy within 7-30 days, PCI only",INTERVENTIONAL,COMPLETED
NCT04717986,Dapagliflozin Effects on Mayor Adverse Cardiovascular Events in Patients With Acute Myocardial Infarction (DAPA-AMI),"Acute Myocardial Infarction, Cardiovascular Morbidity, Heart Failure, Angina, Unstable","* Male and female IMSS eligible patients over 18 years of age
* Meet the criteria of the fourth definition of ST-segment elevation myocardial infarction
* Known with diabetes mellitus 2 or newly diagnosed diabetes according to ADA criteria","* Patients diagnosed with Type 1 Diabetes Mellitus
* Patients on chronic replacement therapy for renal function through peritoneal dialysis or hemodialysis
* Patients who have recently undergone immunosuppressive therapy
* Patients with a history of recurrent urinary tract infection
* Patients known to be allergic to SGLT-2 inhibitors
* Patients presenting as sudden aborted death
* Patients who after percutaneous coronary intervention require orotracheal intubation","Dapagliflozin 10Mg Tab, Placebo",INTERVENTIONAL,COMPLETED
NCT01463163,"Ticagrelor in Comparison to Prasugrel for Early Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)",Platelet Reactivity,"1. Age ≥18 years old
2. Patients with STEMI undergoing primary PCI with stenting
3. Informed consent obtained in writing","* Pregnancy
* Breastfeeding
* Inability to give informed consent or high likelihood of being unavailable until the Day 5
* Prior PCI performed within 30 days prior to randomization
* Cardiogenic shock
* Major periprocedural complications (death, stent thrombosis, vessel perforation, arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents, respiratory failure requiring intubation, vascular injury (arteriovenous shunt, retroperitoneal bleeding), major bleeding (need for bood transfusion or drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding).
* Unsuccessful PCI (residual stenosis \> 30% or flow \< ΤΙΜΙ 3) or planned staged PCI in the next 5 days after randomization
* Requirement for oral anticoagulant prior to the Day 5 visit
* Current or planned therapy with other thienopyridine class of ADP receptor inhibitors.
* Known hypersensitivity to prasugrel or ticagrelor
* History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months.
* Other bleeding diathesis, or considered by investigator to be at high risk for bleeding.
* Any previous history of ischemic stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).
* Thombocytopenia (\<100.000 / μL) at randomization
* Anaemia (Hct \<30%) at randomization
* Polycytaemia (Hct \> 52%) at randomization
* Periprocedural IIb/IIIa inhibitors administration
* Severe allergy to contrast agent, unfractionated heparin, enoxaparin or bivalirudin that cannot be adequately premedicated.
* Recent (\< 6 weeks) major surgery or trauma, including GABG.
* Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
* Concomitant oral or IV therapy with strong CY P3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazana vir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3A inducers (rifampin /rifampicin, phenytoin, carbamazepine).
* Increased risk of bradycardiac events.
* Dialysis required.
* Severe uncontrolled chronic obstructive pulmonary disease
* Known severe hepatic impairement","Prasugrel, Ticagrelor",INTERVENTIONAL,COMPLETED
NCT00883363,Reduction of Myocardial Infarction by Preconditioning in Patients With Ruptured Abdominal Aortic Aneurysm,Abdominal Aortic Aneurysm,"* Patients with ruptured abdominal aortic aneurysm offered surgery
* Age \> 18 years",* Technical inoperable,Precondition,INTERVENTIONAL,COMPLETED
NCT00883727,Ex Vivo Cultured Bone Marrow Derived Allogenic MSCs in AMI,Myocardial Infarction,"* Patients with STEMI aged between 20 and 70 years, either males or females with non-child bearing potential, after 2 days of successful PCI.
* Patient has global left ventricular systolic dysfunction with an ejection fraction of \<50% and \>30%.
* ECG with sign of acute anterior MI with ST-elevation ≥ 2 mm in at least 2 of the following leads I, AVL, V1-V6, or ECG with sign of acute inferoposterior MI with ST-elevation ≥1 mm on all of the following leads- II, III, V5-V6 or STelevation ≥ 2 mm in at least 2 of the leads.
* The target lesion located in the proximal section of the left anterior descending, left circumflex or right coronary artery.
* Patient with acute myocardial infarction within 10 days prior to IP administration.
* Normal liver and renal function.
* Able to understand study information provided to him.
* Able to give voluntary written consent.","* History of acute/chronic inflammatory condition or severe aortic stenosis or insufficiency; severe mitral stenosis or severe mitral insufficiency.
* Severe co-morbidity associated with a reduction in life expectancy of less than 1 year.
* Advanced renal dysfunction and creatinine ≥ 2mg%.
* Advanced hepatic dysfunction.
* Have clinically serious and/or unstable intercurrent infection, medical illnesses or conditions that are uncontrolled or whose control, in the opinion of the Investigator, may be jeopardized by participation in this study or by the complications of this therapy","Stem cell, Plasmalyte A",INTERVENTIONAL,COMPLETED
NCT00675480,Thrombectomy in Acute Myocardial Infarction,Acute Myocardial Infarction,"1. First acute myocardial infarction with ST segment elevation within 12 hours from pain onset
2. Culprit lesion in left anterior descending or right coronary artery.
3. Coronary flow assessed in TIMI scale ≤ 2
4. Presence of total coronary occlusion or angiographically visible thrombus in the culprit vessel
5. Patient signed informed consent","1. Cardiogenic shock.
2. Culprit lesion in left circumflex coronary artery.
3. Status post coronary artery by-pass grafting
4. Previous myocardial infarction
5. Status post percutaneous coronary intervention.","Thrombectomy, Primary angioplasty",INTERVENTIONAL,COMPLETED
NCT01930682,EARLY Routine Catheterization After Alteplase Fibrinolysis vs. PPCI in ST-Segment-Elevation MYOcardial Infarction,Acute ST-segment Elevation Myocardial Infarction,"* Age: over 18 or 18 years old, less than 75 years old;
* Patents with myocardial infarction who have symptom onset within 6h before randomization;
* ECG: ≥2 mm ST-segment elevation in 2 contiguous precordial leads or ≥1 mm ST-segment elevation in 2 contiguous extremity leads ;
* Patents with an expected PCI-related delay \[expected time delay from FMC to first balloon dilation≥90 min, and difference between the time of FMC to balloon dilation minus the time from FMC to start of fibrinolysis ≥60 minutes)\];
* Signed informed consent form prior to trial participation.","1. Evidence of cardiac rupture;
2. ECG: new left bundle branch block;
3. ""Diagnosis to balloon inflation"" time over 3 hours;
4. Thrombolysis contradictions:

   * Definite cerebral apoplexy history;
   * Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal surgery) or recent trauma to the head or cranium (i.e. \< 3 months);
   * Active bleeding or known bleeding disorder/diathesis;
   * Recent administration of any i.v. or s.c. anticoagulation within 12 hours including unfractionated heparin, enoxaparin and/or bivalirudin or current use of oral anticoagulation(warfarin or coumadin);
   * Uncontrolled hypertension, defined as a single blood pressure measurement ≥ 180/110 mm Hg (systolic BP ≥ 180 mm Hg and/or diastolic BP ≥ 110 mm Hg) prior to randomisation;
   * Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 2 months (this includes any trauma associated with the current myocardial infarction); Prolonged or traumatic cardiopulmonary resuscitation (\> 10 minutes) within the past 2 Weeks Major surgery pending in the following 30 days;
5. Severe complication

   * Other diseases with life expectancy ≤12 months;
   * Any history of Severe renal or hepatic dysfunction(hepatic failure, cirrhosis, portal hypertension and active hepatitis); Neutropenia, thrombocytopenia ; Known acute pancreatitis;
   * Known acute pericarditis and/or subacute bacterial endocarditis;
   * Arterial aneurysm, arterial/venous malformation and aorta dissection;
6. Complex heart condition

   * Cardiogenic shock(SBP \<90 mmHg after fluid infusion or SBP\<100 mmHg after vasoactive drugs);
   * PCI within previous 1 month or Previous coronary-artery bypass surgery(CABG);
   * Previously known multivessel coronary artery disease not suitable for revascularization;
   * Hospitalisation for cardiac reason within past 48 hours;
7. Not suitable for clinical trial

   * Inclusion in another clinical trial;
   * Previous enrolment in this study or treatment with an investigational drug or device under another study protocol in the past 7 days;
   * Pregnancy or lactating;
   * Body weight \<40kg or \>125kg;
   * Known hypersensitivity to any drug that may appear in the study;
   * Inability to follow the protocol and comply with follow-up requirements or any other reason that the investigator feels would place the patient at increased risk.","Alteplase, Early post-fibrinolytic catheterisation, Primary PCI",INTERVENTIONAL,COMPLETED
NCT04460482,Near-infrared Spectroscopy Guided Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction,"Myocardial Infarction, Coronary Artery Disease, Myocardial Ischemia, Atherosclerosis, Lipid-Rich Atherosclerosis of Coronary Artery, Vascular Diseases, Infarct Ischemia","* Patients with acute coronary syndrome (ST-elevation myocardial infarction and non-ST elevation myocardial infarction) referred for invasive coronary angiography and percutaneous coronary intervention at Department of Cardiology, Odense University Hospital (Odense, Denmark)","* participation in other randomized clinical trials
* life expectancy \< 1 year
* allergy to aspirin, clopidogrel, ticagrelor or prasugrel
* eGFR \< 30 mL/min
* tortuous and angiographically estimated extremely calcified lesions
* ostial, left main and bifurcation lesions
* lesions in a reference vessel diameter \< 2.0 mm
* hemodynamic instability
* Scheduled for coronary artery bypass grafting","Near-infrared spectroscopy (NIRS), Angiography",INTERVENTIONAL,COMPLETED
NCT01684982,Everolimus Stent in Myocardial Infarction,Acute Myocardial Infarction,* All ST segment elevation myocardial infarction (STEMI) patients eligible for primary PCI,"1. Contraindication to dual antiplatelet therapy for 12 months
2. Known allergy to sirolimus or everolimus
3. Major surgical procedure planned within 1 month.
4. History, symptoms, or findings suggestive of aortic dissection.
5. Participation in other trials
6. Pregnancy.","everolimus eluting stent, sirolimus eluting stent",INTERVENTIONAL,COMPLETED
NCT04507529,Peer-mentor Support for Older Vulnerable Myocardial Infarction Patients,Myocardial Infarction,* ≥65 years and diagnosed with MI and referred to CR and female or low SEP or single living or non-western background.,* Patients unable to provide written consent.,Peer-mentoring,INTERVENTIONAL,COMPLETED
NCT00291629,Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion-3-DES,Myocardial Infarction,* Patients with acute or old myocardial infarction who were successfully revascularized with DES in the culprit lesion were eligible for enrollment.,* 1) Persistent severe heart failure (left ventricular ejection fraction (LVEF) \< 20%) 2) Uncontrolled myocardial ischemia or ventricular tachycardia 3) Culprit lesion of infarct related artery not feasible for percutaneous coronary intervention (PCI) or unsuccessful PCI 4) Age \> 80 years 5) Malignancy 6) Serious current infection or hematologic disease; and 7) Life expectancy under one year.,"G-CSF (Dong-A pharmaceutical, Seoul, Korea), collection of mobilized peripheral blood stem cells, Intracoronary infusion of mobilized cells",INTERVENTIONAL,COMPLETED
NCT00759629,Beyond 12 Hours Reperfusion AlternatiVe Evaluation Trial,Myocardial Infarction,* patients fulfilling the criteria of AMI and presenting at the hospital between 12 and 48 hours after onset of symptoms. The criteria of AMI are fulfilled when at least one episode of typical chest pain lasting ≥ 20 minutes is combined with either unequivocal ECG changes (≥ 0.1 mV of ST-segment elevation in ≥ 2 limb leads or ≥ 0.2 mV in ≥ 2 contiguous precordial leads or new pathological Q-waves) or CK plus concomitant CK-MB increase above twice the upper normal threshold. All patients have to be informed of the nature of the study and should give their informed consent for participation in the study.,"* Age \<18 years and \> 80 years
* Cardiogenic shock (systolic blood pressure \< 80 mm Hg unresponsive to fluids or necessitating the infusion of catecholamines: GUSTO I criteria)
* Persistent severe chest pain
* Prior thrombolysis (for index AMI)
* Malignancies with life expectancy \< 1year
* History of bleeding diathesis, coagulopathy
* Contraindications to the antithrombotic therapy used in conjunction with coronary stenting (clopidogrel and abciximab)
* Stroke within the past 3 months
* Major surgery within the past 30 days
* Platelets \< 100000/mm3 or \>700000/mm3, Hb \< 10g/dl, white blood cell count \<3000/mm3
* Percutaneous coronary intervention within the past 30 days
* Inability to cooperate with study procedures and/or follow-up
* Previous enrollment in this trial","Interventional treatment group, Conservative treatment group",INTERVENTIONAL,COMPLETED
NCT06480929,LV Thrombus Screening in Anterior STEMI: Worth it?,"Thrombus of Left Ventricle, Anterior Wall Myocardial Infarction, ST Elevation Myocardial Infarction, Echocardiography","* Patients aged 18 years or older
* Admitted due to anterior ST-elevation myocardial infarction","* Under 18 years old
* Did not undergo echocardiographic or coronary angiographic evaluation
* Cardiogenic shock
* Previously known thrombus
* Previously known allergic contrast reaction","Contrast TTE procedure, the SonoVue ultrasound agent",INTERVENTIONAL,COMPLETED
NCT03173313,COOL AMI EU Pivotal Trial to Assess Cooling as an Adjunctive Therapy to PCI In Patients With Acute MI (Phase A),Acute Myocardial Infarction,"1. The patient is ≥ 18 years of age.
2. The patient must have symptoms consistent with AMI (i.e. chest pain, arm pain, etc.) and unresponsive to nitroglycerin, with symptoms beginning greater than 30 minutes but less than 6 hours prior to presentation at hospital.
3. Qualifying Infarct location:

   1. Roll-In subjects: Evidence of Acute Anterior or Inferior MI with ST-segment elevation of \>= 0.2 mV in two or more anterior or inferior contiguous precordial leads.
   2. Randomized subjects: Evidence of Acute Anterior MI only with ST-segment elevation of \>= 0.2 mV in two or more anterior contiguous precordial leads.
4. The patient is eligible for PCI.
5. The patient is willing to provide written informed consent to participate in this clinical trial.","1. The patient has had a previous Myocardial Infarction.
2. The patient is experiencing cardiogenic shock (systolic blood pressure \[SBP\] \<80 mmHg and non-responsive to fluids, or SBP \<100 mmHg with vasopressors, or requirement for an intra-aortic balloon pump \[IABP\]).
3. The patient is presenting with resuscitated cardiac arrest, atrial fibrillation, or Killip risk stratification class II through IV.
4. The patient has an aortic dissection or requires an immediate surgical or procedural intervention other than PCI.
5. The patient has known history of Congestive Heart Failure (CHF), hepatic failure, end-stage kidney disease or severe renal failure (clearance \< 30ml/min/1.73m²).
6. The patient is febrile (temperature \> 37.5 °C) or has experienced an infection with fever in the last 5 days.
7. The patient has a known previous CABG.
8. The patient has a known recent stroke within 90 days of admission.
9. Cardio-pulmonary decompensation that has occurred en route to the hospital or, in the opinion of the physician, that is imminent or likely to occur following presentation to the clinical site.
10. Contraindications to hypothermia, such as patients with known hematologic dyscrasias which affect thrombosis (e.g., cryoglobulinemia, sickle cell disease, serum cold agglutinins) or vasospastic disorders (such as Raynaud's or thromboangitis obliterans).The patient has a known hypersensitivity or contraindication to aspirin, heparin, or sensitivity to contrast media, which cannot be adequately pre-medicated.
11. Any contraindication to cardiac MRI, or any implant in the upper body which may cause artifacts on cardiac MRI imaging.
12. The patient has a known hypersensitivity or contraindication to aspirin, heparin, or sensitivity to contrast media, which cannot be adequately pre-medicated.
13. The patient has a known history of bleeding diathesis, coagulopathy, cryoglobulinemia, sickle cell anemia, or will refuse blood transfusions.
14. The patient has a height of \<1.5 meters (4 feet 11 inches).
15. The patient has a known hypersensitivity or contraindication to buspirone hydrochloride or Pethidine (Meperidine) and/or has been treated with a monoamine oxidase inhibitor in the past 14 days.
16. Patient has a known history of severe hepatic or renal impairment, untreated hypothyroidism, Addison's disease, benign prostatic hypertrophy, or urethral stricture that in the opinion of the physician would be incompatible with Pethidine administration.
17. The patient has an Inferior Vena Cava filter in place (IVC).
18. The patient has a pre-MI life expectancy of \<1 year due to underlying medical conditions or pre-existing co-morbidities.
19. The patient has a known, unresolved history of drug use or alcohol dependency, or lacks the ability to comprehend or follow instructions.
20. The patient is currently enrolled in another investigational drug or device trial.
21. The patient is apprehensive about or unwilling to undergo the required MRI imaging at follow-up, has a documented or suspected diagnosis of claustrophobia, or has Gadolinium allergy, or is in permanent Atrial Fibrillation.
22. The patient has received thrombolytic therapy en route to the hospital.
23. The patient shows clinical evidence of spontaneous reperfusion as observed symptomatically and/ or from ECG findings (partial or complete ST resolution in ECG prior to informed consent and randomization).
24. The patient is a vulnerable subject, for instance, a person in detention (i.e., prisoner or ward of the state).
25. The patient is a female who is known to be pregnant.",Intravascular permissive hypothermia as an adjunct to PCI,INTERVENTIONAL,COMPLETED
NCT04769219,Secondary Prevention Education After Acute Myocardial Infarction,"Myocardial Infarction, Acute, Anxiety, Education, Quality of Life","* First time AMI and inpatient treatment in the coronary intensive care unit,
* Not having received training after AMI \*
* Being 18 years or older,
* Speak Turkish,
* No problem in verbal communication,
* Absence of hearing loss,
* Not being diagnosed with a psychiatric illness,
* Being conscious,
* Being volunteer to participate in the study,
* Routine check of cholesterol, HDL, LDL, triglyceride results at the beginning of the study and at 6 months.","Not having had AMI for the first time

* Having received training after AMI
* Not willing to participate in the study,
* Cannot speak Turkish,
* Problems in verbal communication,
* Having hearing loss,
* Having a diagnosis of psychiatric illness,
* Unconsciousness.
* Cholesterol, HDL, LDL, triglyceride results were not routinely checked at the start and 6 months of the study.",Secondary prevention training,INTERVENTIONAL,COMPLETED
NCT05485818,Safety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.Infarction,Acute Myocardial Infarction,"1. The subject or its legal representative will voluntarily participate in the study and sign the informed consent;
2. Age 18 and 75, regardless of gender;
3. STEMI patients with left anterior descending branch single-artery middle occlusion (TIMI grading 0\~1, see Appendix 1 for TIMI grading) and receiving PCI;
4. No obvious collateral of coronary artery (Rentrop grade 0\~1,Rentrop grade see Appendix 2);
5. Chest pain occurred for 6 hours and 12 hours before PCI;
6. TIMI grade 3 after PCI;
7. All subjects (male and female) must agree to use appropriate contraceptive methods (hormonal or barrier contraceptive methods, abstinence) during the study period and up to 6 months after the last administration, and women of childbearing age must test negative for pregnancy before administration.","1. Patients who have a history of myocardial infarction or have received coronary artery acute thrombolytic interventional therapy with bypass surgery;
2. patients who received thrombolytic therapy after onset;
3. patients who were clearly diagnosed as acute heart failure (Killip grade II,Killip classification in annex 3);
4. Severe arrhythmia that cannot be corrected;
5. Aortic dissection or suspected presence;
6. Severe liver and kidney dysfunction or severe depletion, etc;
7. major surgical history or hemorrhagic stroke in half a year;
8. Has or has a history of malignancy;
9. Systolic blood pressure ≥180 mmHg and/or diastolic blood pressure ≥110 mmHg in patients with hypertension after active antihypertensive treatment;
10. Clinically, he had a significant history of allergy, especially to mannitol, drugs, protein preparations and biological products;
11. Screening of patients who participated in other clinical studies within the first 3 months;
12. Failure to perform CMR test: such as claustrophobia, renal failure (eGFR \< 30ml/min);
13. Other conditions not considered suitable for inclusion by the researcher.","Low Dose, Middle Dose, High Dose, Placebo",INTERVENTIONAL,COMPLETED
NCT02122718,"XILO-FIST, the Effect of Allopurinol on the Brain Heart and Blood Pressure After Stroke",Ischaemic Stroke,"* Ischaemic Stroke/ Ischaemic lesion on brain imaging in relevant anatomical territory in patients with transient ischaemic attack.
* Age greater than 50 years. -- Consent within one month of stroke.","* Modified Rankin scale score of 5 (at end of the possible enrolment window of one month after stroke).
* Diagnosis of dementia (defined as a documented diagnosis or a screening Informant Questionnaire for Cognitive Decline in the Elderly (IQCODE) score of 3.6 or more).
* Cognitive impairment deemed sufficient to compromise capacity to consent or to comply with the protocol (in the opinion of the local investigator).
* Dependent on daily help from others for basic or instrumental activities of daily living prior to stroke (defined as assistance needed with toileting, walking or dressing).
* Significant co-morbidity or frailty likely to cause death within 24 months or likely to make adherence to study protocol difficult for participant (in the opinion of the local investigator).
* Contra-indication to or indication for administration of allopurinol (as detailed in Summary of Product Characteristics on the XILO-FIST web portal and in trial master file).
* Concurrent azathioprine, 6-mercaptopurine therapy, other cytotoxic therapies, cyclosporin, theophylline and didanosine.
* Significant hepatic impairment (defined as serum bilirubin, Aspartate Aminotransferase (AST) or Alanine transaminase (ALT) greater than three times upper limit of normal (ULN)).
* Estimated Glomerular Filtration Rate \< 30 mls/min
* Contraindication to MRI scanning.
* Women who are pregnant or breastfeeding.
* Women of childbearing potential who are unable or unwilling to use contraception.
* Prisoners.
* Active participation in another Clinical Trial of Investigational Medicinal Product (CTIMP) or device trial or participation within the past month.","Allopurinol, Placebo",INTERVENTIONAL,COMPLETED
NCT00497419,Reperfusion Time in ST Segment Elevation Myocardial Infarction (STEMI),Myocardial Infarction,* Diagnosis of STEMI,* On site resuscitated patients,fast track,INTERVENTIONAL,COMPLETED
NCT01519518,How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention,Acute ST Elevation Myocardial Infarction,* All patients presenting with a suspected myocardial infarction event with PPCI as the proposed index reperfusion strategy will be included in the trial,"* ≤ 18 years of age
* Known intolerance, hypersensitivity or contraindication to any trial medication
* Active bleeding at presentation
* Artificial ventilation, reduced conscious level or other factors precluding the administration of oral antiplatelet therapy
* Previous enrolment in this trial","unfractionated heparin, Bivalirudin",INTERVENTIONAL,COMPLETED
NCT00548613,Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium,"Coronary Artery Disease, Coronary Arteriosclerosis, Coronary Atherosclerosis, Coronary Disease","ARM: A -

* Patients with acute myocardial infarction with ST elevation who underwent percutaneous revascularization between 4 and 24 hours after the initiation of symptoms.

  1. Able to give written informed consent
  2. Age: 18 to 70 years
  3. Gender: Male and Female
  4. Acute myocardial infarction occurring within 4-24 hours after onset of symptoms documented by at least one of the following:

     1. ST Segment elevation greater than 2mm in two or more consecutive leads
     2. New Bundle Branch Block with symptoms consistent of MI
     3. Troponin I greater than 2.0 ng/ml (Normal Range 0 - 1.5 ng/ml)
     4. Totally occluded artery as visualized by angiography

ARM - B

Patients who are candidates for coronary artery bypass grafting surgery according to ACC/AHA guidelines and have had a myocardial infarction in the past 12 months.

1. Able to give written informed consent
2. Patients with coronary artery disease who need coronary artery bypass surgery according to ACC/AHA guidelines
3. Patients with Left Ventricular Ejection Fraction £ 40%.
4. NYHA symptoms Class II (dyspnea with moderate effort)
5. Defined region of myocardial dysfunction related to previous myocardial infarction (within the past 12 months) involving the anterior, lateral, posterior or inferior walls by either of the followings: echocardiography, ventriculography, MRI, or SPECT.
6. Age: 18 to 70 years
7. Gender: Male and Female","ARM - A

1. Pregnancy
2. Previous angiogenic therapy or myocardial laser therapy
3. History of cancer within 5 years
4. Known sensitivity to gentamycin and/or amphotericin B
5. Use or expected use of antineoplastic drugs
6. No informed consent or unable to provide informed consent.
7. Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient's safety, or interfere with the interpretation of the study results.
8. Any illness which might affect patient's survival over the study follow-up period
9. History of skeletal muscle disease, either primary (i.e., myopathy) or secondary (i.e., ischemic) or any underlying myopathy such as myasthenia gravis, muscular dystrophy, etc.
10. Patients with active infectious disease and/or who are known to have tested positive for HIV, HTLV, HBV-sAg, HCV, CMV and/or syphilis
11. Cardiogenic shock or severe compromise in left ventricular systolic function defined as ejection fraction lower than 20 %.
12. History of intolerance to amiodarone.
13. End stage renal disease
14. Contraindication for MRI
15. Any significant laboratory abnormality which will in the investigator's opinion interfere with the patient's ability to comply with the protocol, compromise the patient's safety, or interfere with the interpretation of the study result.
16. Inability to identify the infarct area intra operatively

ARM - B

1. Previous angiogenic therapy or myocardial laser therapy
2. History of cancer within 5 years
3. Cardiogenic shock or severe compromise in left ventricular systolic function defined as ejection fraction lower than 20 %.
4. Left Ventricular Ejection Fraction ≥ 40%.
5. Known sensitivity to gentamycin and/or amphotericin B
6. Use or expected use of antineoplastic drugs
7. No informed consent or unable to provide informed consent
8. Any illness which, in the Investigator's judgment, will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
9. Any illness which might affect patient's survival over the study follow-up period
10. History of skeletal muscle disease, either primary (i.e., myopathy) or secondary (i.e.,ischemic) or any underlying myopathy such as myasthenia gravis, muscular dystrophy, etc.
11. Patients with active infectious disease and/or who are known to have tested positive for HIV, HTLV, HBV-sAg, HCV, CMV and/or syphilis
12. Poor candidates for coronary artery bypass surgery
13. Patients who are in need of emergency bypass surgery
14. History of prior coronary artery bypass surgery
15. Patients with severe valvular heart disease
16. History of intolerance to amiodarone
17. End stage renal disease
18. Pregnancy
19. Contraindication for MRI
20. Any significant laboratory abnormality which will in the investigator's opinion interfere with the patient's ability to comply with the protocol, compromise the patient's safety, or interfere with the interpretation of the study result.
21. Inability to identify infarct area intra operatively.","MESENDO, MESENDO",INTERVENTIONAL,COMPLETED
NCT01730534,Multicenter Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Cardiovascular Events,"Diabetes Mellitus, Non-Insulin-Dependent, High Risk for Cardiovascular Event","* Provision of informed consent prior to any study specific procedures
* Female or male aged ≥40 years
* Diagnosed with Type 2 Diabetes
* High Risk for Cardiovascular events","* Diagnosis of Type 1 diabetes mellitus History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time
* Chronic cystitis and/or recurrent urinary tract infections
* Pregnant or breast-feeding patients","Dapagliflozin 10 mg, Placebo tablet",INTERVENTIONAL,COMPLETED
NCT04369534,Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction,"Acute Coronary Syndrome, STEMI, NSTEMI - Non-ST Segment Elevation MI, PLATELET AGGREGATION, INDIVIDUALIZED THERAPY","* STEMI
* NSTEMI
* Unstable Angina
* Successful PCI
* Signed informed consent","* \>80 years of age at time of inclusion
* Cardiogenic shock
* Unsuccessful PCI
* GI bleed within the last 6 months
* Hemorrhagic CVI within last 6 months
* Ischemic CVI within last 6 months
* Major surgery within last 6 months
* Malignant disease
* Platelet count \<=150
* Hematocrit \<=30% or \>=52%
* Creatinine \>=200
* Chronic anticoagulant therapy
* Thrombotic thrombocytopenic purpura, leukemia, myelodysplasia
* Other: did not sign informed consent, refused, lives far away, leading physician doesn't want the patient to take part or any other reason leading to not signing the informed consent","Clopidogrel, Ticagrelor",INTERVENTIONAL,COMPLETED
NCT00821834,Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned,"Stable Angina, Myocardial Infarction","Stable Angina / Old Myocardial Infarction patients who met all of the following criteria:

* Myocardial ischemic finding was proven within 2 months before randomization,
* Either ≥ 75% stenosis documented by CAG or severe stenosis confirmed by multi-slice computerized tomography (MSCT) angiography within 1 month before randomization,
* PCI was being planned.","* Planned coronary artery bypass graft (CABG), emergent/urgent PCI, or staged PCI,
* 3-vessel coronary artery disease with significant lesions in each vessel,
* Planned PCI associated with 6 or more stent placements,
* Not less than 50% stenosis of the left main coronary artery,
* Chronic total occlusion (CTO),
* Saphenous vein graft (SVG).

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","clopidogrel (SR25990), ticlopidine, Placebo",INTERVENTIONAL,COMPLETED
NCT00962416,Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI),ST-elevation Myocardial Infarction,"* Age equal or more than 18 years
* Chest pain \> 10 minutes
* Primary pci
* ST-segment elevation of \> 1 mm in \> 2 contiguous leads, or (presumably new) left bundle branch block, or true posterior MI with ST depression of \> 1 mm in \> 2 contiguous anterior leads
* Presence of at least one acute infarct artery target vessel with one or more coronary artery stenoses in a native coronary artery from 2.25-4 mm in diameter that can be covered with 1-multiple stents","* Female of childbearing potential (age 50 and last menstruation within the last 12 months), who did not underwent tubal ligation, ovariectomy or hysterectomy
* Known intolerance to aspirin, clopidogrel, heparin, stainless steel, biolimus or contrast material
* Inability to provide informed consent
* Currently participating in another trial before reaching first endpoint
* Mechanical complication of acute myocardial infarction
* Acute myocardial infarction secondary to stent thrombosis
* Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained throughout the perisurgical period
* Noncardiac comorbid conditions are present with life expectancy 1 year or that may result in protocol malcompliance
* History of bleeding diathesis or known coagulopathy
* Use of Coumadin
* Additional for Imaging Substudy:

  * Age \> 90 years
  * Hemodynamic instability
  * Renal failure
  * OCT/IVUS technically not feasible
  * Any patient in whom angiography demonstrates the infarct lesion to be at the site of a previously implanted stent","Biolimus eluted from an erodable stent coating (Biomatrix), bare-metal stent (Gazelle)",INTERVENTIONAL,COMPLETED
NCT01109134,Tirofiban Intracoronary Bolus-only Versus Intravenous Bolus Plus Infusion in STEMI Patients,Acute Myocardial Infarction,"* Typical ongoing ischemic chest pain for longer than 30 minutes
* ST segment elevation of 0,1 mV or greater in at least two contiguous leads or a new left bundle branch block on the initial ECG.","* Cardiogenic shock and / or clinical instability
* previous STEMI
* Malignant life threatening diseases
* Presence of an additional lesion causing more than 50% narrowing distal to the culprit lesion
* Contraindications to aspirin, clopidogrel, or heparin
* inability to give informed consent.","tirofiban intracoronary bolus-only, tirofiban intravenous bolus plus infusion",INTERVENTIONAL,COMPLETED
NCT00138034,APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3,Myocardial Infarction,* TIMI-3 in infarct-related artery with a stentable lesion with 72 hours of thrombolysis for ST-elevation myocardial infarction,"* Use of oral anticoagulants.
* Known intolerance to aspirin or clopidogrel.
* Bypass graft as infarct-related artery.
* Previously dilated infarct related artery.
* Significant left main stenosis.
* Unidentifiable culprit stenosis.",Percutaneous coronary intervention (PCI),INTERVENTIONAL,COMPLETED
NCT01452139,Pharmacogenetic Approach to Anti-platelet Therapy for the Treatment of ST-segment Elevation Myocardial Infarction (STEMI),STEMI,"* Males and Females between the ages of 18 and 75 years
* STEMI patients treated with percutaneous coronary intervention
* Able to provide informed consent
* Able to comply with assigned treatment strategy and attend 1 month follow-up visit","* Receiving anti-platelet therapy other than aspirin and clopidogrel
* Receiving anti-coagulation with warfarin or dabigatran
* History of stroke or transient ischemic attack
* Platelet count \< 100 000/μL
* Known Bleeding Diathesis
* Hematocrit \<30% or \>52%
* Severe Liver Dysfunction
* Renal Insufficiency (Creatinine Clearance \< 30ml/min)
* Pregnant females","Point-of-Care Genetic Testing, Prasugrel",INTERVENTIONAL,COMPLETED
NCT02627586,High-Intensity Interval Training Early After Left Ventricular Myocardial Infarction,Myocardial Infarction,"Inclusion Criteria:

* first ST-segment elevation myocardial infarction (STEMI)
* Percutaneous intervention within the preceding 4 week","* inability to participate in a 3-month training program
* contraindication to maximal exercise test (CPET)
* known chronic heart failure with LV ejection fraction ≤45% before the acute index event
* angiographically documented significant coronary stenosis (\> 50%) at randomization
* medical condition which would prevent a patient from performing high intensity training
* permanent atrial fibrillation
* alcohol or drug abuse
* inability to follow the procedures of the study","HIIT, MICE",INTERVENTIONAL,COMPLETED
NCT00265239,Pilot Study of Edaravone to Treat Acute Myocardial Infarction,"Myocardial Infarction, Reperfusion Injury",* Initial AMI patients admitted to the investigators' institution within 6 hours of symptom onset and treated primary percutaneous coronary intervention.,"* Renal insufficiency defined as serum creatinine \> 1.2 mg/dl and altered hepatic function defined as serum asparate aminotransferase \> 50 IU/L, alanine aminotransferase \> 50 IU/L and total bilirubin \> 1.2 mg/dl.",edaravone,INTERVENTIONAL,COMPLETED
NCT00355186,SWiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (SWISS-AMI),Acute Myocardial Infarction,"* Visual LVEF at angiogram or echocardiography ≤45%
* Treatment by primary PCI within 24 hours of the onset of chest pain or initial treatment with thrombolysis within the 12 hours followed by PCI within the 24 hours of the onset of chest pain
* Significant regional LV wall motion dysfunction in the infarct related territory
* Age \>18 years","* Abnormal regional wall motion outside the infarct region
* Known previous myocardial infarction in the same target vessel
* Known pre-existing left ventricular dysfunction (EF\<45% prior to admission)
* Need for revascularization in the non infarct-related coronary within 4 months
* Pre-existing symptoms of heart failure or known cardiomyopathy
* Known active infection or chronic infection with HIV, HBV or HCV
* Chronic inflammatory disease
* Serious concomitant disease with a life expectancy of less than one year
* Follow up impossible (no fixed abode, etc)
* Contraindication for cardiac MRI (i.e. pace maker, neurostimulator, claustrophobia)
* Severe renal failure (creatinine \>250 mmol/l)
* Relevant liver disease (GOT \> 2x norm or spontaneous INR \> 1,5)
* Anemia (Hb \< 8.5 mg/dl), Thrombocytopenia (\<100.000/µl)
* Pregnancy
* Participation at a clinical trial in the last 30 days",intracoronary bone marrow cells infusion,INTERVENTIONAL,COMPLETED
NCT00882739,"Safety and Efficacy of Three Different Loading Doses of Clopidogrel, in Patients With Acute Myocardial Infarction",Acute Myocardial Infarction,"* ST-elevation myocardial infarction:

  * chest pain lasting more than 30 minutes
  * not responsive to nitrates
  * ST-segment elevation of more than 0.1 mV in two or more leads on the ECG, or new Left Bundle Branch Block
* With indication to primary PCI, presenting within 12 hour from symptoms onset
* Age \> 18 years
* Planned PCI
* Informed Consent","* bleeding diathesis
* allergy to study drugs
* pregnancy
* the performance of a rescue PCI after thrombolysis
* known existence of a disease resulting in a life expectancy of \<6 months
* lack of informed consent","Clopidogrel 300 mg, Clopidogrel 600 mg, Clopidogrel 900 mg",INTERVENTIONAL,COMPLETED
NCT03718286,"Effects of Acute, Rapid Lowering of LDL Cholesterol With Alirocumab in Patients With STEMI Undergoing Primary PCI","ST Elevation Myocardial Infarction, Acute Coronary Syndrome, Hypercholesterolemia, Hyperlipidemias, Dyslipidemias, Physiological Effects of Drugs","* Patients presenting with STEMI defined as both of the following: a) Symptoms of myocardial ischemia lasting for ≥ 30 minutes, and b) Definite ECG changes indicating STEMI: ST elevation of greater than 0.1 mV in two contiguous limb leads or 0.2 mV in two contiguous precordial leads.
* Referred for primary PCI for presenting symptoms.
* Randomized within 12 hours of symptom onset and prior to diagnostic angiography.","* Age ≤18 years.
* Pregnancy or breastfeeding.
* Current or planned treatment with a PCSK9 inhibitor.
* Allergy or contra-indication to a PCSK9 inhibitor.
* Killip class ≥2.
* Known Creatinine clearance \<30mL/min.
* Suspected takotsubo / stress-induced cardiomyopathy or acute pericarditis.
* Any other medical, geographic, or social factor making study participation impractical or precluding follow-up.","Alirocumab, Sham Control",INTERVENTIONAL,COMPLETED
NCT04050163,MiSaver® Stem Cell Treatment for Heart Attack (Acute Myocardial Infarction),Myocardial Infarction,"* Patients aged 20\~80
* Acute Myocardial Infarction 1 to 10 days
* Cardiac enzyme CK-MB or Troponin \> 2X of high-end normal value
* ST-elevation on EKG (STEMI)
* Presence of regional wall motion abnormality
* Left ventricular ejection fraction (LVEF) of ≤40%
* Hemodynamically stable past 24 hour
* Participants with adequate pulmonary function
* Peripheral artery oxygen saturation ≥97%
* Karnofsky performance status scores of ≥60.","* Age \<20 or \>80
* Pregnant or breast feeding
* Positive adventitious infections (such as HIV, hepatitis )
* Revascularization via coronary artery bypass surgery is required
* Coronary revascularization procedures is anticipated during the 6-month study period
* Severe aortic or mitral valve narrowing
* Evidence of life-threatening arrhythmia on baseline electrocardiogram (ECG)
* Short of breath unable to receive PCI examination or treatment
* Malignant tumor
* Hematopoietic dysplasia
* Severe organ disease
* With less than 1 year of life expectancy
* Chronic kidney disease with CCr\<20ml/min
* Kidney disease on renal dialysis",MiSaver®,INTERVENTIONAL,COMPLETED
NCT02648113,Cost-effectiveness and Cost-utility of Liberal vs Restrictive Red Blood Cell Transfusion Strategies in Patients With Acute Myocardial Infarction and Anaemia.,"Myocardial Infarction, Anemia, Blood Transfusion","* Aged ≥ 18 years
* Recent acute myocardial infarction, with or without ST- segment elevation, with a combination of ischemic symptoms occurring in the past 48 hours,before the MI related admission, and elevation of biomarkers of myocardial injury (troponin)
* Anemia Hb ≤ 10g / dL but \> 7 g/dL on Hb, measured at any time during the index hospital admission for MI.
* Written informed consent
* Coverage for medical insurance.","* Shock (SBP \< 90 mmHg with clinical signs of low output or patients requiring inotropic agents)
* MI occurring post-percutaneous coronary intervention (PCI) or post-coronary artery bypass graft (CABG) (i.e. type IV or V Acute MI according to the 2012 Universal Definition of MI
* Life-threatening or massive ongoing bleeding (as judged by the investigator)
* Any blood transfusion in the previous 30-days
* any known malignant hematologic disease Note: Sickle cell disease, thalassemia and anemia due to chronic renal failure (even under EPO) are not an exclusion criteria","Restrictive transfusion, Liberal transfusion, red blood transfusion",INTERVENTIONAL,COMPLETED
NCT00250913,The Efficacy and Cost-Effectiveness of Behavioral Counseling for Exercise in Men and Women Following Acute Myocardial Infarction (AMI) and Percutaneous Coronary Intervention (PCI),"Coronary Arteriosclerosis, Myocardial Infarction","* Cardiac Diagnosis:

  1) hospitalized patients ready for discharge following successful PCI procedure
* Including patients receiving PCI following admission for AMI or hospitalized post-AMI patients who have not been revascularized
* No lesions with \>50 % stenosis
* English proficiency in reading, writing and speaking
* Age: 20-85 years","* Those patients who are already taking part in another research trial.
* Patient intends to enroll, or is currently enrolled in structured cardiac rehabilitation
* Unable to participate in the on-site cardiac supervised rehab program, cardiac rehab lite, case-managed home cardiac rehab program, Pembroke cardiac rehab program
* Hospitalization for coronary artery bypass (CABG)
* Chronic obstructive pulmonary disease (COPD)
* Hospitalization for diagnostic procedure not associated with previously documented MI
* Patient coming back to hospital for planned staged PCI within 6 months
* Cardiac transplantation
* Presence of, or hospitalization for defibrillator implant
* Hospitalization for pacemaker implantation
* Unresolved unstable angina and/or hospitalization for angina (without MI or PCI)
* Uncontrolled arrhythmias causing symptoms or hemodynamic compromise
* Neuromuscular, musculoskeletal or rheumatoid disorders that are exacerbated by exercise
* Other uncontrolled metabolic conditions (e.g. diabetes)
* Chronic infectious diseases such as mononucleosis, hepatitis, AIDS
* Acute systemic illness or fever
* Uncontrolled tachycardia (\<120 bpm)
* Uncompensated congestive heart failure (and/or NYHA Class III, or IV)
* 3rd degree atrioventricular (AV) block (without pacemaker)
* Active pericarditis or myocarditis
* Recent embolism
* Suspected or known abdominal aortic aneurysm (AAA) \> 4cm
* Uncontrolled hypertension (systolic blood pressure \[SBP\] \>200; diastolic blood pressure \[DBP\] \>110)
* Pregnancy",Telephone-based physical activity counseling program,INTERVENTIONAL,COMPLETED
NCT02663713,"A Randomized, Pharmacodynamic Comparison of Low Dose Ticagrelor to Clopidogrel in Patients With Prior Myocardial Infarction","Myocardial Infarction, Diabetes Mellitus, Renal Disease, Coronary Artery Disease","1. Provision of informed consent prior to any study specific procedures
2. Post-menopausal female (defined as absence of any vaginal bleeding for a year) or male aged \>50 years
3. A spontaneous MI (ST or Non ST segment elevation) 1 to 3 years before enrolment. In addition, at least one of the following high-risk features: age of 65 years or older, diabetes mellitus requiring medication, a second prior spontaneous MI, multivessel coronary artery disease, or non-end stage renal disease (estimated creatinine clearance of \<60 ml per minute).","1. Planned use of a P2Y12 receptor antagonist, dipyridamole, cilostazol, or anticoagulant therapy during the study period;
2. Known allergy, intolerance, hypersensitivity to ticagrelor or clopidogrel or any excipients,
3. Active pathological bleeding, severe hepatic impairment, a bleeding disorder or a history of an ischemic stroke or intracranial bleeding, a central nervous system tumor, or an intracranial vascular abnormality;
4. Gastrointestinal bleeding within the previous 6 months or major surgery within the previous 30 days;
5. Concomitant use of potent Cytochrome P450 3A4 (CYP3A4) inhibitors (atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole, grapefruit juice over 1 litre daily), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or inducers (carbamazepine, dexamethasone, phenobarbital, phenytoin, rifampin, and rifapentine).
6. Increased risk of bradycardic events (e.g. known sick sinus syndrome or third degree AV block or previous documented syncope suspected to be due to bradycardia unless treated with a pacemaker).
7. Inability to adhere to the follow-up requirements or any other reason or condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated.","Ticagrelor, Clopidogrel",INTERVENTIONAL,COMPLETED
NCT00302419,Effect of Complementary Intracoronary Streptokinase Administration Immediately After Primary Percutaneous Coronary Intervention on Microvascular Perfusion and Late Term Infarct Size in Patients With Acute Myocardial Infarction,Acute Myocardial Infarction,"Inclusion criteria:

* Continuous chest pain that lasted \> 30 minutes within the preceding 12 hours
* ST-segment elevation of at least 1 mm in 2 contiguous leads on the 12 leads ECG
* Infarct related artery (IRA) occlusion (TIMI grade 0) at the angiography
* Angiographically detected culprit coronary artery lesion deemed suitable for PCI","* Contraindications to streptokinase, tirofiban, aspirin, clopidogrel, or heparin
* Culprit lesion in saphenous vein graft
* TIMI grade II-III flow in IRA
* Additional epicardial stenosis in the IRA distal to stented segment (significant or insignificant)
* Presence of left bundle branch block
* History of prior MI
* Mechanical ventilation or inotropic support","intracoronary infusion,, primary percutaneous coronary angioplasty",INTERVENTIONAL,COMPLETED
NCT01384019,Distal Protection Device in ST-elevation Myocardial Infarction (STEMI),ST-segment Elevation Myocardial Infarction,"* 30 and less than 80 years presenting with STEMI
* more than 30 minutes but less than 12 hours after symptom onset
* with ≥ 2 mm of ST-segment elevation in 2 or more contiguous leads or with a presumably new left bundle-branch block
* for whom primary PCI was intended","* included thrombolytic therapy before PCI;
* spontaneous restoration of coronary flow (\> TIMI grade II or III);
* cardiogenic shock (Killip class IV);
* major surgery or active bleeding within 6 weeks;
* aspirin, thienopyridine, or heparin allergy;
* neutropenia (\<1000 neutrophils/mm3), thrombocytopenia (\<100000 platelets/mm3), hepatic dysfunction, or renal insufficiency (serum creatinine level \>2.5 mg/dL \[221 μmol/L\]);
* noncardiac condition with expected survival less than 1 year;
* current participation in other investigations.","distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.)), c-PCI",INTERVENTIONAL,COMPLETED
NCT02715518,FFR Versus Angiography-Guided Strategy for Management of AMI With Multivessel Disease,Acute Myocardial Infarction,"(1) Inclusion Criteria

1. Subject must be at least 19 years of age
2. Acute ST-segment elevation myocardial infarction (STEMI) A. ※ STEMI: ""ST-segment elevation ≥0.1 mV in ≥2 contiguous leads B. or documented newly developed left bundle-branch block ""
3. Acute non-ST-segment elevation myocardial infarction (NSTEMI)

   A. ※ NSTEMI: NSTEMI is defined as a combination of criteria with mandated elevation of a cardiac biomarker, preferably high-sensitive cardiac troponin with at least one value above 99th percentile of the upper reference limit and at least one of the following:
4. Symptoms of ischaemia.
5. New or presumed new significant ST-T wave changes
6. Development of pathological Q waves on electrocardiography (ECG).
7. Imaging evidence of new or presumed new loss of viable myocardium or regional wall motion abnormality.
8. Intracoronary thrombus detected on angiography.
9. Primary percutaneous coronary intervention (PCI) in \< 12 h after the onset of symptoms for STEMI patients (In case of NSTEMI, PCI should be performed within 72 hours of symptom onset)
10. Multivessel disease (at least one stenosis of \>50% in a non-culprit vessel ≥ 2.0 mm by visual estimation)
11. Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive physiologic evaluation and PCI and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.

(2)","1. Severe stenosis with TIMI flow ≤ II of the non-IRA artery
2. Unprotected left main coronary artery disease (stenosis \> 50% by visual estimation)
3. Non-IRA stenosis not amenable for PCI treatment by operators' decision)
4. Chronic total occlusion in non-IRA
5. Cardiogenic shock (Killip class IV) already at presentation or the completion of IRA PCI
6. Intolerance to Aspirin, Clopidogrel, Plasugrel, Ticagrelor, Heparin, Bivaluridin, or Everolimus, Zotarolimus
7. Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
8. Pregnancy or breast feeding
9. Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
10. Other primary valvular disease with severe degree: severe mitral regurgitation, mitral stenosis, severe aortic regurgitation, or aortic stenosis
11. Patients with a history of Coronary Artery Bypass Graft (CABG) or treated with fibrinolytic Therapy
12. Unwillingness or inability to comply with the procedures described in this protocol.",PCI using 2nd generation drug-eluting stent,INTERVENTIONAL,COMPLETED
NCT00924118,Sodium Nitrite in Acute Myocardial Infarction,Acute Myocardial Infarction,"* Acute ST segment elevation myocardial infarction
* Eligible for percutaneous coronary intervention","* Cardiogenic shock
* Cardiac arrest
* Prior infarct in the infarct related artery
* Hemoglobinopathy, Glucose-6 Phosphate Dehydrogenase (G6PD) deficiency",Sodium Nitrite,INTERVENTIONAL,COMPLETED
NCT02675322,Danlou Tablets to Prevent Left Ventricular Remodeling,"Left Ventricular Remodeling, Acute Myocardial Infarction","* acute myocardial infarction
* successfully underwent revascularization","* previous myocardial infarction within 30 days
* malignant arrhythmia
* congenital heart disease
* cardiac shock
* documented or suspected history of heart failure or depressed LV ejection fraction \<15%
* planned coronary artery bypass grafting
* a life expectancy of \<1 year
* hepatic impairment
* glomerular filtration rate ≤30 mL/min per 1.73 m2
* autoimmune or connective tissue disease
* chronic substance abuse or psychiatric illness
* unable to complete 3 month clinical follow-up","Danlou Tablets, Placebo",INTERVENTIONAL,COMPLETED
NCT02363725,Interest of COLchicine in the Treatment of Patients With Acute Myocardial INfarction and With Inflammatory Response,Acute Myocardial Infarction,"* Acute myocardial inflarction (occlusion of coronary artery as assessed on the coronaro angiogram)
* Adult (18-90y)
* Men / women
* Aigned informed consent
* Health insurance","* Cardiogenic shock
* Digestive troubles
* Active bowels inflammatory disease (Crhon, chronic, diarrhea...)
* Intolerance to the drug
* Renal insufficiency clearance \< 30mL/min
* Immunosuppression, aplasia
* Active infectious disease, active known neoplasia, chronic inflammatory disease
* Hypersensitivity, allergy to one of studies components
* Active liver disease
* Poor hemodynamic conditions
* Recent severe sepsis
* Chronic treatment with corticoids or no steroids antiinflammatory agents
* No possibility for informed consent
* Protected by the law
* Poor abservance
* History of toxicomania, suicice attempts
* Pregnacy, breeding, project of pregnancy","Colchimax®, Conventional treatment",INTERVENTIONAL,COMPLETED
NCT00865722,Remote Postconditioning in Patients With Acute Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention (PCI),"Myocardial Reperfusion Injury, Myocardial Ischemia, Myocardial Infarction","* Age \>= 18 yrs AND Age =\< 80 yrs
* STEMI definition
* Pain to door time \< 6 hrs
* Killip class 1 - 2 - 3
* Initial TIMI flow 0 - 1 in the anterior descending artery
* Signed informed consent","* Pregnancy
* Cardiogenic shock
* Initial TIMI flow 2 - 3 in the anterior descending artery
* History of prior MI in the past 6 months
* History of prior CABG
* History of peripheral vascular disease III - IV grade
* History of abdominal Aortic Aneurysm \> 5 cm
* Severe coronaropathy that could condition further revascularization before the end of the study
* Other relevant medical or surgical conditions that can influence prognosis at 4 months",Remote Postconditioning,INTERVENTIONAL,COMPLETED
NCT01742130,Early Hydration in Acute Myocardial Infarction,Contrast Induced Acute Kidney Injury,* Consecutive patients with AMI candidates for primary PCI presenting within 12 h of symptom onset with ST-segment elevation of more 1 mm in at least two contiguous leads of electrocardiogram.,"* contrast medium administration within the 10 days
* end-stage renal failure requiring dialysis
* refusal to give informed consent","sodium bicarbonate solution, Isotonic saline",INTERVENTIONAL,COMPLETED
NCT01732822,A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease,Peripheral Artery Disease,* Male and Female patients 50 years old or older Symptomatic peripheral artery disease,"* Patients needing dual anti-platlet drug treatment before start of study Planned revascularisation or amputation
* Patients with known bleeding disorders
* Patients with a history of intracranial bleed
* Patients considered to be at risk of bradycardic events unless already treated with a permanent pacemaker","Ticagrelor, Clopidogrel",INTERVENTIONAL,COMPLETED
NCT02342522,Effect of Remote Ischaemic Conditioning on Clinical Outcomes in STEMI Patients Undergoing PPCI (CONDI2/ERIC-PPCI),"STEMI, Myocardial Reperfusion Injury","Inclusion criteria:

1. Onset of STEMI symptoms within 12 hours, lasting for more than 30 minutes
2. Patients older than 18 years
3. Suspected STEMI (ST-elevation at the J-point in two contiguous leads with the cutoff points: ≥0.2 millivolt (mV) in men or ≥0.15 mV in women in leads V2-V3 and/or ≥0.1 mV in other leads)",":

1. Previous coronary artery bypass graft surgery
2. Myocardial infarction within the previous 30 days
3. Treatment with thrombolysis within the previous 30 days
4. Left bundle branch block
5. Patients treated with therapeutic hypothermia
6. Conditions precluding use of RIC (paresis of upper limb, use of an a-v shunt)
7. Life expectancy of less than 1 year due to non-cardiac pathology","Remote ischemic conditioning, Control",INTERVENTIONAL,COMPLETED
NCT01102439,Clopidogrel/Aspirin Interaction Study,Coronary Artery Disease,"* \> 1 month post myocardial infarction (MI), unstable angina or stent patients with stable condition
* Receiving regular ASA (81mg/d) and clopidogrel (75mg/d) for at least 1 week
* Written informed consent","* Age \< 18 years old
* Liver disease with transaminases and/or bilirubin \> 1.5x upper limits of normal (ULN) (within 3 months of randomization)
* Renal impairment with creatinine clearance \< 30 ml/min (within 3 months of randomization)
* Platelet count \< 100x109/L and/or Hb\< 100g/L (within 3 months of randomization)
* Use of oral anticoagulants or nonsteroidal antiinflammatory drug (NSAID) within the last 10 days or planned use during the study
* Use of antiplatelet agent other than aspirin and clopidogrel within the last 10 days
* High risk of bleeding (e.g. recent gastrointestinal bleeding, bleeding diathesis)
* Uncontrolled hypertension (\> 180/110mmHg)
* Current smoker with ≥ 5 cigarettes/day
* Previously entered in this study or just finished other study within 2 weeks before recruitment
* Medical, geographic, or social factors making study participation impractical, or inability to provide written informed consent","Clopidogrel, Clopidogrel, Aspirin, Aspirin",INTERVENTIONAL,COMPLETED
NCT01634425,Providing Rapid Out of Hospital Acute Cardiovascular Treatment (PROACT),NSTEMI,"Inclusion Criteria

1. Patient that activates pre-hospital Emergency Medical Services (EMS) for symptoms of acute chest discomfort for which acute cardiovascular disease is deemed to be the most probable diagnosis by EMS personnel.
2. Patient is older than 30 years of age
3. Patient is able to give informed consent","1. Patient with documented ST elevation on the initial 12 lead ECG
2. Patient with a prior diagnosis that is compatible with another disease i.e. severe asthma, etc.
3. Patient with Central Nervous System symptoms or syncope
4. Patient with cardiac arrest, ventricular tachycardia or atrial fibrillation with heart rate \> 110 bpm",Alere Triage Meter Pro,INTERVENTIONAL,COMPLETED
NCT01084239,Multicenter Study to Rule Out Myocardial Infarction by Cardiac Computed Tomography,"Acute Coronary Syndrome, Myocardial Infarction, Unstable Angina Pectoris","1. Participant had at least five minutes of chest pain or equivalent (chest tightness; pain radiating to left, right, or both arms or shoulders, back, neck, epigastrium, jaw/throat; or unexplained shortness of breath, syncope/presyncope, generalized weakness, nausea, or vomiting thought to be of cardiac origin) at rest or during exercise within 24 hours of ED presentation, warranting further risk stratification, as determined by an ED attending.
2. 2 or more cardiac risk factors (diabetes, hypertension, hyperlipidemia, current smoker and family history of coronary artery disease).
3. Able to provide a written informed consent.
4. \<75 years of age, but \>40 years of age.
5. Able to hold breath for at least 10 seconds.
6. Sinus rhythm.","1. New diagnostic ischemic ECG changes (ST-segment elevation or depression \> 1 mm or T-wave inversion \> 4 mm) in more than two anatomically adjacent leads or left bundle branch block
2. Documented or self-reported history of CAD (MI, percutaneous coronary interventions \[PCIs\], coronary artery bypass graft \[CABG\], known significant coronary stenosis \[\>50%\])
3. Greater than 6 hours since presentation to ED.
4. BMI \>40 kg/m2
5. Impaired renal function as defined by serum creatinine \>1.5 mg/dL\*
6. Elevated troponin-T (\> 0.09 ng/ml)
7. Hemodynamically or clinically unstable condition (BP systolic \< 80 mm Hg, atrial or ventricular arrhythmias, persistent chest pain despite adequate therapy)
8. Known allergy to iodinated contrast agent
9. Currently symptomatic asthma
10. Documented or self-reported cocaine use within the past 48 hours (acute)
11. On Metformin therapy and unable or unwilling to discontinue for 48 hours after the CT scan
12. Contraindication to beta blockers (taking daily antiasthmatic medication): This exclusion only applies to patients with a heart rate \>65 bpm at sites using a non-dual source CT scanner
13. Participant with no telephone or cell phone numbers or no address (preventing follow-up)
14. Participant with positive pregnancy test. Women of childbearing potential, defined as \<2 years of menopause in the absence of hysterectomy or tube ligation, must have a pregnancy test performed within 24 hours before the CT scan.
15. Participant unwilling to provide a written informed consent.",Cardiac Computed Tomography,INTERVENTIONAL,COMPLETED
NCT00067236,Study of Oral PG-116800 Following a Heart Attack,"Myocardial Infarction, Heart Failure, Heart Enlargement","Inclusion:

* Be at least 18 years of age but not older than 80 years of age at screening;
* Be diagnosed with a heart attack based on electrocardiogram (ECG) and cardiac enzymes criteria;
* The qualifying heart attack has to be a first heart attack;
* The qualifying heart attack has to result in a left ventricular ejection fraction (a measure of the working efficiency of the heart) between 15% and 40%.",":

* Documented previous history of heart attack;
* Any past history of heart failure;
* Hemodynamic instability (no instability of circulatory system);
* History of congenital heart disease and cardiomyopathy (weakened heart muscle) associated with connective tissue disorders;
* Recent history or current moderate-to-severe kidney or liver impairment;
* Significant blood dyscrasias (disorders of the blood cells);
* Females who are currently: pregnant; breast-feeding; or are of childbearing potential.","PG-116800 (given as PG-530742), Placebo tablet",INTERVENTIONAL,COMPLETED
NCT06661018,Effect Supplementation of COenzyme Q10 in Acute STEMI Underwent PPCI,"ST Segment Elevation Myocardial Infarction (STEMI), Coenzyme Q10","* Age \> 21 - 80 years
* Agree to participate in the study
* Patients with a diagnosis of Acute Myocardial Infarction with ST-Segment Elevation (AMI-STE) with onset \< 12 hours who underwent primary percutaneous coronary intervention (PCI)
* Successful primary PCI on the culprit lesion (residual stenosis \< 20%, TIMI flow III)
* Received standard medication therapy according to guidelines (Guideline-Directed Medical Therapy; GDMT) achieved during hospitalization
* Sinus rhythm at the time of echocardiographic examination","* Patients who routinely consume CoQ10 prior to the study
* Patients with hemodynamic conditions of Killip class III-IV and NYHA class III-IV
* Patients with a history of previous acute myocardial infarction
* Patients with a history of previous PCI or fibrinolytic therapy
* Patients with a history of previous coronary artery bypass surgery
* Patients with heart valve disease greater than moderate severity
* Patients receiving warfarin therapy
* Patients with a diagnosis of isolated right ventricular infarction
* Patients with inadequate echocardiographic image quality (poor echo window)","Coenzyme Q 10, Placebo",INTERVENTIONAL,COMPLETED
NCT03309618,Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan,Myocardial Infarction,"* history of MI in the last 0.5 to 5 years
* males
* aged under 55 years","* diabetes mellitus
* manifest peripheral artery disease or carotid artery disease
* acute infection
* chronic diseases
* present therapy with fluvastatin and/or valsartan.","low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val), placebo",INTERVENTIONAL,COMPLETED
NCT00078013,MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients,Myocardial Infarction,"Inclusion Criteria

1. Written informed consent must be obtained from the patient (or, in accordance with state and federal laws and IRB regulations, emergency consent procedures may be employed) before enrollment into the study.
2. The patient is a male or female at least 18 years of age.
3. The patient has an estimated weight between 50 kg (110 lbs) and 140 kg (308 lbs).
4. The patient is suspected to have his/her first-documented ST-segment elevation AMI.
5. The patient has symptoms of ischemia of at least 20 minutes continuous duration, the onset of which occurred \< 6 hours prior to study drug infusion. Examples of ischemic symptoms include chest, arm, and/or jaw pain, shortness of breath, nausea, diaphoresis, or other symptoms that the investigator considers to be of ischemic origin.
6. The patient has

   * Anterior MI: \> 2 mm ST elevation in at least two contiguous leads out of V1-V4
   * Inferior MI: \> 2 mm ST elevation in at least two of II, III, and aVF, with \> 10 mm elevation summed for all leads (14, 15)
   * Infero-apical MI: \> 1 mm ST elevation in at least two of II, III, and aVF, with both V5 and V6
   * Infero-lateral MI: \> 1 mm ST elevation in at least two of II, III, and aVF, with both I and aVL
   * Infero-posterior MI: \> 1 mm ST elevation in II, III, and aVF, with \> 1 mm ST depression in at least two leads out of V1-V3
7. The patient is expected to undergo primary PCI within 8 hours from the onset of ischemic symptoms (see Inclusion Criterion #5 above).
8. Women of childbearing potential must have a negative pregnancy test.","1. The patient has a past history of ST-segment elevation MI.
2. The patient has a pathologic arrhythmia or is considered electrically unstable (K+, Ca2+).
3. The patient has thrombolytic therapy planned.
4. The patient is in cardiogenic shock unresponsive to IV fluid.
5. The patient has severe bradycardia with heart rate \<45 beats/minute.
6. The patient has a pre-existing diagnosis of chronic heart failure (NYHA class III-IV).
7. The patient has left bundle branch block.
8. The patient has any cardiomyopathy or pericarditis.
9. The patient has a history of clinically significant bleeding within the last 3 months.
10. The patient has had any type of major trauma, major surgery, or eye, spinal cord, or brain surgery within the last 3 months that, in the opinion of the investigator, would compromise the patient's response to the standard of care.
11. The patient has a history of clinically significant hepatic disturbance.
12. The patient has a history of chronic renal impairment.
13. The patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the last 6 months.
14. The patient is a woman who is pregnant or lactating.
15. The patient is currently receiving therapy with catecholamines/sympathomimetics, phosphodiesterase inhibitors, or phosphodiesterase inhibitors with calcium sensitizing activity. Patients will be permitted to enter the study if these drugs were discontinued more than 5 half-lives prior to randomization.
16. The patient has a history of multiple drug allergies (including contrast media).
17. The patient has epilepsy or a history of seizures requiring treatment (this does not include febrile seizures as a child).
18. The patient participated in an investigational drug or device study within the last 3 months.
19. The patient has a current dependence on alcohol or history of other drugs of abuse.
20. The patient has current clinically significant psychiatric or neurologic disease or any other condition that, in the investigator's opinion, would prevent adherence to the requirements of the protocol.
21. The patient is clinically significantly immunocompromised (including, but not limited to AIDS and immune-suppressive therapy \[i.e., chemotherapy, radiation, systemic corticosteroids\]).",MCC-135,INTERVENTIONAL,COMPLETED
NCT00491036,Intraaortic Balloon Pump in Cardiogenic Shock II,"Myocardial Infarction, Shock, Cardiogenic","Inclusion Criteria:

Cardiogenic shock complicating acute myocardial (STEMI or NSTEMI) with

* intended revascularization (PCI or CABG)
* Systolic blood pressure \< 90 mmHg \> 30 min or inotropes required to maintain pressure \> 90 mmHg during systole
* Signs of pulmonary congestion
* Signs of impaired organ perfusion with at least one of the following:

  * Altered mental status
  * Cold, clammy skin
  * Urine output \<30 ml/h
  * Serum lactate \>2mmol/l
* Informed consent",":

* Resuscitation \> 30 minutes
* Cerebral deficit with fixed dilated pupils
* No intrinsic heart action
* Mechanical infarction complication
* Onset of shock \> 12 h
* Severe peripheral artery disease
* Aortic regurgitation \> II.°
* Age \> 90 years
* shock of other cause
* Other severe concomitant disease
* participation in another trial",Intraaortic balloon pump,INTERVENTIONAL,COMPLETED
NCT01399736,Comparison Between FFR Guided Revascularization Versus Conventional Strategy in Acute STEMI Patients With MVD.,"Myocardial Infarction, Multivessel Coronary Artery Disease","* All patients between 18-85 years presenting with STEMI who will be treated with primary PCI in \< 12 h after the onset of symptoms\* and have at least one stenosis of \>50% in a non-IRA on QCA or visual estimation of baseline angiography and judged feasible for treatment with PCI by the operator.

  * Patients with symptoms for more than 12 hr but ongoing angina complaints can be randomised","1. Left main stem disease (stenosis \> 50%)
2. STEMI due to in-stent thrombosis
3. Chronic total occlusion of a non-IRA
4. Severe stenosis with TIMI flow ≤ II of the non-IRA artery.
5. Non-IRA stenosis not amenable for PCI treatment (operators decision)
6. Complicated IRA treatment, with one or more of the following;

   * Extravasation,
   * Permanent no re-flow after IRA treatment (TIMI flow 0-1),
   * Inability to implant a stent
7. Known severe cardiac valve dysfunction that will require surgery in the follow-up period.
8. Killip class III or IV already at presentation or at the completion of culprit lesion treatment.
9. Life expectancy of \< 2 years.
10. Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Heparin, Bivaluridin, or Everolimus and known true anaphylaxis to prior contrast media of bleeding diathesis or known coagulopathy.
11. Gastrointestinal or genitourinary bleeding within the prior 3 months,
12. Planned elective surgical procedure necessitating interruption of thienopyridines during the first 6 months post enrolment.
13. Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
14. Pregnancy or planning to become pregnant any time after enrolment into this study.
15. Inability to obtain informed consent.
16. Expected lost to follow-up.","FFR-guided revascularisation strategy, randomised to guidelines group",INTERVENTIONAL,COMPLETED
NCT00126334,Conservative Versus Liberal Red Cell Transfusion in Myocardial Infarction Trial: The CRIT Pilot,"Myocardial Infarction, Anemia","All of the following must be present:

* Acute myocardial infarction with presentation within 72 hours of randomization (acute myocardial infarction is defined as ischemic-type chest discomfort lasting at least 30 minutes associated with creatinine kinase MB (CKMB) or troponin \>upper limit of normal \[ULN\])
* Admission to CCU
* Hematocrit .30 or less
* Written, informed consent","* Inability or unwillingness to receive red cell transfusions
* Active bleeding (overt blood loss accompanied by a decrease in hematocrit of at least 5% in the preceding 12 hours)
* Receipt of red cell transfusion within 7 days of randomization
* Prior severe transfusion reaction
* Pregnancy
* Imminent death
* Decision to provide limited care
* Age \<21
* Participation in another clinical trial in which blood transfusion is a requirement or a component of a primary or secondary endpoint
* Previous participation in the CRIT Pilot",Packed Red Blood Cell Transfusion,INTERVENTIONAL,COMPLETED
NCT00538317,GPIIbIIIa Inhibitors in the RESCUe and RESURCOR Networks at the Acute Myocardial Infarction,Acute Myocardial Infarction,"Inclusion Criteria:

* Age \> 18 years
* Information given to the patient and consent obtained
* Thoracic pain or symptoms of infarction
* Symptoms \< 12 hours
* ST deviation identified by electrocardiography (ECG) in at least 2 contiguous leads
* Transfer time to angioplasty room evaluated by the coordinating doctor as less than 90 minutes (from ECG diagnosis to arrival in angioplasty room)","* Physiological or pathological conditions not compatible with a revascularisation procedure (in the acute phase of myocardial infarction (MI)
* Administration of fibrinolytics or another antiGPIIBIIIa in the previous seven days
* Contraindications to aspirin or tirofiban or heparin
* Diagnosed severe kidney failure (dialysis, creatinin \> 350µmol/l
* Pregnancy
* Time for transfer to the angioplasty room evaluated by coordinating doctor as more than 90 minutes
* Subject participating in another trial
* Subject with high hemorrhagic risk.","tirofiban, tirofiban",INTERVENTIONAL,COMPLETED
NCT01580514,Myocardial Protection of Exenatide in AMI,Myocardial Infarction,"* age between 20 and 79 years
* patients presenting with first ST-segment elevation myocardial infarction
* Thrombolysis in Myocardial Infarction \[TIMI\] flow grade 0)","* cardiac arrest
* ventricular fibrillation
* cardiogenic shock
* hemodynamic instability
* suspicious stent thrombosis
* left bundle branch block
* previous acute myocardial infarction
* previous coronary artery bypass operation
* significant valvular heart disease
* primary myocardial disease
* atrial fibrillation
* significant hepatic or renal dysfunction, hypoglycaemia,
* diabetic ketoacidosis
* active infection or chronic inflammatory disease
* malignancy
* women who were pregnant or who were of childbearing age","exenatide BYETTA® (Amylin-Lilly), Saline",INTERVENTIONAL,COMPLETED
NCT04284995,A Phase 2 Open Label Study to Assess the PK/PD Properties of RUC-4 in Patients With a ST-elevation Myocardial Infarction,"Coronary Disease, Myocardial Infarction, Heart Diseases, Vascular Diseases, STEMI - ST Elevation Myocardial Infarction","1. Patients with STEMI, presenting with persistent chest pain (\>30 min) and ≥1 mm ST-segment elevation in two adjacent electrocardiograph leads, with \>6 mm cumulative ST-segment deviation, in whom the total duration of symptoms to first intracoronary device deployment (excluding a wire) is anticipated to be within 6 hours
2. Adult males and females 18 years of age or older
3. Females must be non-pregnant, non-lactating, and of non-childbearing potential (postmenopausal or surgically sterilized) by history and review of medical record
4. Weight (by history) of between 52 and 120 kg
5. Written informed consent (following short-form of the informed consent form at Cardiac Catheterization Lab)","1. High probability in the opinion of the cardiologist that current STEMI is caused by stent thrombosis and the previous PCI related to this stent thrombosis is \<1 month
2. High suspicion of type II MI
3. Out of hospital cardiac arrest (OHCA)
4. Therapy resistant cardiogenic shock (systolic blood pressure ≤80 mm Hg for \>30 minutes)
5. Persistent severe hypertension (systolic blood pressure \>180 mm Hg or diastolic blood pressure \>110 mm Hg)
6. Current active coronavirus disease 2019 (COVID-19) infection (criteria according to local guidelines)
7. Known severe liver disease
8. Known history of severe renal dysfunction (glomerular filtration rate \<30 mL/min or serum creatinine \>200 mmol/L \[\>2.5 mg/dL\])
9. Known left bundle branch block
10. Requirement of oral anticoagulation (Vitamin K antagonists {VKA} or direct oral antagonists {DOACs})
11. Current treatment with αIIbβ3 receptor antagonist (other than RUC-4)
12. Coagulation abnormality, known bleeding disorder, or history of documented prior hemorrhagic or thrombotic stroke within the past 6 months
13. History of upper or lower GI bleeding within the past 6 months
14. Known clinically important anemia
15. Known clinically important thrombocytopenia (platelet count of less than 150,000/μL)
16. Known history of allergy to any of the ingredients in the RUC-4 formulation (i.e., acetate buffer, sucrose)
17. Major surgery within the past 6 months
18. Life expectancy of less than 6 months
19. Any clinically significant abnormality identified prior to enrollment that in the judgment of the Investigator would preclude safe completion of the study
20. Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, mental, or social) that is likely to affect the patient's ability to comply with the study protocol",RUC-4 Compound,INTERVENTIONAL,COMPLETED
NCT02627950,Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction,Acute Myocardial Infarction,"1. ST-elevation myocardial infarction \< 24 h after symptom onset or non-ST-elevation myocardial infarction with persistent chest pain \< 24 h after symptom onset
2. Intended revascularization by primary percutaneous coronary intervention
3. Informed consent
4. Age ≥18 years","1. Age \<18 years
2. Active bleeding or bleeding diathesis
3. Oral anticoagulation
4. Current treatment with clopidogrel/prasugrel/ticagrelor/glycoprotein-IIb-IIIa-receptor-antagonists
5. Current treatment with morphine and/or MCP \<12 h
6. Contraindication for treatment with platelet inhibitors
7. Fibrinolysis \<48 h
8. Percutaneous coronary intervention or coronary artery bypass grafting \<3 months
9. Known glomerular filtration rate \<30 ml/min
10. Severe liver dysfunction
11. Hypersensitivity to ticagrelor or any excipients
12. History of intracranial hemorrhage
13. Known pregnancy, breast-feeding or intend to become pregnant during the study period
14. Participation in other trial","Morphinhydrochloricum, Metoclopramide, Ticagrelor, Isotonic sodium chloride",INTERVENTIONAL,COMPLETED
NCT00361855,Safety Study of Bone Marrow Derived Cells to Treat Damaged Heart Muscle,Myocardial Infarction,"* 30-75 years of age (inclusive)
* 30-60 days since AMI (defined as the most recent MI causing a doubling in cTnI enzyme concentrations relative to normal levels in addition to ECG changes consistent with MI with confirmation by myocardial perfusion imaging \[SPECT\])
* Successful percutaneous revascularization restoring TIMI II or higher flow to infarcted area
* Negative pregnancy test (serum βhCG) in women of childbearing potential (within 24 hours prior to dosing)
* LVEF ≥ 30% as measured by myocardial perfusion imaging (SPECT)
* Cardiac enzyme tests (CPK, CPK MB, cTnI) within the normal range at baseline
* Willing and able to comply with protocol, including follow-up visits
* Signed Subject Informed Consent Form","* Significant coronary artery stenosis that may require percutaneous or surgical revascularization within six months of enrollment, as determined by the principal investigator
* LV thrombus (mobile or mural)
* High grade atrioventricular block (AVB)
* Frequent, recurrent, sustained (\>30 seconds) or non-sustained ventricular tachycardia \> 48 hours after AMI
* Clinically significant ECG abnormalities that may interfere with subject safety during the intracardiac mapping and injection procedure
* Atrial fibrillation with uncontrolled heart rate
* Severe valvular disease (e.g., aortic stenosis, mitral stenosis, severe valvular insufficiency requiring valve replacement)
* History of heart valve replacement
* Idiopathic cardiomyopathy
* Severe peripheral vascular disease
* Liver enzymes (aspartate aminotransferase \[AST\]/ alanine aminotransferase \[ALT\]) ≥ 3 times upper limit of normal (ULN)
* Serum creatinine ≥ 2.0 mg/dL
* History of active cancer within the preceding three years (with exception of basal cell carcinoma)
* Previous bone marrow transplant
* Known human immunodeficiency virus (HIV) infection
* Evidence of concurrent infection or sepsis on chest X-ray (CXR) or blood culture
* Participation in an experimental clinical trial within 30 days prior to enrollment
* Alcohol or recreational drug abuse within six months prior to enrollment
* Major surgical procedure or major trauma within the 14 days prior to enrollment
* Known autoimmune disease (e.g., systemic lupus erythematosus \[SLE\], multiple sclerosis)
* Clinically significant elevations in PT or PTT relative to laboratory norms
* Thrombocytopenia (platelet count \< 50,000/mm3)
* Inadequately controlled diabetes mellitus type I or type II, defined as a change in anti-diabetic medication regimen within the prior 3 months or HbA1C \> 7.0%
* Uncontrolled hypertension defined as systolic blood pressure (SBP) \> 180 mmHg and/or diastolic blood pressure (DBP) \>100 mmHg
* Use of ionotrophic drugs \> 24 hours post AMI
* Other co-morbid conditions such as hemodynamic instability, unstable arrythmias, and intubation, which, in the opinion of the principal investigator, may place subjects at undue risk or interfere with the objectives of the study
* Any other major illness, which, in the opinion of the principal investigator, may interfere with the subject's ability to comply with the protocol, compromise subject safety, or interfere with the interpretation of the study results",NX-CP105,INTERVENTIONAL,COMPLETED
NCT04534114,"Factor XI LICA to Reduce Events Such as Heart Attack and Stroke in Patients Whose Kidneys Are no Longer Able to Work as They Should and Require Treatment to Filter Wastes From the Blood: Focus is on the Safety of BAY2976217 and the Way the Body Absorbs, Distributes and Removes the Study Drug",End Stage Renal Disease Requiring Hemodialysis,"* Participant must be at least 18 years of age at the time of signing the informed consent form (ICF)
* Participants with ESRD on hemodialysis (HD) for ≥3 months at the time of signing of the ICF, receiving dialysis at least 9 hours a week and stable in the view of the investigator
* Male or female (contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies)
* Capable of giving signed ICF as described in the Protocol, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol","* Participants receiving antiplatelet therapy except daily acetylsalicylic acid (ASA) ≤ 150 mg/day
* Participants receiving anticoagulation in therapeutic doses, other than standard anticoagulation during the hemodialysis procedure
* Known inherited bleeding disorder e.g. von-Willebrand disease or Hemophilia A, B or C
* Recent (\<6 months before screening) clinically significant bleeding, or at high risk of bleeding (in the judgement of the investigator)
* Recent (\<3 months before screening) thromboembolic event, e.g. acute coronary syndrome, stroke, or Venous thromboembolism (except dialysis access thrombosis)
* Recent (\<3 months before screening) major surgery or scheduled major surgery during participation in the study
* Scheduled living donor renal transplant during study participation
* Known Hepatitis B or C
* Known HIV with recent documented detectable viral load (\<3 months before screening)
* Persistent heart failure as classified by the New York Heart Association classification of 3 or higher
* Life expectancy less than 6 months
* Sustained uncontrolled hypertension (persistent measurements of diastolic blood pressure ≥ 100 mmHg, and/or systolic blood pressure ≥ 180 mmHg)
* Hepatic disease associated with either: coagulopathy leading to a clinically relevant bleeding risk, or ALT \> 3x ULN, or total bilirubin \>2x ULN with direct bilirubin \> 20% of the total
* Hb \< 9.0 g/dL at screening
* Platelet count \< 120,000 mm\^3 at screening
* Known hypersensitivity to the investigational drug or to inactive constituents of the study intervention
* Active malignancy requiring treatment during study participation (except non-melanoma skin cancer, or cervical carcinoma in situ)
* Participation in a study with an investigational medicinal product within 30 days or within 5 half-lives of the previous administered drug, whichever is longer, prior to the screening/observational period (Note: Participants from previous BAY2306001/ISIS 416858 and BAY2976217/ ION 957943 studies are eligible)
* Any other conditions, which, in the opinion of the investigator or Sponsor would make the subject unsuitable for inclusion
* Confirmed pregnancy","Fesomersen sodium (BAY2976217), Placebo",INTERVENTIONAL,COMPLETED
NCT02926755,Multi-modality Imaging in Acute Myocardial Infarction,"Acute Myocardial Infarction, STEMI, Coronary Artery Disease, Atherosclerotic Plaque Disruption With Thrombosis of Artery","All patients with ST-elevation acute myocardial infarction (STEMI) and age \> 18 years who meet all of the following criteria:

* Successful primary Percutaneous Intervention (PCI) of the Infarcted Related Artery (IRA) defined as final stenosis \< 30%, Thrombolysis In Myocardial Infarction (TIMI) 3 flow
* At least 1 non-IRA with diameter stenosis ≥ 50% and reference vessel diameter \> 2mm
* None of the exclusion criteria","Patients will be excluded if any of the following are present:

* Cardiogenic shock that persists \> 24 hours after primary PCI
* Diffuse disease in non-IRA that precludes successful stenting
* Estimated Glomerular Filtration Rate (eGFR) \< 30 cc/min/1.73 m2 after hydration or optimization of Congestive Heart Failure (CHF) for cardiac death
* eGFR \<60 cc/min/1.73 m2, will be in the MIAMI study for invasive imaging treatment group/cohort but will not get the coronary CCTA
* eGFR \< 60 cc/min/1.73 m2, for coronary CCTA
* Active bleeding as defined as a fall in hemoglobin (HGB) concentration \> 3 g/dL within 24 hours requiring blood transfusion, vasopressors to maintain Systolic BP \> 100mmhg, or emergency surgical, endovascular, or endoscopic intervention.
* Mechanical complication of MI such as severe Mitral-Valve Regurgitation (MR), Ventricular Septal Defect (VSD) or pulmonary edema
* Uncontrolled Ventricular Tachycardia (VT) after primary PCI
* Inability to provide informed consent
* Ventilator-dependent respiratory failure
* Only non-IRA is a chronic total occlusion
* Non-IRA is in a Saphenous Vein Graft (SVG) or arterial graft
* Non-IRA is in the left main, ostial Left Anterior Descending (LAD), or ostial Left circumflex (LCX)
* Non-IRA includes a bifurcation with side branch \> 2mm, medina 1-1-1
* Need for multivessel primary PCI during the index procedure",Coronary Angiography,INTERVENTIONAL,COMPLETED
NCT03257579,Myocardial Infarction Prescription Duration Adherence Study,Medication Adherence,"* Use of Ontario Drug Benefits (ODB-Age \>65 years, social assistance, and disability);
* Cardiac catheterization during an index admission with an MI;
* Evidence of obstructive coronary artery disease;
* Discharged alive
* Ontario Residents (Ontario, Canada)",* None,"90 Day Supply, Education",INTERVENTIONAL,COMPLETED
NCT02831608,Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis,"Myocardial Infarction, Influenza, Human, Influenza Vaccines, Heart Failure, Stroke","* Patients with a diagnosis of ST-elevation myocardial infarction (STEMI) or
* Patients with a diagnosis of non-STEMI or
* Patients with stable coronary artery disease ≥75 years of age undergoing angiography/PCI AND with at least one additional risk criterion

and

* A finalized coronary angiography/PCI (optional for sites in Bangladesh).
* Male or female subjects ≥18 years.
* Written informed consent.","* Influenza vaccination during the current influenza season or anticipating to be vaccinated during the current influenza season.
* Indication for influenza vaccination for some indication other than myocardial infarction.
* Severe allergy to eggs or previous allergic reaction to influence vaccine.
* Suspicion of febrile illness or acute, ongoing infection.
* Hypersensitivity to the active substances or ingredients of Vaxigrip or against any residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and octoxinol.
* Subjects with endogenic or iatrogenic immunosuppression that may result in reduced immunization response.
* Inability to provide informed consent.
* Age below 18 years.
* Previous randomization in the IAMI trial.","Influenza vaccine, Placebo",INTERVENTIONAL,COMPLETED
NCT03949608,"Randomized, Single Center Study About the Impact of an E-learning Dedicated to Myocardial Infarction Patient",Acute Myocardial Infarction,"* Admission for acute coronary syndrome (ACS) in the cardiology unit of the University hospital of Lausanne (NSTEMI or STEMI)
* Have a percutaneous coronary intervention (PCI) as therapeutic strategy
* Patients going through an elective PCI for a second vessel after having suffered from an acute coronary syndrome in the previous month
* \> 18 years
* Total discernment capacity and French speaking
* Have a digital tablet, a smartphone or a computer to have the possibility to watch the e-learning at home
* Informed Consent as documented by signature (Appendix Informed Consent Form)","* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,
* Refugee claimants, homeless persons, prisoners by impossibility to contact them after discharge
* Patients with communication problems
* Life expectancy \< 6 months caused by other co-morbidities",E-learning,INTERVENTIONAL,COMPLETED
NCT01777750,Cooling in Myocardial Infarction,ST-elevation Myocardial Infarction,"* Age between 18 and 75 years
* Immediate transfer to cath-lab is possible
* Anterior or inferior ST-segment myocardial infarction
* ST-Segment elevation of \>0.2mV in 2 or more anatomically contiguous leads
* Duration of symptoms \<6 hours","* Participation in another study
* Patients presenting with cardiac arrest/cardiogenic shock
* Tympanic temperature \<35.0°C prior to enrolment
* Thrombolytic therapy
* Previous MI
* Previous PCI or coronary artery bypass graft
* Severe heart failure at presentation (defined as a New York Heart Association (NYHA) functional class III or IV), or Killip classes II through IV
* Clinical signs of active infection
* End-stage kidney disease or hepatic failure
* Recent stroke (within the past six months)
* Conditions that may be exacerbated by hypothermia, such as haematological dyscrasias, oral anticoagulant treatment with international normalized ratio \>1.5, severe pulmonary disease
* Pregnancy
* Women of childbearing potential
* Allergy to meperidine, buspirone, magnesium, or polyvinyl chloride
* Use of a monoamine oxidase inhibitor such as selegiline in the previous 14 days
* absolute contraindications against MRI (PM, ICD, ferromagnetic implants)",EMCOOLS flex pad; Philips Innercool RTx,INTERVENTIONAL,COMPLETED
NCT02018055,TicAgrelor Versus CLOpidogrel in Stabilized Patients With Acute Myocardial Infarction: TALOS-AMI,Acute Myocardial Infarction,"Subject should meet all of the following criteria.

1. Age \>= 18 years
2. Patients with AMI (STEMI or NSTEMI) who are administered aspirin and ticagrelor for 30 days after successful PCI with newer-generation drug eluting stents (DES)

   \*Definition of AMI follows the 3rd Universal Definition of MI.
3. Female patients with childbearing potential who agree to mandatory pregnancy test and have committed to using adequate contraception
4. Subjects who agree to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate IRB of the respective institution","Subject should be excluded if they apply to any of the following criteria.

1. Cardiogenic shock
2. Active internal bleeding, bleeding diathesis, or coagulopathy
3. Gastrointestinal bleeding or genitourinary bleeding, hemoptysis, or vitreous hemorrhage within 2 months
4. Major surgery within 6 weeks
5. History of intracranial bleeding, intracranial neoplasm, intracranial arteriovenous malformation, or intracranial aneurysm
6. Anemia (hemoglobin \< 10 g/dL) or platelet count of less than 100,000/mm3 at the time of screening
7. Concomitant treatment with oral anticoagulant agent (vitamin-K antagonists or novel oral anticoagulants such as dabigatran, rivaroxaban, apixaban, or edoxaban)
8. Daily treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 inhibitors
9. Malignancy or life expectancy of less than one year
10. Moderate or severe hepatic dysfunction (Child Pugh B or C)
11. Symptomatic patients with sinus bradycardia (sick sinus syndrome) or atrioventricular (AV) block (AV block grade II or III, bradycardia-induced syncope; except for patients implanted with permanent pacemaker)
12. Symptomatic patients with chronic obstructive pulmonary disease (Medical research council grade \>=3)
13. Intolerance of or allergy to aspirin, ticagrelor or clopidogrel
14. Subjects who are under renal replacement therapy due to end-stage renal disease or who have history of kidney transplantation
15. Galactose intolerance, lactase insufficiency or glucose-galactose malabsorption
16. Subjects who are actively participating in another clinical trial with 3 months of randomization (except for observational study)
17. Pregnant and/or lactating women
18. Subjects considered unsuitable for this study by the investigator","Aspirin+Ticagrelor, Aspirin+Clopidogrel",INTERVENTIONAL,COMPLETED
NCT00199823,Autologous Stem Cell Transplantation in Acute Myocardial Infarction,Acute Anterior Wall Myocardial Infarction,"Inclusion criteria:

* age 40-75 years
* anterior wall AMI with 120-720 minutes from onset of symptoms to PCI
* ST elevation on ECG according to WHO criteria
* angiographically significant stenosis on LAD proximal to the second diagonal branch
* successful PCI with stenting of culprit lesion
* hypokinetic, akinetic or dyskinetic segments assessed by echocardiography in a standard 16 segment model and
* CK-MB above 3 times upper reference value.",":

* previous MI with established significant Q-waves on ECG
* cardiogenic shock
* permanent pacemaker or other contraindication to MRI
* stroke with significant sequela
* short life expectancy due to extra cardiac reason
* uncontrolled endocrinological disturbance
* HIV and/or HBV/HCV positive serology
* mental disorder or other condition which interferes with patient possibility to comply with the protocol.",Intracoronary aotologous stem cell transplantation,INTERVENTIONAL,COMPLETED
NCT05895123,Comparison Between the Effects of High Doses Statin on Ventricular Remodeling in STEMI Patients,ST-segment Elevation Myocardial Infarction,"1. Electrocardiogram showed abnormal elevation of the ST segment.
2. First myocardial infarction occurred.
3. The patients received one-stage percutaneous coronary intervention (PCI) therapy within 12 h.","1. Severe cardiac insufficiency.
2. Hepatic insufficiency (continuous increase of serum transaminase more than 3 times of the upper limit of normal level).
3. Renal insufficiency (creatinine clearance rate \<30 mL/min).
4. Addition of others blood lipid lowering and antioxidant drugs during follow up period.
5. Familial hypercholesterolemia.
6. Malignant tumor.
7. Immune system disease.
8. Acute infectious disease.
9. Hypersensitivity to rosuvastatin and Atorvastatin.","Rosuvastatin 20 mg, Atorvastatin 40mg",INTERVENTIONAL,COMPLETED
NCT00986050,Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial Infarction,Acute Myocardial Infarction,"* STEMI ≤ 12 hours (or STEMI equivalent).
* No contra - indications for primary PCI.
* No contra - indications for abciximab.
* Informed consent from the patient.","* Contra - indication for primary PCI: History of peripheral/coronary artery disease that is inaccessible for angiography or PCI.
* Contra - indications for GPI: Ongoing bleeding, bleeding diathesis, cerebrovascular accident \< 6 months, major surgery/trauma \< 6 months, platelet count \< 100.000 mm3 , intracranial arteriovenous malformation or neoplasm, malignant hypertension, INR \>1.5, severe hepatic dysfunction
* Contra - indications for clopidogrel:

  * Severe liver dysfunction, pathological bleeding disorders such as peptic ulcer or intracranial bleeding.
  * Thrombolytic therapy \< 24 hours.
  * Therapy with GPI \< 24 hours.
  * Anticoagulation therapy.
* Co - morbid conditions with a predictable fatal outcome in the short run.
* No informed consent: refusal, coma, artificial respiration, impaired mentation.","Abciximab, bare metal stent prokinetic, chrono, skylor or bluemedical, drug eluting stent (sirolimus eluting) - CYPHER stent",INTERVENTIONAL,COMPLETED
NCT02942550,Methylnaltrexone as a Method to Improve Ticagrelor Uptake in Morphine Treated STEMI Patients,"STEMI, Morphine, Ticagrelor, Methylnaltrexone","* Diagnosis of STEMI
* Administration of a 180 mg loading dose ticagrelor
* Analgesic treatment with intravenous morphine pre-PCI","* Cardiac arrest
* Body weight \> 114kg
* Vomiting after intake of ticagrelor loading dose
* Use of Naloxone before inclusion or during sampling period
* Inability to understand study outline and instructions
* Methylnaltrexone bromide contraindication
* Age \<18 years; 8) Women in fertile age
* Administration of ticagrelor during the week before inclusion
* Treatment with Cangrexal
* Ongoing long-term opioid treatment.","Methylnaltrexone bromide (Relistor®)., Sodium Chloride 9mg/mL",INTERVENTIONAL,COMPLETED
NCT00103350,Safety of TG100-115 for Heart Attack Treated With Angioplasty,Myocardial Infarction,"* Age 18-80 yrs
* ECG patterns consistent with an acute anterior myocardial infarction with ST segment elevation of 2mm in two contiguous ECG leads among leads V1-V4.
* Have prolonged, continuous (lasting at least 20 mins) signs and symptoms of myocardial ischemia not eliminated with nitrates.
* Intent to proceed to primary PCI within 6 hours of chest pain onset
* Sign an informed consent form and be willing to attend follow-up visits for safety and other study assessments.","* Female of childbearing potential.
* History of previous myocardial infarction.
* History of congestive heart failure.
* Requirement for a cardiac pacemaker or defibrillator.
* Cardiogenic shock.
* Patients previously treated with thrombolytic therapy.
* Myocardial ischemia precipitated by a condition other than atherosclerotic coronary artery disease.",TG100-115,INTERVENTIONAL,COMPLETED
NCT02197117,Effect of Remote Ischemic Conditioning in Heart Attack Patients,ST-segment Elevation Myocardial Infarction (STEMI),"* Age \>18 years
* Presentation within 12 hours of onset of chest pain
* ECG showing ST-segment elevation of ≥0.1mV in two contiguous leads (≥0.2mV in leads V1-V3)",-None -,"Remote ischemic conditioning, Control",INTERVENTIONAL,COMPLETED
NCT01244841,Effects on Health Status in Patients Early Discharged After Primary Percutaneous Coronary Intervention (PCI),Acute Myocardial Infarction,"* ST elevation acute myocardial infarction
* Undergoing primary PCI","* Zwolle low risk criteria score \>4
* Re-infarction, post AMI ischemia.
* Need for urgent repeat invasive procedures.
* Non-cardiac complication (bleeding, stroke oa.) or concomitant diseases likely to increase length of hospital stay.
* Patient or caring physician refuse to early discharge or study inclusion.
* Early discharge impossible due to social, nursing or family reasons.",fast post MI care,INTERVENTIONAL,COMPLETED
NCT01422317,Effects of High-dose n-3 Fatty Acids on Clinical Outcome and Serum Lipids - Omacor Following Acute Myocardial Infarction,"Coronary Disease, Myocardial Infarction","* Verified an acute myocardial infarction (MI) by World Health Organization criteria
* Age above 18 years
* Discontinuation of a regular supplementation of other fish-oil products
* Signed informed consent","* Assumed noncompliance to protocol
* Expected survival \< 2 y because of severe heart failure (New York Heart Association class IV), malignancy, or other reasons
* Ongoing gastrointestinal bleeding or verified stomach ulcer
* Thrombocytopenia or blood platelets \< 100 x 10'9/L
* Liver insufficiency
* Participation in any other study
* Residence outside the recruitment area of this study","EPA / DHA / Alpha-Tocopherol, Corn Oil / Alpha-Tocopherol (4 mg)",INTERVENTIONAL,COMPLETED
NCT01890317,Mild Hypothermia in Cardiogenic Shock Complicating Myocardial Infarction,"Acute; Myocardial Infarction, Complications, Cardiogenic Shock","* Acute myocardial infarction complicated by cardiongenic shock
* Patients on mechanical ventilation at time of randomization","* Out of hospital resuscitation with indication for mild hypothermia
* mechanical complications after acute myocardial infarction
* duration of cardiogenic shock \> 12 hours
* age \> 90 years",Mild hypothermia,INTERVENTIONAL,COMPLETED
NCT00607217,The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases,"Coronary Artery Diseases, Myocardial Infarction, Stable Angina","* Coronary artery disease (CAD) group (CAD-Exp and CAD-Control):
* Patients with the diagnosis of acute, evolving or recent MI (after recovered the acute phase) as defined by:

  1. Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of the following:
* Ischemic symptoms
* Development of pathologic Qwaves on the ECG
* ECG changes indicative of ischemia (ST segment elevation or depression); OR
* Coronary artery intervention (e.g., coronary angioplasty). 2. Pathologic findings of an acute MI \[1\]:
* Patients with stable angina pectoris (SA) and documented coronary artery stenosis (angiography).
* Healthy Control group: healthy controls, proportionally matched by gender and age with the patient group (separate control groups for MI and SA patients).","* Any acute disease
* Chronic liver or kidney diseases
* Conditions accompanied by immunosuppression (like organ transplantation, HIV)
* Diagnosed malignancy
* Incubation with influenza vaccine within the past 5 years
* Any psychological disease that interferes with regular follow-up
* Congestive heart failure (Killip class IV)
* Unstable angina; AND
* Contradictions of vaccine incubation (like egg allergy).","influenza vaccine, placebo for influenza vaccine, influenza vaccine",INTERVENTIONAL,COMPLETED
NCT04285736,Efficacy of Oral Ivabradine in Patients Presenting With NSTEMI,NSTEMI,* Patients with NSTEMI with normal sinus rhythm and heart rate (HR) more than 70 beats per minute (bpm) and systolic blood pressure (SBP) \>90 mm Hg undergoing PCI,"* Patients needing urgent cardiac surgery, IV inotropic agents or had a HR less than 60 bpm without any medication.","Ivabradine, Conventional Treatment",INTERVENTIONAL,COMPLETED
NCT01489449,Bare Metal Stent Versus Drug Coated Balloon With Provisional Stenting in Non-ST-Elevation Myocardial Infarction,"Coronary Heart Disease, NSTEMI","* NSTEMI with
* Ischemic symptoms (angina pectoris) \> 30 minutes
* Last symptoms within 72 hours before randomization
* Positive cardiac troponin T, I, or hs-Troponin above 99th percentile
* age \> 18 years
* Identifiable culprit lesion without angiographic evidence of large thrombus with intended early PCI (treatment of up to two lesions allowed)","* Cardiogenic shock
* ST-elevation myocardial infarction
* No identifiable culprit lesion, Indication for acute bypass surgery
* Comorbidity with limited life expectancy \< 9-12 months
* Contraindication for treatment with heparin, ASA and thienopyridines","Stent, SeQuent(R) Please coated balloon",INTERVENTIONAL,COMPLETED
NCT01927549,Culprit Lesion Only PCI Versus Multivessel PCI in Cardiogenic Shock,"Cardiogenic Shock, Acute Myocardial Infarction, Complications","Cardiogenic shock complicating acute myocardial infarction (STEMI or NSTEMI) with obligatory:

I) Planned early revascularization by PCI II) Multivessel coronary artery disease defined as more than 70% stenosis in at least 2 major vessels (more than 2 mm diameter) with identifiable culprit lesion III)

1. Systolic blood pressure less than 90 mmHg for more than 30 min or
2. catecholamines required to maintain pressure more than 90 mmHg during systole and IV) Signs of pulmonary congestion V) Signs of impaired organ perfusion with at least one of the following criteria

a) Altered mental status b) Cold, clammy skin and extremities c) Oliguria with urine output less than 30 ml/h d) Serum-lactate more than 2.0 mmol/l VI) Informed consent","* Resuscitation more than 30 minutes
* No intrinsic heart action
* Cerebral deficit with fixed dilated pupils (not drug-induced)
* Need for primary urgent bypass surgery (to be determined after diagnostic angiography)
* Single vessel disease
* Mechanical cause of cardiogenic shock
* Onset of shock more than 12 h
* Massive lung emboli
* Age more than 90 years
* Shock of other cause (bradycardia, sepsis, hypovolemia, etc.)
* Other severe concomitant disease with limited life expectancy \<6 months
* Pregnancy
* Known severe renal insufficiency (creatinine clearance \<30 ml/kg)","Immediate multivessel PCI, Culprit Lesion only PCI",INTERVENTIONAL,COMPLETED
NCT02251249,Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study.,"Impairment of Gastric Emptying, Acute Phase of Myocardial Infarction","* Patient over 18 years weighing between 65 and 85 Kg
* Referred for STEMI within 6 hours from beginning of chest pain or stable coronary artery disease requiring a loading dose of Prasugrel or Ticagrelor according to the international recommendations.
* No previous treatment with Clopidogrel, Prasugrel or Ticagrelor.
* Patient fasting for at least 6 hours.
* Affiliate or receiving a social security system.
* Written informed consent.","* Allergy or contraindication to paracetamol, Prasugrel or Ticagrelor
* Paracetamol ingestion in the previous 48 hours
* Patient treated with drugs supposed to alter gastric emptying times (calcium antagonists, Alimentary tract treatments, opioid analgesics, tricyclic antidepressants, antibiotics).
* Conditions or pathologies supposed to alter gastric emptying times (Thyroid dysfunction, chronic renal failure, Parkinson's disease, scleroderma, amyloidosis, any gastrointestinal disease, any not cured malignancy, and any advanced psychiatric or neurological disease).
* Presence of vomiting
* Cardiogenic shock, ventricular arrhythmia or resuscitated cardiac arrest
* Hepatic insufficiency
* Severe respiratory disease
* Pregnant or breastfeeding women",Paracetamol concentration time curve from 0 to 120 min,INTERVENTIONAL,COMPLETED
NCT04382313,Effect of Hydration Guided by Vigileo on the Prevention of CIN After PCI for Patients With AMI,"Myocardial Infarction, Contrast-induced Nephropathy","* Clearly diagnosed STEMI or NSTEMI patients:
* Patients aged 18-80 years
* Patients are scheduled to undergo emergency percutaneous coronary interventions
* Estimated glomerular filtration rate eGFR \<120ml / min (according to MDRD formula)
* Sign the informed consent to join the group.","* Patients with mechanical complications
* Patients with cardiogenic shock
* Patients with aortic dissection
* Patients who have malignant tumors or short-term progressive diseases that researchers believe improper to be included in the group
* Hemodialysis-dependent patients with end-stage renal failure
* Patients who had a history of exposure to radioactive contrast media within 1 week before or 72 hours after direct PCI
* Patients who are allergic to radioactive contrast agents
* Patients diagnosed with right ventricular myocardial infarction with hypotension (defined as systolic blood pressure ≤90 mmHg) on admission.",the adequate hydration group guided by Vigileo,INTERVENTIONAL,COMPLETED
NCT06468982,Use of Intra-aortic Balloon Pump Before Surgery for Acute Myocardial Infarction,"Acute Myocardial Infarction, Coronary Artery Disease, Coronary Bypass Graft Stenosis of Autologous Vessel, Troponin, IABP - Disorder of Intra-Aortic Balloon Pump",* Patients who have had acute myocardial infarction and have been decided on coronary surgical revascularization,"* mechanical complications of Acute Myocardial Infarction (such as a ruptured chordal or ventricular septum)
* peripheral arterial disease
* renal failure
* history of cerebrovascular accident
* acute cardiogenic shock and cardiac arrest
* reoperation and combined operations",Intra-aortic Balloon Pump,INTERVENTIONAL,COMPLETED
NCT03260582,Implementation and Assessment of a Life-style Focused Patient Support Application in Myocardial Infarction Patients,Myocardial Infarction,"Inclusion criteria

* Age \< 75 years. This cut-off is set as only those \< 75 years of age are followed in the national Secondary Prevention after Heart Intensive Care Admission (SEPHIA) registry
* Has suffered an MI within the last 2 weeks
* Owns a smartphone and/or has access to internet via a computer or surf pad and can handle the software","* Expected survival \< 1 year
* Dementia, severe psychiatric illness or drug abuse
* Severe physical handicap limiting the patient´s ability to participate in exercise-based CR
* Not able to speak or understand the Swedish language
* Three-vessel disease requiring coronary artery bypass grafting",LifePod®,INTERVENTIONAL,COMPLETED
NCT03087773,Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction,Acute Myocardial Infarction,"1. Myocardial infarction with evidence of significant myocardial necrosis defined as a rise in creatinine kinase \>800 U/l and a troponin T-level (or troponin I-level) \>10x upper limit of normal (ULN). In addition at least 1 of the following criteria must be the met:

   * Symptoms of ischemia
   * ECG (electrocardiogram) changes indicative of new ischemia (new ST-T changes or new LBBB)
   * Imaging evidence of new regional wall motion abnormality
2. 18 - 80 years of age
3. Informed consent has to be given in written form
4. estimated glomerular filtration rate (eGFR) \> 45 ml/min/1.73m2
5. Blood pressure before first drug dosing: Riva Rocci (RR) systolic \>110 mmHg
6. Blood pressure before first drug dosing: Riva Rocci (RR) diastolic \>70 mmHg
7. ≤72h after myocardial infarction (after the performance of a coronary angiography)","1. Any other form of diabetes mellitus than type 2 diabetes mellitus, history of diabetic ketoacidosis
2. Blood potential hydrogen (pH) \< 7,32
3. Known allergy to SGLT-2 inhibitors
4. Hemodynamic instability as defined by intravenous administration of catecholamine, calcium sensitizers or phosphodiesterase inhibitors
5. \>1 episode of severe hypoglycemia within the last 6 months and treatment with insulin or sulfonylurea
6. Females of childbearing potential without adequate contraceptive methods (i.e. sterilization, intrauterine device, vasectomized partner; or medical history of hysterectomy)
7. Acute symptomatic urinary tract infection (UTI) or genital infection
8. Patients currently being treated with any SGLT-2 inhibitor or having received treatment with any SGLT-2 inhibitor within the 4 weeks prior to the screening visit","Empagliflozin 10 mg, Placebo Oral Tablet",INTERVENTIONAL,COMPLETED
NCT02725099,Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients,"Acute Coronary Syndromes, ST Elevation Myocardial Infarction","1. Patients presenting with STEMI
2. Informed, written consent","1. Age \< 18 years or Age \> 90 years
2. Active bleeding; bleeding diathesis; coagulopathy
3. Increased risk of bradycardic events
4. History of gastrointestinal or genitourinary bleeding \<2 months
5. Major surgery in the last 6 weeks
6. History of intracranial bleeding or structural abnormalities
7. Suspected aortic dissection
8. Any other condition that may put the patient at risk or influence study results or investigator's opinion (severe hemodynamic instability, unconsciousness, known malignancies or other comorbid conditions with life expectancy \<1 year)
9. Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux.
10. Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers, CYP3A with narrow therapeutic windows
11. Known relevant hematological deviations: Hb \<10 g/dl, PLT\<100x10\^9/l
12. Use of coumadin derivatives within the last 7 days
13. Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine
14. Known severe liver disease, severe renal failure
15. Known allergy to the study medications
16. Pregnancy
17. Human immunodeficiency virus treatment
18. The use of IIBIIIA receptor antagonists in the 48 hours before enrollment (if abciximab use then in the last 14 days).
19. If the patients cannot sign percutaneous coronary intervention (PCI) informed consent for any reason.","Chewing Ticagrelor, Oral Ticagrelor",INTERVENTIONAL,COMPLETED
NCT02938949,Alirocumab in Patients With Acute Myocardial Infarction,"Myocardial Infarction, Hypercholesterolemia","1. Acute type I (spontaneous) NSTEMI defined as chest pain (or equivalent) with an onset of symptoms within 12 hours of presentation, a duration of \>15 minutes, and elevated cardiac troponin I levels, with or without electrocardiographic changes \[with the exclusion of ST elevation\];
2. On medical therapy with high intensity statin prior to admission (either atorvastatin 40-80 mg or rosuvastatin 20-40 mg) as documented by hospital or pharmacy records and with known LDL cholesterol ≥70 mg/dL within the prior 12 months.","1. Age \<21 years of age
2. Inability to give informed consent
3. Previous, current or planned treatment with a PCSK9 inhibitor
4. Known history of loss of function of PCSK9 (genetic mutation or sequence variation)
5. Patient with homozygous familial hypercholesterolemia (clinically or by previous genotyping)
6. Recent (\<14 days) or active use of immunosuppressive drugs (including but not limited to high-dose corticosteroids \[\>1mg/kg of prednisone equivalent\], Tumor Necrosis Factor-α blockers, cyclosporine) not including non-steroidal antinflammatory drugs or corticosteroids used for IV dye allergy or corticosteroids used as replacement therapy for pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to randomization (note: topical, intra-articular, nasal, inhaled, and ophthalmic steroid therapies are not considered ""systemic"" and are allowed);
7. Chronic auto-immune or auto-inflammatory disease (including but not limited to rheumatoid arthritis, systemic lupus erythematosus);
8. History of cancer within the past 5 years, except for adequately treated basal cell skin cancer, squamous cell skin cancer, or in situ cervical cancer;
9. Known chronic hepatitis B or C infection (excluding patients with a positive antibody who were successfully treated or who have demonstrated no viral load);
10. Known human immunodeficiency virus infection.
11. Use of fibrates other than fenofibrate within 6 weeks of the screening visit.
12. Uncontrolled hypothyroidism. Note: patients on thyroid replacement therapy can be included if the dosage of thyroxin has been stable for at least 12 weeks prior to screening.
13. Known history of a hemorrhagic stroke.
14. Has been previously treated with at least 1 dose of alirocumab or any other anti-PCSK9 monoclonal antibody in other clinical studies.
15. Conditions/situations such as:

    1. Any clinically significant abnormality identified at the time of screening that in the judgment of the investigator or any sub-investigator would preclude safe completion of the study or constrain assessment of endpoints, such as major systemic diseases or patients with short life expectancy.
    2. Patients considered by the investigator or any sub-investigator to be inappropriate for this study for any reason:

    i. Those patients deemed unable to meet specific protocol requirements, such as scheduled visits.

    ii. Those patients the investigator deems unable to administer or tolerate long-term injections.

    c. Investigator or any sub-investigator, pharmacist, study coordinator, other study staff, or relative thereof directly involved in the conduct of the protocol.

    d. Presence of any other conditions (geographic or social), actual or anticipated, that the investigator feels would restrict or limit the patient's participation for the duration of the study.
16. Thyroid-stimulating hormone (TSH) \< lower limit of normal (LLN) or \> upper limit of normal (ULN); if TSH is abnormal due to controlled hypothyroidism (patient is on a stable dose of thyroid replacement therapy), the patient may be enrolled into the study;
17. Exclusion Criteria Related to the Active Comparator and/or Mandatory Background Therapies: All contraindications to the background therapies or warnings/precautions of use (when appropriate) as displayed in the respective national product labeling.
18. Exclusion Criteria Related to the Current Knowledge of Alirocumab

    1. Known hypersensitivity to monoclonal antibody therapeutics
    2. Pregnant or breastfeeding women
19. Women of childbearing potential who are not protected by highly effective method(s) of birth control throughout the entire duration of study treatment and for 10 weeks after the last dose of study drug and/or who are unwilling or unable to be tested for pregnancy.
20. Men capable of impregnating women who are not protected by highly effective method(s) of birth control and/or who are unwilling to use an effective contraceptive method throughout the entire duration of study treatment and for 10 weeks after the last dose of study drug.","alirocumab, placebo",INTERVENTIONAL,COMPLETED
NCT00354406,Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary Angioplasty,Myocardial Infarction,"* Prolonged, continuous signs and symptoms of ischemia lasting more than 20 min, starting within 6 hours prior to randomization, and ST segment elevation ≥ 2mm or new left bundle branch block
* Absence of contraindications to Abciximab (for details cf. below section)
* Written informed consent","* Low-risk (ST elevation in ≤2 leads) inferior AMI
* Previous infarction in the same area (assessed by ECG)
* PCI in the 2 weeks prior to AMI
* Know hypersensitivity to abciximab
* Active internal bleeding
* History of cerebrovascular accident in the previous 2 years or cerebrovascular accident with a significant residual neurological deficit
* Head or spine surgery or trauma in the previous 2 months
* Recent (within six weeks) gastrointestinal (GI) or genitourinary (GU) bleeding of clinical significance
* Administration of oral anticoagulants within seven days unless prothrombin time is \<1.2 times control
* Bleeding diathesis or severe uncontrolled arterial hypertension
* Thrombocytopenia (\<100 000 cells/mL)
* Recent (within six weeks) major surgery or trauma
* Intracranial neoplasm, arteriovenous malformation, or aneurysm
* Severe renal or liver failure
* Allergy to aspirin
* Contraindication to MRI examination",abciximab,INTERVENTIONAL,COMPLETED
NCT00442806,Randomized Clinical Trial of Adipose-Derived Stem Cells in the Treatment of Pts With ST-elevation Myocardial Infarction,"Myocardial Infarction, Coronary Arteriosclerosis, Cardiovascular Disease, Coronary Disease","Key 

* Acute myocardial infarction (AMI)
* Clinical symptoms consistent with AMI for a minimum of 2 and a maximum of 12 hours from onset of symptoms to Percutaneous Coronary Intervention (PCI), and unresponsive to nitroglycerin
* Successful revascularization of the culprit lesion in the major epicardial vessel
* Area of hypo- or akinesia corresponding to the culprit lesion, as determined by left ventriculogram at the time of primary PCI
* Left ventricular ejection fraction (LVEF) ≥30% and ≤50% by Left Ventricular Angiography at the time of successful revascularization.
* Ability to undergo liposuction

Key","* Prior MI, prior known cardiomyopathy, or prior hospital admission for congestive heart failure (CHF)
* More than 24 hours after acute PCI
* Significant valvular disease
* More than twelve hours between the onset of first symptoms of AMI and revascularization
* Hemodynamic instability within 24 hours prior to randomization
* Neoplasia
* Acute or chronic bacterial or viral infectious disease
* Pacemaker, ICD or any other contra-indication for MRI
* LVEF \<30% or \>50% by Left Ventricular Angiography
* Moderate or severe COPD","Injection of ADRC's, Injection of Placebo",INTERVENTIONAL,COMPLETED
NCT01596036,Readiness for Behavior Change After a Heart Attack,"Myocardial Infarction, Stable Angina, Coronary Artery Disease","* Stable Angina
* Myocardial infarction
* Percutaneous coronary intervention
* willingness to participate and consent for medical record review
* willingness to complete survey's","* Recent illicit drug use
* Unstable psychiatric condition
* Moderate or severe dementia
* Inability to follow-up
* Leaving system with plans to enroll in cardiac rehabilitation out-of-system
* Inability to exercise (amputee, severe claudication)
* Unstable medical condition that would prevent regular exercise training
* Uncorrected severe aortic stenosis or severe mitral stenosis
* Referring physician feels that exercise is contra-indicated due to safety or other patient specific factors
* CABG, LVAD, or Heart Transplant","Early appointment (within 10 days), Routine referral (at 5 weeks)",INTERVENTIONAL,COMPLETED
NCT02804906,Rehabilitation in the Home Setting for Older Adults In the Early Period After Myocardial Infarction,Acute Myocardial Infarction (AMI),* Clinical diagnosis of acute myocardial infarction (AMI).,"* moderate to severe cognitive impairment; non-ambulatory
* severe heart failure (NYHA Class IV); decisional impairment as assessed by the University of California
* San Diego Brief Assessment of Capacity to Consent (UBACC) 22, if the RC questions capacity; very limited life expectancy (e.g. anticipated discharge to hospice)
* non-English/non-Spanish speaking.","Home-based physical therapy, Usual Care",INTERVENTIONAL,COMPLETED
NCT00590070,THE REOPEN-AMI STUDY - Intracoronary Nitroprusside Versus Adenosine in Acute Myocardial Infarction,Myocardial Infarction,"1. Symptoms onset \< 12 hours prior to enrollment
2. ST-segment elevation of at least 2 mm in two or more contiguous leads
3. TIMI flow 0-1 at baseline angiography","Demographic, history and clinical examination

1. age less than 18 years
2. previous STEMI
3. patients presenting in cardiogenic shock
4. pregnancy
5. patients with renal failure
6. contraindications to contrast agents, which cannot be managed medically or study medications, including aspirin, clopidogrel and ticlopidine, and heparin

   Electrocardiogram
7. left bundle branch block, paced rhythm, frequent ventricular ectopy, pre-excitation or other conditions or artifacts interfering with interpretation of ST segment resolution Angiography
8. culprit lesion located in a by-pass graft
9. stent thrombosis
10. culprit lesion non identified
11. left main disease","adenosine, nitroprusside, placebo",INTERVENTIONAL,COMPLETED
NCT04564742,Dapagliflozin Effects on Cardiometabolic Outcomes in Patients With an Acute Heart Attack.,"Acute Myocardial Infarction, Heart Failure","* Participant must be ≥18 at the time of signing the informed consent
* Confirmed MI, either STEMI or NSTEMI, according to the fourth universal definition of MI (Thygesen et al 2019), within the preceding 7 days, or 10 days if earlier randomisation is not feasible
* Evidence of impaired regional or global LV systolic function at any timepoint during current MI-related hospitalisation (established with echocardiogram, radionuclide ventriculogram, contrast angiography or cardiac MRI) or definitive evidence on ECG of Q wave MI (defined as presence of Q waves in two or more contiguous leads, excluding leads III and aVR, and meeting all the following criteria: at least 1.5 mm in depth; at least 30 ms in duration; and, if R wave present, more than 25% of the size of the subsequent R wave)
* Hemodynamically stable at randomization (no episodes of symptomatic hypotension, or arrhythmia with haemodynamic compromise in the last 24 hours).
* Male or female
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
* Provision of signed and dated, written informed consent prior to any mandatory study specific procedures, sampling, and analyses","* Known type 1 diabetes mellitus (T1DM) or T2DM at the time for admission. Patients with hyperglycaemia, but without a diagnosis of diabetes mellitus prior to the index event, are eligible at the discretion of the Investigator. Patients who present with signs and symptoms consistent with ketoacidosis, including nausea, vomiting, abdominal pain, malaise and shortness of breath should be assessed for ketoacidosis, and if ketoacidosis is confirmed the patient should not be randomized.
* Chronic symptomatic HF with a prior HHF within the last year and known reduced ejection fraction (LVEF≤40 %), documented before the current MI hospitalization
* Severe (eGFR \<20 mL/min/1.73 m2 by local laboratory), unstable or rapidly progressing renal disease at the time of randomization
* Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the trial
* Active malignancy requiring treatment at the time of screening, except for basal cell- or squamous cell carcinoma of the skin, presumed possible to treat successfully
* Any non-CV condition, eg malignancy, with a life expectancy of less than two years based on the investigator´s clinical judgement
* Currently on treatment, or with an indication for treatment, with a sodium glucose co-transporter 2 inhibitor (SGLT2-inhibitor)","Dapagliflozin, Placebo",INTERVENTIONAL,COMPLETED
NCT00279175,REPAIR-AMI: Intracoronary Progenitor Cells in Acute Myocardial Infarction (AMI),Myocardial Infarction,"* Patients with acute myocardial infarction (ST elevation in at least 2 leads \>= 0.2 mV in V1,V2 or V3 or \>= 0.1 mV in other leads), treated by one of the following procedures

  * Either acute PCI with stent implantation within 24 hours after symptom onset or
  * treatment with thrombolysis within 12 hours of symptom onset followed by PCI with stent implantation within 24 hours after thrombolysis.
* Acute PCI / stent implantation has been successful (residual stenosis visually \< 30% and TIMI flow \>= 2).
* At the time of inclusion patient does no longer require i.v. catecholamines or mechanical hemodynamic support (aortic balloon pump)
* Significant regional wall motion abnormality in LV angiogram at the time of acute PCI (ejection fraction \<= 45% on visual estimation).
* Maximal CK elevation \>= 400 U/l (measured at 37° C) with significant MB fraction \> 6%
* Age 18 - 80 Years
* Written informed consent","* Regional wall motion abnormality outside the area involved in the index acute myocardial infarction.
* Need to revascularize additional vessels, outside the infarct artery.
* Arteriovenous malformations or aneurysms
* Active infection (CRP \> 10 mg/dl) now, or fever or diarrhea within last 4 weeks.
* Chronic inflammatory disease
* HIV infection or active hepatitis
* Neoplastic disease without documented remission within the past 5 years.
* Cerebrovascular insult within 3 months
* Impaired renal function (creatinine \> 2 mg/dl) at the time of cell therapy
* Significant liver disease (GOT \> 2x upper limit) or spontaneous INR \> 1,5)
* Anemia (hemoglobin \< 8.5 mg/dl)
* Platelet count \< 100.000/µl
* Hypersplenism
* Known allergy or intolerance to clopidogrel, heparin or abciximab.
* History of bleeding disorder
* Gastrointestinal bleeding within 3 months
* Major surgical procedure or traumata within 2 months
* Uncontrolled hypertension
* Pregnancy
* Mental retardation
* Previously performed stem / progenitor cell therapy
* Participation in another clinical trial within the last 30 days.","Intracoronary infusion of enriched bone marrow-derived progenitor cells, Placebo medium supplemented with autologous serum",INTERVENTIONAL,COMPLETED
NCT01124942,MGuard Stent in ST-elevation Myocardial Infarction,"ST-elevation Myocardial Infarction, Thrombus, Stents","* \>/= 18-year-old patients, willing to participate the study, after informed consent signature
* Female not pregnant or potentially child-bearing
* \> 1 mV ST segment elevation in two or more contiguous leads
* Acute MI lasting more than 30 minutes and less than 12 hours
* De novo acute MI
* Infarct related artery reference vessel diameter \>/= 2.5 mm
* Patient suitable for stenting according to vessel and lesion features","* Dual antiplatelet therapy contraindication
* Ischemic stroke less than 30 days or previous haemorrhagic stroke
* WBC count less than 1000 per mm3;
* Platelet count less than 50.000 per mm3
* Life expectancy less than 1 year
* Cardiogenic shock at admission
* Previous stented infarct related artery
* Stent thrombosis as the responsible for current STEMI
* Inability to identify infarct related artery
* True bifurcation lesion, or lesion near a side branch with a reference vessel diameter \>/= 2.5 mm that could be diseased after stenting procedure
* LBBB
* Definitive pacing (or ECG abnormalities precluding ST-segment resolution evaluation
* Participation other study","MGuard net protective coronary stent, Bare-metal stent and manual thrombectomy device",INTERVENTIONAL,COMPLETED
NCT01360242,Minimal Invasive Procedure for Myocardial Infarction,ST Elevation Myocardial Infarction,"* Patients with acute STEMI presenting within 12 hours of symptom onset, requiring a primary percutaneous coronary intervention; and written informed consent.
* Patients will be randomized during the angiography if the initial TIMI flow is 0 or 1 in a major artery and if TIMI-3 flow can be restored after thrombus aspiration and sustained for 10 minutes.
* Acute STEMI is defined as typical chest pain with 30 minutes of sustained ST-segment elevation \>1 mm in two or more consecutive limb leads or \>2 mm in two or more precordial leads in the ECG. Major artery is defined as the proximal or mid segment of the left descending artery, the proximal segment of the circumflex artery (before the first marginal), or the right coronary artery before the posterior descendant artery.","* Patients less than 18 years' old
* Pregnant and breast feeding women
* Patients with a pacemaker, automated implantable cardioverter-defibrillator (AICD), or left bundle branch block
* Contraindication to abciximab, prasugrel, or clopidogrel
* Cardiac arrest as initial presentation
* Current medical condition with a life expectancy of \< 6 months
* Patients not living in France
* Patients in cardiogenic shock
* Culprit artery \<2.5 mm
* Absence of informed consent
* Patients with initial TIMI 2 or 3 flow or no TIMI-3 flow restored after thrombus aspiration
* Rescue PCI after fibrinolysis
* Known creatinine clearance \< 30 ml/min.","MIMI procedure (two-step strategy), Immediate Stenting (one-step strategy)",INTERVENTIONAL,COMPLETED
NCT00922675,Postconditioning in ST-elevation Myocardial Infarction,Myocardial Infarction,"* acute symptoms consistent with an acute myocardial infarction of less than 6 hours duration
* an occluded infarct related artery must be demonstrated (TIMI-flow 0-1)","* Prior myocardial infarction
* Demonstration of collaterals to the infarcted area
* TIMI-flow \>1 before intervention or TIMI-flow \<2 after initial balloon inflation
* Demonstration of a distal occlusion
* Patients given thrombolytic treatment
* Patients in cardiogenic shock
* Any contraindication to MRI (magnetic resonance imaging)
* Unwillingness to participate","Postconditioning, Control intervention",INTERVENTIONAL,COMPLETED
NCT03135275,MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial,"ST-elevation Myocardial Infarction, Multivessel Coronary Disease","* Age ≥ 18 years
* Spontaneous acute STEMI (patients presenting within 24 hours of symptom onset)
* Suitability for PCI from femoral or radial access
* Coronary anatomy suitable for complete coronary revascularization with Synergy® stent implantation
* Identifiable culprit lesion/artery
* At least one non-culprit coronary stenosis ≥ 70% in at least two projections, in a vessel with a lumen diameter ≥2.25 - ≤5.75 mm, other than the culprit artery
* TIMI Flow 3 or TIMI flow 2 after revascularization of the culprit artery
* Stable hemodynamics at the end of the culprit vessel revascularization","* Inability to give informed consent
* Cardiogenic shock
* Prolonged resuscitation \>10 min
* General unsuitability for PCI
* Need for emergency CABG
* Previous CABG
* Planned hybrid revascularization
* Coronary artery dissection
* STEMI due to ST
* Previous documented allergic reaction to everolimus or to any stent material
* Severe mechanical complication of acute myocardial infarction
* Pre-existing severe renal failure (eGFR \<30 mL/min) or renal replacement therapy
* Chronic total occlusion of a major coronary artery
* Left main stem stenosis ≥50% or left main stem equivalent (ostial left anterior descending and ostial circumflex stenosis ≥70%)
* In-stent restenosis
* Panned coronary, cerebrovascular, or peripheral arterial revascularization
* Planned cardiac or major surgery
* Any contraindications for dual antiplatelet therapy with aspirin and a P2Y12 Inhibitor for at least 90 days, except for patients on oral anticoagulation
* Known pregnancy at the time of inclusion
* Participation in another clinical study with an investigational product
* Life expectancy \<1 year","Staged complete PCI, Immediate complete PCI, Synergy™ stent",INTERVENTIONAL,COMPLETED
NCT03000270,Door To Unloading With IMPELLA CP System in Acute Myocardial Infarction - Safety and Feasibility Study,STEMI,"Main 

* Age 21-80 years
* First myocardial infarction
* Acute anterior STEMI with ≥ 2 mm in 2 or more contiguous anterior leads or≥ 4 mm total ST-segment deviation sum in the anterior leads
* Signed Informed Consent

Main","* Cardiogenic shock defined as: systemic hypotension (systolic BP less than 90 mmHg or the need for inotropes/pressors to maintain a systolic BP Greater than 90mmHg) plus one of the following: any requirement for pressors/inotropes prior to arrival at the cath lab, clinical evidence of end organ hypoperfusion, lactate level greater than 2.5mmol/L
* Inferior STEMI or suspected right ventricular failure
* Suspected or known pregnancy
* Suspected active infection
* History or known hepatic insufficiency prior to catheterization
* On dialysis therapy
* Known contraindication to:
* Undergoing MRI or use of gadolinium
* Heparin, pork, pork products or contrast media
* Receiving a drug-eluting stent
* Participation in the active treatment or follow-up phase of another clinical study of an investigational drug or device",Impella unloading prior to PPCI,INTERVENTIONAL,COMPLETED
NCT01936675,Myocardial Infarction Genes (MI-GENES) Study,"Coronary Artery Disease, Myocardial Infarction, Genomic Risk Communication","* Patients between the ages of 45-70 years
* Patients who have participated in the Mayo Clinic Biobank or a previous research study at Mayo Clinic
* Patients who live in Southeast Minnesota","* Taking statin or other lipid lowering medications
* Patients with a history of myocardial infarction, coronary artery disease, or other atherosclerotic medical conditions",Genetic Risk Score,INTERVENTIONAL,COMPLETED
NCT03251859,Effectiveness of Lower Maintenance Dose of Ticagrelor Early After Myocardial Infarction (ELECTRA) Pilot Study,Myocardial Infarction,"* provision of informed consent prior to any study specific procedures
* diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment elevation myocardial infarction according to the Third Universal Definition of Myocardial Infarction
* index event treatment with percutaneous coronary intervention
* male or non-pregnant female, aged 18-80 years old","* contraindications for ticagrelor
* further coronary revascularization planned during the first 45 days after myocardial infarction
* indications for chronic treatment with oral anticoagulant or low-molecular-weight heparin
* active bleeding
* history of intracranial hemorrhage
* recent gastrointestinal bleeding (within 30 days)
* history of coagulation disorders
* history of moderate or severe hepatic impairment
* history of major surgery or severe trauma (within 3 months)
* active neoplastic disease
* patient requiring dialysis
* chronic inflammatory disease
* current therapy with strong CYP3A inhibitors or strong CYP3A inducers","Ticagrelor 90 mg, Ticagrelor 60 mg",INTERVENTIONAL,COMPLETED
NCT03087175,MGuard Stent and Microcirculation,"Coronary Disease, Coronary Artery Disease, Coronary Atherosclerosis, Cardiovascular Diseases","* Age \> 18 years
* Patients affiliated to social security
* Patients with an NSTEMI or STEMI (1)
* Thrombus containing coronary lesions on angiography (TIMI thrombus grade ≥ 3)
* Eligible patients for revascularization with angioplasty
* Patients consenting to participate in the study.","* Age \< 18 years
* Prior myocardial infarction
* Prior CABG
* Inability to comply with the protocol
* Major patient protected by law (article L1121-8),
* Person deprived of liberty (article L1121-8),
* Pregnant woman
* Breastfeeding women
* Patient with terminal illness,
* Terminal Renal failure
* Allergy to iodine
* Adenosine's contraindications: Asthmatic patients, Second- or third-degree AV block without a pacemaker or sick sinus syndrome. Systolic blood pressure less than 90mmHg. Recent use of dipyridamole or dipyridamole-containing medications, Methyl xanthenes such as aminophylline caffeine or theobromine block the effect of adenosine and should be held for at least 12 hours prior to the test. Known hypersensitivity to adenosine. Unstable acute myocardial infarction or acute coronary syndrome.","MGuard stent, Drug eluting stent and bare metal stent",INTERVENTIONAL,COMPLETED
NCT03552575,The Effects of Sacubitril/Valsartan Compared to Valsartan on LV Remodelling in Asymptomatic LV Systolic Dysfunction After MI,Heart Failure,"* Acute myocardial infarction (AMI) at least 3 months prior to recruitment

  * Left ventricular ejection ≤40% as measured by transthoracic echocardiography
  * Ability to provide written, informed consent
  * Age ≥18 years
  * Tolerance of a minimum dose of ACE inhibitor/ARB (ramipril 2.5mg BD or equivalent)
  * Treatment with a beta-blocker unless not tolerated or contraindicated.","* Contraindication to CMR (ferrous prosthesis, implantable cardiac device or severe claustrophobia)

  * Clinical and/or radiological heart failure (NYHA≥2)
  * Symptomatic hypotension and/or systolic blood pressure \<100mmHg
  * eGFR \< 30 mL/min/1.73m2 and/or serum potassium \>5.2mmol/L
  * Persistent/permanent atrial fibrillation
  * History of AMI within last 3 months
  * History of hypersensitivity or allergy to ACE-inhibitors/ARB
  * History of angioedema
  * Known hypersensitivity to the active study drug substances, contrast media or any of the excipients
  * Obesity (where body girth exceeds MRI scanner diameter)
  * Pregnancy, planning pregnancy, or breast feeding
  * Inability to give informed consent or comply with study protocol
  * Evidence of hepatic disease as determined by any one of the following: AST or ALT values exceeding 2 x ULN at Visit 1, history of hepatic encephalopathy, history of oesophageal varices, or history of portacaval shunt
  * History of biliary cirrhosis and cholestasis
  * Active treatment with cholestyramine or colestipol resins
  * Active treatment with lithium or direct renin inhibitor
  * Participation in another intervention study involving a drug or device within the past 90 days (co-enrolment in observational studies is permitted)","sacubitril/valsartan, Valsartan",INTERVENTIONAL,COMPLETED
NCT01585259,Anfibatide Phase Ib-IIa Clinical Trial,Non-ST Segment Elevation Myocardial Infarction,"1. Aged 18-70 years;
2. Laboratory tests show increase of the markers of myocardial damage (CK-MB,CTnI), or reduction after increase, with at least one values exceeding the 99th percentile of the upper limit of the reference value;
3. Ischemia symptoms (ischemic chest pain lasts for over 15 minutes, little release after taking nitroglycerin sublingually) or a new myocardial ischemia on electrocardiogram(ECG), i.e. a new ST-T variation (a new or transient depression of ST segment by over 0.1mV, or T-wave inversion≥0.2mV);
4. Patients receive PCI after coronary angiography;
5. Patients, or their family or guardian give signed informed consent forms.","1. Patients with severe unstable hemodynamics who should receive urgent PCI;
2. Patients with untreated hypertension (SBP\>180 mmHg or DBP \>110mmHg) and hypotension shock (SBP\<90mmHg/80mmHg for over 30min);
3. Investigator considers patients need to use GPIIb/IIIa receptor antagonists during the study period;
4. After coronary angiography, the number of stenosed vessels \>2；lesions in left main branch, severe calcification and artery graft lesions;
5. Patients with heart function in decompensatory phase (Killip grade 3-4) or cardiac shock;
6. Patients with malignant arrhythmia, e.g. the third-degree atrioventricular block, ventricular tachycardia or fibrillation ventricular;
7. Patients with severe hepatic or renal dysfunction, with serum aspartate transaminase(AST) and alanine transaminase (ALT) exceeding 1.5 times the upper limit of reference values, creatinine clearance \<30ml/min or serum creatinine ≥200μmol/L or 2.5mg/dl;
8. Patients who have received PCI in the past six months;
9. Patients who have received coronary artery bypass grafting (CABG) previously;
10. Patients who have received invasive operation in the past 3 months;
11. Patients who have suffered from ischemic stroke or transient ischemic attack (TIA) in the past 6 months, or patients with past history of hemorrhagic stroke;
12. Patients who need a long-term treatment of oral anticoagulants (such as warfarin);
13. Patients with active peptic ulcer, or other diseases of hemorrhagic tendency;
14. Patients with disease of coagulation disorder;
15. Hematology test shows platelet count \<100,000mm3,or hemoglobin\<100g/L;
16. Women in pregnant or lactation period, or women of child-bearing age do not take efficient contraception measures;
17. Patients with an allergic constitution;
18. Patients who is participating in other clinical trials;
19. Patients who do not give a signed informed consent forms;
20. Patients who are not suitable to enroll in the trial according to the investigator's judgement.","Anfibatide, Placebo",INTERVENTIONAL,COMPLETED
NCT00126100,Bone Marrow Stem Cell Mobilisation Therapy for Acute Myocardial Infarction (AMI)(REVIVAL-2),Myocardial Infarction,"* ST-elevation acute myocardial infarction (5 days before randomization)
* Successful percutaneous coronary intervention \[PCI\] (performed within 12 hours from symptom onset)
* Scintigraphic infarct size \>5% of left ventricle
* Written informed consent","* Age \<18 years or \>80 years
* Congestive heart failure defined as Killip class \>2
* A history of myocardial infarction
* Electrical or hemodynamic instability
* Autoimmune diseases
* Fructose intolerance
* Malignancies
* Incompatibility of filgrastim
* Known or suspected pregnancy","G-CSF Granulocyte-Colony Stimulating Factor, Placebo",INTERVENTIONAL,COMPLETED
NCT01905475,CXCR4 Antagonism for Cell Mobilisation and Healing in Acute Myocardial Infarction (CATCH-AMI),Large Reperfused ST-Elevation Myocardial Infarction,"1. Patients with symptoms suggestive of an acute MI with ST-segment elevation or new left bundle-branch block and a rise or fall in cardiac necrosis markers.
2. Patients must be scheduled to undergo coronary angiography for the purposes of primary PCI (percutaneous coronary intervention) culminating in successful stent implantation.
3. Age between 18 and 80 years. Male and WOCBP (women of child bearing potential) willing to use highly effective methods of contraception from the time of first dose until 3 months after the last dose of the drug.
4. Markedly reduced LVEF at baseline cardiac MRI.
5. No previous occurrence of Myocardial Infarction.
6. Estimated glomerular filtration rate (eGFR) equal or higher than 40 mL/minute prior to MRI.
7. Signed Informed Consent.","1. Evidence of multi-vessel coronary artery disease likely to require repeat PCI or coronary artery bypass grafting within 4 months.
2. Pulmonary oedema or cardiogenic shock requiring intubation or mechanical support at the time of the planned baseline MRI.
3. Fitted with a non-MRI-compatible cardiac pacemaker or implantable cardioverter defibrillator, or expected to require such a device within 4 months after randomisation.
4. Terminal illness or malignant disease.
5. Advanced hepatic disease.
6. Diagnosis of severe obesity which precludes MRI assessments.
7. Claustrophobia.
8. Acute systemic infection or fever.
9. Anemia (where hemoglobin levels are \<10 g/dL), thrombocytopenia (platelet count \<100000/μL) or coagulopathy.
10. History of multiple drug allergies or with a known allergy to the drug class of CXCR4 antagonists.
11. Pregnancy or females of childbearing potential who are not using double contraception
12. Known history of human immunodeficiency virus (HIV) infection, chronic hepatitis B or hepatitis C infection or significant active chronic inflammatory disease that requires immunosuppressive medication or regular systemic corticosteroids.
13. Patients who have participated in any investigational drug or device trial within 30 days prior to signing informed consent.
14. Patients who are unwilling or unable to abide by the study requirements.","POL6326, Placebo",INTERVENTIONAL,COMPLETED
NCT03507270,One-hour Diagnostic Algorithm for NSTEMI,Non ST Segment Elevation Myocardial Infarction,"* Patients aged 18-80 years old
* Male patients
* Acute pain in the chest similar to myocardial infarction with/or without ECG changes
* Admission to the hospital within 4 hours from onset of the disease.","* Patients with ACS in the preceding 30 days
* Cerebral blood circulation disorder
* Recent surgical intervention
* Extensive burns of degree 2-3
* Massive wounds and injuries
* Percutaneous coronary intervention or cardioversion
* Pregnancy or lactation
* Malignant tumors of stage 4
* Severe renal insufficiency (GFR\< 30 mL/min)",FABP,INTERVENTIONAL,COMPLETED
NCT00610870,Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention,"Angioplasty, Transluminal, Percutaneous Coronary","* Presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset
* ST segment elevation more than 1 mm in two or more contiguous leads or presumably a new onset left bundle branch blockage","* Cardiogenic shock
* History of myocardial infarction
* Chronic liver disease
* Previous or current statin use",atorvastatin,INTERVENTIONAL,COMPLETED
NCT01898442,High Ticagrelor Loading Dose in STEMI,Coronary Artery Disease,"* Patients with ST-elevation myocardial infarction undergoing primary PCI.
* Age between 18 and 80 years old.","* History of prior intracranial bleeding.
* On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in past 30 days.
* Known allergies to aspirin or ticagrelor.
* On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban).
* Treatment with IIb/IIIa glycoprotein inhibitors.
* Fibrinolytics within 24 hours
* Known blood dyscrasia or bleeding diathesis.
* Known platelet count \<80x106/mL.
* Known hemoglobin \<10 g/dL.
* Active bleeding.
* Hemodynamic instability.
* Known creatinine clearance \<30 mL/minute.
* Known severe hepatic dysfunction.
* Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker protection.
* Current treatment with drugs interfering with CYP3A4 metabolism (to avoid interaction with Ticagrelor): Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.
* Pregnant females\*.

  * Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.","Ticagrelor 180mg, Ticagrelor 270mg, Ticagrelor 360mg",INTERVENTIONAL,COMPLETED
NCT00127452,Alpha Omega Trial: Study of Omega-3 Fatty Acids and Coronary Mortality,Cardiovascular Diseases,"Inclusion criteria:

* Men and women
* Aged 60 through 80 y
* Verified clinically diagnosed myocardial infarction up to 10 y before randomization
* Written informed consent",":

* Living in a nursing home or other institution
* Participation in another scientific study
* Habitual margarine intake \< 10 g per day
* Habitual fish intake \> 150 g per day
* Habitual alcohol intake \> 6 drinks per day
* Use of fish oil capsules or other supplements containing omega-3 fatty acids
* Presence of cancer with \< 1 y of life expectancy
* Cognitive impairment, as indicated by the Mini Mental State Examination (score \<= 21)
* Unintended weight loss \> 5 kg in the past year
* Lack of facilities for cooled margarine storage at home
* Inability or unwillingness to comply with study procedures",margarine spread,INTERVENTIONAL,COMPLETED
NCT05200052,Effect of Colchicine On Left Ventricle Function After Anterior Myocardial Infarction Assessed By Speckle Tracking,"Anterior MI, Colchicine",▪︎Anterior S-T segment elevation myocardial infarction with time of presentation less than 12 hours.,"* Severe renal impairment.
* Cardiac arrest.
* Cardiogenic shock.",Colchicine 0.5 mg Oral Tablet,INTERVENTIONAL,COMPLETED
NCT02054000,Intracoronary Tirofiban on No-Reflow Phenomena,No-Reflow Phenomenon,- Patients with ST-elevated myocardial infarction who developed no-reflow phenomena,"* Treatment with thrombolytic drugs in the previous 24 hours
* Known malignancy
* Pain to balloon time \>6 hours
* Uncontrolled hypertension (\>180/110 mmHg)
* Bleeding diathesis
* Thrombocytopenia
* End-stage liver disease
* Cardiogenic shock
* Renal failure
* Life expectancy of less than 1 year
* Contraindication for the use of tirofiban.","Tirofiban, Placebo",INTERVENTIONAL,COMPLETED
NCT01311700,Effect of METOprolol in CARDioproteCtioN During an Acute Myocardial InfarCtion. The METOCARD-CNIC Trial.,Myocardial Infarction,"1. Confirmed\* acute anterior wall myocardial infarction (ST segment elevation ≥ 2mm in ≥ 2 contiguous leads \[one of which should be V2, V3, or V4\]).
2. Killip class I or II on diagnosis.

   * Cases of non-confirmed infarction by enzymatic release (above 2 standard deviations from upper limit of CK and Troponin) are excluded from efficacy analysis but kept in the safety analysis.","1. COPD or asthma on active bronchodilator therapy
2. Active treatment with beta blockers
3. Left bundle branch block or pacemaker.
4. Systolic blood pressure \<120 mmHg, Heart rate \<60 bpm, or AV block (PR˃240 mS or superior) on diagnosis.",Injectable (i.v.) metoprolol tartrate (up to 15 mg).,INTERVENTIONAL,COMPLETED
NCT02756000,Timing of Complete Revascularization for Multivessel Coronary Artery Disease in STEMI,Myocardial Infarction,"* Clinical and electrocardiographic signs of first ever ST elevation myocardial infarction (chest pain lasting less than 12 hours with persistent ST elevation of ≥ 1mm in two contiguous leads on ECG recording)
* Multivessel coronary artery disease (MVD) on initial coronary angiogram, defined as visually assessed stenosis of more than 70% of any of the non-culprit vessels
* Treated with primary PCI of infarct related artery (IRA) only.","* Hemodynamically unstable patients defined as presence of cardiogenic shock, intraaortic balloon pump (IABP) implantation and mechanical ventilation prior, during and after primary PCI;
* Presence of significant valvular disease;
* Decision that patient needs to be treated with coronary artery bypass graft (CABG) and/or valvular replacement or reconstruction surgery after initial culprit only PCI;
* Myocardial infarction is caused by stent thrombosis:
* Chronic total occlusion of any of the coronary arteries on initial angiogram;
* Previously treated by CABG surgery;
* Estimated life expectancy less than one year.","PCI, dobutamine stress echocardiography",INTERVENTIONAL,COMPLETED
NCT04082442,Evolocumab in Patients With Acute MI,Acute Coronary Syndrome,"1. Age 25 to 90 years.
2. ST elevation myocardial infarction, with compatible symptoms and ECG changes.
3. Non ST elevation myocardial infarction, with a troponin I \> 5ng/mL and with compatible symptoms and ECG changes.
4. Permission of attending physician.
5. Ability to understand the risk, benefits, and alternatives of participation.","1. Scheduled for cardiac surgery.
2. Current treatment with a PCSK9 antibody.
3. Current participation in an intervention clinical trial.
4. Latex allergy
5. Previous adverse reaction to monoclonal antibodies
6. Non-English speaking
7. Female of childbearing potential. This is a female subject who has not used acceptable method(s) of birth control (see below) for at least one month prior to screening, unless the subject is sterilized or postmenopausal. Menopause is defined as: 12 months of spontaneous and continuous amenorrhea in a female \> 55 year of age.

   * Acceptable method(s) of birth control definition: One highly effective method (methods that can achieve a failure rate of less than 1% per year when used consistently and correctly)

     * Combined hormonal (estrogen and progestogen) contraception associated with inhibition of ovulation (oral, intravaginal, transdermal)
     * Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
     * Intrauterine device (IUD)
     * Intrauterine hormone-releasing system (IUS)
     * Bilateral tubal occlusion
     * Vasectomized partner
     * Sexual abstinence
8. Subject likely not to be available to complete all protocol-related study visits or procedures.","Evolocumab, Placebos",INTERVENTIONAL,COMPLETED
NCT01390142,Remote Ischemic Preconditioning Combined to Local Ischemic Postconditioning in Acute Myocardial Infarction,Myocardial Infarction,"* Age \> 18
* ST-Segment elevation myocardial infarction \<6h
* Written informed consent","* Previous Q-wave myocardial infarction or previous coronary artery bypass graft
* Cardiogenic shock
* Cardiac arrest resuscitated before angioplasty
* Infarct related artery : circumflex coronary artery, right coronary artery after segment 3, left main, diagonal and marginal branches, and all coronary artery with jeopardized myocardium estimated too small.
* TIMI 2 or 3 before angioplasty
* Collateral branches Rentrop \>1
* TIMI 0 or 1 flow grade after PCI
* Any contraindications to magnetic resonance imaging
* Allergy to gadolinium
* Patient refusal / patient not having provided written informed consent","Control, RIPer, RIPer + IPost",INTERVENTIONAL,COMPLETED
NCT01633502,Danish Cardiogenic Shock Trial,"Cardiogenic Shock Acute, Acute Myocardial Infarction","1. ST segment elevation myocardial infarction of less than 36 hours' duration, confirmed by new onset ST-segment elevation, or emergency angiography demonstrating acute occlusion of coronary artery, and
2. Cardiogenic shock of less than 24 hours' duration, confirmed by:

   * peripheral signs of tissue hypoperfusion (arterial blood lactate ≥2.5mmol/l and/or SvO2 \<55% with a normal PaO2) and
   * systolic blood pressure less than 100mmHg and/or need for vasopressor therapy (dopamine/ norepinephrine or epinephrine), and
3. Left ventricular ejection fraction of less than 45% visually estimated or by wall motion score index \>1,6.","1. Other causes of shock (hypovolemia, hemorrhage, sepsis, pulmonary embolism or anaphylaxis).
2. Shock due to mechanical complication to myocardial infarction (papillary muscle rupture, rupture of the ventricular septum or rupture of free wall).
3. Severe aorta valve regurgitation/stenosis.
4. Predominant right ventricular failure.
5. Out of hospital cardiac arrest with persistent Glasgow coma scale \<8 after return of spontaneous circulation.
6. Shock duration\>24 hours.
7. Known heparin intolerance.
8. Already established mechanical circulatory support
9. Do not resuscitate wish.","Conventional circulatory support, Impella CP",INTERVENTIONAL,COMPLETED
NCT00285064,Assessment of Myocardial Viability Using Multidetector Computed Tomography,Myocardial Infarction,"* acute ST elevation myocardial infarction
* after primary angioplasty","* iodine allergy
* renal failure
* old MI
* arrhythmia
* inability to perform 20 second breath-hold",CT,INTERVENTIONAL,COMPLETED
NCT02071602,CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function,ST Elevation (STEMI) Myocardial Infarction of Anterior Wall,"* Significant chest discomfort and /or shortness of breath
* ST segment elevation (1.5 mV total) in two or more adjacent anterior precordial leads
* Successful reperfusion therapy (\>TIMI grade 2 flow) either with thrombolytics or any mechanical forms of revascularization, including stent, PTCA, thrombectomy, etc. within 24 hours of onset of symptoms as documented by coronary angiography
* No previously known history of AMI (prior to current cardiac event) or no previous ECG (prior to current cardiac event) suggesting an old AMI (Q wave on presenting ECG is not an exclusion)..","(Assessed at the time of enrollment unless otherwise stated)

* Cardiogenic shock, acute heart failure or hypotension (Systolic BP \< 90 mmHg)
* Previous known decreased EF \< 40%
* Atrial Fibrillation
* Persistent signs and symptoms of Post MI ischemia
* Requirement of pressors for maintenance of blood pressure.
* Intra-aortic blood pump use
* Significant (moderate-severe) valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension.
* Severe congenital heart diseases
* Sustained ventricular tachycardia or ventricular fibrillation
* Second or third degree heart block without a permanent cardiac pacemaker
* Stroke within 3 months or other evidence of significantly compromised CNS perfusion
* Total bilirubin of \> 2.5 mg/dL or other liver enzymes \>2.5 times the upper limit of normal if available clinically and measured within the last 7 days
* Patients with calculated GFR \<30 ml by MDRD equation or those with acute kidney injury as defined by an increase of plasma creatinine of 0.5 mg/dL from a plasma creatinine measured within the last 7 days
* Serum sodium of \< 125 mEq/dL or \> 160 mEq/dL if available clinically and measured within the last 7 days
* Serum potassium of \< 3.0 mEq/dL or \> 5.8 mEq/dL if available clinically and measured within the last 7 days
* Hemoglobin \< 8.5 gm/dl if available clinically and measured within the last 7 days
* Other acute or chronic medical conditions or laboratory abnormality which may increase the risks associated with study participation or may interfere with interpretation of the data
* Received an investigational drug within 1 month prior to dosing
* Female subject who is pregnant or breastfeeding
* In the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for any reasons",CD-NP,INTERVENTIONAL,COMPLETED
NCT02305602,A Study of VentriGel in Post-MI Patients,"Myocardial Infarction, Heart Failure, Left Ventricular Remodeling","1. The subject is 30-75 years of age
2. The subject must be able to provide informed consent
3. At least 60 days and no more than 3 years will have passed since the first ST elevation myocardial infarction (Index STEMI) at time of VentriGel administration
4. The Index STEMI must meet the following criteria:

   1. First time diagnosis of STEMI AND;
   2. Meet the STEMI criteria of the American College of Cardiology (ACC)/American Heart Association (AHA) (e.g. ST elevation in at least 2 contiguous leads \>0.2 mV in V1, V2 or V3 and/or \>0.1mV in at least two other leads), or new left bundle branch block (LBBB)
5. Evidence of left ventricular remodeling secondary to the myocardial infarction using 2-D echocardiography or cMR;

   1. the LVEF must be ≥ 25% and ≤ 45% AND;
   2. The left ventricular wall thickness is ≥ 8 mm in target area.
6. Successful percutaneous coronary intervention (PCI) restoring TIMI II of higher flow to infarcted area
7. Negative pregnancy test \[serum human chorionic gonadotropin (βhCG)\] in women of childbearing potential within 24 hours prior to dosing) or if less than 2 years postmenopausal agree to use of adequate contraception during the study.
8. Must be ambulatory, willing and able to comply with protocol, including follow-up visits
9. Subject must be receiving best medical treatment for their post-MI clinical presentation according to the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines
10. For those subjects indicated for heart failure medical therapy, subjects must be on stable therapy including beta-blockers and angiotensin converting enzyme inhibitors, if tolerated, for at least 45 days prior to therapy delivery","1. Contraindications to cardiac MR
2. NYHA Functional Classification 4 heart failure within the prior 6 months.
3. Significant coronary artery stenosis that may require percutaneous or surgical revascularization within six months of enrollment, as determined by the principal investigator
4. Left ventricular thrombus, left ventricular aneurysm, subjects with post-infarction pericarditis, or subjects with wall motion abnormalities outside the region of the infarct related artery
5. Frequent, recurrent, sustained (\>30 seconds) ventricular tachycardia in 30 days prior to VentriGel administration
6. ECG or 24 hour Holter Monitor with any of the following findings:

   * Bifascicular block (left bundle branch block or right bundle branch block plus left hemi-block)
   * Higher grade AV block (i.e. 3rd degree)
   * Ventricular tachycardia (\>= 5 seconds of VT OR any symptomatic VT)
7. Atrial fibrillation with heart rate greater than 110 bpm.
8. Severe valvular disease (e.g. aortic stenosis of moderate or worse severity, valvular insufficiency requiring surgical repair) or history of heart valve replacement.
9. Known allergy to porcine proteins or prior implantation of a porcine derived medical product including cardiac valves or other ECM products.
10. Etiology of heart failure due to any cause (e.g. hypertrophic cardiomyopathies, restrictive cardiomyopathies, constrictive pericardial disease, amyloidosis, active myocarditis) other than the index MI.
11. Severe peripheral vascular disease that impairs femoral arterial access.
12. Less than 3 years, cancer free, since end of treatment for cancer (with exception of basal cell carcinoma)
13. Alcohol or drug dependency within six months prior to enrollment
14. Cerebrovascular event within the 90 days prior or major surgical procedure or major trauma within the 14 days prior to enrollment
15. Participation, defined as receiving test article, in an experimental clinical study within 30 days prior to administration of VentriGel (i.e. screen failure from other study does not exclude subject)
16. Uncontrolled hypertension defined as systolic blood pressure (SBP) \> 180 mmHg and/or or diastolic blood pressure (DBP) \>110 mmHg
17. Abnormal laboratory values as defined below performed at screening:

    * Aspartate aminotransferase \[AST\]/ alanine aminotransferase \[ALT\] ≥ 3 times upper limit of normal (ULN)
    * Serum creatinine ≥ 2.0 mg/dL
    * Platelet count \< 50,000/mm3
    * Hemoglobin \< 9.0 g/dL
    * HbA1c \> 9.0%
    * PT or aPTT with clinically significant elevations relative to local laboratory norms
18. Any other cardiac or non-cardiac conditions or illness which, in the opinion of the principal investigator, may place subjects at undue risk or compromise the objectives of the study.
19. Institutional interpretation of cMR EF data outside the ≥ 25% and ≤ 45% limits",VentriGel,INTERVENTIONAL,COMPLETED
NCT00587002,Differences in Epicardial Plaque and Microvascular Function in Women With an Acute Myocardial Infarction,Myocardial Infarction,"* Age of 18 years or older
* Acute coronary syndrome defined as at least two of the following:

A) an elevated cardiac biomarker (troponin or CK-MB), B) new or dynamic ECG changes in at least 2 contiguous standard electrocardiographic leads of ST depression \> 1 mm or ST elevation of \>1 mm or T-wave inversions, C) chest pain or discomfort of at least 15 minutes duration, D) a new wall motion abnormality by echocardiography

* Patient who is undergoing coronary angiography
* Physician planning to perform IVUS for treatment of the infarct-related vessel","* Creatinine \> 2.0 mg/dL (most recent)
* Hemodynamically unstable patients (systolic blood pressure \< 90 mmHg or heart rate \> 110 beats/ minute or presence of an intra-aortic balloon pump)
* Coronary revascularization (percutaneously or surgically) within 6 months
* The use of chronic immunosuppressive agents
* No target lesion was found at the time of cardiac catheterization that will be percutaneously intervened upon (the patient must undergo percutaneous coronary intervention)
* Inability to give informed consent
* Pregnant or lactating women
* Prisoners",IVUS,INTERVENTIONAL,COMPLETED
NCT00684021,Use of Adult Autologous Stem Cells in Treating People Who Have Had a Heart Attack (The TIME Study),Left Ventricular Dysfunction,"Inclusion criteria

1. Patients at least 21 years of age
2. Patients with first acute MI with successful primary percutaneous coronary intervention (PCI) in an artery at least 2.5 mm in diameter within 24 hours of onset of symptoms.
3. No contraindications to undergoing cell therapy procedure within three to seven days following AMI and PCI.
4. Hemodynamic stability as defined as no requirement for IABP, inotropic or blood pressure supporting medications.
5. Ejection fraction following reperfusion with PCI \<=45% as assessed by echocardiography.
6. Consent to protocol and agree to comply with all follow-up visits and studies.
7. Women of child bearing potential willing to use an active form of birth control.","Patients will be excluded from the study if they meet any of the following conditions:

1. History of sustained ventricular arrhythmias not related to their AMI (evidenced by previous holter monitoring and/or medication history for sustained ventricular arrhythmias in patient's medical chart).
2. Require CABG or PCI due to the presence of residual coronary stenosis \>70% luminal obstruction in the non-infarct related vessel (Additional PCI of non-culprit vessels may be performed prior to enrollment).
3. History of any malignancy within the past five years excluding non-melanoma skin cancer or cervical cancer in-situ.
4. History of chronic anemia (hemoglobin (Hb) \<9.0 mg/dl).
5. History of thrombocytosis (platelets \>500k).
6. History of thrombocytopenia in the absence of recent evidence that platelet counts are normal
7. Known history of elevated INR (PT) or PTT.
8. Life expectancy less than one year.
9. History of untreated alcohol or drug abuse.
10. Currently enrolled in another investigational drug or device trial
11. Previous CABG.
12. Previous MI resulting in LV dysfunction (LVEF \<55%)
13. History of stroke or transient ischemic attack (TIA) within the past six months.
14. History of severe valvular heart disease (aortic valve area \<1.0 cm2 or \>3+ mitral regurgitation).
15. Pregnancy or breast feeding
16. Subjects with a known history of HIV, or has active hepatitis B,active hepatitis C, or active TB
17. Patients with active inflammatory or autoimmune disease on chronic immuno-suppressive therapy.
18. Contraindications to cMRI.
19. Previous radiation to the pelvis with white blood cell count (WBC) and platelet counts below hospital specific normal values.
20. Women child bearing potential not willing to practice an active form of birth control.
21. Chronic liver disease that might interfere with survival or treatment with cell therapy.
22. Chronic renal insufficiency as defined by a creatinine ≥ 2.0 mg/dL or requires chronic dialysis.","Adult stem cells, Placebo",INTERVENTIONAL,COMPLETED
NCT01374321,Safety and Efficacy Study of TRO40303 for Reduction of Reperfusion Injury in Patients Undergoing Percutaneous Coronary Intervention for Acute Myocardial Infarction,Acute Myocardial Infarctus,"1. Male and Female with non childbearing potential patients
2. Age \> 18 years old
3. First acute myocardial infarction
4. Occlusion should affect the following coronary arteries: LAD,or the dominant or balanced RCA, or the dominant or balanced LCx
5. Acute myocardial infarction defined as

   * nitrate resistant chest pain ≥ 30 min
   * ST elevation: New ST elevation at the J-point in two contiguous leads with the cut-off points: ≥ 2 mV in men or ≥ 0.15 mV in women in leads V2-V3 and/or ≥ O.1 mV in other leads
6. Presenting within 6h of onset of chest pain
7. Clinical decision to treat with percutaneous coronary intervention
8. Occlusion of culprit artery with a Thrombolysis In Myocardial Infarction (TIMI) flow grade 0-1 at time of admission and before percutaneous coronary intervention
9. Have signed an Informed Consent to participate to the trial before any study related procedure has been taken","1. Cardiac arrest, ventricular fibrillation, cardiogenic shock, stent thrombosis, previous AMI, angina within 48h before admission, previous CABG, treatment with intravenous fibrinolytic therapy within the 72 hours to PCI
2. Atrial fibrillation (could confound CMR analysis)
3. Pace-maker
4. Concurrent inflammatory, infectious or malignant disease
5. Biliary obstruction or hepatic insufficiency at the time of inclusion in the study
6. Be possibly dependent on the Investigator or the Sponsor (eg including but not limited to affiliated employee)
7. Participated in any other investigational drug or therapy study with a non-approved medication, within the previous 3 months
8. Patient under guardianship
9. History of egg allergy","TRO40303, Placebo",INTERVENTIONAL,COMPLETED
NCT03551964,Dual Antiplatelet Therapy For Shock Patients With Acute Myocardial Infarction,"Acute Myocardial Infarction, Cardiogenic Shock","1. Age over 18 years
2. Acute myocardial infarction according to the definition of ESC/ACC/AHA, indicated for emergency percutaneous coronary intervention (primary PCI strategy)
3. Cardiogenic shock present upon admission due to the AMI (≥ 2 of the criteria below are satisfied)

   1. sBP \< 90 mmHg with the absence of hypovolemia
   2. Need of vasopressor and/or inotropic therapy
   3. Presence of the signs of the organ hypoperfusion - cyanosis, cold acra, disorder of consciousness, congestive heart failure
4. Informed consent form signed
5. Women of childbearing potential should be protected from pregnancy throughout the study (relevant for long-term use of ticagrelor). Suitable methods of contraception in this case include hormonal contraceptives, barrier methods, or complete withdrawal - as long as it is consistent with the patient's lifestyle.","1. Contraindications of antiplatelet therapy with ticagrelor/cangrelor

   * Recent (\< 6 months) major bleeding
   * Recent (\< 1 month) major surgery/injury
   * History of intracranial bleeding
   * History of stroke/TIA
   * Known intolerance to ticagrelor/cangrelor
   * Severe impairment of hepatic function
   * Concomitant administration of strong CYP3A4 inhibitors (for example, ketoconazole, clarithromycin, nefazodone, ritonavir, and atazanavir)
2. Administration of a loading dose of an oral P2Y12 inhibitor prior to admission (clopidogrel ≥ 300 mg, ticagrelor 180 mg, prasugrel 60 mg)
3. Need of concomitant chronic anticoagulation therapy due to indications such as atrial fibrillation, artificial valve, thromboembolic disease, etc.","Cangrelor, Ticagrelor",INTERVENTIONAL,COMPLETED
NCT01912690,The Influence of Different Training Regimens on Electrical Stability Following Myocardial Infarction,"Ischemic Heart Disease, Congestive Heart Failure","* s/p acute myocardial infarction 14-30 days
* ability to perform exercise","* unstable angina
* chronic atrial fibrillation
* severely reduced LV function
* NYHA 4
* severe valvular disease","aerobic training, aerobic and strength training",INTERVENTIONAL,COMPLETED
NCT00495664,Titanium Nitride Oxide Coated Stents and Paclitaxel Eluting Stents for Acute Myocardial Infarction,Acute Myocardial Infarction,"* Patients \> 18 years of age presenting with acute MI (NSTEMI or STEMI) were eligible for this trial.
* Wtitten informed consent","* Restenosis
* Unprotected left main disease
* Ostial lesion
* Contraindication to asa, heparins, thienopyridines
* life expectancy \< 12 months
* stent length needed \> 28 mm",Titan stent and Taxus-Liberte stent,INTERVENTIONAL,COMPLETED
NCT02548364,Effect of Vitamin D on Ventricular Remodeling in Patients With Acute Myocardial Infarction (VITDAMI),Myocardial Infarction,"* Age ≥ 40 years and maximum 85 years.
* Anterior myocardial infarction
* Sign informed consent","* Death during the index event
* Age younger than 40 or older than 85 years
* Previous Infarction
* More than 7 days in hospitalization
* Systemic inflammatory or autoimmune disease
* Concomitant disorders limiting survival
* Concomitant cardiomyopathy
* Left ventricular hypertrophy \> 16mm in females and \> 17mm in males
* eGFR\<45
* LVEF\<30
* Incomplete revascularization
* Valvular prosthesis
* Aortic stenosis with mean gradient\> 25 mmHg
* Moderate or severe valvular regurgitation
* Hypersensitivity or intolerance vitamin D supplement o excipient
* Blood Calcium \>10.5 mg/dl
* Inability to follow.
* Difficulty in treatment compliance
* Contraindication for MRI, including indication to place a cardiac device
* Indication of therapy with vitamin D. Patient desires to take vitamin D.
* Drugs or conditions that interfere with the pharmacokinetics of calcifediol","Calcifediol, Placebo",INTERVENTIONAL,COMPLETED
NCT01495364,NBS10 (Also Known as AMR-001) Versus Placebo Post ST Segment Elevation Myocardial Infarction,ST Segment Elevation Myocardial Infarction,"Inclusion Criteria:

1. Age 18 years or older.
2. Acute ST elevation myocardial infarction meeting ACC/AHA criteria, with symptoms of chest pain within 3 days of admission. Criteria include (ST elevation \> 1mm in limb leads or 2 mm in two or more precordial leads, and increased levels of troponin, CPK MB or both).

   Chest pain syndrome can extend to more than 3 days prior to admission if its course is consistent with transient/intermittent ischemia rather than symptoms that are continuous suggesting ongoing infarction extending beyond 3 days.
3. Successful stent placement and reperfusion within 3 days of chest pain onset and with TIMI Flow score of 2 or 3 and infarct related artery (IRA) with \<20% stenosis after revascularization.
4. Wall motion abnormality associated with the target lesion
5. NYHA heart failure class I, II or III.
6. Study entry LVEF \<48% determined by CMR no sooner than 96 hours from stent placement.
7. Able to provide informed written consent and willing to participate in all required study follow-up assessments.
8. Subjects must have an INR ≤ 2.0 within 2 days of the bone marrow collection.
9. Subjects must have a Hgb ≥ 10 grams/dL, WBC ≥ 3500 cells/mm3, a platelet count ≥ 100,000 cells/mm3, serum creatinine ≤ 2.5, and total bilirubin ≤ 2.0 within 7 days of the bone marrow collection or by end of screening phase.
10. Expected survival of at least one year.
11. Females of child bearing potential agree to use birth control (barrier method accepted) for one month post bone marrow harvest.","1. Continuous/ongoing chest pain - unremitting and unresponsive to nitroglycerin or rest - persisting 4 or more days before stent placement. If the chest pain syndrome is transient and/or intermittent - even if it began more than 3 days prior to admission - the patient is not excluded.
2. Subjects in cardiogenic shock (systolic pressure \< 80mm/Hg, on vasopressors, or intra-aortic counterpulsation) at the time of consenting. Subjects who recover from cardiogenic shock by the time of consenting are eligible.
3. Subjects unable to receive antiplatelet agents (e.g. aspirin, clopidogrel, ticlopidine, prasugrel, etc).
4. Subjects receiving warfarin who have an INR \>2 or with major bleeding requiring active transfusion support.
5. Subjects who require continuous anticoagulation during the time when the bone marrow harvest is scheduled, as heparin must be discontinued for 4 hours prior to and 24 hours after bone marrow harvest procedure. (See Appendix VII.)
6. Subjects with severe cardiac valvular disease expected to undergo surgery within 1 year.
7. Subjects with known severe immunodeficiency states (AIDS).
8. Cirrhosis requiring active medical management.
9. Malignancy requiring active treatment (except basal cell skin cancer).
10. Subjects with documented active alcohol and /or other substance abuse.
11. Females of child bearing potential unless a pregnancy test is negative within 7 days of the mini-bone marrow harvest.
12. Re-occlusion of the IRA prior to the infusion procedure.
13. Planned revascularization intervention during the next 6 months (A second PCI can be performed if done prior to qualifying CMR at least 96 hours post primary PCI).
14. Participation in an ongoing investigational trial.
15. Active or suspected bacterial infection requiring systemic intravenous antibiotics.","NBS10, placebo",INTERVENTIONAL,COMPLETED
NCT01781390,Safety Study of Allogeneic Mesenchymal Precursor Cell Infusion in Myocardial Infarction,Acute Myocardial Infarction,"Key 

* Clinical symptoms consistent with acute myocardial infarct (AMI) (pain, etc.) for a maximum of 12 hours from onset of symptoms to percutaneous coronary intervention (PCI).
* De Novo anterior AMI.
* Successful revascularization of the culprit lesion.

Key","* Prior AMI, known cardiomyopathy, or hospital admission for heart failure (HF).
* Significant valvular disease.
* Need for other interventional or surgical procedure to treat heart disease (planned or scheduled).
* Cardiogenic shock or hemodynamic instability within 24 hours of randomization.
* Prior PCI to LAD.
* Pacemaker, ICD (Implantable Cardioverter Defibrillator), or any other contra-indication for cardiac MRI.
* Prior or current participation in any stem cell study or any other investigational trial in the past 30 days.","Placebo, Mesenchymal Precursor Cells (MPC) 12.5 M, Mesenchymal Precursor Cells (MPC) 25 M",INTERVENTIONAL,COMPLETED
NCT00164190,Routine Angioplasty and Stenting After Fibrinolysis for Acute Myocardial Infarction,Myocardial Infarction,"1. Patients \>= 18 years old who present within 12 hours of symptom onset with more than 30 minutes of continuous symptoms of an acute myocardial infarction to a centre that does not perform primary PCI, with either:

* \>= 2 mm ST-segment elevation in 2 or more contiguous anterior leads
* \>= 1 mm ST-segment elevation in 2 or more contiguous inferior leads with at least one of the following high-risk features:

  * Systolic blood pressure \< 100 mm Hg
  * Heart rate \> 100/minute
  * Killip Class II-III
  * \>= 2 mm ST-segment depression in anterior leads
  * \>= 1 mm ST-segment elevation in right-sided lead V4 (V4R), indicative of right ventricular involvement","1. Left bundle branch block
2. Cardiogenic shock (Killip Class IV requiring vasopressors or inotropic support to maintain a systolic blood pressure \> 90) prior to randomization
3. Active bleeding or known hemorrhagic diathesis
4. Availability of primary PCI with door-to-balloon time ≤ 60 minutes
5. Time from thrombolysis to initiation of consent process \> 30 minutes
6. Use of thrombolytic agent other than tenecteplase (TNK) for index event
7. Major surgery, biopsy of parenchymal organ, or significant trauma in the past 6 weeks
8. Systolic blood pressure \> 200 mm Hg or diastolic \> 110 mm Hg after arrival to the hospital and before enrollment
9. Concomitant use of oral anticoagulants (e.g. warfarin) with International Normalized Ratio (INR) of \> 2
10. Recent non-compressible vascular puncture
11. History of central nervous system structural damage (e.g. aneurysm, neoplasm, arteriovenous malformation, stroke) at any time, or transient ischemic attack within the last year
12. History of heparin-induced thrombocytopenia
13. Documented allergy to aspirin
14. Participation in other clinical research studies involving experimental therapies including drugs or devices within 7 days of enrollment or prior participation in this study
15. Inability to cooperate with the protocol or undergo cardiac catheterization
16. Other serious illness (e.g. active cancer, significant hepatic disease)
17. Serum creatinine \> 140 umol/L
18. Percutaneous coronary intervention within one month
19. Previous bypass surgery
20. Pregnancy
21. Use of enoxaparin (or other low molecular weight heparin) in last 12 hours in patient \> 75 years of age
22. Inferior ST-elevation myocardial infarction with none of the 5 high-risk features listed in the inclusion criteria",Routine Early Percutaneous Coronary Intervention after Thrombolysis,INTERVENTIONAL,COMPLETED
NCT00650143,Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction,Acute Myocardial Infarction,"Inclusion criteria

1. Be at least 18 years old, male or female
2. Have acute ST segment elevation myocardial infarction (typical chest pain of more than 30 minutes duration, presence of ST-segment elevation in at least two contiguous leads or left bundle-branch block) and/or occluded coronary artery
3. Intervention of infarct related artery by PCI/Stenting within 2-24 hours after onset of acute myocardial infarction.
4. have creatinin kinase elevation of more than three times of upper normal level (i.e. 540 U/l) accompanied by a significant elevation of CK-MB isoenzyme and/or Troponin I/T
5. Have regional wall motion abnormality (comprising hypo-, a- or dyskinesia) of at least one myocardial segment demonstrated with MRI.
6. Patients who are further suitable for coronary angiography and angioplasty with stenting of the infarct related artery.
7. Have the ability to understand the requirements of the study, and agree and be able to return for the required assessments.
8. Give a written informed consent.","General:

1. Women of childbearing potential, pregnancy or being lactating.
2. Be unable to undergo percutaneous cardiac catheterisation
3. Have contraindications against magnetic resonance imaging (e.g. non-MR compatible implants or medical devices)
4. Have conditions that may severely degrade image quality (e.g. severe arrhythmia) or prevents from MR scanning (e.g. claustrophobia)
5. Previous enrolment in the present trial or administration of any study medication within the previous 30 days. Study drug is defined as any material (placebo or drug) dispensed under the provisions of a protocol.
6. Have other severe concurrent illness (e.g., active infection, malignancy).
7. Life expectancy of less than one year.
8. Have a history of alcohol or drug abuse within 3 months prior to admission or factors jeopardising follow-up.

Renal, hepatic, metabolic:

1. Moderate to severe renal impairment (Crea level \>1.7 mg/dL or glomerular filtration rate \<35 ml/min).
2. Diabetes type 1 patients.
3. Diabetic ketoacidosis.
4. Concomitant medications known to cause hypoglycemia, such as sulfonylureas.
5. Severe liver dysfunction.

Haematologic:

1. Malignant haematological diseases, i.e. chronic myeloic leukemia (CML) or myelodysplastic syndromes (MDS)
2. Severe congenital neutropenia with cytogenetic abnormalities
3. Known allergic reaction vs. Lenograstim

Cardiovascular:

1. Acute cardiogenic shock
2. Cardiomyopathy with an ejection fraction below 0.25 (i.e. ischemic or dilated cardiomyopathy resulting in congestive heart failure)
3. Infective endocarditis
4. Factors contraindicating cardiac catheterisation (e.g. severe allergy against iodine, severe thyroid disease)
5. Planned operative revascularisation
6. Left ventricular thrombus
7. Severe cardiac arrhythmias (i.e. malignant sustained or non-sustained ventricular tachycardia or ventricular fibrillation) within 24 hours after admission.

Pulmonary:

1. Acute massive pulmonary infiltrations
2. History of pneumonia in the last 4 weeks

Other:

1. Therapy with immunosuppressants, cytostatics, corticoids.","Lenograstim (GRANOCYTE)=GCSF, Sitagliptin (Januvia), Sodium Chloride (NaCl) 0.9 %, Gelatin",INTERVENTIONAL,COMPLETED
NCT00417638,Rapid Intravascular Cooling in Myocardial Infarction as Adjunctive to Percutaneous Coronary Intervention,Acute Anterior Myocardial Infarction,"Each eligible patient must meet the following inclusion criteria :

1. Have ECG evidence of ongoing acute anterior myocardial infarction, involving a large area of myocardium, as defined by the following ECG criteria: a. Anterior infarct: ST-segment elevation \>0.2mV measured 0.08 sec after the J point in 2 or more anatomically contiguous precordial leads, V1 through V4; and/or \>0.2mV in lead V5 V6
2. Present to the RAPID MI-ICE site within six (6) hours of the onset of acute cardiac ischemic signs or symptoms (such as chest pain or pressure, arm or jaw pain, dyspnea, nausea/vomiting, or syncope)
3. Be a candidate for PCI and have PCI planned as the immediate intervention.
4. Be willing and able to comply with study procedures, including returning for the MRI scan at 4 ±2 days and return for the clinical examination on Day 30
5. Provide written informed consent prior to the initiation of study-specific procedures
6. Be in Killips Class I","Patients are not eligible for the study if they meet one or more of the following criteria:

1. Age less than eighteen (\<18) years of age
2. Age greater than seventy-five (\>75) years of age
3. Are pregnant
4. Have a suspected aortic dissection
5. History of a prior anterior myocardial infarct or prior large myocardial infarct.
6. The suspected etiology of myocardial infarction is primarily related to substance abuse (e.g., cocaine, methamphetamine, etc.)
7. Acute administration of a thrombolytic agent for the qualifying MI
8. If (during the screening process) the determination is made by site-study personnel that initiation of cooling prior to diagnostic coronary angiography is technically not feasible for any reason (should the patient be randomized to the Hypothermia Arm), the prospective subject should not be enrolled
9. Require an immediate surgical or procedural intervention other than PCI (e.g. CABG)
10. Present in cardiogenic shock or with end-stage cardiomyopathy
11. Have undergone at least ten (10) minutes of cardiopulmonary resuscitation (CPR) prior to presentation to the PCI facility
12. History of previous MI with known, pre-existing, anterior pathologic Q-waves
13. History of surgical coronary artery revascularization (e.g., CABG, MIDCAB, or OPCAB)
14. Recent stroke (within 3 months)
15. Active bleeding, coagulopathy, or other contraindication to the placement of a heparin-coated 14F central venous catheter via a 14F femoral venous introducer sheath (e.g., known history of heparin induced thrombocytopenia, or IVC filter)
16. Contraindications to hypothermia, such as patients with known hematologic dyscrasias which affect thrombosis (e.g., cryoglobulinemia, sickle cell disease, serum cold agglutinins) or vasospastic disorders (such as Raynaud's or thromboangitis obliterans)
17. Personal or familial history of malignant hyperthermia
18. Known end-stage renal disease (ESRD; e.g., on dialysis, or status-post renal transplant), known hepatic failure (e.g., cirrhosis, or acute hepatitis), or any other contraindication to receiving meperidine (such as use of MAO inhibitors within previous 14 days, history of seizures, history of hypersensitivity to meperidine, etc.) \[Note: Patients with a contraindication to buspirone administration may be enrolled but should not be given buspirone as part of the anti-shivering regimen.\]
19. Any other acute or chronic condition which the Investigator believes will unacceptably increase the risk of study participation or interfere with study procedures and assessments
20. Deemed unsuitable by the investigators to participate in the study.
21. Signs of cardiogenic shock or other signs of significant heart failure such as rales over the lungs
22. Active or recent (within 1 month prior to study enrollment) participation in another investigational clinical research study","Endovascular cooling by the Celsius Control System, Standard of care",INTERVENTIONAL,COMPLETED
NCT00841438,Efficacy of Early Administration of Clotinab in Acute Myocardial Infarction,Myocardial Infarction,"1. The patient must be at least 18-80 years of age.
2. The patient had the symptoms of acute myocardial infarction within 12 hours with ST segment elevation of more than 1 mm in at least two contiguous leads of EKG or new onset LBBB.
3. The patient or guardian agrees to the study protocol and provides informed, written consent.","1. Patients to whom PCI can not be undergone within 12 hours from receiving the study drug
2. Cardiogenic shock or symptomatic hypotension or sitting SBP \< 95 mmHg
3. The history of major surgery, trauma, retinal hemorrhage, significant gastrointestinal or genitourinary bleeding within recent 6 weeks;
4. History of cerebrovascular attack within two years, or cerebrovascular attack with a significant residual neurological deficit
5. Severe or malignant hypertension (= sitting SBP \> 180 mmHg and/or sitting DBP \> 105 mmHg)
6. The patients who require oral anticoagulants during the trial; patients who have been administrated oral anticoagulants within 7 days
7. The history or diagnosis of vasculitis; renal insufficiency (the level of serum creatinine is two times higher than the upper limit of normal of each center)
8. The patients who could not take anti-platelet drugs
9. The patients who might die of other disease than cardiac disease during the trial.","Clotinab, Clotinab",INTERVENTIONAL,COMPLETED
NCT05215743,Combined Antioxidant Therapy Against Myocardial Reperfusion Injury. Phase I Study.,"Acute Myocardial Infarction, Ischemia-reperfusion Injury, Reperfusion Injury, Myocardial, Reperfusion Arrhythmias, Reperfusion Injury","* Healthy subjects from 18 to 35 years old
* Not obese (BMI 19-29.9 kg/m2)","* Impaired renal function (creatinine \> 1.5 mg/dL)
* Liver impairment (liver enzymes more than 3 times over normal values)
* Glucose 6-phosphate dehydrogenase deficiency
* Any chronic disease
* Any acute disease in the last two weeks
* To be enrolled in another clinical study","Antioxidant therapy, NaCl 0.9%",INTERVENTIONAL,COMPLETED
NCT01046838,SIDAMI - Sildenafil and Diastolic Dysfunction After Acute Myocardial Infarction (AMI),"Heart Failure, Diastolic","* Age \>50 years
* Recent AMI (within 21 days) defined according to ESC/ACC guidelines
* Doppler echocardiographic signs of elevated filling pressures defined as

  * diastolic E/e' ratio \>15, or
  * diastolic E/e' ratio 8-15 and left atrial volume index\>32 ml/m2
* Preserved LV systolic function (EF\>45%)
* Written informed consent","* Ongoing myocardial ischemia
* Ongoing treatment with nitrates.
* Poor echocardiographic window
* Inability to exercise
* Permanent atrial fibrillation or paced rhythm
* Planned coronary artery bypass grafting
* Other noncardiac condition with expected survival less than 6 months
* Unwilling to participate
* Known intolerance to sildenafil
* Non-arteritic anterior ischaemic optic neuropathy","Sildenafil, Placebo",INTERVENTIONAL,COMPLETED
NCT01152138,Closed Versus Open Cells Stent for Acute Myocardial Infarction,"Acute Myocardial Infarction, Primary Percutaneous Coronary Intervention",* patients with an age \> 18 years with acute ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PPCI) within 12 hours from symptom onset and who agree and provide written informed consent. STEMI is defined as chest pain associated with ST-elevation of 1 mm or more in two or more contiguous leads or new left bundle-branch block within 12 hours after the onset of chest pain,"* implanted stent with diameter \< 2.5 mm
* cardiogenic shock
* time from pain onset to PPCI \>12 hours
* previous thrombolytic therapy (rescue PPCI)
* inability to provide informed consent.","Open cells stent, Closed Cells Stent",INTERVENTIONAL,COMPLETED
NCT01076764,Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy,Acute Coronary Syndrome,"Inclusion criteria:

Patient with non-ST-segment elevation Acute Coronary Syndrome (NSTE-ACS) with:

1. Ischemic symptoms (chest pain or equivalent) at rest ≥ 10 minutes within 24 hours of randomization,

   AND
2. One of the two following criteria:

   * New ST-segment depression ≥ 0.1 mV (≥1 mm), or transient (\< 30 minutes) ST-segment elevation ≥ 0.1 mV (≥ 1 mm) in at least 2 contiguous leads on the electrocardiogram,
   * Elevation of cardiac biomarkers within 24 hours of randomization, defined as elevated troponin T, troponin I, or CK-MB level above upper limit of normal,

   AND
3. Planned to have a coronary angiography (followed, when indicated, by PCI) as early as possible (after at least 2 hours of treatment with study drug) and within 36 hours (at the latest on Day 3, if justified),

   AND
4. Informed consent obtained in writing.",":

* Revascularization procedure already performed for the qualifying event Acute ST-segment elevation MI.
* Patient having received curative dose of anticoagulant treatment (including UFH, LMWH, or bivalirudin) for more than 24 hours prior to randomization or who have been treated by abciximab.
* Inability to discontinue current anticoagulation in order to transition to Investigational Products according to the specified transition timing.
* Patient who can not be treated by aspirin and clopidogrel (or any other oral antiplatelet agent) according to their local labeling.
* Patient who cannot be treated with eptifibatide according to the national labeling (when available). In countries where eptifibatide is not approved the reference label to be considered is either the European labeling or the US labeling
* Patient who cannot be treated with unfractionated heparin according to the national labeling.
* Allergy to otamixaban.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.","Otamixaban, Placebo (for Otamixaban), UFH, Placebo (for UFH), Eptifibatide, Placebo (for Eptifibatide)",INTERVENTIONAL,COMPLETED
NCT01124890,Southwest German Interventional Study in Acute Myocardial Infarction III,Acute Myocardial Infarction,"* Symptoms of MI present for 12 h
* ST segment elevation of at least 1 mm in two or more limb leads,
* ST segment elevation of at least 2 mm in the precordial leads,
* or new bundlebranch block
* Patients eligible for thrombolysis
* Informed consent for participation","* Secondary or iatrogenic infarction
* Chronic renal insufficiency requiring dialysis
* Coronary anatomy unsuitable for stent placement
* Anticipated indication for surgical coronary revascularization within 6 months
* Previous MI in the area of the infarct related vessel
* Infarct related lesion not clearly defined","early percutaneous coronary intervention, late percutaneous coronary intervention",INTERVENTIONAL,COMPLETED
NCT02543502,Treatment of Periodontal Disease in Patients With Acute Myocardial Infarction,Periodontitis,"* patients admitted to our institution with a diagnosis of AMI (ST segment elevation\> 0.1mV)
* older than 30 years
* with more than 8 teeth in the mouth
* with advanced periodontal disease","* acute or chronical infection
* impossibility of attending the following interviews and/or the periodontal treatment
* refusing to signing the consent form
* individuals with substance abuse
* anticonvulsants and immunosuppressant drugs users
* pregnant and \\ or lactating women.",periodontal treatment,INTERVENTIONAL,COMPLETED
NCT01616121,Preemptive Lung Impedance-Guided Therapy in Evolving Acute Heart Failure in Acute Myocardial Infarction Patients,Heart Failure,* Patients hospitalized in the ICCU for acute myocardial infarction and developing acute heart failure,* Patients with acute myocardial infarction with clinical and radiological signs of acute heart failure at admission,"Usual treatment of patients with developing acute heart failure, Lung Impedance-Guided Therapy",INTERVENTIONAL,COMPLETED
NCT00976521,The INFUSE - Anterior Myocardial Infarction (AMI) Study,Acute Anterior Myocardial Infarction,"Key 

* The subject must be \>18 years of age;
* Subject is experiencing clinical symptoms consistent with AMI (e.g., chest pain, arm pain, etc.,) \>30 minutes duration and unresponsive to nitroglycerin;
* Anterior MI with ECG showing at least 1 mm of ST-segment elevation in 2 or more contiguous leads in V1-V4, or new (or presumably new) left bundle branch block;
* Anticipated symptom onset to balloon or aspiration time of ≤5 hours;
* The subject and his/her physician are willing to comply with specified follow-up evaluations;
* The subject or legally authorized representative has been informed of the nature of the study, agrees to its provisions and has been provided and signed written informed consent, approved by the appropriate Medical Ethics Committee (MEC) or Institutional Review Board (IRB)
* Infarct artery located in the proximal or mid left anterior descending coronary artery, with TIMI 0/1/2 flow at the time of initial diagnostic angiography (prior to wire passage);
* Based on coronary anatomy, PCI is indicated for revascularization;
* Only one epicardial coronary artery will be treated;
* Expected ability to deliver a ClearWay™ RX Infusion Catheter to the infarct lesion (absence of excessive tortuosity, diffuse disease or moderate/heavy calcification).

Key","* Prior myocardial infarction, or known prior systolic dysfunction (known ejection fraction \<40% by any prior measure or regional wall motion abnormalities);
* An elective surgical procedure is planned that would necessitate interruption of anti-platelet agents during the first twelve months post enrollment;
* Subjects who previously underwent coronary stent implantation and in whom coronary angiography demonstrates stent thrombosis to be the cause of the AMI;
* Subject has previously undergone an angioplasty or stenting procedure in the left anterior descending artery;
* Definite planned use of aspiration, atherectomy, thrombectomy and/or distal protection catheters prior to PTCA or stent implantation (other than in subjects randomized to thrombus aspiration);
* Any contraindication to undergo MRI imaging.
* Multivessel intervention required during the index procedure (subjects may be enrolled if treatment of more than one lesion in the LAD or its branches is required, however) (planned staged procedures are permitted with strong recommendation to be performed after 30-day clinical and MRI endpoints are completed);
* Severe vessel tortuosity, diffuse disease or severe calcification is present which may impede successful delivery of the ClearWay™ RX Infusion Catheter or the Export® Aspiration Catheter;
* Features are present highly unfavorable for PCI;
* Target lesion is present within a bypass graft conduit;
* MI is due to thrombosis within or adjacent to a previously implanted stent;
* Left ventriculography demonstrates severe mitral regurgitation or a VSD;
* Unprotected left main stenosis \>40% or that will require intervention","Abciximab local infusion, No local infusion, Thrombus aspiration",INTERVENTIONAL,COMPLETED
NCT01341964,Clopidogrel and Aspirin Interaction Study-2,Drug Action Increased,"* Stable patients \>1 month post ACS (including ST elevated myocardial infarction, non-ST elevated myocardial infarction or unstable angina) or stent
* Receiving regular ASA (81mg/d) and clopidogrel (75mg/d) for at least 1 week
* Written informed consent","* Age \< 18 years
* Liver disease with ALT or bilirubin \>2x upper limits of normal (ULN)\*
* Renal impairment with creatinine clearance \<30 ml/min\*
* Deemed to be at high risk of bleeding (e.g., recent bleeding, platelet count\<100x109/L or hemoglobin \<100g/L)\*
* Anticoagulant or NSAID therapy within the last 5 days
* Antiplatelet agent other than aspirin and clopidogrel within the last 10 days
* Uncontrolled hypertension (\>=180/110mmHg)

  * within 3 months of planned randomization","Clopidogrel, Aspirin, Aspirin",INTERVENTIONAL,COMPLETED
NCT03445884,68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis,Acute Myocardial Infarction,"* Age over 50 years

Acute myocardial infarction Group:

* Verified first-time acute myocardial infarction treated with PCI

Control Group:

* Previous healthy
* No known cardiac disease","* No prior history of acute coronary infarction
* No prior history of Heart surgery
* Not treated with anti-angiogenic medicine
* Subject with pacemaker, cochlear implant or insulin pump
* Pregnancy
* Lactation
* Severe claustrophobia
* Severe obesity (weight above 140kg)
* If a subject is in the fertile age, a pregnancy test will be use prior to injection to the PET_tracer
* If a subject is having a severe allergic reaction to the PET-tracer, the person will be excluded for the rest of the trial
* If the PET-tracer is administered subcutaneous, the person will be excluded for the rest of the trial¨
* Tupe I or II diabetes",68Ga-NODAGA-E[c(RGDyK)]2,INTERVENTIONAL,COMPLETED
NCT01882179,Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size,ST-elevation Myocardial Infarction,"Inclusion criteria for entry into trial

* Patients \>18 years
* Patients presenting with acute STEMI (as assessed by 12 lead ECG; ST segment elevation ≥2 mm (0.2 mV) in 2 or more contiguous precordial leads or ≥1mm (0.1mm) in 2 or more adjacent limb leads).
* Presentation within 12 hours after symptom onset

Inclusion criteria for randomization (assessed in catheter laboratory)

* Angiographically proven proximal occlusion (TIMI 0) of a major coronary vessel (LAD, LCX, RCA).
* Normal potassium (\<5.0 mmol/l)","* Patients with known LVEF ≤40%
* Participation in another trial
* Cardiogenic shock (positive shock index OR need for catecholamine support OR systolic blood pressure \< 90 mmHg)
* Killip class \> 2
* Prior myocardial infarction
* Known compromised renal function (eGFR \< 30 ml/min/1.73 m2) or potassium \> 5.0 mmol/l
* Current treatment with mineralocorticoid receptor antagonists
* Pregnant or lactating females
* Allergies to IMP or its excipients
* Known contraindication to cardiac magnetic resonance imaging (MRI) such as significant claustrophobia, severe allergy to gadolinium chelate contrast, , presence of MRI contraindicated implanted devices (eg, pacemaker, implanted cardiac defibrillator, cardiac resynchronization therapy device, cochlear implant), imbedded metal objects (eg, shrapnel), or any other contraindication for cardiac MRI.","Mineralocorticoid receptor antagonist potassium-canrenoate, placebo",INTERVENTIONAL,COMPLETED
NCT05360602,Alpha Lipoic Acid Effect on No-Reflow Phenomenon,No-Reflow Phenomenon,"1. Female or male aged \>18
2. STEMI patients undergoing PCI","1. Patients with a recent history of myocardial infarction (MI), a previous PCI or a previous coronary artery bypass graft
2. A late presentation (\>12 h), unsuccessful primary PCI (residual stenosis \>50% in the culprit lesion after procedure)
3. Pretreatment with thrombolytic or glycoprotein IIb/IIIa inhibitor therapy before primary PCI
4. Infectious or inflammatory disease
5. Severe liver or renal disease, (AST or ALT \>3x ULN or Total bilirubin \>2.5 x ULN), (CrCl \< 60 ml/min (based on the Cockroft-Gault equation)
6. Neoplasm, or hematological disorders
7. Pregnant or breast-feeding patients
8. Active participation in another clinical study
9. Patients taking Alpha Lipoic Acid.
10. Systolic Blood pressure \<90","Alpha Lipoic Acid plus the standard care for post-PCI MI, The standard care for post-PCI MI",INTERVENTIONAL,COMPLETED
NCT02139202,Heartstrong Pilot Program,Acute Myocardial Infarction,"* Patients admitted to the University of Pennsylvania Health System who are discharged (or scheduled to be discharged) to their homes with a principal or secondary diagnosis code of International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) 410 (except when the fifth digit was 2) and a length of stay of 1 to 180 days will be considered eligible for the study. Patients must be between 18 and 80 years old and have been discharged to home, 3) Patients are only eligible to enroll in the study for up to 60 days after their hospital discharge for a heart attack.","* Patients will be excluded if they are less than 18 years old, will not or cannot give consent, or have a markedly shortened life expectancy (diagnosis of metastatic cancer, end-stage renal disease on dialysis, or dementia). Patients who have a known allergy or history of side effects to any of the 4 targeted classes of medications will be enrolled but provided GlowCaps only for the remaining medications.

Patients with insurance coverage of one of the main study partners. (Horizon, Independence Blue Cross, Aetna, Keystone Mercy, and HealthFirst) (Please note, patients who are prescribed the anti-platelet Effient® (prasugrel) will not be given a GlowCap to use for this medication due to specific guidance about pill maintenance. The package insert for Effient® (prasugrel) (http://pi.lilly.com/us/effientppi.pdf) indicates the medication should remain in the original bottle, it should be kept at room temperature between 59°F to 86°F (15°C to 30°C) and the container should be closed tightly with the gray cylinder inside and be protected from moisture. This does not necessarily exclude these patients from participation in the study, they will still be eligible as long as they have been prescribed at least 2 of the remaining 3 medications being observed in this study. Also, those who are taking an anti-platelet other than Effient® (prasugrel) (ie, Plavix) will be given a GlowCap to use to take that medication.","Social Influence, Electronic Pill Bottles, Financial Incentives",INTERVENTIONAL,COMPLETED
NCT03991143,"Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction",ST Elevation Myocardial Infarction,"* Acute myocardial infarction with ST elevation at the J-point in two contiguous leads
* Start of PCI less than 4 hours after symptom onset.","* Cardiogenic chock, non-compensated acute heart failure and/or pulmonary edema.
* Previous major vascular intervention within the last 4 weeks.
* History of an infarct in the same artery that is currently affected.
* Conditions contraindicating MRI","ATH3G10, Placebo",INTERVENTIONAL,COMPLETED
NCT01367743,Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock,Cardiogenic Shock,"* man or woman older than 18 years
* cardiogenic shock due to myocardial infarction treated by angioplasty
* SAP \< 90 MM Hg or MAP \< 65 mm Hg without vasopressor or vasopressor necessity
* sign of tissue hypoperfusion
* cardiac index \< 2.2 l/mn/m2 in the absence of vasopressive or inotropic therapy
* pulmonary artery occlusion pressure \> 15 mmHg or echocardiographic evidence of high pressure (mitral profile)
* exclusion of covert hypovolemia : Delta PP if feasible should be \> 13% (patient adapted to the ventilator and sinus rhythm) and /or no response to passive leg raising
* ejection fraction \< 40% in ultrasound without inotrope support. This criteria will not be taken into account in instances of treatment with dopamine, norepinephrine, epinephrine, dobutamine or milrinone.","* shock of other origin
* immediate indications for mechanical assistance device
* minor aged patients
* patients for whom written consent - by patient or family - has not been obtained. Given the seriousness of the medical situation at the time of inclusion, patient consent will be difficult if not impossible to obtain. The inclusion will only be possible after information is provided and consent is obtained from a family member. As soon as possible, protocol information will be issued to the patient in order to obtain consent for continuance.
* cardiac arrest with early signs of cerebral anoxia.
* septic, toxic and obstructive cardiomyopathy
* arrhythmogenic cardiomyopathy
* patient with coronary insufficiency
* patient with ventricular rhythm disorders
* patient treated with a medicine listed in contre indication
* patient without social assurance
* patient major under legal protection or safeguard justice","epinephrine perfusion, norepinephrine perfusion",INTERVENTIONAL,COMPLETED
NCT03004703,ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial,"Coronary Disease, Myocardial Infarction","Patients will be screened for eligibility upon admittance due to acute STEMI at either participating site. All of the following conditions must apply to the prospective patient at screening prior to receiving study agent:

* New ST elevation at the J-point in two contiguous leads (cut-points: 0.2mV in men and \>0.15 mV in women in leads V2-V3 and/or \>0.1 mV in other leads) in combination with symptoms consistent with acute MI.
* Presentation within 6 hours of chest pain.
* Indication for urgent coronary angiography with intent to reperfuse presumed occluded vessel.
* Age between 18 and 80 years.
* Informed consent obtained and documented according to ICH/GCP, and national/local regulations.","Patients will be excluded from the study if they meet any of the following criteria:

* NSTEMI (non-ST segment elevation in ECG).
* Left bundle branch block in ECG
* History of previous MI
* Cardiogenic shock.
* Fibrinolytic therapy within 72 hours prior to admission.
* Cardiac arrest / ventricular fibrillation.
* History of severe renal failure with estimated glomerular filtration rate \< 30 ml/minutes.
* Known, current liver disease
* History of concurrent inflammatory, biliary obstructive or malignant disease
* A history of chronic or concurrent infectious disease, including a history of HIV, tuberculosis, or hepatitis B or C.
* Known, uncontrolled lower gastrointestinal (GI) disease such as diverticulitis, Crohn's disease, ulcerative colitis, or other symptomatic lower GI conditions that could predispose to GI perforations
* Major surgery within 8 weeks prior or after baseline
* History of central nervous system demyelinating or seizure disorders
* History of primary or secondary immunodeficiency
* Treatment with immunosuppressants other than low dose corticosteroids (equivalent to 5 mg of prednisone or less) at the time of randomisation
* Immunization with a live/attenuated vaccine within 4 weeks prior to baseline
* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or to tocilizumab
* Other contraindications to study medication
* Pregnancy, possible pregnancy or breast-feeding - women of child-bearing potential or breastfeeding mothers cannot participate. A woman is considered of childbearing potential following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause.
* Contraindications to CMR (pacemaker, CRT, ICD, certain ferromagnetic implants, severe claustrophobia, allergy to contrast medium).
* Any condition/circumstances believed to interfere with the ability to comply with protocol.
* Any reason why, in the opinion of the investigator, the patient should not participate.
* Failure to obtain written, informed consent by patient or next of kin, for instance in case of patient death after consent has been provided in oral.","Tocilizumab, Sodium chloride 0.9%",INTERVENTIONAL,COMPLETED
NCT02131103,The Short- and Long Term Outcomes of Early Routine PCI With the Standard Treatment in Low-intermediate Risk ST-elevation Myocardial Infarction Patients Who Successfully Fibrinolysis.,ST-elevation Myocardial Infarction,"1. The patients who received the percutaneous coronary intervention after fibrinolysis
2. Adult patients with age more than 18 years old
3. GRACE risk score less than 155 (low-intermediate risk)","1. The patients who received primary PCI or rescue PCI
2. The patients who had the previous history of coronary-artery bypass surgery
3. The high risk patients (such as cardiogenic shock, complete heart block, GRACE ≥155)",Percutaneous coronary intervention,INTERVENTIONAL,COMPLETED
NCT01065103,Fractional Flow Reserve (FFR) Stability in Non-Culprit Vessels at ST Elevation Myocardial Infarction(STEMI),Myocardial Infarction,"1. Any patient \>18 years of age with an acute STEMI eligible for primary PCI
2. Readily identifiable culprit vessel and at least one other (non-culprit) vessel of a least \>50% severity by traditional angiography
3. Deemed appropriate for a strategy of delayed revascularization of the NCV.","1. Inability to provide informed consent
2. Cardiogenic shock or severe (Killip III) congestive heart failure
3. Hemodynamically significant ventricular arrhythmias
4. Severe recurrent clinically significant ischemia following successful PCI of the IRA
5. Thrombocytopenia (platelet count \<100,000)
6. Severe anemia (HgB \<100 g/L)
7. Major bleeding during hospitalization of the index STEMI",FFR (Fractional Flow Reserve),INTERVENTIONAL,COMPLETED
NCT01759043,Safety and Feasibility of Using a Single Transradial Guiding Catheter for Primary PCI,Myocardial Infarction,"* Patient must be \> 18 years of age.
* Patients have typical chest pain for at least 20 minutes and have ECG changes typical for STEMI (ST elevation≥2mm in two continuous precordial leads or ST elevations≥1mm in two limb leads or new left bundle branch block) or ECG changes compatible with true posterior MI.
* Symptoms ≥ 30 min and ≤12 hours
* Patient and treating interventional cardiologist agree for randomization.
* Patient provides written informed consent.
* Diagnostic and therapeutic intervention performed through trans-radial/ulnar artery approach.
* Palpable radial or ulnar artery
* Previous experience of the operator with at least 100 cases of radial artery access within the past year","* Concurrent participation in other investigational study
* Current platelet count \<100 x 10\^9cells/L or Hgb \<10 g/dL.
* Absence of radial or ulnar artery pulsation
* Active bleeding or significant increased risk of bleeding, severe hepatic insufficiency, current peptic ulceration, proliferative diabetic retinopathy.
* Uncontrolled hypertension
* Prior CABG surgery
* Fibrinolytic therapy for current MI treatment
* patient have a life expectancy of \<180days","guiding catheter, diagnostic catheter",INTERVENTIONAL,COMPLETED
NCT02742103,A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction,"Acute Myocardial Infarction, Moderate Renal Impairment","• Men or women, at least 18 years of age, with evidence of moderate renal impairment (an eGFR ≥ 30 and \<60 mL/min/1.73 m2) and myocardial necrosis in a clinical setting consistent with a type I (spontaneous) acute myocardial infarction (AMI).","* Symptoms, biomarker elevation or electrocardiogram (ECG) changes other than those of the index event that are consistent with a diagnosis of AMI but are likely not due to primary myocardial ischemia
* Ongoing hemodynamic instability
* Planned coronary artery bypass surgery
* Evidence of hepatobiliary disease
* History of acute kidney injury (AKI) after previous exposure to an intravenous contrast agent.
* History of nephrotic range proteinuria.
* Known history of allergy to soy beans or peanuts, immunoglobulin A (IgA) deficiency, antibodies to IgA , or hypersensitivity to CSL112 or any of its components.
* Other severe comorbid condition, concurrent medication, or other issue that renders the subject unsuitable for participation in the study.","CSL_112, Placebo",INTERVENTIONAL,COMPLETED
NCT00877903,Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI),Myocardial Infarction,"* Male or female between 21 and 85 years old, inclusive
* First heart attack within 7 days prior to randomization and drug infusion
* Baseline left ventricular ejection fraction (LVEF) 20-45%
* Hemodynamically stable within 24 hours prior to randomization
* Adequate pulmonary function","* Previous medical history of heart attack, heart failure, significant valvular heart disease, aortic dissection
* Pacemaker or other device
* Pregnant, breast-feeding, or intends to become pregnant during the study
* Allergy to cow or pig derived products
* Evidence of active malignancy or prior history of active malignancy
* Major surgical procedure or major trauma within the past 14 days
* Autoimmune disease (e.g., Lupus, Multiple Sclerosis)
* Any medical condition, which in the opinion of the Investigator, renders participation unsuitable
* Undergone pharmacologic cardioversion or external defibrillation within 24 hours of randomization.
* Experienced cardiac arrest more than 36 hours after presentation to site or within 24 hours of randomization.","Prochymal®, Placebo",INTERVENTIONAL,COMPLETED
NCT01864343,Target Temperature Management In Myocardial Infarction - A Pilot Study,ST-elevation Myocardial Infarction,"* Age between 18 and 75 years
* Immediately transfer to cath-lab is possible
* Anterior or inferior ST-Elevation myocardial infarction
* ST-Segment elevation of \>0.2mV in 2 or more anatomically contiguous leads
* Duration of symptoms \<6 hours","* Participation in another study
* Patients presenting with cardiac arrest
* Tympanic temperature of \<35.0°C prior enrolment
* Thrombolysis therapy
* Previous myocardial infarction in medical history
* Previous percutaneous coronary intervention or coronary artery bypass graft
* Severe heart failure (defined as a New York Heart Association (NYHA) score of III or IV), Killip class II through IV at presentation
* Clinical signs of infection
* End-stage kidney disease or hepatic failure
* Recent stroke (within the last six month)
* Conditions that may be exacerbated by hypothermia, such as haematological dyscrasias, oral anticoagulant treatment with international normalized radio \>1.5, severe pulmonary disease
* Pregnancy. Women of childbearing potential are excluded
* Allergy to meperidine, buspirone, magnesium, or polyvinyl chloride
* Use of a monoamine oxidase inhibitor such as selegiline in the previous 14 days",EMCOOLS flex pad; Philips Innercool RTx,INTERVENTIONAL,COMPLETED
NCT01986803,ABSORB STEMI: the TROFI II Study,Acute ST Segment Elevation Myocardial Infarction,"1. Subject must be at least 18 years of age;
2. Primary PCI within 24 hours of symptom onset;
3. ST-segment elevation of \> 1mm in \> 2 contiguous leads, or (presumably new) left bundle branch block, or true posterior MI with ST depression of \>1mm in \>2 contiguous anterior leads;
4. Presence of at least one acute infarct artery target vessel with one or more coronary artery stenoses in a native coronary artery within planned device deployment segment (Dmax) by visual estimation of ≥ 2.5 mm and ≤ 3.8 mm;
5. Subject agrees to not participate in any other investigational or invasive clinical study for a period of 6 months following the index procedure.","1. Inability to provide informed consent;
2. Known pregnancy at time of randomization. Female who is breastfeeding at time of randomization;
3. Known intolerance to aspirin, heparin, PLLA (poly(L-lactic acid), everolimus, contrast material;
4. Cardiogenic Shock;
5. Unprotected left main coronary artery stenosis;
6. Distal occlusion of target vessel;
7. Acute myocardial infarction secondary to stent thrombosis;
8. Mechanical complications of acute myocardial infarction;
9. Severe tortuous, calcified or angulated coronary anatomy of the study vessel that in the opinion of the investigator would result in sub-optimal imaging or excessive risk of complication from placement of an OFDI catheter;
10. Fibrinolysis prior to PCI;
11. Active bleeding or coagulopathy or patients at chronic anticoagulation therapy;
12. Subject is currently participating in another clinical trial that has not yet completed its primary endpoint.",Percutaneous Coronary Intervention,INTERVENTIONAL,COMPLETED
NCT02492243,Continuous Rhythm Monitoring in Patients After Acute Myocardial infaRction andpREServed Lef venTricle Ejection Fraction (ARREST),Myocardial Infarction,"Inclusion Criteria

* Informed consent signed
* Documented myocardial infarction in the 7days prior to enrolment
* Age \> 18 yrs
* Left ventricular ejection fraction \>=40% as assessed by echocardiography within 7 days window after MI.","* subject is unwilling or unable to comply with the study procedures
* documented ventricular tachycardia or survived cardiac arrest outside of an acute coronary syndrome
* Subject has indications for active implanted cardiac medical device (IPG, ICD, CRT).
* contraindications for implantation of a ICM - Planned CABG procedure","PCI, ILR implantation",INTERVENTIONAL,COMPLETED
NCT02648464,Hydroxychloroquine for the Prevention of Cardiovascular Events in Myocardial Infarction Patients - a Safety Pilot Trial,"Myocardial Infarction, Acute Coronary Syndrome, Inflammation, Hydroxychloroquine, Antirheumatic Agents, Cardiovascular Diseases","Patients must have high-sensitivity troponin or CKMB above the upper limit of normal with at least one of the following criteria:

1. Anginal symptoms suggestive of cardiac ischemia

   1. Accelerating pattern of anginal pain (episodes of angina that have at least 5 minutes duration and are more frequent, severe, longer in duration and/or precipitated by less exertion).
   2. Prolonged (\>20 minutes) or recurrent anginal pain at rest or with minimal effort.
   3. Anginal pain at rest or with minimal exertion, and at least 20 minutes of duration, occurring \>48 hours after an acute Q-wave myocardial infarction.
2. ECG criteria

   1. New, persistent or transient ST-segment depression \>0,1 mV (0,08 seconds after the J-point) in at least 2 extremity leads or 3 precordial leads.
   2. New, persistent or transient ST-segment elevation in two contiguous leads ≥0.2 mV in men or ≥0.15 mV in women in leads V2-V3, and/or ≥0.1 mV in other leads.

Patients will be enrolled within 96 hours of coronary angiography","* Contraindication for hydroxychloroquine (porphyria, psoriasis, retinopathy, hypersensitivity)
* Rheumatoid arthritis or other rheumatic disease
* Significant neuropathy of any cause
* Cardiomyopathy (diagnosed before the onset of index hospitalization)
* Muscle disease (that could worsen by the use of hydroxychloroquine)
* Pregnant or nursing women, and women of childbearing potential without efficient contraceptives.
* Angina precipitated by obvious provoking factors
* Prolonged ECG's corrected QT interval (\>480 ms)
* Ongoing antibiotic therapy of any duration
* Uncontrolled severe cardiac arrhythmia resulting in hemodynamic instability
* Severe hepatic failure (alanine transaminase or gamma-glutamyltransferase ≥2 times above normal limits or international normalized ratio (INR) \>1,5 and patient not using warfarin, and due to other than cardiac reasons).
* Renal failure, glomerular filtration rate \<50 ml/min/1,73m2
* Hemoglobin \<100 g/l (if not possible to correct with transfusion)
* Planned percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)
* Index myocardial infarction due to PCI or CABG restenosis.
* Inability to interpret ST-T segment changes on ECG (e.g. complete left bundle branch block or paced rhythm)
* Prior thrombolytic therapy (within 12 hours)
* Inability to give informed consent
* Fulminant vomiting or other disability to give oral medication
* Over 80 years of age
* Life expectancy less than one year
* Receiving another investigational drug within 4 weeks prior to the study. (Patients who have participated in investigational trials before the 4-week time period may be randomized as long as they have reached the primary endpoint).
* Patients with any other medical condition which, in the investigator's opinion, would interfere with optimal participation in the study or produce a significant risk to the patient

In addition, patients are not eligible for the PET/CT subgroup if they have received statin-therapy in the last 2 months prior to the hospitalization (i.e. statin therapy started during the index hospitalization is not an exclusion criteria).","Hydroxychloroquine, Placebo",INTERVENTIONAL,COMPLETED
NCT01655290,Comparison of Gadobutrol and Gadobenate Dimeglumin for Delayed Enhancement Cardiac MRI,Subacute/Chronic Myocardial Infarction,"* Diagnosis of myocardial infarction
* Age ≥ 18 years and ≤ 80 years
* Informed consent
* Male patients as well as female patients using contraceptives","* Patients with a heart pacemaker, with magnetic material or other magnetic implants.
* Renal failure (GFR \<30ml/min)
* Patients with known allergy to a Gadolinium-containing contrast agent
* Drugs or alcohol addiction, dementia","Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)",INTERVENTIONAL,COMPLETED
NCT01839890,Paclitaxel Eluting Balloon in St Elevation Myocardial Infarction,Acute Myocardial Infarction,"* Patients aged less than 18 years.
* Acute myocardial infarction (AMI) within 12 hours of evolution (from the onset of symptoms) systolic time elevation of at least 1 mm (recorded in two or more contiguous leads), new left bundle branch block, or true posterior infarction.
* Patients candidates for primary angioplasty as medical criteria
* Written informed consent according to International Conference on Harmonization / Guide Clinical Practice and local legislation, obtained before any study procedure.
* Diameter vascular coronary artery to treat between 2 mm and 4 mm.
* Patients with 90-100% stenosis.","* Patients who refuse to participate in the study
* Cardiogenic shock (defined as systolic blood pressure less than 80 mm Hg for more than 30 minutes or need for vasopressors or intra-aortic balloon counterpulsation)
* Concomitant diseases associated with a life expectancy of less than one year
* Angiographic variables:

  * Trunk unprotected
  * Branching (side branch greater than 2.5 mm)
  * Sinus tachycardia segment elevation myocardial infarction thrombosis secondary to stent
  * If more than one stent to treat a single segment (overlapping stents).
  * Patient candidate for surgical revascularization within 30 days
  * Stenosis of greater than 30 mm in length (corresponding with the ball longer available)
  * Reference vessel diameter less than 2.5 mm and greater than 4 mm (larger ball)
  * More severe stenosis in the same artery in which is expected to be addressed in the next 9 months
* Women at childbearing age, where there is the possibility of pregnancy during the first year of follow-up, or nursing.
* Any clinical condition, which in the opinion of the investigator, is considered clinically significant as to participate in the study.
* Subjects who are participating in any study drug or medical.
* Individuals who show inability to follow instructions or help during the course of the study.
* Bleeding diathesis or other disorders such as gastrointestinal ulceration or cerebral circulatory disorders, restricting the use of treatments platelet aggregation inhibitors and anticoagulants.
* Patients with an ejection fraction \<30% (if known).
* Allergy or hypersensitivity to paclitaxel intolerance, or compounds structurally related to the Butyryl tri-n-hexyl citrate (BTHC) matrix of administration.
* Severe allergy to contrast media.
* Coronary artery spasm in the absence of significant stenosis.
* Cases in which is indicated bypass surgery within 30 days after infarction.","Bare metal Stent plus Paclitaxel Balloon, Bare metal Stent",INTERVENTIONAL,COMPLETED
NCT02170103,Microvascular Recovery With Ultrasound in Myocardial Infarction (MRUSMI) Post PCI Trial,"STEMI, Chest Pain","* Patients presenting to participating centers with chest pain and EKG evidence of an acute STEMI (two contiguous leads with \>0.1 millivolt (mV) ST elevation or \>0.1 ST depression in V2-V4) will be asked to participate. The inclusion criteria will be:

  1. Age ≥30 years.
  2. Eligible for emergent PCI/antithrombotic/antiplatelet therapy.
  3. Adequate apical and/or parasternal images by echocardiography.
  4. No contraindications or hypersensitivities to ultrasound contrast agents.","1. Known or suspected hypersensitivity to ultrasound contrast agent used for the study.
2. Cardiogenic Shock
3. Life expectancy of less than two months or terminally ill.
4. Known severe cardiomyopathy.
5. Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors, anticoagulants, or aspirin
6. Known large right to left intracardiac shunts.","percutaneous intervention (PCI), Microbubbles, Ultrasound",INTERVENTIONAL,COMPLETED
NCT00806403,Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction,Acute Myocardial Infarction,* Patients presenting within 6 h after onset of chest pain lasting for more than 30 min and with significant ST-segment elevation on ECG.,"* BP \>180/110
* Known bleeding disorder
* Cardiogenic shock
* CPR\>10 min
* Ongoing anticoagulant therapy
* Renal insufficiency
* Weight \>120 kg","reteplase 10+10 U, primary PCI",INTERVENTIONAL,COMPLETED
NCT00093184,Bivalirudin in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary PCI,Myocardial Infarction,"1. Patients \>18 years of age.
2. Symptoms of STEMI for at least 30 min within previous 12 hours AND

   * ST-segment elevation in at least 2 contiguous leads or new Left Branch Bundle Block (LBBB), OR existing LBBB with positive troponin
   * Residual high grade stenosis and associated abnormalities in regional wall motion.
3. Planned primary PCI in native coronary vessel.","1. Confirmed pregnancy
2. Fibrinolytic therapy - Any alteplase, reteplase, tenectoplase, or streptokinase within the last 24 hours
3. Culprit lesion within SVG or bypass conduit
4. Dependency on renal dialysis
5. Administration of LMWH within 8 hours prior to PCI
6. Administration of abciximab within 7 days prior to PCI
7. Administration of eptifibatide or tirofiban within 12 hours prior to PCI
8. Warfarin MUST BE discontinued prior to procedure, and the INR must be ⎕1.5, or the PT\<15,
9. Heparin. If heparin is administered in the ER as long as it is discontinued at least 30 minutes prior to procedure, OR ACT \<250, a patient may be enrolled. No clotting measurements are required if patient received heparin ⎕30 minutes prior to the initiation of bivalirudin.
10. Allergy to heparin or bivalirudin, or known sensitivity to any component of the products
11. Allergy to aspirin, clopidogrel, or abciximab
12. Contraindication to abciximab
13. Angiomax within 24 hours prior to study drug administration
14. Neurosurgery with three months
15. Severe hypertension not adequately controlled by antihypertensive therapy at the time of study entry (BP \>180/110 mm Hg)
16. Cardiogenic shock (SBP \<80 for \>30 min or a need for intravenous pressors)
17. Stroke within three months
18. Any hemorrhagic diathesis
19. Life expectancy \<1 year
20. Participation in another clinical trial",Angiomax (bivalirudin) anticoagulant,INTERVENTIONAL,COMPLETED
NCT03708484,Aerobic Interval Training v/s Resistance Interval Training On Ejection Fraction In Stable Post MI Patients,Myocardial Infarction,"* Patient who experienced just 1 episode of MI
* Stable post MI patients after 6 weeks of MI episode
* Patient who remained asymptomatic for first 3 minutes of ETT","* Poor LV ejection fraction below 35 % was excluded
* Lung diseases ( lung function test moderate and severe intensity )
* Unstable MI patients
* Those who had undergone any cardiac surgery
* Patients with Post MI Arrhythmias were excluded","Aerobic Interval Training, Aerobic + Resistive Interval Training",INTERVENTIONAL,COMPLETED
NCT01136187,Trial Comparing Radial and Femoral Approach in Primary Percutaneous Coronary Intervention (PCI),ST Elevation Myocardial Infarction,"* Age over 18 years
* Admission for STEMI less than 12 hours after onset of symptoms

  1. Patients have typical chest pain for at least 20 minutes and have ECG changes typical for STEMI (ST elevation ≥ 2 mm in two continuous precordial leads or ST elevations ≥ 1 mm in two limb leads or new left bundle branch block) or ECG changes compatible with true posterior MI.
  2. Patients are planned to be treated with primary PCI
* Ability to sign written informed consent","* Killip IV class or unconsciousness
* Patient disagreement
* Prior aortobifemoral bypass
* Absence of both radial or femoral artery pulsation
* Participation in another clinical trial randomizing ACS patients using antithrombotic drug.
* Negative Allen's test or Barbeau test type D
* Treatment with oral anticoagulants",Access site in primary PCI,INTERVENTIONAL,COMPLETED
NCT00483587,Does Heme Oxygenase-1 Induction Ameliorate Cardiac Injury After Myocardial Infarction?,Acute Myocardial Infarction,"1. Inclusion criteria for the interventional part of this study

   * Before any study-specific procedures, the appropriate written informed consent must be obtained.
   * Male and female between 18 to 80 years of age.
   * Having NSTEMI confirmed by elevated CK (CK-total (\>200 U/l), CK-MB act, CK-mass (\>5.00 µg/l) and/or Troponin T (\>0.01µg/l) levels.
2. Inclusion criteria for the non-interventional part of this study

   * Before any study-specific procedures, the appropriate written informed consent must be obtained.
   * Male en female between 18 and 80 years of age.

     * 15 patients having NSTEMI confirmed by elevated CK (CK-total (\>200 U/l), CK-MB act, CK-mass (\>5.00 µg/l) and/or Troponin T (\>0.01µg/l)levels.
     * 15 patients with non-typical angina pectoris in whom no cardiac disease could be detected.","1. Exclusion criteria for the interventional part of this study

   * ST-elevation on the electrocardiogram.
   * An unstable medical condition, defined as having been hospitalized for a noncardiac condition within 4 weeks of screening, or otherwise unstable in the judgment of the investigator (e.g. at risk of complications or adverse events unrelated to study participation).
   * Younger than 18 and older than 80 years of age.
   * Normal levels of CK en Troponin T.
   * Clinical history of chronic kidney disease (at any point prior to registration).
   * Any known hepatic disease.
   * Recent (within 3 months) history of alcohol or illicit drug abuse disorder, based on self report.
   * Clinically significant abnormality in chemistry, hematology, or urinalysis parameters performed within the screening period.
   * Participation in any investigational device or drug trial(s) or receiving investigational agent(s) within 30 days.
   * Any condition (e.g. psychiatric illness, etc.) or situation that, in the investigator's opinion, could put the subject at significant risk, confound the study results, or interfere significantly with the subject's participation in the study.
   * Legally incompetent adults, for which reason what so ever.
   * Any known hypersensitivity/allergic reaction to one of the constituents of heme arginate (hemin, L-arginin, propylene glycol, ethanol).
   * Any known hypersensitivity/allergic reaction to any known drugs or constituents of medication.
2. Exclusion criteria for the non-interventional part of this study

   * ST-elevation on the electrocardiogram.
   * An unstable medical condition, defined as having been hospitalized for a noncardiac condition within 4 weeks of screening, or otherwise unstable in the judgment of the investigator.
   * Younger than 18 and older than 80 years of age.
   * Clinical history of metabolic diseases, e.g. chronic kidney disease, hepatic disease or otherwise in the investigator's opinion.
   * Clinically significant abnormality in chemistry, hematology, or urinalysis parameters performed within the screening period.
   * Participation in any investigational device or drug trial(s) or receiving investigational agent(s) within 30 days.
   * Legally incompetent adults, for which reason what so ever.
   * For the 15 patients which act as controls for the NSTEMI patients: no history for cardiac disease.",Heme arginate,INTERVENTIONAL,COMPLETED
NCT00536887,Effects of Atorvastatin 10 mg Versus 40 mg in Eight Months Follow-up Coronary Flow Reserve and Bone Marrow Stem Cell Mobilization in Patients With Acute Myocardial Infarction,Acute Myocardial Infarction,"* Age 18 years and above
* Gender eligible for study both
* Patients with acute myocardial infarction requiring sirolimus-eluting stent implantation
* Acute myocardial infarction affecting proximal to mid coronary arteries
* No lesions greater than 50 percent diameter stenosis distal to the stent implantation
* Patients with informed consent","* Left main lesion
* Killip Class IV acute myocardial infarction
* Patients with current use of any statin
* Tortuous lesion with difficult intracoronary Doppler wiring
* Acute myocardial infarction affecting distal coronary arteries
* Acute myocardial infarction affecting branching coronary arteries
* The use of thiazolidinediones within 3 months
* Previous history of PCI or bypass surgery on infarct-related coronary artery
* Patients with any contraindications to the treatment of atorvastatin
* Pregnant or lactating patients
* Chronic alcohol or drug abuse
* Hepatic dysfunction (3 times above upper normal limit 5 days after AMI)
* Renal dysfunction (Creatinine greater than 2.0 mg/dL)
* Severe Heart failure (EF less than 25 percent)
* Expected life expectancy of less thna 1 year",atorvastatin,INTERVENTIONAL,COMPLETED
NCT01015287,A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction,Acute Coronary Syndromes,"* Have acute coronary syndrome consisting of non-ST-segment elevation with elevated troponin
* Scheduled for coronary angiography/PCI greater than or equal to 2 and less than 24 hours from time of planned randomization, but no more than 48 hours from randomization
* Must be eligible for treatment with prasugrel, aspirin (ASA), and a glycoprotein IIb/IIIa receptor (GPIIb/IIIa) inhibitor as per respective labels
* May be on a maintenance dose of clopidogrel 75 mg and must be able to switch to prasugrel
* Must be enrolled at a cardiac catheterization laboratory hospital or at a hospital/ambulance service affiliated with a cardiac catheterization laboratory hospital","* Present with ST-segment elevation myocardial infarction (STEMI) at the time of entry or randomization
* Have cardiogenic shock
* Have refractory ventricular arrhythmias
* Have New York Heart Association (NYHA) Class IV congestive heart failure (CHF)
* Have had cardiac arrest within 1 week of entry or randomization into the study","Placebo, Prasugrel",INTERVENTIONAL,COMPLETED
NCT02509832,COOL AMI EU Pilot Trial to Assess Cooling as an Adjunctive Therapy to Percutaneous Intervention in Patients With Acute Myocardial Infarction,Acute Myocardial Infarction,"All Inclusion Criteria must be answered YES for subject to be eligible for trial 

1. ≥ 18 years of age.
2. symptoms consistent with AMI (chest pain, unresponsive to nitroglycerin, ≥ 30 minutes and \< 6 hours.
3. Anterior MI with ST-segment elevation of 0.2 mV in two or more anterior contiguous precordial leads.
4. Eligible for PCI.
5. Opportunity for at least 10 minutes of cooling with the Proteus IVTM System prior to PCI.
6. Written, informed consent to participate in this clinical trial.","All Exclusion Criteria must be answered NO for subject to be eligible for trial inclusion.

1. Previous myocardial infarction.
2. Cardiogenic shock (systolic blood pressure \[SBP\] \<80 mmHg and non-responsive to fluids, or SBP \<100 mmHg with vasopressors, or requirement for an intra-aortic balloon pump \[IABP\]).
3. Resuscitated cardiac arrest, atrial fibrillation, or Killip risk stratification class II through IV
4. Aortic dissection or requires an immediate surgical or procedural intervention other than PCI
5. Congestive Heart Failure (CHF), hepatic failure, end- stage kidney disease or severe renal failure (clearance \< 30ml/min/1.73m2).
6. Fever (temperature \> 37.5 °C) or infection with fever in the last 5 days.
7. Previous CABG.
8. Stroke within 90 days of admission.
9. Cardio-pulmonary decompensation present or imminent
10. Contraindications to hypothermia, such as patients with known hematologic dyscrasias which affect thrombosis (e.g., cryoglobulinemia, sickle cell disease, serum cold agglutinins) or vasospastic disorders (such as Raynaud's or thromboangitis obliterans)
11. Hypersensitivity or contraindication to aspirin, heparin, or sensitivity to contrast media, which cannot be adequately pre-medicated.
12. History of bleeding diathesis, coagulopathy, cryoglobulinemia, sickle cell anemia, or will refuse blood transfusions.
13. Height of \<1.5 meters (4 feet 11 inches).
14. Hypersensitivity to buspirone hydrochloride or Pethidine (Meperidine) and/or treatment with a monoamine oxidase inhibitor in the past 14 days.
15. History of severe hepatic or renal impairment, untreated hypothyroidism, Addison's disease, benign prostatic hypertrophy, or urethral stricture that in the opinion of the physician would be incompatible with Pethidine administration.
16. Inferior Vena Cava filter in place (IVC).
17. The patient has a pre-MI life expectancy of \<1 year due to underlying medical conditions or pre-existing co-morbidities.
18. Known, unresolved history of drug use or alcohol dependency, or lacks the ability to comprehend or follow instructions.
19. Currently enrolled in another investigational drug or device trial that has not completed the primary endpoint.
20. Apprehension or unwilling to undergo the required MRI imaging at follow-up, has a documented or suspected diagnosis of claustrophobia, or has Gadolinium allergy
21. Received thrombolytic therapy en route to the hospital
22. Clinical evidence of spontaneous reperfusion as observed symptomatically and/ or from ECG findings (partial or complete ST resolution in ECG before randomization) upon admission
23. Vulnerable subject, for instance, a person in detention (i.e., prisoner or ward of the state)
24. Female who is known to be pregnant.","Cooling + PCI, PCI only",INTERVENTIONAL,COMPLETED
NCT01950299,Interleukin-1 (IL-1) Blockade in Acute Myocardial Infarction (VCU-ART3),Acute Myocardial Infarction,"INCLUSION CRITERIA:

In order to be eligible for this study, patients must meet ALL the 3 Inclusion criteria and NONE of the",".

1. Acute STEMI defined as chest pain (or equivalent) with an onset within 12 hours and ECG evidence of ST segment elevation (\>1 mm) in 2 or more anatomically contiguous leads that is new or presumably new
2. Planned or completed coronary angiogram for potential intervention
3. Age\>21

EXCLUSION CRITERIA:

* Inability to give informed consent
* Pregnancy
* Preexisting congestive heart failure (American Heart Association/American College of Cardiology class C-D, New York Heart Association III-IV)
* Preexisting severe left ventricular dysfunction (EF\<20%)
* Preexisting severe valvular heart disease
* Active infections (acute or chronic) - excluding Hepatitis C Virus (HCV)+ with undetectable RNA
* Recent (\<14 days) or active use of anti-inflammatory drugs (not including non-steroidal anti-inflammatory drugs \[NSAIDs\] or corticosteroids used for IV dye allergy only)
* Chronic inflammatory disease (including but not limited to rheumatoid arthritis, systemic lupus erythematosus)
* Active malignancy - excluding carcinoma in situ \[any organ\] and non-melanoma skin cancer
* Anticipated need for cardiac surgery
* Neutropenia (absolute neutrophil count\<1,800/mm3)","Anakinra 100 mg, Anakinra 100 mg, Placebo",INTERVENTIONAL,COMPLETED
NCT01008085,STENTYS Self-expanding Versus Balloon-expandable Stent in Acute Myocardial Infarction (AMI),STEMI,"Inclusion Criteria:

1. Subject 18 years old.
2. Acute Myocardial Infarction defined as presence of at least two of the three items below:

   1. Detection of rise of cardiac biomarkers with a least one value above the 99th percentile of the upper reference limit (URL)
   2. Symptoms of ischaemia (chest pain) \>20 minutes
   3. ECG changes indicative of new ischaemia: new ST-T changes (ST deviation ≥0.2mV precordial leads and/or ≥0.1mV limb leads) or new LBBB)
3. Reperfusion expected to be achieved within 12 hours from the onset of symptoms
4. Subject understands the nature of the procedure and provides written informed consent prior to the catheterization procedure.
5. Subject is willing to comply with specified follow-up evaluation and can be contacted by telephone.
6. Acceptable candidate for coronary artery bypass graft (CABG) surgery.
7. Male or non-pregnant female subject.

Angiographic Inclusion Criteria:

1. Reference vessel diameter \>2.5mm and \<4.0mm by visual estimate.
2. Target lesion \<30mm in length by visual estimate",":

1. Currently enrolled in another investigational device or drug study that has not completed the primary endpoint or that clinically interferes with the current study endpoints.
2. Coronary or cardiac intervention or major surgery of any kind within 30 days prior to the procedure.
3. Target vessel supplied by by-pass vessel
4. Patients on anticoagulation therapy (Coumadin)
5. Patient received thrombolytic therapy.
6. Myocardial infarction due to stent thrombosis, or infarct lesion at the side of a previously implanted stent
7. Cardiogenic shock
8. Any previous stent placement within 10mm (proximal or distal) of the target lesion.
9. Co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or impact the scientific integrity of the study.
10. Concurrent medical condition with a life expectancy of less than 6 months.
11. Left ventricular ejection fraction (LVEF) \<30% at the most recent evaluation.
12. Cerebrovascular accident or transient ischemic attack in the last 6 months.
13. Known hypersensitivity or contraindication to aspirin, heparin or bivalirudin, clopidogrel or ticlopidine, cobalt, nickel, or sensitivity to contrast media, which cannot be adequately pre-medicated.
14. Known serum creatinine level \>2.5mg/dl or presence or history of renal failure

Angiographic Exclusion Criteria:

1. Unprotected left main coronary artery disease (obstruction greater than 50% in the left main coronary artery that is not protected by at least one non-obstructed bypass graft to the left anterior descending (LAD) or left circumflex (LCX) artery or a branch thereof).
2. Target vessel is excessively tortuous (two bends \>90˚ to reach the target lesion).
3. Lesion location that is aorto-ostial or within 5mm of the origin of the LAD or LCX.
4. Target lesion is severely calcified.","Stentys coronary stent, Balloon-expandable stent",INTERVENTIONAL,COMPLETED
NCT00430885,Effect of Intravenous Immunglobulin (IVIG) After Myocardial Infarction,Acute Myocardial Infarction,"* Age of 18-80 years
* Have a recent MI (\<5days)
* Have ASAT \>100 U/L or CKMB \> 50 U/L.
* Have LVEF \<40%.
* Are on optimal medical treatment and considered unsuitable for surgical intervention.","* Evidence of unstable disease, concomitant ischemia or unstable angina during the hospitalization.
* Significant concomitant disease such as infections, pulmonary disease or connective tissue disease.
* Participating in other studies.
* Inability to participate.
* Diseases that require surgery.
* Planned revascularisation.
* Known hypersensitivity to IVIG.",Octagam (IVIG),INTERVENTIONAL,COMPLETED
NCT01381185,REsistance to Aspirin and Clopidogrel in acuTe Myocardial Infarction,Acute Myocardial Infarction,"* acute myocardial infarction (verified by troponin I elevation and ST-segment deviation ≥0.1mV in ≥2 contiguous ECG leads persisting for at least 20 minutes and angiographical proof of coronary stenosis )
* preceding antiplatelet medication with aspirin100mg qd/5 and more days before PCI
* pre-treatment with 600mg Clopidogrel loading dose
* preferably patients with drug eluting stent implantation
* signed informed consent","* stable/unstable angina pectoris
* active malignancy
* contraindication to antiplatelet therapy
* increased risk of bleeding (trauma, surgery or non-ischemic stroke in last month)
* effective anticoagulation therapy:LMWH, Pradaxa, Xarelto, Warfarin
* known thrombophile disorder
* SIRS
* renal insufficiency (eGFR under 15ml/min)
* severe anemia (\<80 g/l)
* polyglobulia (\>160 g/l)
* pregnancy
* Hematocrit \<0.25 \> 0.55","Aspirin 200mg qd, Clopidogrel 2x75mg qd",INTERVENTIONAL,COMPLETED
NCT00390832,Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3),"Myocardial Infarction, Angioplasty, Transluminal, Percutaneous Coronary","* Patients with ST-Segment elevation myocardial infarction \<24 h from pain onset
* Successful primary PCI and left ventricular ejection fraction \<50%
* Informed, written consent
* In women with childbearing potential a pregnancy test is mandatory","* Age \< 18 and \> 80 years
* Cardiogenic shock
* pericarditis
* thrombolysis for the index infarction
* malignancies/other comorbid conditions with life expectancy \< 1 year
* previous myocardial infarction
* planned staged PCI or prior PCI within 30 days from index procedure
* uncontrolled hypertension \>160/100mmHg unresponsive to therapy
* epilepsy
* active bleeding; bleeding diathesis; history of gastrointestinal or genitourinary bleeding, recent trauma or major surgery \< 1 month; history of intracranial bleeding or structural abnormalities; suspected aortic dissection; patient's refusal to blood transfusion
* hematologic disorders such as essential thrombocytosis, megakaryoblastic leukemia, polycythemia vera
* relevant hematologic deviations: hemoglobin \< 100 g/l or hemoglobin \> 160 g/l platelet count \< 100 x 10\^9 cells/l or platelet count \> 600 x 10\^9 cells/l
* any contraindication to magnetic resonance imaging: electronically, magnetically and mechanically activated implants such as cardiac pacemakers, automatic cardioverter defibrillators, joint prostheses, surgical/vascular clips/ hearing aids, neurostimulators, infusion pumps etc metallic splinters in the eye ferromagnetic haemostatic clips in the central nervous system cochlear implants lead wires or similar wires prosthetic heart valves, if dehiscence is suspected non-ferromagnetic stapedial implants, hemostatic clips
* glomerular filtration rate \< 30 ml/min or serum creatinine \> 30 mg/l or dependence on renal dialysis
* chronic liver disease with GOT \> 5-fold over the normal range
* allergy to erythropoietin/true anaphylaxis after prior exposure to contrast media
* phenylketonuria
* previous enrollment in this trial
* women who are known to be pregnant, who are of childbearing potential and test positive for pregnancy, who have given birth within the last 90 days, who are breastfeeding
* patient's inability to fully cooperate with the study protocol
* other contraindication according to the summary of product characteristics of recombinant human erythropoietin beta (NeoRecormon®)","Erythropoietin, Placebo",INTERVENTIONAL,COMPLETED
NCT03072199,Rituximab in Patients With Acute ST-elevation Myocardial Infarction Study,"Ischemic Heart Disease, Myocardial Infarction, Inflammation","* Age 18-75 years old
* Acute anterior (left anterior descending artery) STEMI and successful primary percutaneous coronary intervention (PCI) with stent implantation in the culprit lesion during the first 24h after onset of symptoms","* A previous history of STEMI
* Cardiogenic shock (systolic blood pressure \<80 mm Hg, unresponsive to fluids, or necessitating catecholamines), electrical instability or severe congestive heart failure
* Residual severe proximal bystander disease awaiting inpatient revascularisation
* Corrected QT interval (QTc) \> 500 msecs using Bazett's formula
* Hematologic abnormalities (hemoglobin \<10 g/dL or hematocrit \<30%, platelet cell count of \<100 x103/μL, white blood cell count \<4 x103/μL)
* Hypogammaglobulinaemia (defined as \<3g/L of IgG)
* Renal failure (estimated GFR by the MDRD formula \< 45 ml/min/1.73m2);
* Known hepatic failure or abnormal liver function tests at baseline (ALT \> 2 x ULN).
* Active or recurrent hepatitis (type B).
* Known HIV infection
* Current or previous tuberculosis (Chest X-Ray)
* Current infections
* Presence or history in the previous five years of an ongoing cancer, except in situ cancer of the cervix or basal cell carcinoma
* Any oral or intravenous immunosuppressive treatment (other than concomitant 100 mg methylprednisolone), disease modifying drugs, or other immune modulatory monoclonal antibodies or immunodepleting therapy at any time
* Allergy to rituximab or one of its excipients
* Expected need for vaccination with a live attenuated vaccine during the study including incomplete vaccination courses.
* Known or suspected pregnancy at screening or lactating woman
* Women of childbearing age unless confirmed by direct questioning that they are reproductively sterile or post-menopausal
* Participation in other clinical trials
* Inability to comply with study procedures",RiTUXimab Injection,INTERVENTIONAL,COMPLETED
NCT04056819,Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction,Acute Myocardial Infarction,"Donor-Inclusion Criteria:

1. Pregnant women who are aged ≥ 20, \<50 years old on date of consent.
2. Pregnant women who are willing to and has given her signed written informed consent.
3. Pregnant women whose gestation age ≥ 34 weeks and have intact placenta.
4. Pregnant women who have not had any complication of pregnancy.
5. Pregnant women who are willing to provide a personal and family medical history (as much available) of herself and the biologic father (as much available), prior to or following collection of the umbilical cord.

Donor-",":

1. Pregnant women who have clinically severe and/or life-threatening disease(s) such as uncontrolled diabetes mellitus (fasting sugar level \> 250 mg/dL) and malignant tumor.
2. Pregnant women who have been tested positive for the following tests within 7 days before or after umbilical cord acquirement:

   * Human immunodeficiency virus-1 (HIV-I): anti-HIV-I and nucleic acid test (NAT)
   * HIV-II
   * Hepatitis B virus (HBV): Hepatitis B surface antigen (HBsAg), anti- Hepatitis B core (HBc) and NAT
   * Hepatitis C virus (HCV): anti-HCV and NAT
   * Cytomegalovirus (CMV) (Note: If the pre-screened CMV result shows positive 8 weeks prior to umbilical cord acquirement will also be excluded.)
   * Treponema pallidum
   * Chlamydia trachomatis
   * Neisseria gonorrhea
   * Human T cell leukemia virus-I/II (HTLV-I/II)
   * West Nile virus (WNV) NAT
3. Pregnant women are with increased risk for Creutzfeldt-Jakob disease (CJD) if you have received a non-synthetic dura mater transplant, human pituitary-derived growth hormone, or have one or more blood relatives diagnosed with CJD.
4. Pregnant women had spent three months or more cumulatively in the United Kingdom from the beginning of 1980 through the end of 1996; or had received any transfusion of blood or blood components in the U.K. or France between 1980 and the present; or lived 5 years or more cumulatively in Europe.
5. Pregnant women or her sexual partners were born or lived in certain countries in Africa (Cameroon, Central African Republic, Chad, Congo, Equatorial Guinea, Gabon, Niger, or Nigeria) after 1977 (risk factor for HIV group O).
6. Pregnant women who have medical diagnosis of Zika virus (ZIKV) infection or residence in, or travel to, an area with active ZIKV transmission (according to the list from Centers for Disease Control and Prevention. Zika Virus: Areas with Zika.) at any point during that pregnancy.
7. Pregnant women who have sex at any point during that pregnancy with a male who is known to medical diagnosis of ZIKV infection or residence in, or travel to, an area with active ZIKV transmission.
8. Pregnant women who have received blood infusion or stayed for more than 3 months in WNV potential countries.
9. Pregnant women who have unexplained post-donation febrile illness with headache or other symptoms suggestive of WNV infection (i.e., flu-like symptoms that include fever with headache, eye pain, body aches, generalized weakness, new skin rash or swollen lymph nodes or other evidence of WNV infection) within two weeks.
10. Pregnant women who have medical history of tuberculosis.
11. Pregnant women who have medical history of malignant tumor.
12. Fetuses that have found with genetic disease in prenatal checkups.
13. Pregnant women who would like to store cord blood or umbilical cord cells, other than this study usage.
14. Pregnant women who are not suitable to donate as judged by the Investigator(s).

Subject-Inclusion Criteria:

1. Male or female patients are aged ≥20, \<76 years old on date of consent.
2. Patients who presented typical ischemic chest pain within 12 h after symptoms onset and are diagnosed first acute STEMI according to the 2013 American College of Cardiology (ACC) Foundation/American Heart Association (AHA) guideline for the Management of STEMI.
3. Patients who have undergone standard-of-care for STEMI; the immediate reperfusion management should include primary percutaneous coronary intervention (PCI), aspiration thrombectomy and adjunctive antithrombotic therapy within 12 hours after the onset of symptoms.
4. Patients who undergo successful acute reperfusion therapy (residual stenosis visually \<50% and TIMI flow ≥2) with placement of an intracoronary stent have a patent infarct-related artery suitable for cell infusion to the target area of abnormal wall motion following myocardial infarction.
5. Patients who have left ventricular ejection fraction (LVEF) ≥ 30% and \< 50% diagnosed by echocardiogram.
6. Patients are willing to sign informed consent or assent by the next of kin.
7. Patients who have stable vital signs for at least 48 hours, defined as normal respiration, afebrile, systolic pressure ≥ 90 mmHg and \< 180 mmHg, heart rate \> 50/min and \<110/min.
8. Adequate pulmonary function test defined as a force expiratory volume 1s (FEV1) \> 50% predicted and peripheral artery oxygen saturation ≥95% at room air.
9. All male patients and female patients with child-bearing potential (between puberty and 2 years after menopause) should use appropriate contraception method(s) shown below, for at least 4 weeks after UMSC01 treatment.

   1. Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception).
   2. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
   3. Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject
   4. Combination of any two of the following listed methods: (d.1+d.2 or d.1+d.3, or d.2+d.3):

   d.1 Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \<1%), for example hormone vaginal ring or transdermal hormone contraception.

   d.2 Placement of an intrauterine device (IUD) or intrauterine system (IUS). d.3 Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository.

Subject-Exclusion Criteria:

1. Patients with cardiogenic shock (defined as systolic blood pressure \< 80 mmHg requiring vasopressors, intra-aortic balloon pump (IABP) or extracorporeal membrane oxygenation (ECMO).
2. Patients who have severe aortic stenosis or regurgitation according to the recommendation of the 2014 ACC/AHA guideline for the Management of Patients with Valvular Heart Disease.
3. Patients who have severe mitral stenosis or regurgitation according to the recommendation of 2014 ACC/AHA guideline for the Management of Patients with Valvular Heart Disease.
4. Patients who need to undergo staged coronary intervention therapy or coronary artery bypass grafting (CABG) surgery.
5. Patients who have immuno-compromised condition, or is with known clinically significantly autoimmune conditions or is receiving immunosuppressive treatments.
6. Patients who are unable to undergo cardiac magnetic resonance imaging (CMRI) scans for any reason.
7. Patients with inadequate hepatic and renal function after onset of STEMI: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≥ 4 x upper limit of normal (ULN); estimated glomerular filtration rate (eGFR) \< 30 mL/min.
8. For patients with diabetes mellitus: patients with uncontrolled diabetes mellitus (fasting sugar level \> 250 mg/dL).
9. Patients who have medical history of malignant tumor or other clinically significant cardiovascular diseases that will confound the evaluation of this study.
10. Patients who participated other clinical trial within last 3 months.
11. Female patient who is pregnant, lactating or with child-bearing potential but not practicing effective contraceptive method(s).
12. Patients not suitable to participate the trial as judged by the Investigator(s).",Allogeneic umbilical cord mesenchymal stem cells,INTERVENTIONAL,COMPLETED
NCT02026219,Comparison of Clopidogrel and Ticagrelor on Microvascular Dysfunction in ST-Segment Elevation Myocardial Infarction,"Non-ST Segment Elevation Myocardial Infarction, ST Segment Elevation Myocardial Infarction","* 

  * Males and Females
  * between the ages of 18 and 75 years
  * STEMI patients treated with percutaneous coronary intervention
  * Able to provide informed consent
*","* History of stroke or transient ischemic attack
  * Platelet count \< 100 000/μL
  * Known Bleeding Diathesis
  * Hematocrit \<30% or \>52%
  * Severe Liver Dysfunction
  * Renal Insufficiency (Creatinine Clearance \< 30ml/min)
  * Pregnant females
  * Cardiogenic shock or symptomatic hypotension or sitting SBP \< 95 mmHg","Clopidogrel, Ticagrelor",INTERVENTIONAL,COMPLETED
NCT02312336,A Pilot Study of Transcoronary Myocardial Cooling,Acute Myocardial Infarction,* Men and women aged between 18 and 80 years presenting with ischaemic chest pain of \<6 hours and STsegment elevation on the ECG of \>0.2 mV in 2 contiguous leads.,"* Patients with cardiac arrest, previous AMI or CABG, known congestive heart failure, endstage kidney disease or hepatic failure, recent stroke, coagulopathy, pregnancy, or cardiogenic shock.
* Patients who are unable or unwilling to provide assent and informed consent.","Cohort A - Room temperature coronary perfusate, Cohort B - Cooled coronary perfusate",INTERVENTIONAL,COMPLETED
NCT01059136,Aldosterone Blockade Early After Acute Myocardial Infarction,Myocardial Infarction,"1. Age ≥ 18 ans
2. Ischemic symptom of ≥ 20 minutes
3. Randomization within 72 hours after symptom onset
4. Electrocardiogram or biological evidence of myocardial infarction:

   * ST segment elevation ≥ 2 mm in ≥ 2 adjacent precordial derivations
   * ST segment elevation ≥ 1 mm in ≥ 2 adjacent peripheral derivations
   * New left bundle branch block
   * New significant Q wave in ≥ 2 adjacent peripheral derivations
   * Troponin levels ≥3 times upper local limit of normal values and Thrombolysis In Myocardial Infarction (TIMI) non-ST elevation myocardial infarction risk score ≥ 3.
5. Patients with health insurance
6. Written informed consent obtained from:

   1. - the patient
   2. -A member of the family or the person of confidence if the patient is unable to provide informed consent","1. Contraindication or known intolerance to study drugs
2. Patients already treated by aldosterone blockers for diseases other than systemic hypertension (e.g. primary hyperaldosteronism)
3. Hyperkaliemia \>5.5 mmol/l at the time of randomization
4. Renal function impairment :Plasma creatinin level \> 220 µmol/l and/or Creatinin clearance 30 ml/min
5. Severe liver deficiency (Child-Pugh Class 3)
6. Pregnant or breast feeding women, or women desiring pregnancy within 6 months after randomization
7. Patients already included in another biomedical intervention trial
8. Life expectancy \< 1 year
9. Cardiac arrest lasting (ECM) \>10 minutes prior to randomization
10. Patient unable or unwilling to comply with the treatment or the follow-up visits",Spironolactone,INTERVENTIONAL,COMPLETED
NCT02545933,Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor,Myocardial Infarction,"Inclusion criteria:

1. Patients with a prior MI within the previous 2 weeks to 12 months.
2. On DAPT with low-dose aspirin (81mg od) and either prasugrel (10mg od) or ticagrelor (90mg bid) as per standard-of-care for at least 2 weeks.
3. Free from bleeding and ischemic events after the index MI event.
4. Age between 18 and 75 years old.",":

1. History of stroke, transient ischemic attack, or intracranial hemorrhage.
2. Active pathological bleeding, history of bleeding events or increased risk of bleeding.
3. Known severe hepatic impairment.
4. Age \>75 years.
5. Body weight \<60 Kg.
6. Use of strong Cytochrome P450 3A inhibitors (e.g., ketoconazole, itraconazole, posaconazole, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, boceprevir, telaprevir, telithromycin and conivaptan) or inducers (e.g., rifampin, carbamazepine, St. John's Wort and phenytoin).
7. On treatment with any oral anticoagulant (vitamin K antagonists, dabigatran, rivaroxaban, apixaban, edoxaban).
8. On treatment with any antiplatelet agent other than aspirin, prasugrel and ticagrelor in the past 14 days.
9. Creatinine clearance \<30 mL/minute.
10. Platelet count \<80x106/mL
11. Hemoglobin \<10g/dL
12. Hemodynamic instability
13. Pregnant females","Prasugrel, Vorapaxar, Aspirin, Ticagrelor",INTERVENTIONAL,COMPLETED
NCT00828087,A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial Infarction: EXAMINATION Study,Myocardial Infarction,"* Patients presenting with a ST-elevation myocardial infarction who must meet at least one of the following criteria

  * Patients presenting with a ST-elevation myocardial infarction \<12 hours after onset of symptoms who are treated with primary angioplasty + stent implantation
  * Cardiogenic shock.
  * Rescue PCI after failed thrombolysis.
  * PCI indicated early (\<24h) after effective thrombolysis following current ESC guidelines.
  * Patients presenting late (""latecomers"") with ST-elevation myocardial infarction (\>12h-48h) after the onset of symptoms.
* Written informed consent.
* The patient or his/her family (in the event the patient can not be clinically available) accept clinical controls.

Angiographic:

* Vessel size has to range between 2.25-4.0 mm by visual estimation to allow the implantation of currently available stents.","* Age \< 18 years.
* Pregnancy or breastfeeding.
* Known intolerance to aspirin, clopidogrel, heparin, stainless steel, Everolimus, contrast material.
* Patients with absolute indication of being chronic treated with acenocoumarol
* Myocardial infarction due to a previously implanted stent thrombosis
* Patients with myocardial infarction that will require elective surgical coronary revascularisation within a 1 year period (example: inferior MI with severe disease in left main with surgical indication).","Everolimus Eluting Coronary Stent System, cobalt chromium balloon expandable stent ( non drug eluting stent Arm)",INTERVENTIONAL,COMPLETED
NCT01473433,Pericardic Adipose Pedicle Transposition Over the Myocardial Infarct (adiFLAP Trial),Myocardial Infarction,"* Established transmural myocardial infarction non candidate to revascularization (\>3 months-old)
* Candidate to coronary by-pass for other territories different from the previous transmural infarct.
* \> 18 years of age, male or female, capable of giving an informed consent.","* Severe co-morbidity associated with a reduction in life expectancy of less than 1 year.
* Severe valvular disease candidate for surgical restoration.
* Candidate to ventricular remodeling.
* Contraindication for NMR (creatinin clearance \<30 ml/min/1.73m2, metallic implants, claustrophobia).
* Severe renal or hepatic failure.
* Abnormal laboratory tests (no explanation at the time of inclusion).
* Previous cardiac intervention.
* High surgical risk (Euroscore 2).
* Pregnant or breast feeding women.","Pericardial adipose pedicle (adiFLAP) transposition., Control",INTERVENTIONAL,COMPLETED
NCT03771937,The Effect of Education and Telephone Follow-up Intervention Based on the Roy Adaptation Model,Myocardial Infarction,"1. Participants were adults aged ≥30 years and had been admitted to the hospital with a diagnosis of MI (which must be supported by ECG and an increase in biomarkers).
2. were clinically stable
3. willing to participate
4. able to understand and write Turkish
5. able to receive telephone calls or fill in questionnaires.
6. able to come to the hospital for checkups.","Patients were excluded from the study if according to medical file records they had chronic renal failure, cancer, heart failure, severe aortic stenosis, if they were planned for surgical treatment or had chronic cognitive and psychiatric disease, if they had problems with hearing and speaking on the phone, or if they had mobility restriction.",Education and telephone follow-up intervention,INTERVENTIONAL,COMPLETED
NCT06426537,Colchicine's Efficacy in MI Patients: Comparing PCI and Non-Reperfusion Approaches,ST-Elevation Myocardial Infarction,"Men and women aged 18 years or older. Able and willing to provide informed consent. Presenting with clinical symptoms and supporting examinations indicative of a first-time diagnosis of IMA-EST.

Eligible for treatment according to the IMA-STEMI guidelines, which may include:

Antiplatelet therapy Renin-angiotensin-aldosterone system inhibitors Beta-blockers

Specifically, includes patients who have:

Undergone early PCI. Not received reperfusion therapy. Female patients must commit to avoiding pregnancy during the study. Willing to participate in follow-up via face-to-face or telephone contact.","Presence of concurrent diseases such as infections, inflammation, or malignancy.

Diagnosed with gastrointestinal disorders including Crohn's disease, ulcerative colitis, or exhibiting chronic diarrhea.

Recent abnormal laboratory results (within the last 30 days) including:

Hemoglobin below 11.5 g/L Leukocytes below 3.0 x 10\^9/L Platelets below 110 x 10\^9/L ALT more than three times the upper limit of normal Total bilirubin more than twice the upper limit of normal Creatinine more than twice the upper limit of normal History of liver cirrhosis, acute hepatitis exacerbation, or severe liver disease.

Currently pregnant, breastfeeding, or planning to become pregnant during the study.

History of alcohol abuse. Receiving long-term steroid therapy or using colchicine for other indications. History of hypersensitivity to colchicine. Severe renal failure (eGFR below 30). History of cardiac arrest, ventricular fibrillation, cardiogenic shock, or hemodynamic instability.

Unwilling or unable to provide informed consent.",Colchicine 0.5 MG Oral Tablet,INTERVENTIONAL,COMPLETED
NCT02181985,"Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)",Myocardial Infarction,"* Onset of symptoms of AMI within six hours prior to randomisation
* A twelve-lead electrocardiogram with one of the following: ST-segment elevation ≥ 0.1 millivolt (mV) in two or more limb leads, or ≥ 0.2 mV in two or more contiguous precordial leads indicative of AMI, or left bundle-branch block
* Age ≥ 18
* Informed consent received","* Hypertension defined as blood pressure \> 180/110 mm Hg (systolic BP \>180 mm Hg and/or diastolic BP \>110 mm Hg) on repeated measurements during current admission prior to randomization
* Use of abciximab (ReoPro ®) or other glycoprotein-IIb/IIIa antagonists within the preceding 7 days
* Major surgery, biopsy of a parenchymal organ, or significant trauma within 2 months
* Any minor head trauma and any other trauma occurring after onset of the current myocardial infarction
* Any known history of stroke or transient ischemic attack or dementia
* Any known structural damage of the central nervous system
* Prolonged cardiopulmonary resuscitation (\>10 minutes) in the previous two weeks
* Current oral anticoagulation
* Standard unfractionated heparin (heparin sodium) \>5000 IU or a subcutaneous dose within 6 hours of randomization of a therapeutic dose of any low molecular weight heparin
* Known thrombocytopenia (prior platelet count below 100000 cells/μl (100 x10\*\*9/l))
* Known renal insufficiency (prior S-creatinine \>2.5 mg% (\>220 μmol/l) for men and \>2.0 mg% (\>175 μmol/l)) for women
* Pregnancy or lactation, parturition within the previous 30 days. Women of childbearing potential must have a negative pregnancy test, or use a medically accepted method of birth control
* Treatment with an investigational drug under another study protocol in the past 7 days
* Previous enrollment in this study
* Known sensitivity to TNK-tPA, tPA, abciximab, heparin or low molecular weight heparin
* Any other condition that the investigator feels would place the patient at increased risk if the investigational therapy is initiated
* Inability to follow protocol and comply with follow-up requirements","Full dose TNK-tPA, Half dose TNK-tPA, Heparin, Enoxaparin, Abciximab",INTERVENTIONAL,COMPLETED
NCT05415085,Culprit-first in Primary Percutaneous Coronary Intervention,"Coronary Artery Disease, Ischemic Heart Disease, Myocardial Infarction, STEMI, Stent",* Patients presenting with STEMI who are eligible for PPCI,"* Cardiac arrest
* Cardiopulmonary resuscitation or extracorporeal membrane oxygenation on arrival to the catheterization laboratory
* Prior coronary artery bypass grafting surgery",Culprit-first PCI,INTERVENTIONAL,COMPLETED
NCT00756756,"The Effect of Granulocyte Colony Stimulating Factor (G-CSF) on Myocardial Function After Acute Anterior Myocardial Infarction, a Prospective Double Blind Randomized Placebo Controlled Study",Myocardial Infarction,"* First anterior myocardial infarction.
* Low systolic ventricular function.","* Bleeding tendency
* Contraindication to G-CSF
* Cardiogenic shock
* Hemodynamic instability
* Hepatic or renal disease
* Multivessel disease","G-CSF, placebo infusion of normal saline",INTERVENTIONAL,COMPLETED
NCT02419937,Short-Term Application of Tocilizumab Following Myocardial Infarction,Myocardial Infarction,"* Subjects over the age of 18 years old
* Subjects who present to Keesler Medical Center with clinical, physical examination, serologic, and electrocardiographic evidence of an acute MI (NSTEMI or STEMI), as determined by the treating physician","* Subjects with clinical, physical examination, or radiographic evidence suspicious for active Tuberculosis (TB)
* Subjects with a known history of Hepatitis B or Hepatitis C infection This exclusion refers specific subjects who are actively being treated with medications for Hepatitis B or C or who have known virologic evidence on ongoing infection with Hepatitis B or C
* Subjects who are immune compromised including transplant recipients, patients with HIV, etc.
* Subjects with evidence of Tuberculosis infection on chest xray
* Subjects with known allergic reaction to tocilizumab or other IL-6 inhibitors
* Subjects with clinical, physical examination, serologic, or radiographic evidence of active infection
* Subjects receiving therapy for malignancy-this will not exclude subjects receiving therapy for non-melanoma skin cancer such as basal cell carcinoma or squamous cell carcinoma of the skin
* Female subjects who are pregnant or breast-feeding
* Subjects with existing cognitive impairment such as known moderate to severe dementia or subjects who present with new onset delirium","Tocilizumab, Placebo",INTERVENTIONAL,COMPLETED
NCT00091637,Pexelizumab in Conjunction With Angioplasty in Acute Myocardial Infarction (APEX-AMI),Acute Myocardial Infarction,"* Cardiac symptoms for at least 20 minutes within past 6 hours;
* Will undergo primary PCI;
* Has ECG evidence of acute high risk ST elevation myocardial infarction;
* Willing and able to be followed for at least 12 months.","* Isolated low risk inferior wall myocardial infarction;
* Received fibrinolytic therapy;
* History of complement deficiency;
* Suspected neisserial infection;
* Participating in other investigational study;
* Pregnancy;
* Previous enrollment.","Pexelizumab, Placebo infusion",INTERVENTIONAL,COMPLETED
NCT00321009,LV Thrombus Pilot Study for Comparing Enoxaparin Vs. Warfarin,"Coronary Artery Disease, Acute Myocardial Infarction","* Age 18 to 80
* Anterior myocardial infarction with:

  1. Pathological Q-waves in at least 3 contiguous anterior precordial leads, assumed to be new
  2. CK peak\>5 times the upper limit of normal with positive MB bands
* Ejection fraction \<=40% or anterior dyskinesis or documented LV Thrombus
* MI onset \< 7 days from randomization","* Inability to give written informed consent
* Medical conditions that would prohibit discharge within 48 hours with the exception of need for anticoagulation
* Cardiogenic shock, rest angina unresponsive to medical therapy or serious ventricular arrhythmia in the 24 hours prior to randomization
* Patients scheduled for surgical procedure in the next 4 months that would prevent use of enoxaparin or warfarin
* Anemia: Baseline Hgb\<=9 gm for women, \<=10 gm for men or platelet count\<100,000
* Renal insufficiency (creatinine \>2.0 mg/dl)
* Serious liver disease as reflected by INR\>1.3
* Stroke within past 6 months or a prior documented intracranial or subarachnoid hemorrhage
* Active bleeding or major surgery within 2 weeks prohibiting the use of anticoagulants
* Acute pericarditis
* Women of childbearing potential unless pregnancy test negative
* Cardiac or non-cardiac condition with expected survival\< 6 months
* Severe peripheral vascular disease
* Patients who undergo cardiac surgery, including CABG, as a result of their index myocardial infarction
* Allergy to aspirin, heparin or warfarin, pork or pork products
* History of recurrent thromboembolic disease or a history of Protein C, Protein S, antithrombin III deficiency or known bleeding disorder.
* Current use of warfarin or need for chronic anticoagulation
* Current participation in other trials using investigational drugs or devices
* Prior enrollment in this trial",Enoxaparin,INTERVENTIONAL,COMPLETED
NCT00414609,Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE),Myocardial Infarction,"Core Study Inclusion Criteria:

* Male or female patients 18 years and older.
* Patients within 7-42 days of an acute myocardial infarction associated with left ventricular systolic dysfunction.
* Documented left ventricular systolic dysfunction associated with the qualifying acute myocardial.
* Patients must be on stable doses of the following concomitant medications for at least 2 weeks prior to Visit 1 unless contraindicated due to intolerance:

  * A Beta-blocker
  * An Anti-platelet agent
  * A Statin
  * An evidence-based dose of an Angiotensin Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB) but not both.
* Qualifying Echocardiogram at Visit 1:

Core Study",":

* Patients requiring both Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin Receptor Blocker (ARB) combination therapy at V1 or any time during the study.
* Severe refractory hypertension defined as mean sitting systolic blood pressure (MSSBP) ≥ 180 mmHg and/or mean sitting diastolic blood pressure (MSDBP) ≥ 110 mmHg) at Visit 2.
* Cardiogenic shock or systolic BP \< 100 mmHg or diastolic \< 60 mmHg within the 24 hours prior to Visits 1 or 2
* Estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1.73m2 using the MDRD formula at Visit 1.
* Stroke or transient ischemic event (TIA) within 6 months of Study Visit 1

Extension Study Inclusion Criteria:

* Male or female patients who completed the core study through Visit 10 while on double-blind study drug
* Patients who were able to participate in the study, and who consented to do so after the purpose and nature of the study had been clearly explained to them (written informed consent)

Extension Study Exclusion Criteria:

* New York Heart Association (NYHA) class IV Congestive Heart Failure at Visit 1 (Core study Visit 10)
* Symptomatic hypotension or reported systolic blood pressure (BP) \< 90 mmHg within 24 hours prior to Visit 1 (Core study Visit 10)
* Known Estimated Glomerular Filtration Rate (eGFR) \< 30 mL/min/1.73m\^2 using the Modification of Diet in Renal Disease (MDRD) formula at Visit 1 (Core study Visit 10)
* Pregnant or nursing (lactating) women, where pregnancy was defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (\> 5 mIU/mL)
* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant Unless post-menopausal or using an acceptable method of contraception
* Any surgical or medical condition that in the opinion of the investigator may place the patient at higher risk from his/her participation in the study or was likely to prevent the patient from complying with the requirements or completing the study

Other protocol-defined inclusion/exclusion criteria applied","Aliskiren, placebo",INTERVENTIONAL,COMPLETED
NCT04340609,Stem Cell in Acute Myocardial Infarction,Acute Myocardial Infarction,"* STEMI patients within 5 days after symptom onset of a first ST-segment elevation myocardial infarction
* Have undergone successful percutaneous coronary intervention (PCI) with drug eluting stent implantation of the infarct-related artery and demonstrated hypokinesia or akinesia that involved more than two thirds of the LV anteroseptal, lateral, or inferior wall with LV ejection fraction of \< 45% by echocardiography.
* Ability to understand and provide signed informed consent, or have a designated legal guardian or spouse legally able and willing to make such decisions on the subject's behalf,
* Willingness to attend all scheduled safety follow-up visits
* Subjects need to have a specific criteria of having a single vessel disease (ostial or proximal LAD vessels) that caused extensive anterior infarction (EF \<45).","* Hemodynamic instability as demonstrated by any of the following,
* Requirement of intra-aortic balloon pump of left ventricular assist device,
* Need for inotropic support (e.g. dopamine and/or dobutamine) for more than 36 hours for the maintenance of mean arterial blood pressure ≥ 60 mmHg,
* Previous or current concomitant serious illnesses, such as cancer, hematological disorders (Hb \< 10 g/dL, WBC \< 4 or \> 11x109/L, or platelets \< 100x109/L), kidney failure (creatinine level \> 2.5 mg/dL, or creatinine clearance \< 30 cc/min), serious infection or any other co-morbidities that could impact patient's short-term survival, psychiatric illness, history of drug of alcohol abuse,
* Prosthetic valves,
* Hypertrophic or restrictive cardiomyopathy,
* Women of child-bearing potential,
* Inability to comply with the protocol,
* Currently using implantable electronic defibrillator or pacemaker",Mesenchymal Stem Cells,INTERVENTIONAL,COMPLETED
NCT03578809,A Study to Evaluate the Safety and Efficacy of MEDI6012 in Acute ST Elevation Myocardial Infarction,ST Elevation Myocardial Infarction,"* Acute STEMI (ST segment elevation myocardial infarction) diagnosed by ST elevation
* Planned for primary PCI (percutaneous coronary intervention)
* Men and women without child-bearing potential aged 30-80 years of age
* Capable and willing to provide informed consent.
* Capable of completing study visits","* Fibrinolytic administration for index event
* Known prior MI or prior coronary artery bypass graft (CABG) surgery
* Known pre-existing cardiomyopathy
* History of anaphylaxis
* Suspected non-thrombotic etiology (ie, vasospasm, dissection, Takotsubo cardiomyopathy)","MEDI6012, Placebo",INTERVENTIONAL,COMPLETED
NCT00971607,Sevoflurane In Acute Myocardial Infarction,Acute Myocardial Infarction,"* First STEMI, presenting within 6 hours after the onset of chest pain
* Symptoms lasting \> 30 minutes
* Persistent ST-segment elevation \> 0.1 mV in 2 or more contiguous leads","* Hypersensitivity to sevoflurane or other halogenated agents
* Malignant hyperthermia
* Cardiac arrest
* Cardiogenic shock
* Previous myocardial infarction or coronary bypass surgery
* Pre-infarction angina
* Heart failure (NYHA III/IV)
* Chronic inflammatory disease
* Severe renal impairment
* Hepatic dysfunction
* Use of Glyburide","Oxygen + Sevoflurane, Oxygen (placebo)",INTERVENTIONAL,COMPLETED
NCT01572909,Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events,"Reperfusion Injury, STEMI","Inclusion Criteria:

* Age ≥18 and \<85 years
* The patient presents with first-time acute, anterior wall STEMI scheduled to undergo primary PCI and stenting.
* The patient has symptoms of cardiac ischemia of ≥10 minutes.
* The patient must demonstrate an anterior wall STEMI with \>0.1 millivolt (mV) ST-segment elevation in at least two contiguous precordial leads (i.e., V1-V4) or presumed new left bundle branch block.
* The time from onset of symptoms of cardiac ischemia to the anticipated time of initial PCI balloon inflation does not exceed four (4) hours and it is anticipated that the door-to-balloon time will be \<2 hours.
* For female patients of child-bearing potential, an adequate form of contraception must be adhered to prior to entry into the study and for a further 3 months after the follow-up visit. Female patients of childbearing potential must have a negative serum pregnancy test prior to entry into the study.
* Female patients not of childbearing potential (i.e. female patients who are postmenopausal since last regular menses, or have been surgically sterilized at least 1 year prior to screening visit) are eligible to enter the study.
* For male patients with female partners of child-bearing potential, an adequate form of contraception must be adhered to prior to entry into the study and for a further 3 months after the post-study medical.
* Written informed consent obtained that strictly adheres to the written guidelines from the local Institutional Review Board (IRB)/ Ethical Committee (EC).","* Cardiogenic shock or maximal systolic blood pressure (BP) \<80 mm Hg after fluid and/or vasopressor resuscitation on at least two consecutive readings.
* Ongoing vasopressor support.
* Uncontrolled hypertension defined as a systolic BP \>180 mm Hg or a diastolic BP \>110 mm Hg on at least two consecutive readings.
* Cardiac arrest or arrhythmia requiring prolonged (\>5 minutes) chest compressions/ cardiopulmonary resuscitation (CPR).
* Prior coronary artery bypass graft surgery (CABG).
* Prior myocardial infarction (MI).
* Implantable cardioverter-defibrillator (ICD) or permanent pacemaker (PPM) unless known to be MRI safe. The presence of an MRI-compatible pacemaker or other MRI-compatible hardware will not be a contraindication to participation in this trial.
* Known left ventricular ejection fraction \<30% prior to the qualifying infarct.
* History of clinically significant hepatic disturbance or chronic renal impairment at the time of admission.
* Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the last 30 days.
* Any known disorder that is associated with immunologic dysfunction (e.g., cancer, lymphoma, a positive serologic test for the human immunodeficiency virus, or hepatitis) more recently than 6 months before presentation or the administration of immunosuppressive drugs within 10 days of the STEMI at doses expected to be associated with immunosuppression including high dose steroids (\>2.5 mg/d hydrocortisone or equal potency of synthetic steroids), tumor necrosis factor-alpha (TNF-α) blockers or methotrexate/azathioprine.
* Any condition that, in the Investigator's opinion, would prevent adherence to the requirements of the protocol including language barrier or current alcohol or drug abuse.
* Contraindications (including claustrophobia) to cardiac MRI at study entry.
* Participation in an investigational drug or device study within the 30 days prior to enrollment into the EMBRACE-STEMI Trial or anticipated within the next 4 days.
* Female patients who are pregnant or breastfeeding during the study or intend to within 30 days of receiving study drug.","Bendavia (MTP-131), Placebo",INTERVENTIONAL,COMPLETED
NCT00627809,Effect of Adjunctive Intracoronary Streptokinase on Late Term Left Ventricular Infarct Size and Volumes in Patients With Acute Myocardial Infarction,"Acute Coronary Syndromes, Acute Myocardial Infarction, Reperfusion Injury","* Continuous chest pain that lasted \> 30 minutes within the preceding 12 hours
* ST-segment elevation of at least 1 mm in 2 contiguous leads on the ECG
* Infarct related artery (IRA) occlusion (TIMI grade 0) at the angiography","* Contraindications to streptokinase, tirofiban, aspirin, clopidogrel, or heparin
* Culprit lesion in saphenous vein graft
* TIMI grade II-III flow in IRA
* Additional epicardial stenosis in the IRA distal to stented segment (significant or insignificant)
* Presence of left bundle branch block
* History of prior MI","Streptokinase, primary percutaneous coronary intervention",INTERVENTIONAL,COMPLETED
NCT01961856,Ticagrelor Loading Dose Versus Clopidogrel Loading and Reloading With Ticagrelor.,Platelet Reactivity,"* Age 18-80 years old
* Patients with STEMI (pain onset \<12 hours) undergoing primary PCI
* P2Y12 inhibitor naive
* Written informed consent","* Peri-procedural IΙb/IIIa inhibitor administration
* Cardiogenic shock/hemodynamic instability
* Pseudo-aneurism, retroperitoneal hematoma, major bleeding (need for transfusion or Hb decline≥5 gr/ dl)
* Need for anticoagulant treatment
* Current or future administration of other thienopyridines or ADP receptor inhibitors
* Known thrombocytopenia (\<100.000 / μL) at randomization
* Hct \<30% or Hct \> 52% during randomization
* Known allergy to clopidogrel or ticagrelor
* Recent (\< 6 weeks) major operation, including CABG
* History of bleeding disorders
* Known intracranial mass, arteriovenous shunt or aneurism
* Previous intracranial bleeding
* INR\>1,5
* Other clinical conditions associated with increased bleeding risk, according to the investigators' judgment
* Known creatinine Clearance \<30ml/h at randomization or hemodialysis
* Severe/moderate liver failure
* Pregnancy/ breastfeeding
* Increased risk for bradyarrhythmias, according to the investigator's judgment
* Administration of potent CYP3A inhibitor (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice N1 L/d), substrates of CYP3A with narrow therapeutic range (cyclosporine, quinidine), or potent CYP3A inducers (rifampin /rifampicin, phenytoin, carbamazepine)
* Severe uncontrolled chronic obstructive pulmonary disease","Clopidogrel and Ticagrelor, Ticagrelor",INTERVENTIONAL,COMPLETED
NCT04438356,"M-Health Care for Patients After AMI on Disease Perception, Self-Efficacy, Anxiety and Cardio-Respiratory Fitness","Mobile Health, Acute Myocardial Infarction, Undefined, Self-efficacy, Anxiety, Cardio-respiratory Fitness","* Taiwanese, understand Chinese
* Patients who are over 20 years old and have AMI (including ST segment ascending and non-ST segment ascending), diagnosed by percutaneous coronary intervention and without complications within 30±5 days, the left ventricular injection rate is greater than 40% .
* Ability and willingness to provide informed consent.
* Have a smartphone.
* Can receive and send smartphone messages.","* Those who can't express their wishes clearly (such as mental dysfunction)
* mental disorder
* Patients who participate in other research projects
* Planned coronary artery bypass surgery or other diseases that require continuous heart care.
* Abuse of alcohol or narcotics.
* Left ventricular ejection fraction (LVEF) is less than 40%.",M-Health,INTERVENTIONAL,COMPLETED
NCT00888485,Randomized Trial of Behavioral Intervention Versus Standard Treatment,Coronary Heart Disease,"* Discharged from hospital with CHD
* Age 75 years or less
* Living in hospital catchment area
* Able to understand Swedish
* Willing to accept randomized group","* Psychiatric disease
* Participated in similar study previously",Behavioral interventional program,INTERVENTIONAL,COMPLETED
NCT02824107,Psychosocial Risk Factors in Stroke and Myocardial Infarction,"Myocardial Infarction, Stroke","* Patients who have provided oral consent to participate
* Patients over 18 years
* Patients hospitalized for type 1 MI or ischemic stroke/TIA \< 24H after symptom onset
* Age \< 65 years
* With a professional activity (INSEE definition) at the time of the neuro or cardiovascular event
* At least one of the following risk factors: current smoking, obesity (waist circumference \> 88 cm (W)/102 cm (M) or a waist/hip ratio 0.85(W)/0.9(M), sedentarity (physical activity \< 150 min / week), alcohol consumption (\> 3 standard glasses per day for men, \> 2 standard glasses/d for women)","* Adult under guardianship
* Patients without national health insurance cover
* Pregnant or breast-feeding women
* Clinical state making it impossible to use questionnaires or to measure risk factors
* Stroke or TIA not related to atheroma or cardioembolism (dissection, hemopathy...)
* type \> 1 MI","blood sample, questionnaires for psychosocial factors",INTERVENTIONAL,COMPLETED
NCT01877915,"A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure","Heart Failure, Coronary Artery Disease","* Must have symptomatic heart failure for at least 3 months prior to Screening
* Participants must have an episode of decompensated heart failure (index event) requiring (a) an overnight stay \[that is, staying past midnight\] in a hospital, emergency department, or medical facility with the capability of treating with intravenous medications and observing heart failure patients before randomization or (b) an unscheduled outpatient visit to a heart failure management center, where parenteral therapy is required for heart failure stabilization. An episode of decompensated heart failure is defined as symptoms of worsening dyspnea or fatigue, objective signs of congestion such as peripheral edema or ascites, and/or adjustment of pre-hospitalization/outpatient visit heart failure medications. Participants are eligible for randomization at discharge from the facility treating the index event and up to 30 days after discharge if they are in stable condition
* Must have a documented left ventricular ejection fraction (LVEF) of less than or equal to 40 percent (%) within 1 year before randomization
* Must have evidence of significant coronary artery disease
* Must be medically stable in terms of their heart failure clinical status at the time of randomization
* Must have a brain natriuretic peptide (BNP) level greater than or equal to (\>=) 200 picogram per milliliter (pg/mL) or N-terminal-proBNP (NT-proBNP) level \>=800 pg/mL (preferred assay) during the Screening period and before randomization","* Any condition that, in the opinion of the investigator, contraindicates anticoagulant therapy or would have an unacceptable risk of bleeding, such as, but not limited to, active internal bleeding, clinically significant bleeding, bleeding at a noncompressible site, or bleeding diathesis within 28 days of randomization
* Severe concomitant disease such as (a) atrial fibrillation (AFib) or another condition that requires chronic anticoagulation (participants with isolated transient AFib may be allowed at the discretion of the treating physician investigator) and (b) Documented acute myocardial infarction (MI) during index event
* Prior stroke within 90 days of randomization
* Has been hospitalized for longer than 21 days during the index event
* Planned intermittent outpatient treatment with positive inotropic drugs administered intravenously","Rivaroxaban, Placebo, Standard of care for heart failure and coronary artery disease",INTERVENTIONAL,COMPLETED
NCT02452515,A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction,Heart Failure,"* Clinically stable patients with left-ventricular dysfunction (LVEF ≤ 45%) after myocardial infarction, whereby the MI occurred 6 or more months before randomization.

  * New York Heart Association (NYHA) class I-II.
  * Left-ventricular ejection fraction ≤ 45%, confirmed by any imaging technique within the last 3 months prior to screening visit will be accepted for screening purposes. If no data are available, an echocardiography has to be performed at screening for inclusion.
  * Treatment with evidence-based therapy for left-ventricular dysfunction post MI for at least 4 weeks prior to screening visit. This therapy has to include at least an Angiotensin-converting enzyme (ACE) inhibitor or an Angiotensin receptor blockers (ARB). Beta-blockers, diuretics, mineralocorticoid receptor antagonist (MRAs), antiplatelet therapy, statins, and aspirin are to be used if indicated. Treatment with stable doses of ACE inhibitors or ARBs using at least half of the recommended target dose (as defined in the European Society of Cardiology (ESC) guidelines, see appendix 16.4) ≥ 4 weeks prior to the screening visit is mandatory.
  * No planned changes to post MI drug therapy during the active treatment phase of the study.
  * Men or confirmed postmenopausal women (defined as being amenorrheic for longer than 2 years with an appropriate clinical profile, e.g. age appropriate and a history of vasomotor symptoms) or women without childbearing potential based on surgical treatment such as bilateral tubal ligation, bilateral oophorectomy or hysterectomy (documented by medical report verification).

Men of reproductive potential must agree to use 2 reliable and acceptable methods for contraception simultaneously when sexually active and not to act as sperm donor. This applies for the time period between signing of the informed consent form and 12 weeks after the last administration of study drug.

Acceptable methods of contraception include, but are not limited to, (i) condoms (male or female) with or without a spermicidal agent; (ii) diaphragm or cervical cap with spermicide; (iii) intra-uterine device; (iv) hormone-based contraception.

* Age: 40 to 79 years (inclusive) at the screening visit.
* Race: Caucasian","* Non-ischemic causes for cardiomyopathy will be excluded (including, but not limited to: primary cardiomyopathy, constrictive, restrictive or hypertrophic cardiomyopathy, acute myocarditis, cardiomyopathy secondary to cardiotoxic chemotherapeutic agents).
* Hospitalization for decompensated heart failure within the last 3 months prior to randomization.
* Coronary revascularization within 6 weeks prior to randomization or if revascularization is anticipated or needed during the study duration.
* Clinically relevant, cardiac ischemia in a stress test within 3 months before screening.
* Patients carrying implantable cardioverter defibrillators, cardiac resynchronisation therapy devices or left ventricular assist devices that had any significant clinical events requiring treatment or changes to background medical therapy such as ventricular tachycardias, ventricular fibrillation in the last 6 months before randomization while carrying the devices
* Primary and uncorrected valvular disease with foreseen requirement of valve repair within the next 6 months.
* Any stroke, TIA, any acute coronary syndrome within 6 months prior to randomization.
* Clinically relevant hepatic dysfunction at the screening visit indicated by at least one of the following:
* hepatic insufficiency (Child-Pugh B or C) as documented in medical history
* total bilirubin \> 2 times the upper limit normal (ULN) and
* alanine amino transferase (ALT) \> 3 times the ULN or
* glutamate dehydrogenase (GLDH) \> 3 times the ULN or
* gamma glutamyl transpeptidase (GGT) \> 5 times the ULN.
* Systolic blood pressure below 100 or above 160 mm Hg at the screening visit based on the average of 3 readings taken from the arm with the highest recordings.","BAY1142524, BAY1142524, BAY1142524, BAY1142524, Placebo",INTERVENTIONAL,COMPLETED
NCT01058915,Influence of Intensive Lipid Lowering Treatment Compared to Moderate Lipid Lowering Treatment on Plaque Composition in Patients With ST-Segment Elevation Myocardial Infarction (MI),Acute Coronary Syndrome,"* ST segment elevation acute myocardial infarction
* 20% \< angiographic diameter stenosis \< 50% on a not previously revascularized native coronary artery
* Statin naïve","* Pharmacologic lipid lowering treatment before index hospitalization
* Atrial fibrillation, not well rate-controlled
* Ventricle frequency variation with more than a factor 2 over 1 minute
* Unconscious patients
* Total cholesterol \> 7.0 mmol/l
* History of statin induced myopathy, or serious hypersensitivity reaction to other HMG-CoA reductase inhibitors (statins) including rosuvastatin
* Pregnant women, women who are breast feeding, and women of childbearing potential who are not using chemical or mechanical contraception or have a positive serum pregnancy test (a serum-human chorionic gonadotrophin \[Beta-HCG\] analysis)
* History of malignancy (unless a documented disease free period exceeding 5-years is present) with the exception of basal cell or squamous cell carcinoma of the skin, or in the case of a study designed to investigate antineoplastic properties of rosuvastatin. Women with a history of cervical dysplasia would be permitted to enter the study provided they had 3 consecutive clear Papanicolaou (Pap) smears
* Uncontrolled hypothyroidism (TSH \> 1.5xULN)
* Abnormal LFT's
* History of alcohol or drug abuse within the last 5 years (this may affect compliance)
* Current active liver disease (ALT/SGPT \>2xULN or severe hepatic impairment (to protect patient safety as directed on the labels of currently approved statins)
* Unexplained creatine kinase (CK \> 3xULN) (To protect patient safety) (will be increased at baseline because of acute ST segment elevation myocardial infarction a few days before enrolment)
* Serum creatinine \>176mmol/L (2.0mg/dL) (unless the protocol specifically aims to investigate a chronic renal disease population)
* Participation in another investigational drug study less than 4 weeks before enrolment in the study, or according to subjects local ethics committee requirements where a larger period is stipulated (to avoid potential misinterpretation of overlapping adverse events)
* Treatments with cyclosporine
* Treatment with gemfibrozil","Rosuvastatin 5mg, Rosuvastatin 40mg",INTERVENTIONAL,COMPLETED
NCT03596385,"TREatment With Beta-blockers After myOcardial Infarction withOut Reduced Ejection fracTion""",Myocardial Infarction,"* ≥18 years old
* Admitted for STEMI or NSTEMI and invasive management (i.e. coronary angiography during index hospitalization).
* LVEF\>40% as evaluated by any imaging technique anytime during hospitalization.
* Signed informed consent","* Known allergy or intolerance to beta-blockers
* Absolute contraindication to beta-blocker therapy according to treating physician judge
* Prior history of HF, Killip class on admission or during hospitalization ≥ II
* Severe valvular heart disease (\> 3+ for aortic or mitral insufficiency, aortic or mitral valve area ≤1.0 cm2).
* Any condition (appart from AMI) that requires beta-blocker prescription on discharge according to treating physician judge
* Any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year),
* Patients participating in other clinical trials",Beta blocker,INTERVENTIONAL,COMPLETED
NCT00942500,Effects of Postconditioning On Myocardial Reperfusion,"Myocardial Reperfusion, Myocardial Infarction","Inclusion Criteria General Inclusion Criteria

* Subject must be at least 18 years of age.
* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving postconditioning and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure
* Diagnosis of STEMI

  1. presence of chest pain for more than 30 minutes but less than 12 hours after symptom onset
  2. ST-segment elevation more than 1 mm in at least 2 contiguous leads

Angiographic Inclusion Criteria

* Target lesion(s) must be located in a native coronary artery
* Target lesion(s) must be amenable for percutaneous coronary intervention
* TIMI flow grade of infarct related arteries \<2

General","* Patients with hemodynamic instability or those with cardiogenic shock
* Target lesion is located in left main stem
* Rescue PCI after thrombolysis or facilitated PCI
* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
* Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study",Post-conditioning,INTERVENTIONAL,COMPLETED
NCT02415400,"A Study of Apixaban in Patients With Atrial Fibrillation, Not Caused by a Heart Valve Problem, Who Are at Risk for Thrombosis (Blood Clots) Due to Having Had a Recent Coronary Event, Such as a Heart Attack or a Procedure to Open the Vessels of the Heart",Acute Coronary Syndromes,"For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com



* Adults with either active or a history of non-valvular atrial fibrillation or flutter with the planned or existing use of an oral anticoagulant for prophylaxis of thromboembolism. In addition, subjects must have had an acute coronary syndrome or percutaneous coronary intervention with a stent within the prior 14 days
* Planned use of antiplatelet agents for at least 1 to 6 months
* Males and Females ≥ 18 years of age
* Women of childbearing potential must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug","* Conditions other than atrial fibrillation that require chronic anticoagulation. (e.g. prosthetic mechanical heart valve)
* Severe renal insufficiency (serum creatinine \> 2.5 mg/dL or a calculated creatinine clearance \< 30 mL/min
* Patients with a history of intracranial hemorrhage
* Patients have had or will undergo Coronary arterial bypass graft (CABG) for their index acute coronary syndrome (ACS) event
* Patients with known ongoing bleeding and patients with known coagulopathies
* Any contraindications or allergies to VKA, apixaban, or to intended P2Y12 antagonists or to aspirin","Apixaban, vitamin K antagonist, Acetylsalicylic acid, Acetylsalicylic acid placebo",INTERVENTIONAL,COMPLETED
NCT01404507,Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMI,Acute Myocardial Infarction,"* Subject must be between at least 18 years of age and less than 80 years of age.
* Subject is able to verbally confirm understandings of risks, benefits and treatment alternatives of receiving intracoronary abciximab and/or aspiration thrombectomy.
* He/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.
* Subject must have evidence of acute ST-segment elevation myocardial infarction with TIMI 0 or 1 flow, or visible thrombi (thrombus grade ≥ 3)
* Target lesion(s) must be located in a native coronary artery in the proximal to mid segment with estimated reference diameter of ≥ 2.5 mm and ≤ 4.0 mm.
* Target lesion(s) must be amenable for percutaneous coronary intervention.","* The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Abciximab, Contrast media (Patients with documented sensitivity to contrast media which can be effectively premedicated with steroids and diphenhydramine \[e.g. rash\] may be enrolled. Those with true anaphylaxis to prior contrast media, however, should not be enrolled.)
* Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
* History of bleeding diathesis or known coagulopathy (including heparin-induced thrombocytopenia), or refuses blood transfusions.
* Baseline hemogram with Hb\<10g/dL or PLT count \<100,000/μL
* Gastrointestinal or genitourinary bleeding within the prior 3 months, or major surgery within 2 months.
* Patients with severe LV systolic dysfunction (LVEF\<25%) or in cardiogenic shock
* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.","Gp 2b 3a inhibitor, aspiration thrombectomy, Both use",INTERVENTIONAL,COMPLETED
NCT00938847,Bone Marrow Derived Mononuclear Cells For Myocardial Regeneration,Left Ventricular Dysfunction,"* LVEF \<40%
* PCI at latest 6 hours after infarction
* BMI \>20 kg/m² and \<30 kg/m²","* PCI elder than 14 days
* relevant valvular disease
* left ventricular dysfunction caused by other reasons than ischemic cardiomyopathy
* history of stroke, chronic atrial fibrillation, multivessel disease, thromboembolic event
* scheduled for CABG
* DM Type 1 \& extensive hypercholesterinemia
* pacemaker
* systemic disease
* Pregnancy",PCI,INTERVENTIONAL,COMPLETED
NCT00373451,Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome,"Myocardial Infarction, Coronary Disease","* Episode of unstable angina
* Elevated cardiac markers
* Angiographic lesions requiring PCI
* Informed, written consent","* Age \< 18 years and \> 80 years
* ST-segment elevation acute myocardial infarction within 48 hours
* Cardiogenic shock
* Pericarditis
* Malignancies or other comorbid conditions with life expectancy less than one year or that may result in protocol non-compliance
* Active bleeding; bleeding diathesis; history of gastrointestinal or genitourinary bleeding, recent trauma or major surgery in the last month; history of intracranial bleeding or structural abnormalities; suspected aortic dissection; pericarditis; and patient's refusal to blood transfusion
* Oral anticoagulation therapy with coumarin derivative within the last 7 days
* Recent use of GPIIb/IIIa inhibitors within 14 days
* Treatment with unfractionated heparin within 4 hours unless ACT \> 150sec; or low-molecular weight heparin within 8 hours before randomization
* Treatment with bivalirudin within 24 hours before randomization
* Severe uncontrolled hypertension \> 180/110 mm Hg unresponsive to therapy
* Planned staged PCI procedure within 30 days from index procedure or prior PCI within the last 30 days
* Relevant hematologic deviations
* Glomerular filtration rate (GFR) \< 30 ml/min or serum creatinine \> 30 mg/L or dependence on renal dialysis
* Known allergy or intolerance to the study medications, stainless steel or true anaphylaxis after prior exposure to contrast media
* Previous enrollment in this trial
* Women who are known to be pregnant, who are of childbearing potential and test positive for pregnancy, who have given birth within the last 90 days, who are breastfeeding
* Patient's inability to fully cooperate with the study protocol","Abciximab + UFH, Bivalirudin, Heparin",INTERVENTIONAL,COMPLETED
NCT00765453,Bone Marrow Derived Adult Stem Cells for Acute Anterior Myocardial Infarction,Acute Myocardial Infarction,"* Patients presenting to the Heart Attack Centre with acute anterior myocardial infarction (ST elevation in at least 2 contiguous anterior leads ≥ 0.2 mV) and treated with acute PCI with stent implantation within 24 hours after symptom onset
* Acute PCI / stent implantation has been successful (residual stenosis visually \< 30% and TIMI flow ≥ 2).
* At the time of inclusion patient no longer requires i.v. catecholamines or mechanical hemodynamic support (aortic balloon pump)
* Significant regional wall motion abnormality in LV angiogram at the time of acute PCI in the LAD territory
* Age 18 - 80 Years (primary angioplasty confers an adverse prognosis in those over the age of 80 years)
* Written informed consent in the recruiting centres native language","* Regional wall motion abnormality outside the area involved in the index acute myocardial infarction
* Need to revascularise additional vessels, outside the infarct artery as a planned procedure (these vessels can be treated at baseline)
* Arteriovenous malformations or aneurysms
* Active infection, or fever or diarrhoea within last 4 weeks
* Chronic inflammatory disease
* Known HIV infection or active hepatitis
* Neoplastic disease without documented remission within the past 5 years
* Cerebrovascular insult within 3 months
* Impaired renal function (creatinine \> 200mmol) at the time of cell therapy
* Significant liver disease (GOT \> 2x upper limit) or spontaneous INR \> 1,5)
* Anemia (hemoglobin \< 8.5 mg/dl)
* Platelet count \< 100.000/µl
* Hypersplenism
* Known allergy or intolerance to clopidogrel, heparin or abciximab
* History of bleeding disorder
* Gastrointestinal bleeding within 3 months
* Major surgical procedure or trauma within 2 months
* Uncontrolled hypertension
* Pregnancy
* Mental retardation leading to inability to obtain informed consent
* Previously performed stem / progenitor cell therapy
* Participation in another clinical trial within the last 30 days","Bone marrow derived progenitor cells or placebo infusion, Placebo infusion",INTERVENTIONAL,COMPLETED
NCT01324453,Phase II Clinical Trial to Evaluate the Benefits of Postconditioning in ST-Elevation Myocardial Infarction (STEMI),Acute Myocardial Infarction,"* Age \> 18 years old, \< 80 years old
* Able to give informed consent
* Able to undergo cMRl (cardiac magnetic resonance imaging
* ST-segment elevation infarction with 100% occlusion of a major epicardial vessel (\> 2.5 mm)
* No angiographic evidence of collateral flow distal to occluded artery
* Ischemic duration between 1.0 and 6 hours
* Thrombolysis in myocardial infarction (TIMI) 3 Flow following PCI","* Visible collateral blood flow to the distal vasculature of the occluded vessel
* Previous Coronary Artery Bypass Graft surgery
* Previous q-wave myocardial infarction in the same territory
* Inability to give informed consent
* Inability to undergo cMRl
* Life expectancy less than one year
* History of Non-compliance or alcohol or drug addiction
* Patients with cardiogenic shock, cardiac arrest, hypothermia on presentation
* Chronic dialysis or significant renal insufficiency (Creatinine Clearance \< 35 mI/mm/i .73 m2)
* TIMI Flow \> 0 on presentation
* Ischemic Time \> 6 hours or \< 1.0 hours
* Presence of significant valvular heart disease (\>mod Aortic Stenosis, \>2+ Mitral Regurgitation)
* Known Left Ventricular systolic dysfunction (Left Ventricular Ejection Fraction \< 50% prior to STEMI)","Post Conditioning + Primary PCI, Standard Primary PCI",INTERVENTIONAL,COMPLETED
NCT03208153,the Invasive and Conservative Strategies in Elderly Frail Patients With Non-STEMI,"Non-ST Elevation Myocardial Infarction, Frail Elderly Syndrome","* Non-ST-elevation acute myocardial infarction
* Age ≥70 years
* Frailty criteria defined by =\>4 points in the Clinical Frailty Scale (Rockwood K CMAJ 2005).","* Prior known non-revascularizable coronary artery disease
* Significant concomitant non-ischemic heart disease (i.e. severe heart valve disease, hypertrophic cardiomyopathy...)
* Unable to understand/sign informed consent
* Life expectancy \<12 months","Invasive, Conservative",INTERVENTIONAL,COMPLETED
NCT02715453,Intervention in Frailty Versus Usual Care in Frail Patients After an Acute Myocardial Infarction,Fragility,"* Admission for acute myocardial infarction and survivors in the hospitalization phase
* Age =\>70 years
* Prefrail or frail status (Fried scale =\>1 points)","* Cognitive impairment (Pfeiffer test)
* Severe concomitant disease that could hamper the participation in the study
* Patient refusal to participate",Intervention on frailty,INTERVENTIONAL,COMPLETED
NCT01437553,Imaging Whole Coronary Artery With Intravascular Ultrasound (Ivus) And Imap For Plaque Tissue Composition In Patients With Acute Myocardial Infarction,Acute Coronary Syndrome,"* Age \< 75 years
* Diagnosis of NSTEMI/STEMI with prior use of fibrinolytics in the past 7 days
* Signature of the Term of Informed Consent","* Hemodynamic instability
* Clinical signs of post-AMI ventricular dysfunction (Killip III/IV)
* Angiographic findings of (1)coronary anatomy with significant tortuosity, (2) critical coronary obstruction preventing the passage of the IVUS catheter and (3) total occlusion of any of the three epicardial coronary arteries.",iMAP,INTERVENTIONAL,COMPLETED
NCT01205347,Effect of Statin Treatment on Insulin Sensitivity During Myocardial Infarction,Myocardial Infarction,"* Less than 24 hours after the onset of MI symptoms
* ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads
* Myocardial necrosis, as evidenced by increased Creatine Kinase-MB (CK-MB) and troponin levels",* Diabetes or prior use of statins in the last 6 months,"Simvastatin 80mg, Simvastatin 10mg",INTERVENTIONAL,COMPLETED
NCT00699998,A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects,Acute Coronary Syndrome,"Key 

* Have had a Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) index event within 10 days prior to randomization
* Had a medical management strategy decision made with reasonable certainty that neither percutaneous coronary intervention (PCI) nor coronary artery bypass graft (CABG) is planned for treatment of the index event
* Had at least 1 of 4 specified high-risk features at the time of the UA/NSTEMI event

Key","* Decision for medical management greater than 72 hours after onset of index event without commercial clopidogrel treatment within 72 hours following onset of the index event.
* Insignificant coronary artery disease (CAD) on coronary angiography if performed for Index Event (absence of greater than or equal to 30% stenosis in at least one native vessel)
* Previous or planned PCI or CABG as treatment for the index event
* PCI/CABG within previous 30 days
* ST-segment elevation myocardial infarction (STEMI) as the index event
* Cardiogenic shock, Refractory ventricular arrhythmias, New York Heart Association (NYHA) Class IV congestive heart failure (CHF) within the previous 24 hours
* History of ischemic or hemorrhagic stroke, transient ischemic attack (TIA), Intracranial neoplasm, arteriovenous malformation, or aneurysm
* History of spontaneous gastrointestinal (GI) or non-GI bleeding requiring hospitalization for treatment, unless definitive treatment has occurred and there is low likelihood of recurrence
* Hemodialysis or peritoneal dialysis","Clopidogrel, Prasugrel, Commercially-available Aspirin",INTERVENTIONAL,COMPLETED
NCT03487445,A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack,Acute Myocardial Infarction,"Main 

* Informed consent obtained prior to any study-mandated procedure,
* Males aged from 18 to 85 and postmenopausal females aged up to 85 years,
* Onset of symptoms of AMI of more than 30 min and less than 6 hours prior to randomization,
* Subjects presenting a type I AMI including STEMI or NSTEMI.

Main","* Cardiogenic shock or severe hemodynamic instability,
* Cardiopulmonary resuscitation,
* Loading dose of any oral P2Y12 receptor antagonist prior to randomization,
* Planned fibrinolytic therapy or any fibrinolytic therapy administered within 24 h prior to randomization,
* Known platelet disorders (e.g., thromboasthenia, thrombocytopenia, von Willebrand disease).
* Active internal bleeding, or bleeding diathesis or conditions associated with high risk of bleeding.
* Known clinically important anemia.
* Oral anticoagulation therapy within 7 days prior to randomization","Selatogrel 8 mg, Selatogrel 16 mg",INTERVENTIONAL,COMPLETED
NCT00419198,Clinical Outcomes of Angioplasty Postconditioning,Acute Myocardial Infarction,"* Male and female patients, aged more than 18, with suspected first acute myocardial infarction, within 6 hours of the onset of chest pain, with a need for emergency revascularization by angioplasty. Patients must display a fully occluded (TIMI zero flow) culprit coronary artery, absence of visible collaterals and exhibit TIMI flow \>2 after direct stenting by angioplasty.","* Cardiac arrest or cardiogenic shock
* occlusion of the circumflex coronary artery","Postconditioning, standard angioplasty",INTERVENTIONAL,COMPLETED
NCT00874354,Randomized Evaluation of Intracoronary Transplantation of Bone Marrow Stem Cells in Myocardial Infarction,Myocardial Infarction,"* Patients with acute myocardial infarction (ST elevation in at least 2 leads ≥ 0.2 mV in V1,V2 or V3 or ≥ 0.1 mV in other leads), treated by one of the following procedures:

  * Acute PCI with stent implantation for acute ST elevation MI for either denovo lesions or in-stent thrombosis
  * Treatment with thrombolysis followed by PCI with stent implantation.
* Acute PCI / stent implantation has been successful (residual stenosis visually \< 30% and TIMI flow ≥ 2).
* At the time of inclusion (≥ 1 day post PCI) patient does no longer require i.v. catecholamines or mechanical hemodynamic support (aortic balloon pump)
* Significant regional wall motion abnormality on echocardiography at the time of acute PCI (ejection fraction ≤ 50% on visual estimation).
* Maximal cardiac troponin elevation ≥ 4 (measured at 37° C)
* Age 18 - 80 Years
* Written informed consent","* Regional wall motion abnormality outside the area involved in the index acute myocardial infarction.
* Need to acutely revascularize additional vessels, outside the infarct artery.
* Arteriovenous malformations or aneurysms
* Active infection or fever or diarrhea within last 4 weeks.
* Chronic inflammatory disease
* HIV infection or active hepatitis
* Neoplastic disease without documented remission within the past 5 years.
* Cerebrovascular insult within 3 months
* Impaired renal function (creatinine \> 2 mg/dl) at the time of cell therapy
* Significant liver disease (GOT \> 2x upper limit) or spontaneous INR \> 1.5)
* Anemia (hemoglobin \< 8.5 g/dl)
* Platelet count \< 100,000/µl
* Hypersplenism
* History of bleeding disorder
* Gastrointestinal bleeding within 3 months
* Major surgical procedure or trauma within 2 months
* Uncontrolled hypertension
* Pregnancy
* Mental retardation
* Previously performed stem / mononuclear cell therapy
* Participation in another clinical trial within the last 30 days",Intracoronary Transplantation of Bone Marrow Stem Cells,INTERVENTIONAL,COMPLETED
NCT02419833,Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients,Myocardial Infarction,"1. episode of chest pain occurring no longer than 24 hours prior to admission
2. elevation of cardiac troponin I above the upper limit of normal (ULN)
3. new ST-segment depression at least 1 millivolt (mV) and/or T-wave inversion or transient ST-segment elevation in ≥ 2 contiguous leads","1. age \< 18 years
2. persistent ST-segment elevation
3. hemodynamic instability
4. cardiogenic shock on admission
5. life-threatening ventricular arrhythmias on admission
6. refractory angina on admission
7. active bleeding
8. any contraindication for the use of dual antiplatelet therapy (DAPT)
9. presence of comorbidities with life expectancy \< 6 months","Immediate invasive intervention, Delayed invasive intervention, Coronary artery stenting",INTERVENTIONAL,COMPLETED
NCT00453947,Non-Invasive Ventilation in Pulmonary Edema,"Pulmonary Edema, Myocardial Infarction","* rapid onset of the symptoms
* severe dyspnoea at rest
* respiratory rate \> 30 breaths per minute
* use of accessory respiratory muscles
* oxygen saturation (SpO2) inferior to 90% with an inspiratory oxygen fraction of 60% via a Venturi mask
* radiological findings of ACPE","* acute ischemic heart disease (myocardial infarction, chest pain, ST elevation)
* hemodynamic instability (i.e. systolic blood pressure \< 90 with dopamine or dobutamine infusion ≥ 5 mcgr/Kg/min) or life-threatening arrhythmias
* need for immediate endotracheal intubation (respiratory arrest, bradypnea or gasping)
* inability to protect the airways
* impaired sensorium (i.e. unconsciousness or agitation)
* inability to clear secretions
* respiratory tract infection
* recent oesophageal/gastric surgery
* gastrointestinal bleeding
* facial deformities
* hematological malignancy or cancer with an Eastern Cooperative Oncology Group performance status ≥ 2
* chronic respiratory failure necessitating long-term oxygen therapy
* diagnosis of myocardial infarction, pulmonary embolism, pneumonia, exacerbation of chronic obstructive pulmonary disease, pneumothorax in the previous 3 months
* denial or refusal of intubation
* claustrophobia
* inclusion in other research protocols",CPAP and Non Invasive Ventilation,INTERVENTIONAL,COMPLETED
NCT00901277,Supporting Post Myocardial Infarction (MI) Risk Modification Intervention Via Telemedicine Evaluation,Cardiovascular Disease,"* Admitted to Duke University Medical Center (DUMC) with both the diagnosis of acute MI (ICD code 410.01-410.91) and hypertension (ICD-9 code 401.X or clinical diagnosis)
* A cardiac catheterization at DUMC within the past 3 years
* Age \> 18 years
* Established or planned follow-up with a primary care/cardiology provider within the Duke University Health System or its Affiliated Clinics","Medical Records Exclusion (occurs prior to mailing invitation):

* Diagnosis of metastatic cancer in the past 6 months
* Active diagnosis of psychosis or dementia
* Currently receiving hemodialysis
* Patients who have had a transplant

Patient-Level Exclusion (occurs at initial interview):

* Does not have access to a telephone
* Does not have access to a computer
* Refusal to provide informed consent
* Resident in nursing home or receiving home health care
* Severely impaired hearing or speech (patients must be able to respond to phone calls)
* Participating in another study (i.e., pharmaceutical trial)
* NYHA class IV heart failure
* Does not plan to have long-term follow-up with a primary care provider cardiologist","web intervention, nurse intervention",INTERVENTIONAL,COMPLETED
NCT01835353,"High (100mg) Versus Standard (60mg) Loading Dose of Prasugrel in Patients With ST-elevation Myocardial Infarction (STEMI), Undergoing Primary Percutaneous Coronary Intervention (PCI)",Platelet Reactivity,"* ST elevation myocardial infarction
* Pain onset \<12 hours
* Age \>18 and \<75 years
* Written informed consent","* history of stroke/transient ischemic attack
* oral anticoagulation
* hemodynamic instability
* platelet count \<100000/μL
* hematocrit \<30%
* creatinine clearance \<30 ml/min
* severe hepatic dysfunction
* active bleeding
* weight \<60 Kg
* periprocedural IIb/IIIa inhibitor administration","Prasugrel 100mg loading dose, Prasugrel 60mg loading dose",INTERVENTIONAL,COMPLETED
NCT04573751,The EPIVER Randomized Controlled Trial,"ST Elevation Myocardial Infarction, Percutaneous Coronary Intervention, No-Reflow Phenomenon","* patients with ST-elevation myocardial infarction
* Infarct-related artery TIMI flow grade 0-2 during the interventional procedure after the initial opening of the vessel.
* Written the informed consent to participate in research",* Unable to undergo or contra-indications for MRI or SPECT,"Standard therapy, Epinephrine, Verapamil, Epinephrine + verapamil",INTERVENTIONAL,COMPLETED
NCT00426751,Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI),"Infarction, Myocardial","* Women must be postmenopausal (i.e.12 months without menstrual period), or surgically sterile, i.e. women of child bearing potential are not allowed to be included into the study. In cases of doubt a pregnancy test should be performed. (NB -post menopausal women currently receiving hormone replacement are permissible)
* Acute myocardial infarction \< 12 h defined as:

  1. Angina or equivalent symptoms \> 20 min and
  2. ST elevation in 2 contiguous ECG leads (= 2 mm precordial lead, = 1 mm limb lead). This ECG recording serves as baseline ECG, i.e. ECG I.
* Planned primary percutaneous coronary intervention
* The subject has given written informed, dated consent to participate in the study","* Subjects not able to give informed consent
* Left Bundle Branch Block
* Thrombolytic therapy within 24 hours before randomization
* Oral anticoagulation with International Normalized Ratio (INR) \> 2
* Known platelets \< 100.000/µl or known hemorrhagic diathesis
* Stroke or Transient Ischemic Attack (TIA) within the past 6 months or any permanent residual neurological defect
* Evidence of an active gastrointestinal or urogenital bleeding
* Major surgery within 6 weeks
* History of allergic reaction to abciximab or eptifibatide or any component used in the study (including contrast media)
* Known severe renal (creatinine clearance \<30ml/min) or hepatic insufficiency as well as Alanine transaminase (ALT)/aspartate transaminase (AST) elevations = 3xUpper limit normal (ULN); isolated AST-elevation is not considered an exclusion criteria from study participation
* Severe concomitant disease with life expectation \< 1 year
* Subject has participated in any study using an investigational drug or device within 30 days or within 5 half-lives of the investigational drug (whichever is longer) of entry into this study.
* Subjects who will be inaccessible due to geographic or social factors during treatment or follow-up
* In France, a subject is neither affiliated with nor a beneficiary of a social security category.","Abciximab, Eptifibatide",INTERVENTIONAL,COMPLETED
NCT03435133,Prasugrel vs. Ticagrelor on Myocardial Injury in STEMI,ST Elevation Myocardial Infarction,"* age 18 years or older and equal or less than 75 years
* symptom onset within 12 hours before random assignment
* chest pain lasting more than 30 minutes
* ST-segment elevation of at least 0.1 mV in at least 2 limb leads, ST-segment elevation of at least 0.2 mV in 2 or more contiguous precordial leads, or left bundle-branch block or paced rhythm
* time from symptoms onset to randomization less than 6 hours
* no severe heart failure (Killip class \<3)
* informed, written consent","* history of myocardial infarction with Q wave
* history of surgical or percutaneous coronary revascularization
* cardiogenic shock, defined as a systolic blood pressure \<90 mm Hg with no response to fluid administration or \<100 mm Hg in patients with supportive treatment and no bradycardia
* history of stroke
* history of bronchial asthma
* symtomatic sinusal bradicardia or advance AV block
* history of hypersensitivity to aspirin, prasugrel or ticagrelor or contraindication to the doses established in the study
* patients pretreated with 600 mg of clopidogrel or more
* contraindication for the use of gadolinium during the magenitc resonance","Prasugrel, Ticagrelor",INTERVENTIONAL,COMPLETED
NCT01398254,Femoral Versus Radial Access for Primary PCI,"Myocardial Infarction, STEMI","1. Ischemic chest discomfort of greater or equal to 30 minutes duration,
2. Onset of chest pain of greater or equal to 12 hrs prior to entry into the study,
3. ST segment elevation of \> 1 mm (0.1 mV) in two or more contiguous electrocardiographic leads (on a standard 12 lead ECG) or left bundle branch block not known to be old","1. Age \< 18 yrs
2. Active bleeding
3. Inadequate vascular access from the femoral arteries (i.e. severe peripheral vascular artery disease precluding right or left femoral approach)
4. Abnormal Allen's test precluding either right or left radial approach
5. PCI within the last 30 days
6. Fibrinolytic agents within the last 7 days
7. Warfarin, dabigatran or other oral anticoagulant within the last 7 days
8. Known coagulation disorder (i.e. INR \>2.0, platelets \<100,000 / mm3)
9. Allergy to aspirin
10. Participation in a study with another investigational device or drug \< four weeks
11. Known severe renal impairment (creatinine \>200 umol/L)\*
12. Known severe contrast (dye) allergy
13. Prior coronary artery bypass surgery
14. Inability to provide informed consent

    * Bivalirudin is contraindicated in renal failure.",Primary Percutaneous Coronary Intervention (PPCI),INTERVENTIONAL,COMPLETED
NCT02931045,Antiplatelet Therapy Effect on Extracellular Vesicles in Acute Myocardial Infarction,Myocardial Infarction,"* Age \> 18 years
* Informed consent to participate in the study
* Percutaneous coronary intervention with stent implantation due to first S T elevation myocardial infarction, or first non S T -elevation myocardial infarction
* Administration of a loading dose of clopidogrel","* Known coagulopathy
* Known history of bleeding disorder
* Suspicion of intracranial haemorrhage
* Need for oral anticoagulation therapy
* Administration of glycoprotein (GP) II b - III a antagonists
* Cardiogenic shock
* Severe chronic renal failure (estimated glomerular filtration rate \< 30 mL/min)
* Severe liver insufficiency
* Chronic dyspnea
* Increased risk of bradycardia
* Autoimmune disease
* Infectious disease
* Neoplasms
* Pregnancy
* Study drug intolerance
* Co-administration of ticagrelor or clopidogrel with strong CYP3A4 inhibitors
* Participation in any previous study with ticagrelor or clopidogrel","Ticagrelor, Clopidogrel",INTERVENTIONAL,COMPLETED
NCT04723953,Cardiac Fibroblast Activation Detected by 68Ga-FAPI PET/MR,Myocardial Remodeling After AMI,"* between 18-75 years old
* diagnosed with coronary angiography
* performed percutaneous coronary intervention，with successful myocardial reperfusion","* unstable hemodynamics
* MR contraindications (such as pacemaker or nerve stimulator or metal foreign body, high fever, severe renal failure, etc.)
* Claustrophobia",68Ga-FAPI PET/MRI,INTERVENTIONAL,COMPLETED
NCT00257153,Thrombus Aspiration Before Standard Primary Angioplasty Improves Myocardial Reperfusion in Acute Myocardial Infarction.,Acute Myocardial Infarction,* ST-segment elevation myocardial infarction patients undergoing primary angioplasty within 12 hours from symptom onset.,"* Cardiogenic shock, previous infarction, previous coronary bypass surgery,bundle branch block or pacemaker induced rythm, controindications to IIb/IIIa inhibitors.",Coronary thrombus aspiration catheter,INTERVENTIONAL,COMPLETED
NCT01584453,Safety and Effectiveness of Intra-coronary Nitrite in Acute Myocardial Infarction,"Myocardial Infarction, Reperfusion Injury, Myocardial Ischemia, Cardiovascular Diseases","* Patients aged at least 18 years
* Acute STEMI with ECG showing ST-segment elevation of 1mm or more in two adjacent limb leads or 2mm or more in at least two contiguous precordial leads or new left bundle branch block;
* Haemodynamically stable
* Estimated symptom to balloon or aspiration time \< 6 hours
* Angiographically i) PPCI indicated for revascularisation ii) Single epicardial artery to be treated iii) Expected ability to use over the wire balloon","* Patients on organic nitrate treatment (Nicorandil, isosorbide mononitrate)
* Previous history of AMI, systolic dysfunction or CABG
* Subjects presenting with cardiogenic shock (systolic blood pressure \<80 mmHg for \> 30 minutes, or requiring inotropes/emergency intra aortic balloon pump or cardiopulmonary resuscitation
* Current diagnosis of or treatment for malignancy, other than non-melanoma skin cancer.
* Current life-threatening condition other than vascular disease that may prevent a subject completing the study.
* Use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is the longer) preceding the first dose of study medication.
* Patients considered unsuitable to participate by the research team (e.g., due to medical reasons, laboratory abnormalities, or subject's unwillingness to comply with all study-related procedures).
* Severe acute infection, or significant trauma (burns, fractures).
* Pregnancy.
* Contra-indications to CMR scanning i) Pacemakers, intracranial clips or other metal implants ii) Claustrophobia iii) Renal failure (eGFR \< 30mls/min)
* History of alcohol or drug abuse within the past 6 months.
* History of congenital methaemoglobinaemia.
* Angiographically severe vessel tortuosity, diffuse disease or severe calcification which may impede successful delivery of the the over the wire balloon.","Sodium Nitrite, Sodium Chloride Placebo",INTERVENTIONAL,COMPLETED
NCT03400553,Troponin POCT in the Diagnosis of an Acute Myocardial Infarction,"Acute Myocardial Infarction, Troponin","* Non-traumatic thoracic pain
* Transportation via ambulance or MUG
* Written informed consent form (ICF) has to be obtained from the patient",* Age \<18 years,Blood analysis,INTERVENTIONAL,COMPLETED
NCT01523054,Metoprolol in Acute Myocardial Infarction. A PK/PD Study,Acute Myocardial Infarction,"* Male and female patients admitted to the CCU with suspected acute myocardial infarction
* Age 18 years or older
* Treated with and tolerated the full dose of metoprolol IR 50 mr four times daily or metoprolol CR/XL 200 mg once daily on study day 1
* Expected to stay in the CCU until the morning of study day 4
* Sinus rhythm on the day of admission and at randomisation","* Pregnancy or childbearing potential without adequate contraception
* Participation in a clinical study during the last 30 days or previous randomisation in the present study","Metoprolol- Toprol XL, Metoprolol- Lopressor",INTERVENTIONAL,COMPLETED
NCT04463251,Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction,Acute ST Segment Elevation Myocardial Infarction,"* Subjects who gave voluntary written Informed consent to participate in the study and to follow all Protocol procedures.
* STEMI diagnosis defined as chest pain or its equivalent with ECG findings evidencing ST elevation (\>1 mm) in two or more consecutive leads or acute left bunch branch block according the investigator's judgement.
* Percutaneous coronary intervention (PCI) with stenting was performed within no more than 12 hours after onset of chest pain or its equivalent and randomization was performed in no more than 12 hours after PCI (overall within 24 hours of onset of chest pain or equivalent).
* Consent of female subjects with childbearing potential defined as all female subjects with physiological potential to conceive, to use highly effective contraceptive methods throughout the study starting from screening (signing Informed Consent Form) and negative pregnancy test.

Highly effective contraceptive methods include combination of two of the following methods (a+b or a+c or b+c):

1. oral, injection or implanted hormonal contraceptives; in case of oral contraceptives, the female subjects should administer the same product for at least 3 months prior to the study therapy;
2. intrauterine device or contraceptive system;
3. barrier methods: condom or occlusive cap (diaphragm or cervical cap / vaginal fornix cap) with spermicidal foam/gel/film/cream/vaginal suppository

   * Ability and willingness of the subject, according to the reasonable investigator's judgment, to attend the study site at all scheduled visits, undergo the study procedures and follow the Protocol requirements including subcutaneous injections by qualified site personnel.","* Hypersensitivity to test product (RPH-104) and/or its ingredients/excipients.
* Pregnancy and breastfeeding.
* Verified chronic heart failure (The American Heart Association / The American College of Cardiology (AHA/ACC) C-D class, New York Heart Association (NYHA) Functional class (FC) III-IV)
* Pre-existing severe valvular heart disease according to the investigator's assessment.
* Pre-existing left ventricular (LV) dysfunction (ejection fraction (EF)\<40%)
* History of STEMI
* Complications of acute myocardial infarction (MI) in the form of acute left ventricular failure and cardiogenic shock defined as stable blood pressure decrease (SBP\<90 mm Hg) associated with signs of hypoperfusion as well as cases when inotropic and/or mechanical support is required to maintain SBP; and / or unstable hemodynamics.
* Active infections (acute or chronic); active tuberculosis.
* Recent (less than 5 half-life periods) or current administration of colchicine, as well as agents with an immunosuppressant mechanism of action, including, but not limited to:

glucocorticoids at doses of \> 1 mg/kg of methylprednisolone equivalent, tumor necrosis factor-alfa (TNFα) blockers, Interleukin-1 (IL-1) and other biological drugs, cyclosporine and other immunosuppressants. Non-steroidal anti-inflammatory drugs (NSAIDs) are allowed.

* Immunization with live vaccines within 90 days prior to the study product administration.
* Chronic systemic autoimmune or autoinflammatory diseases
* Suspected necessity in cardiosurgery.
* Oncology (or diagnosis of oncology within the last 5 years).
* History of organ transplantation or necessity in transplantation at the screening initiation or scheduled transplantation during the study.
* Neutropenia (absolute neutrophil count \<1800/mm\^3).
* Participation in another clinical study within the previous 3 months prior to Screening visit.
* Other medical (including mental) conditions or abnormal laboratory findings which may increase the risk for the subject associated with the study participation or administration of the study products or which may affect interpretation of the study results and, according to the investigator, render the subject ineligible for the study.\*

  \*If, in the Investigator's opinion, administration of a non-live COVID-19 (SARS-CoV-2) vaccine increases the risk for the patient related to his/her participation in the study, the Investigator can make a decision not to include this patient into the study.
* The subjects working at the study site or subjects working for Sponsor directly involved in this clinical study.","RPH-104 80 mg, Placebo",INTERVENTIONAL,COMPLETED
NCT01235351,Escalating Clopidogrel by Involving a Genetic Strategy - Thrombolysis In Myocardial Infarction 56,"Myocardial Infarction, Percutaneous Coronary Intervention","Inclusion Criteria (major):

1. Between 18 and 75 years of age, inclusive.
2. Have an indication for the use of clopidogrel defined as either spontaneous MI \[hospitalized with final diagnosis of MI, excluding periprocedural or definite secondary MI (e.g., due to anemia or hypertensive emergency)\] or PCI within the past 6 months.
3. Clinically stable and at least 4 weeks following the MI or PCI.","(major):

1. Conditions that alter platelet function.
2. Conditions that increase bleeding risk.","Clopidogrel, Clopidogrel",INTERVENTIONAL,COMPLETED
NCT01187654,Bone Marrow Derived AC 133+ and Mono-Nuclear Cells (MNC) Implantation in Myocardial Infarction (MI) Patient,Myocardial Infarction,"* BMI\> 30
* First acute MI in LAD territory
* St elevation MI
* Ejection fraction: 20-45%
* at least two non - mobile or less mobile segment of left ventricular myocard.
* Successful PCI with stenting","* Multivessel ceremony artery disease
* Pulmonary edema
* SBP \< 80 mmHg
* Thrombocytopenia (PLT \< 50, 000)
* INR \> 2
* Hepatic failure or dysfunction
* Renal failure or dysfunction
* Positive HIV Ab/ HBC Ab/ HCV Ab/ HSV Ag
* Documental terminal illness
* Documental Malignancy
* Patient with sever coronary disease and unstability of vital sign
* History of leukopenia, Anemia, hepatic or renal dysfunction or malignancy","AC133, MNC, CONTROL",INTERVENTIONAL,COMPLETED
NCT01529554,Controlled Level EVERolimus in Acute Coronary Syndromes,Acute Coronary Syndromes,"1. Elevation Myocardial Infarction (STEMI) as defined by:

   * ST-Elevation \> 1mm in \> 2 leads OR
   * Novel left bundle branch block (LBBB) OR
   * Posterior MI with ST-Depression \> 1mm in \> 2 leads
2. Chest pain duration of \> 10 minutes
3. Primary Coronary Intervention (PCI) with drug-eluting stent (DES) within 24 hours of chest pain onset in the occluded culprit artery
4. First Myocardial Infarction
5. Occluded coronary artery at angiography specifically occlusion of one coronary vessel in the proximal third of either LAD, RCX or RCA, the mid segment of right coronary artery (RCA) or mid segment of a large left anterior descending (LAD) coronary artery, i.e. when the latter reaches the apex.
6. Male and female patients 18 years to 90 years of age
7. Signed informed consent","1. Participation in another drug or stent trial
2. Pregnant women or nursing mothers
3. Mechanical complication during acute coronary syndrome
4. Scheduled PCI for additional lesion within 30 days
5. Multivessel disease
6. Major elective surgery planned in trial period
7. Malignancy (unless healed or remission \> 5 years)
8. Chronic infection (HIV, Tbc, empyema)
9. Severely compromised renal function (GFR\< 30 ml/min)
10. Positive PCR Test for SARS-CoV-2 and/or at least one positive answer to questions regarding symptoms/contact related to COVID-19.","Everolimus, Placebo",INTERVENTIONAL,COMPLETED
NCT00915733,Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction (AMI) Patients According to CYP2C19 Polymorphism,Myocardial Infarction,"1. The patient must be at least 18 years of age.
2. clinical symptoms compatible with acute myocardial ischemia within 12 h before admission with a subsequently documented increase in cardiac markers.
3. Measured pre-discharge platelet reactivity in case of normalized CK-MB value after coronary stenting.","1. A history of active bleeding and bleeding diatheses.
2. Oral anticoagulation therapy with coumadin.
3. Contraindication to antiplatelet therapy.
4. LV ejection fraction \< 30% or NYHA 3/4.
5. Leukocyte count \< 3,000/mm3 and/or platelet count \< 100,000/mm3.
6. AST or ALT ≥ 3 times upper normal.
7. Serum creatinine level ≥ 2.5 mg/dl.
8. Stroke within 3 months.
9. Non-cardiac disease with a life expectancy \< 1 year.
10. Inability to follow the protocol.","cilostazol, clopidogrel (Plavix), CYP2C19, aspirin (Acetylsalicylic acid)",INTERVENTIONAL,COMPLETED
NCT00785954,Safety and Efficacy Study of KAI-9803 to Treat Subjects With ST Elevation Myocardial Infarction [Heart Attack],"Myocardial Infarction, Cardiovascular Diseases, Pathologic Processes","* Acute STEMI and has a planned emergent primary PCI procedure
* Continuous symptoms of cardiac ischemia and present to the primary PCI facility within 6 hours of symptom onset",* Persistent systolic blood pressure \< 90 mm Hg,KAI-9803,INTERVENTIONAL,COMPLETED
NCT02298088,Ticagrelor in Patients With ST Elevation Myocardial Infarction Treated With Pharmacological Thrombolysis,"Acute ST Segment Elevation Myocardial Infarction, Thrombolysis in Myocardial Infarction Flow","* Patients of both sexes aged ≥ 18 years and \< 75 years with ACS with ST segment elevation with onset during the previous 24 hours, documented by cardiac ischemic symptoms due to atherosclerosis of \> 10 minutes duration at rest, treated with pharmacological thrombolysis
* Fibrinolytic therapy should be given to patients with STEMI and onset of ischemic symptoms within the previous 12 hours

Patients with acute coronary syndrome with ST segment elevation will be included provided they present ST segment elevation at the J point in two contiguous leads in electrocardiogram with cut-points: \> 0.1mV in all leads other than leads V2-V3, where the following cut points apply: \> 0.2 mV in men \> 40 years; \> 0.25 mV in men \< 40 years, or \>0.15 mV in women and at least 1 of the following criteria:

* Angina-like chest pain or ischemic equivalent chest pain;
* Abnormalities above the reference value for markers of myocardial necrosis (troponin and CK-MB).

The patient must be able to give informed consent in accordance with ICH GCP guidelines and local legislation and/or regulations.","* Any contraindication against the use of clopidogrel (eg, hypersensitivity, moderate or severe liver disease, active bleeding or bleeding history, history of intracranial hemorrhage)
* Need for oral anticoagulation therapy,
* Concomitant oral or IV therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazodone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, grapefruit juice N1 L/d), CYP3A substrates with narrow therapeutic indices (cyclosporine, quinidine), or strong CYP3Ainducers (rifampin/rifampicin, phenytoin, carbamazepine)
* Increased risk of bradycardia events
* Dialysis required
* Known clinically important thrombocytopenia
* Known clinically important anemia
* Any other condition that may put the patient at risk or influence study results in the investigators' opinion (eg, cardiogenic shock, severe hemodynamic instability, active cancer)
* Participant in another investigational drug or device study within 30 d
* Pregnancy or lactation
* Any condition that increases the risk for noncompliance or being lost to follow-up
* Involvement in the planning or conduct of the study
* Previous enrollment or randomization in this study
* Contraindications to fibrinolytic therapy including: 15

  * Any prior intracranial hemorrhage
  * Known structural cerebral vascular lesion (eg, Arterial Venous Malformation - AVM)
  * Known malignant intracranial neoplasm (primary or metastatic)
  * Ischemic stroke within 3 months
  * Suspected aortic dissection
  * Active bleeding or bleeding diathesis (excluding menses)
  * Significant closed head trauma or facial trauma within 3 months","Ticagrelor 180 mg, Clopidogrel",INTERVENTIONAL,COMPLETED
NCT01172171,The Effect of Melatonin on Ischemia-reperfusion Injury Following Acute Myocardial Infarction,"Acute Myocardial Infarction, Ischemia-reperfusion Injury","Inclusion criteria:

* Adults who are able to give informed consent
* 1 significant coronary occlusion (\>2mm) with TIMI 0-1 expected to undergo PCI.
* The occlusion must be ECG-verified with new ST-elevations ≥ 0.2 mV in V2-V3 and/or ≥ 0.1 in the other leads or a new onset left bundle branch block.
* Having onset of symptoms of qualifying AMI and undergo PCI within 6 hours.
* If the patients do not fulfill the ECG inclusion criteria they can still be included if the primary PCI reveals an acute coronary occlusion (\>2mm) with TIMI 0-1.",":

* Patients with prior myocardial infarction
* more than one significant occlusion
* prehospital thrombolysis
* known history of renal failure
* history of autoimmune diseases
* pregnancy, fertile women or breastfeeding
* severe concurrent illness with reduced short-term prognosis
* pacemaker
* claustrophobia
* cardiogenic shock
* metals in the body
* atrial fibrillation
* BMI ≥ 40.","Melatonin, N-acetyl-5-methoxytryptamine, Isotonic saline, Natrium chloride",INTERVENTIONAL,COMPLETED
NCT02217878,Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Acute Myocardial Infarction,"ST-segment Elevation Myocardial Infarction, Non-ST-segment Elevation Myocardial Infarction, VA Drug Interactions","* provision of informed consent prior to any study specific procedures
* diagnosis of acute ST-segment elevation myocardial infarction or acute non-ST-segment elevation myocardial infarction
* male or non-pregnant female, aged 18-80 years old
* provision of informed consent for angiography and PCI","* chest pain described by the patient as unbearable or patient's request for analgesics
* prior morphine administration during the current STEMI or NSTEMI
* treatment with ticlopidine, clopidogrel, prasugrel or ticagrelor within 14 days before the study enrollment
* hypersensitivity to ticagrelor
* current treatment with oral anticoagulant or chronic therapy with low-molecular-weight heparin
* active bleeding
* history of intracranial hemorrhage
* recent gastrointestinal bleeding (within 30 days)
* history of coagulation disorders
* platelet count less than \<100 x10\^3/mcl
* hemoglobin concentration less than 10.0 g/dl
* history of moderate or severe hepatic impairment
* history of major surgery or severe trauma (within 3 months)
* patients considered by the investigator to be at risk of bradycardic events
* second or third degree atrioventricular block during screening for eligibility
* history of asthma or severe chronic obstructive pulmonary disease
* patient required dialysis
* manifest infection or inflammatory state
* Killip class III or IV during screening for eligibility
* respiratory failure
* history of severe chronic heart failure (NYHA class III or IV)
* concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir) or strong CYP3A inducers (rifampicin, phenytoin, carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment
* body weight below 50 kg","Morphine, Placebo, Ticagrelor",INTERVENTIONAL,COMPLETED
NCT00362778,Intensive Insulin Therapy in Non-diabetic Patients With Acute Myocardial Infarction and Hyperglycaemia,"Diabetes, Hyperglycemia, Acute Myocardial Infarction","1. Confirmed diagnosis of AMI, either with or without ST segment elevation
2. Presence of high blood glucose at admission with no previously known diabetes mellitus (DM)","1. Age under 18 years old
2. History of DM
3. Presence of other cardiopathies (dilated cardiomyopathy, valvular or hypertrophic heart disease)
4. Unstable AMI patients (haemodynamic instability or arrhythmic disorders)
5. Platelet aggregation or coagulation disorders
6. Severe conditions with an estimated short (under 1 year) life expectancy
7. Participation in other trials
8. Patient refusal to participate in the study",Insulin,INTERVENTIONAL,COMPLETED
NCT01569178,BAMI. The Effect of Intracoronary Reinfusion of Bone Marrow-derived Mononuclear Cells(BM-MNC) on All Cause Mortality in Acute Myocardial Infarction,"Myocardial Infarction, Death","* signed and dated informed consent form
* men and women of any ethnic origin aged≥18years
* patients with acute ST-elevation myocardial infarction as defined by the universal definition of AMI (including new LBBB)
* Patients with acute ST-elevation myocardial infarction as defined by the universal definition of AMI.
* Successful acute reperfusion therapy (residual stenosis visually \<50% and TIMI flow ≥2) within 24 hours of symptom onset or thrombolysis within 12 hours of symptom onset followed by successful percutaneous coronary intervention (PCI) within 24 hours after thrombolysis
* Left ventricular ejection fraction ≤ 45% with significant regional wall motion abnormality assessed by quantitative echocardiography (central, independent core lab analysis) 2 to 6 days after reperfusion therapy
* Open coronary artery suitable for cell infusion supplying the target area of abnormal wall motion","* Participation in another clinical trial within 30 days prior randomisation unless non interventional trials or trials where patients are randomised to only standard care and this has been discussed and agreed with the CI/sponsor prior to consenting
* Previously received stem/progenitor cell therapy
* Pregnant or nursing women
* Mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study or to follow the protocol
* Necessity to revascularise additional vessels, outside the target coronary artery at the time of progenitor cell infusion (additional revascularisations after primary PCI and before BM-MNC cell infusion are allowed), unless clinically indicated and according to latest guidelines. This decision should be made at the time of the index procedure and explicitly stated at that time.
* Cardiogenic shock requiring mechanical support
* Platelet count \<100.000/µl, or hemoglobin \<8.5 g/dl
* Impaired renal function, i.e. creatinine \>2.5 mg/dl
* Fever or diarrhoea not responsive to treatment within 4 weeks prior screening
* Cliinically significant bleeding disorder within 3 months prior screening
* Uncontrolled hypertension (systolic \>180 mmHg and diastolic \>120 mmHg)
* Life expectancy of less than two years from any non-cardiac cause or uncontrolled neoplastic disease",Bone Marrow aspiration and intracoronary reinfusion,INTERVENTIONAL,COMPLETED
NCT00607178,The Efficacy of Influenza Vaccine in Reducing Cardiovascular Events in Patients With Coronary Artery Diseases,"Coronary Artery Diseases, Myocardial Infarction, Stable Angina","* Patients with the diagnosis of acute, evolving or recent MI (after recovered the acute phase) as defined by:

  1. Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of the following:

     * Ischemic symptoms
     * Development of pathologic Qwaves on the ECG
     * ECG changes indicative of ischemia (ST segment elevation or depression); OR
     * Coronary artery intervention (e.g., coronary angioplasty).
  2. Pathologic findings of an acute MI \[12\]
* Patients with stable angina pectoris and documented coronary artery stenosis (angiography).","* Any acute disease
* Chronic liver or kidney diseases
* Conditions accompanied by immunosuppression (like organ transplantation, HIV)
* Diagnosed malignancy
* Incubation with influenza vaccine within the past 5 years
* Any psychological disease that interferes with regular follow-up
* Congestive heart failure (Killip class IV)
* Unstable angina, and contradictions of vaccine incubation (like egg allergy).","influenza vaccine, placebo for influenza vaccine",INTERVENTIONAL,COMPLETED
NCT02070471,"Phase 2 Study to Evaluate the Efficacy, Safety and PK of Intravenous Single Injection LC28-0126 Immediately Before PCI in STEMI Patients",ST-segment Elevation Myocardial Infarction,"* Age between 20 and 75
* Within 12 hours after the onset of chest pain
* ST-segment elevation of more than 0.1 mV in two contiguous leads or new LBBB(left bundle-branch block) patients
* Signed for written informed consent","* Left Main disease
* Multi-vessel disease","Placebo, LC28-0126 Dose A, LC28-0126 Dose B, LC28-0126 Dose C",INTERVENTIONAL,COMPLETED
NCT01995799,IRon Nanoparticle Enhanced MRI in the Assessment of Myocardial infarctioN,"Myocardial Infarction, Inflammation","* \>18 years
* Plasma troponin concentration \>5 ng/mL; upper limit of normal 0.04 ng/mL)
* Acute myocardial infarction defined according to the Universal Definition of myocardial infarction","* Critical (≥95%) left main stem coronary artery stenosis
* Continued symptoms of angina at rest or minimal exertion
* Past history of systemic iron overload or haemochromatosis
* Renal failure (estimated glomerular filtration rate \<25 mL/min)
* Contraindication to magnetic resonance imaging
* Significant heart failure (Killip class ≥2)
* Known allergy to dextran- or iron-containing compounds",Ferumoxytol enhanced MRI,INTERVENTIONAL,COMPLETED
NCT00114452,Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction,Myocardial Infarction,"* Male or female between 21 and 85 years old
* First heart attack within 1 to 10 days","* Positive for HIV 1 and 2
* Previous heart attack
* Pacemaker or other device
* Pregnant or breastfeeding
* Allergic to cow or pig derived products
* Previous bone marrow transplant
* Involved in another clinical trial within the past 30 days
* Alcohol or recreational drug abuse within the past 6 months
* Hepatitis Positive
* Major surgical procedure or major trauma within the past 14 days
* Body weight greater than 300 pounds
* Autoimmune disease ( e.g. Lupus, Multiple Sclerosis)","Provacel, Placebo",INTERVENTIONAL,COMPLETED
NCT02402400,Sub Lingual Versus Traditional Oral Administration of Ticagrelor in Acute Coronary Syndrome/Non ST-elevation Myocardial Infarction - A Platelet Reactivity Study,"Acute Coronary Syndromes, Non ST Elevation Myocardial Infarction","1. Patients presenting with ACS/NSTEMI
2. Informed, written consent","1. Age \< 18 years or Age \> 90 years
2. Active bleeding; bleeding diathesis; coagulopathy
3. Increased risk of bradycardiac events
4. History of gastrointestinal or genitourinary bleeding \<2 months
5. Major surgery in the last 6 weeks
6. History of intracranial bleeding or structural abnormalities
7. Suspected aortic dissection
8. Any other condition that may put the patient at risk or influence study results or investigator's opinion (severe hemodynamic instability, known malignancies or other comorbid conditions with life expectancy \<1 year)
9. Administration in the week before the index event of clopidogrel, ticlopidine, prasugrel, ticagrelor, thrombolytics, bivalirudin, low-molecular weight heparin or fondaparinux.
10. Concomitant oral or IV therapy with strong CYP3A inhibitors or strong CYP3A inducers, CYP3A with narrow therapeutic windows
11. Known relevant hematological deviations: Hb \<10 g/dl, PLT\<100x10\^9/l
12. Use of coumadin derivatives within the last 7 days
13. Chronic therapy with ticagrelor, prasugrel, clopidogrel or ticlopidine
14. Known severe liver disease, severe renal failure
15. Known allergy to the study medications
16. Pregnancy
17. Human immunodeficiency virus treatment",Sub Lingual Ticagrelor,INTERVENTIONAL,COMPLETED
NCT00378352,REVEAL: Reduction of Infarct Expansion and Ventricular Remodeling With Erythropoietin After Large Myocardial Infarction,Acute ST Elevation Myocardial Infarction,"* INCLUSION CRITERIA:

Age greater than 21 years

Acute ST-elevation myocardial infarction

Referral for primary or rescue angioplasty

Revascularization procedure within 8 hours from the onset of ischemic symptoms

TIMI (Thrombolysis in myocardial infarction) flow grade 0 or 1 in the culprit coronary artery at the beginning of coronary angiography

Successful revascularization of infarct-related artery",":

Clinical indication for erythropoietin

STEMI (ST-elevation myocardial infarction) due to occlusion of a branch vessel

Any history of prior MI, PCI (Percutaneous coronary intervention), CABG (Coronary artery bypass graft), cardiomyopathy, myocarditis, or CHF (congestive heart failure)

Hypersensitivity to human albumin, mammalian cell-derived products, or erythropoietin

Hematocrit greater than 42% in men or greater than 40% in women at the time of study drug administration

Uncontrolled hypertension at the time of study drug administration

Cardiogenic shock

Need for coronary surgical revascularization as determined at the time of the index coronary catheterization

History of hypercoagulable disorder, thromboembolic event, or venous thrombosis

History of stroke or TIA (transient ischemic attack)

History of seizures

Contraindication to MRI

Pregnancy or nursing mother",Epoetin alfa,INTERVENTIONAL,COMPLETED
NCT01995552,IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study),Post MI Left Ventricular Dysfunction,"Patients must meet all of the below criteria to be eligible for the study:

* Patients must provide written informed consent/data release consent to
* participate in the study.
* Acute Myocardial Infarction (STEMI or non-STEMI) documented within 10 days of onset, matching one of the following criteria:
* Acute ST segment elevation greater than or equal to 0.1 mv on ECG in 2 or more leads or new LBBB, with symptoms of ischemia
* In all other situations, including non ST segment elevation MI, at least one cardiac biomarker value \[preferably cardiac troponin (cTn)\] above the 99th percentile of a normal reference population (upper reference limit (URL)) AND with at least one of the following (1) new or presumed new ST-T changes (2) Symptoms or signs of Ischemia (3) Development of pathological Q waves in the ECG (4) Identification of an intracoronary thrombus by angiography
* LVEF less than or equal to 35 percent as measured by echocardiography Simpsons method, biplane one day before or on the day of hospital discharge","* Patients who cannot be discharged from the hospital within14 days after index Myocardial Infarction event
* Age less than 18 years
* Psychologically incapacitated
* Patient is pregnant, or is expecting to become pregnant during the course of the trial per Investigator discretion.
* Patients contraindicated for NUVANT system
* Comorbidities likely to limit survival to less than the minimal study duration (12 months)
* Participation in an investigational study with known or suspected cardiac effect expected to confound the results of this study (e.g. stem cell trials, stent trials, cardiac intervention trials, drug trials)
* Patients with an existing pacemaker or ICD implanted.
* Patients that are dialysis dependent at discharge",External Loop Recorder,INTERVENTIONAL,COMPLETED
NCT00400959,CD133+ Autologous Cells After Myocardial Infarction,Acute Myocardial Infarction,"* Informed consent;
* age: 18-65 years;
* large acute myocardial infarction (due to proximal occlusion of the left anterior descending or the right coronary artery) after successful primary PTCA carried out between the IV and the XXIV hour from the onset of AMI symptoms;
* signs of microvascular dysfunction in the infarcted area: absence of STeR and angiographic MB, graded according to the dye density score (see van't Hof et al., Circulation, 1998); life expectancy more than 6 months.","* Pregnancy;
* indication to aorto-coronaric by-pass;
* neoplasia (previous or in progress);
* primary diseases of the BM;
* diabetes;
* immunosuppressive therapy;
* laboratory alterations of protein S, protein C, ATIII or Fibrinogen;
* severe co-morbidity.",cd133+cell intracoronary administration,INTERVENTIONAL,COMPLETED
NCT00212056,Japan-Working Groups of Acute Myocardial Infarction for the Reduction of Necrotic Damage by ANP,Acute Myocardial Infarction,"1. Age 20-79 years
2. Chest pain of more than 30 min
3. 0.1 mV ST-segment elevation in 2 contiguous ECG leads
4. Admission to hospital within 12 h of symptom onset
5. First episode of AMI
6. Candidates for PCI","1. History of old myocardial infarction
2. Left main coronary artery stenosis
3. Severe liver and/or kidney dysfunction
4. Suspected aortic dissection
5. History of coronary artery bypass graft
6. History of allergic response to drugs
7. Severe hypovolemia
8. Right ventricular infarction","ANP(hANP), Control",INTERVENTIONAL,COMPLETED
NCT01338909,Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Reactivity in Patients With ST-elevation Myocardial Infarction (STEMI),Myocardial Infarction,"1. Age ≥18 years old
2. Patients with STEMI undergoing primary PCI with stenting
3. Platelet reactivity in PRU ≥235 2 hours post 600 mg clopidogrel loading dose
4. Informed consent obtained in writing","1. Treatment with other investigational agents (including placebo) or devices within 30 days prior to randomization or planned use of investigational agents or devices prior to the Day 5.
2. Pregnancy
3. Breastfeeding
4. Inability to give informed consent or high likelihood of being unavailable until Day 5.
5. Cardiogenic shock
6. Major periprocedural complications (death, stent thrombosis, vessel perforation, arrhythmias requiring cardioversion, temporary pacemaker insertion or intravenous antiarrhythmic agents, respiratory failure requiring intubation, vascular injury (pseudoaneurysm, arteriovenous shunt, retroperitoneal bleeding or hematoma \>5 cm at the arterial catheter insertion site), major bleeding (need for bood transfusion or drop in haemoglobin post-PCI by ≥ 5 gr/ dl or intracranial bleeding).
7. Unsuccessful PCI (residual stenosis \> 30% or flow \< ΤΙΜΙ 3) or planned staged PCI in the next 5 days after randomization
8. Requirement for oral anticoagulant prior to the Day 5
9. Current or planned therapy with other thienopyridine class of ADP receptor inhibitors.
10. Known hypersensitivity to prasugrel or ticagrelor
11. History of gastrointestinal bleeding, genitourinary bleeding or other site abnormal bleeding within the previous 6 months.
12. Other bleeding diathesis, or considered by investigator to be at high risk for bleeding on thienopyridine therapy.
13. Any previous history of ischemic stroke, intracranial hemorrhage or disease (neoplasm, arteriovenous malformation, aneurysm).
14. Thrombocytopenia (\<100.000 / μL) at randomization
15. Anaemia (Hct \<30%) at randomization
16. Polycythaemia (Hct \> 52%) at randomization
17. Periprocedural IIb/IIIa inhibitors administration
18. Severe allergy to contrast agent, unfractionated heparin, enoxaparin or bivalirudin that cannot be adequately premedicated.
19. Recent (\< 6 weeks) major surgery or trauma, including GABG.
20. Subjects receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX-2) inhibitors that cannot be discontinued for the duration of the study.
21. INR\>1.5 at randomization","Prasugrel, Clopidogrel",INTERVENTIONAL,COMPLETED
NCT05118009,Artificial Intelligence Based Rapid Identification of ST-elevation Myocardial Infarction Using Electrocardiogram (ARISE),"Myocardial Infarction, Acute","* Patients in emergency department or inpatient department.
* Patients recieved at least 1 ECG examination.",* The patients recieved ECG at the period of inactive AI-ECG system.,AI-enabled ECG-based Screening Tool,INTERVENTIONAL,COMPLETED
NCT00507156,Postconditioning in the Treatment of Acute ST-segment Elevation Myocardial Infarction,ST-segment Myocardial Infarction,"* Patients more than 18 years
* STEMI \< 12 hours
* TIMI 0-1 in infarct related artery","* Multivessel disease (stenoses in non-infarct related arteries \>70%)
* Cardiogenic shock
* Left main occlusions
* Lesions that cannot be treated with stents
* Previous CABG
* Pregnancy
* Severe renal insufficiency
* Previous extensive Q-wave infarction
* LBBB","Standard primary PCI, Mechanical postconditioning",INTERVENTIONAL,COMPLETED
NCT00268307,Bone Marrow Stem Cell Infusion Following a Heart Attack,Acute Myocardial Infarction,"* Patients age at least 21 years of age
* Patients with an acute anterior myocardial infarction limited to the proximal or mid-LAD with an artery diameter of at least 2.5 mm.
* Ability to undergo cell therapy procedure within 2 to 7 days following acute MI and PTCA/stenting.
* Ejection fraction following reperfusion with PTCA/stenting is between 30% and 50% as assessed by left-ventriculography or echocardiography.
* Consent to protocol and agree to comply with all follow-up visits and studies.","* History of sustained ventricular arrhythmias not related to their acute myocardial infarction who do not have an ICD.
* Require coronary artery bypass surgery or percutaneous revascularization due to the presence of residual coronary stenosis \> 70% luminal obstruction in the non-infarct related vessel.
* History of malignancy within the past 5 years excluding non-melanoma skin cancer or cervical cancer in-situ.
* History of anemia (Hb \< 9.0 mg/dl).
* History of thrombocytosis.
* PT or PTT greater than the upper limits of normal.
* Life expectancy less than one year.
* Patients on chronic dialysis.
* History of untreated alcohol or drug abuse.
* Currently enrolled in another Investigational drug or device trial.
* History of stroke or TIA within the past 6 months.
* History of severe valvular heart disease (aortic valve area \< 1.0 cm2 or \> 3+ mitral regurgitation.
* Pregnancy
* Subjects who are HIV, hepatitis B or C positive.
* Patients with active inflammatory or autoimmune disease on chronic immunosuppressive therapy.
* Contraindications to cardiac MRI","Autologous, Unfractionated Bone Marrow Mononuclear Cells",INTERVENTIONAL,COMPLETED
NCT00888537,Wiser Choices in Acute Myocardial Infarction,Acute Myocardial Infarction,"* Between the ages of 18 and 90
* Hospitalized at Saint Marys Hospital
* A primary diagnosis of AMI,
* Have heart rate, blood pressure, troponin and creatinine measurements,
* There is an intention to offer treatment medications
* Are able and willing to provide informed consent","* Have not had a myocardial infarction
* Have significant cognitive, visual impairment,
* Non-English speaker
* Have a Do Not Intubate/Do Not Resuscitate (DNI/DNR) status
* Will be discharged to a nursing home
* AMI is not the presumptive diagnosis","AMI Choice Decision Aid, Usual Care",INTERVENTIONAL,COMPLETED
NCT03473015,Oxford Acute Myocardial Infarction - Pressure-controlled Intermittent Coronary Sinus Occlusion,ST Elevation Myocardial Infarction,"* Male or Female, aged 30 to 90 years,
* Clinical presentation with STEMI
* Referred for coronary angiography with view to proceed to PCI with stenting.","* Patients in whom safety or clinical concerns preclude participation.
* Known anaemia (Hb \<9).
* Pregnant or breast feeding females.
* Revascularization by mean of balloon angioplasty without stenting
* History of stroke, TIA or reversible ischemic neurological disease within last 6 months
* Known severe renal failure (eGFR \< 30 ml/min/1.73m2) or history of dialysis or renal transplant
* Previous coronary bypass artery grafting
* Known severe valvular abnormalities
* Previous STEMI presentation
* Presentation with cardiogenic shock
* Severe bradycardia (Heart rate \< 50 beats per minutes)
* STEMI due to stent thrombosis
* Unconscious on presentation
* Non-cardiac comorbidities and life expectancy \< 1 year
* Use of warfarin
* Presence of pacemaker or other electrodes in the coronary sinus
* Contraindications to adenosine
* Additional exclusion criteria for participants undergoing CMR

  * claustrophobia which limits / prevents participants from remaining in CMR scanner.
  * patients who cannot lie flat on the scan table.
  * patients with metallic implants, pacemakers, implantable defibrillators etc, unless known to be CMR compatible.
  * patients with known allergy to medium of contrast (gadolinium)",PICSO,INTERVENTIONAL,COMPLETED
NCT01493037,PICSO in Patients With STEMI Treated by Primary Percutaneous Coronary Intervention,ST Elevation (STEMI) Myocardial Infarction,"* First time anterior STEMI defined by the following:

  * Symptoms of myocardial ischemia \> 30 minutes and \< 12 hours
  * ST-segment elevation \> 1mm (\> 0.1 mV) in two contiguous precordial leads in the anterior territory on a 12-lead ECG
* Uncomplicated PCI of a LAD culprit lesion (defined as angioplasty followed by stent placement or direct stenting without the occurrence of an adverse event(s) that would preclude further study participation, such as major bleeding, perforation, hypotension, pulmonary edema or instability that in the judgement of the investigator preclude participation in the trial)","* Younger than 18 years of age
* Hospitalization with a primary diagnosis of acute myocardial infarction (AMI) previously or has evidence of previous Q-wave infarct
* Left main coronary artery culprit lesion
* Additional stenosis in the LAD for which PCI or CABG is likely to be needed in the next 6 months and which is not treated during the index procedure
* Cardiogenic shock (systolic blood pressure ≤90 mmHg in spite of conservative measures) or pulmonary edema (O2 saturation \<90% by pulse oximetry and the presence of rales or crackles)
* Cardiac arrest requiring chest compression or resuscitation
* Anatomical complications limit capacity to place PICSO Impulse device or achieve stable catheter placement or occlude coronary sinus
* Known renal disease (GFR \< 30 mL/min/1.73m2) or dialysis
* History of stroke, TIA or reversible ischemic neurological disease within last 6 months
* Left bundle branch block
* Known contra-indication for magnetic resonance imaging (Metallic implant precluding MRI, claustrophobia, obesity precluding MRI, etc.)
* Presence of any lead in the coronary sinus
* Active or treated malignancies in the last 12 months
* Previous coronary artery bypass graft surgery
* Known severe anemia (Hgb \< 10 g/dL or \< 6.2 mmol/L)
* Known platelet count \< 100,000, known coagulopathy or bleeding diathesis, or unwilling to accept transfusions
* Participation in another ongoing clinical study
* Women of child-bearing age
* Non-cardiac comorbidities and life expectancy \< 1 year
* Legal incompetence
* A condition that, in the opinion of the Investigator, precludes participation, including compliance with all follow-up procedures
* No dependents neither to the sponsor nor to the investigator",PICSO (Pressure-controlled Intermittent Coronary Occlusion,INTERVENTIONAL,COMPLETED
NCT05424315,Impact of DApagliflozin on Cardiac Function Following Anterior Myocardial Infarction in Non-Diabetic Patients,Anterior MI,"* Patients admitted with ECG Criteria for Anterior ST-elevation myocardial infarction according to the fourth universal definition of myocardial infarction\*, \*\* \& show echocardiographic evidence of reduced LV ejection fraction \<50% \& have undergone successful reperfusion by primary percutaneous coronary angiography (pPCI).

  * New ST segment elevation in contagious precordial leads consistent anatomically with the anterior wall of myocardium:

    * Men ≥ 40 years: 2 mV in leads V2-V3 \&/or 1 mV in other precordial leads
    * Men \<40 years: 2.5 mV in leads V2-V3 \&/or 1 mV in other precordial leads
    * Women (regardless of age): 1.5 mV in leads V2-V3 \&/or 1 mV in other precordial leads \*\* Patients with admission ECG showing DeWinter's Syndrome, Wellen Syndrome, New onset left bundle branch block, new onset right bundle branch block will also be included.","1. Patients with Diabetes Miletus (Type 1 (DMT2), Type 1 (DMT1), secondary diabetes (e.g., endocrinopathies)
2. Patients already diagnosed with heart failure prior to this event
3. Patients on cardiotoxic chemotherapeutic medications.
4. Patients with haemoglobinopathies.
5. Patients with chronic organ damage (i.e., chronic hepatitis with MELD score \>10, Stage 4 \& 5 renal disease).
6. Patients already on SGLT2i.
7. Patients who will require additional anticoagulant therapy (i.e.: patients with transthoracic echocardiographic evidence of left ventricular thrombus).
8. Patients with contraindications for use of dapagliflozin including patients with severely impaired renal function (eGFR \<30ml/min/1.73m2) \&/OR previous history of genitourinary infections (i.e.: urosepsis, pyelonephritis \& fournier's gangrene) \&/OR at high risk of such infections.","Dapagliflozin 10mg, Glucose Tab",INTERVENTIONAL,COMPLETED
NCT00335452,Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS,"Acute Coronary Disease, Angina Unstable",* Diagnosed with acute coronary disease with clinical symptoms and at least electrocardiogram changes or cardiac enzymes elevated,"* Use of anticoagulants within 10 days with an international normalized ratio (INR) \> 1.5 or planned use during the hospitalisation period
* Administration of clopidogrel \> 75 mg prior to randomization
* Contraindication to clopidogrel or aspirin
* Active bleeding or significant risk of bleeding","Clopidogrel, acetylsalicyclic acid (ASA)",INTERVENTIONAL,COMPLETED
NCT03274752,Paroxetine-mediated GRK2 Inhibition to Reduce Cardiac Remodeling After Acute Myocardial Infarction,"Cardiac Remodeling, Myocardial Infarction","* Anterior wall ST-segment elevation myocardial infarction
* Primary percutaneous coronary intervention (PCI) within 24 hours of symptom onset
* Left ventricular ejection fraction ≤ 45% within 48-96 hours after primary PCI (transthoracic echocardiography)","* Female patients at reproductive age (\<50 years)
* Known intolerance to paroxetine
* Inability to provide informed consent
* Currently participating in another trial before reaching first endpoint
* Current medical therapy with MAO-blocker (during, 14 days before, and 14 days after treatment with MAO-blocker), lithium, thioridazide, or pimozide
* Concomitant tamoxifen intake
* Previous myocardial infarction
* Previous revascularization procedure (percutaneous coronary intervention or coronary artery bypass grafting).
* Contraindication to cardiac magnetic resonance imaging
* Obvious or questionable inability to appropriately cooperate (alcohol, drugs etc.)
* Relevant nephropathy or hepatopathy","Paroxetine, Placebo oral capsule",INTERVENTIONAL,COMPLETED
NCT02753478,Safety and Feasibility of Intracoronary Hypothermia in Acute Myocardial Infarction,Myocardial Infarction,"Patients will be eligible for this study when they are admitted for acute ST elevation myocardial infarction with a total ST-segment deviation of more than 5 mm and presenting within 6 hours after onset of complaints.

Patients should have a TIMI 0, 1 or 2 flow in the infarction related artery.","• Age \< 18 year

* Cardiogenic shock or pre-shock
* Poor clinical condition with concomitant inconvenience like repeated vomiting, severe chest pain or elsewise according to the judgment of the treating interventionalist.
* Patients with previous myocardial infarction in the culprit area of with previous bypass surgery
* Tortuous coronary arteries
* Complex or long-lasting primary PCI expected
* Inability to understand and give informed consent either in first instance on the table or in second instance on the coronary care unit.
* Other known myocardial diseases, such as moderate or severe left ventricular hypertrophy or cardiomyopathy
* Pregnancy
* First degree AV-block, Mobitz I and Mobitz II block, trifascicular block, or total AV block, Left- and Right Bundle Branch Block
* Patients in whom no access to the coronary circulation can be obtained by the femoral artery or in whom femoral access was problematic Severe concomitant disease or conditions with a life expectancy of less than one year",intracoronary infusion with saline on 22 and 4°C,INTERVENTIONAL,COMPLETED
NCT01368471,Safety and Efficacy Study of MGuard Stent After a Heart Attack,Myocardial Infarction,"Inclusion Criteria

* 18 years of age
* ST-segment elevation (more than 2mm in more than contiguous leads)
* MI with symptom onset less than 12h
* The patient is willing to comply with specified follow-up evaluations
* Signed ICF
* Single de novo lesion in the target (culprit) vessel
* Target lesion maximum length is 33 mm (by visual estimation)
* Reference vessel diameter must be more than 3.0 to less than 4.0 mm by visual estimation
* Randomization should occur as soon as Presence of TIMI 2 or 3 before randomization","* Pregnant or nursing patients
* Left Bundle Branch Block (LBBB), paced rhythm, or other Electrocardiogram (ECG) abnormality
* Impaired renal function
* Prior coronary artery bypass graft surgery
* Bleeding diathesis
* Contraindication to aspirin
* cardiopulmonary resuscitation
* Cardiogenic shock
* chronic warfarin anticoagulation
* LVEF less than 20%
* other medical illness
* participation in another investigational drug or device study that has not reached its primary endpoint
* Left main coronary artery disease with 50% stenosis
* Ostial target lesion
* Failure to visualize vessel anatomy distal to the culprit lesion
* Moderate to heavily calcified target lesion or vessel
* excessive tortuosity
* bifurcation with a side branch more than 2.0 mm in diameter
* A significant (greater than 50%) stenosis proximal or distal to the target lesion is present that cannot be covered by same single stent
* Diffuse disease distal to target lesion with impaired runoff
* Any prior stent proximal to the target lesion, or within 10 mm distal of the target lesion
* PCI of another lesion performed within 6 months before the index procedure
* Target lesion located in a saphenous vein graft","MGuard, Control BMS or DES",INTERVENTIONAL,COMPLETED
NCT00440778,A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI,"Myocardial Infarction, Ischemia","* Patient with acute myocardial infarction eligible for primary PCI within 6 h of symptoms: patient must have prolonged, continuous (lasting at least 20 minutes) signs and symptoms of ischemia not eliminated with nitrates and onset within 6 h of randomization, and one of the following:

  * ST-segment elevation ≥ 2 mm in 2 or more contiguous precordial ECG leads (anterior infarction)
  * ST-segment depression ≥ 2 mm in V1, V2 or V2, V3 with reciprocal 1 mm ST-elevation in II, augmented unipolar foot (left leg) lead (AVF), and V6 (true posterior infarction)
  * ST-segment elevation ≥ 1 mm in 2 or more contiguous limb ECG leads (other infarction)
  * New or presumably new left bundle branch block (LBBB)
* Patient must be \> 18 years of age.
* Patient and treating interventional cardiologist agree for randomization.
* Patient will be informed of the randomization process and will sign an informed consent.
* Diagnostic and therapeutic intervention performed through trans-radial/ulnar artery approach.
* The culprit lesion can be identified on a native coronary vessel, which is suitable for primary PCI with stent implantation.","* Patient has received thrombolytic therapy (within the last 4 weeks) and is referred for rescue PCI
* Concurrent participation in other investigational study
* Femoral sheath (artery)
* Intolerance or allergy to ASA, clopidogrel or ticlopidine precluding treatment for at least 12 months
* Any significant blood dyscrasia, diathesis or INR \> 2.0
* Any clinical contraindication to abciximab (ReoPro®) administration i.e. known structural intracranial lesion, thrombocytopenia \< 100,000, active or recent bleeding or hemoglobin level known \< 10 g/dl.
* Any glycoprotein IIb-IIIa inhibitors use in the previous 30 days
* Uncontrolled high blood pressure i.e. systolic blood pressure ≥ 180 mmHg and/or diastolic blood pressure ≥ 100 mmHg.
* Life expectancy less than 6 months owing to non-cardiac cause
* Infarction caused by in-stent thrombosis or restenosis
* Cardiogenic shock evident before randomization",Abciximab,INTERVENTIONAL,COMPLETED
NCT00220571,CARESS in Acute Myocardial Infarction,Myocardial Infarction,"- ECG with ST-elevation (≥ 1mm in at least 2 ECG limb leads or ≥ 2 mm in 2 contiguous precordial leads) AMI within \<12 hours from symptoms onset fulfilling 1 or more of the following criteria of ""high risk"":

1. Summation of ST-segment elevation or depression ≥ 15 mm in all 12 electrocardiographic leads or new onset complete left bundle branch block;
2. Previous myocardial infarction (Q- and non Q-wave);
3. Killip Class 2 or 3;
4. LV ejection fraction at transthoracic ultrasound \< 40%.","1. Inability to provide informed consent;
2. Age \> 75 years
3. CABG or PCI procedure in past history involving the infarct-related artery;
4. Participation in another study with any investigational drug or device within the previous 30 days;
5. Concomitant non-cardiac disease likely to limit long-term prognosis (e.g. cancer);
6. Cardiogenic shock (hypotension with Systolic Blood Pressure (SBP) \< 90 mmHg and tachycardia \> 100 beats / min, not due to hypovolemia and requiring inotropic support or balloon counterpulsation);
7. Need for concomitant major surgery (e.g. valve surgery or resection of aortic or left ventricular aneurysm, carotid endarterectomy, abdominal aortic aneurysm surgery, congenital heart disease etc);
8. Severe hepatic disease;
9. Patients with acute or chronic renal impairment (serum creatinine \> 2.0 mg % or 200 mg/l or creatinine clearance \< 30 ml/min);
10. Transmural MI in different location within the previous week;
11. Previous administration of thrombolytics within 7 days;
12. Intolerance or contraindications to ASA or Clopidogrel;
13. Known leucopenia, defined as a leukocyte count of \< 3.500 White Blood Cells (WBC)/ml
14. Known neutropenia, defined as \< 1000 neutrophils / ml;
15. Known thrombocytopenia (\< 100.000 platelets / ml );
16. Documented active peptic ulcer or upper gastrointestinal bleeding within the previous 6 months;
17. Previous hemorrhagic stroke;
18. Previous ischemic cerebrovascular event within 3 months;
19. Intracranial neoplasm;
20. Recent major surgery at risk of bleeding;
21. Episodes of uncontrolled hypertension (\> 180/110 mmHg despite treatment) in past 2 years;
22. Administration of oral anticoagulants within the previous 7 days unless INR ≤ 1.2;
23. Severe recent trauma;
24. Known or possible pregnancy;
25. Absence of suitable vascular access (diffuse peripheral arterial disease);
26. Basal ECG changes which make identification of ST-segment elevation impossible (i.e.: ventricular activation from artificial pacemaker, etc.).",Coronary Angioplasty (PTCA),INTERVENTIONAL,COMPLETED
NCT01538771,Intracoronary Darbepoetin-alpha to Reduce The Infarct Size and Post-Infarct Remodeling,Myocardial Infarction,"* Patients with ST-elevation myocardial infarction (MI) within 12 hours of onset
* Suitable coronary anatomy for PCI
* Age \< 80 yrs","* Uncontrolled congestive heart failure (Killip classes II and III, or cardiogenic shock)
* History of malignancy
* Serious hematological disease
* Current infectious disease requiring antibiotic therapy
* Baseline creatinine level \> 2.0 mg/dL or dependence on dialysis
* Known hypersensitivity to or contraindication for heparin, aspirin, clopidogrel, sirolimus, everolimus, contrast medium and darbepoetin-α","Darbepoetin alfa, Control Saline",INTERVENTIONAL,COMPLETED
NCT00516178,Intravenous Fish Oil in Critically Ill Cardiac Patients,Coronary Artery Disease,"* Coronary artery disease requiring elective surgical repair under cardiopulmonary bypass
* Acute myocardial infarction requiring ICU management","* Absence of consent
* Ventricular ejection fraction \< 35%
* Beating heart surgery or emergency surgery
* Hypercholesterolemia \> 5 mmol/l
* Thrombolysis
* Chronic steroid therapy
* Acute or chronic renal failure prior to surgery (plasma creatinine \> 150 umol/l)
* Chronic coagulation disorder
* Premenopausal female
* Consumption of more than 3 times fish per week","Fish oil emulsion, Saline",INTERVENTIONAL,COMPLETED
NCT00827788,Comparison Between Iso-Osmolar and Ipo-Osmolar Contrast Agents in Patients With Acute Myocardial Infarction (AMI) Undergoing Primary Percutaneous Coronary Intervention (PCI),"Contrast Induced Nephropathy, Acute Myocardial Infarction","* Men or women aged ≥ 18
* Patients with ST-elevation Myocardial Infarction presenting within 12 hours after the onset of symptoms (18 hours in case of cardiogenic shock), who are scheduled to undergo primary PCI
* Patients who have signed and dated the written informed consent form","* Patients in pregnancy or lactation
* Long-term dialysis
* Administration of any investigational drug within the previous 30 days
* Intra-arterial or intravenous administration of iodinated contrast medium from 7 days before to 72 hours after the administration of study drug
* Intake of any nephrotoxic medications 24 hours before or after the administration of study drug
* Contraindications to the study drug or the cardiac catheterization procedure
* Previous participation in this study
* As the discretion of the investigator, the patient has any conditions not appropriate to the usage of iodinated contrast agent or not appropriate to undergo cardiac catheterization procedure","Iodixanol, Iopromide",INTERVENTIONAL,COMPLETED
NCT00449488,Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction,Myocardial Infarction,"Successful primary PCI (TIMI 2/3) for a first acute myocardial infarction, diagnosed by:

* chest pain suggestive for acute myocardial infarction
* symptom onset \< 12 hour before hospital admission, or \< 24 hour in case ongoing ischemia
* ECG with ST-T segment elevation \> 1 mV in 2 or more leads
* TIMI flow 0/1 before primary PCI on diagnostic coronary angiography;","* Hemoglobin levels \> 10.6 mmol/L;
* Anticipated additional revascularisation within 4 months;
* Cardiogenic shock;
* Presence of other serious medical conditions
* Pregnancy/breast feeding
* Malignant hypertension
* End stage renal failure (creatinin \> 220 micromol/l)
* Previous treatment with rh-EPO
* Blood transfusion \<12 weeks prior to randomisation
* Polycythemia vera
* Previous acute myocardial infarction
* Concomitant inflammatory or malignant disease
* Recent trauma or major surgery
* Unwilling to sign informed consent
* Atrial fibrillation",epoetin alfa,INTERVENTIONAL,COMPLETED
NCT00683111,Prevention of Gastrointestinal Bleeding in Patients With Severe Ischemic Heart Disease,"Acute Coronary Syndrome, Acute Myocardial Infarction",* patients admitted for acute coronary syndrome or acute myocardial infarction requiring active treatment with aspirin clopidogrel and (enoxaparin or thrombolytics.),"* known active peptic ulcer disease or gastrointestinal within 8 wk
* known iron deficiency anemia with Hb \< 10 gm/dl
* mechanical ventilation
* active cancer, liver cirrhosis, end-stage renal failure
* life expectancy \< 1 yr
* known allergic to aspirin, clopidogrel, enoxaparin famotidine or esomeprazole
* pregnancy, lactation, child-bearing potential in the absence of contraception,
* co-prescription of NSAID, corticosteroid, or warfarin
* non-oral feeding or impaired GI absorption e.g. vomiting
* already on proton pump inhibitor for \> 1 day or another clinical trial drug for ulcer disease","esomeprazole 20 mg daily, famotidine 40 mg daily",INTERVENTIONAL,COMPLETED
NCT03913793,Aerobic Training in Post-MI Patients With DPN,"Myocardial Infarction, Diabetes Mellitus, Type 2, Diabetic Peripheral Neuropathy","* diagnosed as having MI according to the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of MI
* DM according to the 2016 American Diabetes Association guidelines","* contraindication to exercise stress test (EST)
* contraindication to cardiac rehabilitation,
* systemic illness other than DM or hypertension,
* neurological disorders other than DPN,
* had loss of protective sensation (anesthesia)
* had ulcerations in the lower limbs.",Exercise based-cardiac rehabilitation (EB-CR) program,INTERVENTIONAL,COMPLETED
NCT00200707,BONAMI (BOne Marrow in Acute Myocardial Infarction),Acute and Severe Myocardial Infarction,"* Men or women between 18-75 years.
* Acute myocardial infarction
* Absence of viability in the infarcted zone and LVEF \<45%.","* History of prior myocardial infarction
* Significant stenosis in another coronary territory than the acutely treated vessel",Intracoronary injection of autologous bone marrow mononuclear cells,INTERVENTIONAL,COMPLETED
NCT04649307,Cognitive Behavioral Therapy Following Myocardial Infarction,Myocardial Infarction,( - )MI ≥ 6 months before assessment (type 1 STEMI/NSTEMI) ( - )Age 18-69 years endorsed cardiac anxiety that leads to significant distress or interferes with daily life (Cardiac Anxiety Questionnaire (CAQ); score ≥20) ( - ) On optimal medical treatment ( - )Able to read and write in Swedish.,"( - ) heart failure with severe systolic dysfunction (ejection fraction ≤ 35%) ( - ) significant valvular disease ( - ) planned coronary artery bypass surgery or other invasive therapy ( - ) other severe medical illness ( - )any medical restriction to physical exercise ( - )severe psychiatric disorder, severe depression, or risk of suicide ( - )alcohol dependency.",MI-CBT,INTERVENTIONAL,COMPLETED
NCT01542385,Primary Reperfusion Secondary Stenting Trial,ST-elevation Myocardial Infarction,"1. Age between 18 and 80 years;
2. STEMI, presenting within 12 hours of symptoms onset, and persisting for more than 20 minutes;
3. ECG that fulfills any of the following criteria: ≥ 2 mm ST elevation in two anterior or lateral leads; or ≥ 1 mm ST elevation in two inferior leads; or new left bundle branch block (LBBB) with at least 1 mm concordant ST elevation;
4. Infarct-related artery with TIMI flow 0 or 1 at baseline angiogram;
5. Successful reperfusion (TIMI 2-3 flow), either spontaneously or after wire passage, thrombectomy, small size (≤ 2.0mm) angioplasty catheter, and persisting for more than 10 minutes;
6. Infarct related artery with a diameter above 2.5 mm.","1. Prior STEMI in the qualifying coronary artery;
2. Coronary dissection following reperfusion;
3. STEMI caused by acute stent thrombosis or a venous or arterial bypass graft occlusion;
4. Significant left main disease, as determined by angiography (≥ 50%) or other imaging technologies;
5. Cardiac condition requiring emergent or urgent surgical repair;
6. Failed thrombolysis and rescue PCI;
7. High risk of bleeding;
8. Contraindication to either ticagrelor or GpIIb/IIIa inhibitors;
9. STEMI with Killip III-IV or cardiogenic shock or presenting as sudden death, ventricular fibrillation, or sustained ventricular tachycardia;
10. Women who are pregnant or breastfeeding;
11. Creatinine clearance \< 20 ml/min;
12. Other contraindication to PCI;
13. Participation with another investigational drug or investigational device study within 30 days prior to randomization (participation to registries is allowed);
14. Any condition that in the opinion of the investigator would preclude compliance with the study protocol.",Stent,INTERVENTIONAL,COMPLETED
NCT05208398,Apixaban in Patients With Left Ventricular Thrombus,Left Ventricular Thrombus,"All the following criteria must be fulfilled:

* Ages between 18 and 80 years,
* History of anterior wall MI, either acute (within a week) or recent (within a month)
* Evident left ventricular thrombus (LVT) by transthoracic echocardiography,
* Naïve to oral anticoagulants (OAC)
* stable to start OAC","* Other indications for OAC,
* Patients with contraindications for OAC,
* Right ventricular thrombus or atrial thrombus,
* History of confirmed stroke or other systemic embolization within the previous six months,
* High bleeding risk,
* Severe renal impairment,
* Patients with expected difficulties to follow the INR strictly.","Apixaban, Warfarin",INTERVENTIONAL,COMPLETED
NCT03715998,Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction,Myocardial Infarction,"* Diagnosis of first acute anterior MI (ST-elevation myocardial infarction) defined as chest pain \>30 minutes and ST elevation ≥0.2 mV in at least 2 consecutive electrocardiogram (ECG) leads in the anterior area (DI, aVL, V1 V6).
* Primary PCI of the index-MI-related artery within 24 hours after the MI.","* Body mass index \>45 kg/m².
* Subject is hemodynamically unstable or has cardiogenic shock.
* Subjects with clinical signs of HF (Kilipp III and IV).
* Systolic blood pressure \<100 mmHg at inclusion visit
* Early primary PCI of the index-MI-related artery performed within 3 hours after MI.
* Subjects treated with angiotensin-converting-enzyme inhibitor (ACE I), angiotensin receptor blocker (ARB) or sacubitril/valsartan prior to the index magnetic resonance imaging. Note: if treatment was for HTN, ACE I/ARB should be stopped, and, if necessary, another therapeutic class can be prescribed for HTN. If the ACE I/ARB was prescribed for congestive HF, the subject is not considered eligible; if the ACE I/ARB prescribed for another reason cannot be stopped, the subject is not eligible for study inclusion.
* Subjects scheduled for implantable cardioverter defibrillator (ICD), cardiac resynchronization therapy, or pacemaker within the next 3 months. If an ICD is indicated for ventricular arrhythmia during the course of the study, a life vest, when possible, should be prescribed and the ICD scheduled after study completion.","Ramipril, Firibastat",INTERVENTIONAL,COMPLETED
NCT00704561,Vessel Wall Response of the Zotarolimus Drug-eluting Stent Implanted in AMI Assessed by Optical Coherence Tomography,Acute Myocardial Infarction,"* Acute Myocardial MI with ST segment Elevation, within 12 hours from symptoms onset
* Native coronary artery disease with \>70% diameter stenosis (no prior stent implant, no prior brachytherapy)
* Vessel size in between 2.5 and 3.75 mm
* Signed patient informed consent","* Lesions in coronary artery bypass grafts
* Significant left main disease
* Killip class IV
* Reecent major bleeding (6 months)
* Renal failure with creatinine value \> 2.5 mg/dl
* Allergy to aspirin and or clopidogrel/ticlopidine
* Patient in anticoagulant therapy
* IMA due to a stent thrombosis
* No suitable anatomy for OCT scan: (only ostial location, very tortuous anatomy, very distal or large vessels \[≥ 3.75 mm in diameter\])","ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA), DRIVER bare metal stent (Medtronic, Santa Rosa, Ca), Coronary stent implantation, Bare Metal Coronary Stent",INTERVENTIONAL,COMPLETED
NCT00954161,Bystander Helping Behaviour for Myocardial Infarction Following First Aid Training,Acute Myocardial Infarction,* Course participants that are 18 years or older,"* Course participants that are younger than 18 years
* Health care students
* Health care professionals","Helping behaviour curriculum, First aid only curriculum",INTERVENTIONAL,COMPLETED
NCT00790907,Fondaparinux Trial With Unfractionated Heparin (UFH) During Revascularization in Acute Coronary Syndromes (ACS),Acute Coronary Syndrome,"The following are inclusion and exclusion criteria for enrollment in the study:



* Presenting or admitted to hospital with symptoms suspected to represent UA or NSTEMI, i.e., clinical history consistent with new onset, or a worsening pattern of, characteristic ischemic chest pain or ischemic symptoms occurring at rest or with minimal activity (lasting longer than 5 minutes or requiring sublingual nitro-glycerine for relief of the pain).
* Available to be enrolled within 48 hours of the onset of the most recent episode of symptoms.
* Planned coronary angiography, with PCI if indicated, within 72 hours of enrollment where possible.
* At least two of the three following additional criteria:
* Age greater than or equal to 60 years
* Troponin T or I or CK-MB above the upper limit of normal for the local institution;
* Electrocardiogram (ECG) changes compatible with ischemia, i.e., ST depression at least 1 mm in 2 contiguous leads or T wave inversion \> 3 mm or any dynamic ST shift or transient ST elevation.
* Written informed consent dated and signed","* Age \< 21 years.
* Any contraindication to UFH or fondaparinux
* Contraindication for angiography or PCI at baseline
* Subjects requiring urgent (\<120 minutes) coronary angiography as characterized by those with:
* refractory or recurrent angina associated with dynamic ST-deviation
* heart failure
* life-threatening arrhythmias
* hemodynamic instability
* Subjects already receiving treatment with enoxaparin (or other LMWH), bivalirudin or UFH for treatment of the qualifying events unless the last administered (intravenous(i.v.) or s.c.) dose was:
* ≥ 8 hours for low molecular weight heparin (LMWH)
* ≥60 minutes for bivalirudin
* ≥90 minutes for unfractionated heparin (UFH)
* Hemorrhagic stroke within the last 12 months.
* Indication for anti-coagulation other than acute coronary syndrome (ACS) during the index hospitalization.
* Pregnancy or women of childbearing potential who are not using an effective method of contraception.
* Co-morbid condition with life expectancy less than 6 months.
* Currently receiving an experimental pharmacological agent.
* Revascularization procedure already performed for the qualifying event.
* Severe renal insufficiency (i.e., estimated creatinine clearance \<20 ml/min)

Following angiography and confirmation that the subject is to undergo PCI, the subject must also meet all of the following additional criteria in order to be randomised:

* Subjects will have received at least 1 dose of open-label fondaparinux
* The most recent dose of open-label fondaparinux will not have been more than 24 hours before the start of the PCI procedure.","fondaparinux background and standard dose UFH, Fondaparinux background and low dose heparin, Open label fondaparinux",INTERVENTIONAL,COMPLETED
NCT01217307,Metformin to Reduce Heart Failure After Myocardial Infarction,"ST Elevation Myocardial Infarction (STEMI), Coronary Artery Disease, Heart Failure, Diabetes","* The diagnosis acute MI defined by chest pain suggestive for myocardial ischemia for at least 30 minutes, the time from onset of the symptoms less than 12 hours before hospital admission, and an ECG recording with ST- segment elevation of more than 0.1 mV in 2 or more leads.
* Successful primary PCI (post-procedural TIMI 2/3);
* At least one stent sized ≥ 3.0 mm;
* Eligible for 3T CMR imaging;
* Verbal followed by written informed consent.","* rescue PCI after thrombolytic therapy;
* need for emergency coronary artery bypass grafting;
* creatinin \>177 μmol/L measured pre-PCI;
* Younger than 18 years;
* Mechanical ventilation;
* Diabetes;
* Prior myocardial infarction;
* Contra-indication to metformin (see safety);
* The existence of a life-threatening disease with a life-expectancy of less than 6 months.","Metformin, Placebo",INTERVENTIONAL,COMPLETED
NCT00093197,Safety of KAI-9803 for Injection With Angioplasty Following Heart Attack,Myocardial Infarction,"* Symptoms of cardiac ischemia at rest or with increasing frequency (angina or angina equivalent), with episodes lasting for at least 30 minutes within 6 hours of presentation
* Persistent ST-segment elevation of ≥ 0.2 mV in at least 2 contiguous precordial leads indicative of anterior Myocardial Infarction (MI) location (leads V1-V4)
* At least 18 years old
* Complete occlusion of the left anterior descending artery (Thrombolysis in Myocardial Infarction (TIMI) 0-1 flow) demonstrated on the initial angiogram
* Culprit lesion suitable for primary percutaneous coronary intervention (PCI)","* Any left bundle branch block (new or old), intraventricular conduction defect, or paced rhythm that would obscure the diagnosis of acute anterior ST Elevation Myocardial Infarction (STEMI)
* Any prior documented myocardial infarction (MI), including old Q waves documented on prior ECGs or a clinical history of definite MI
* Any prior coronary artery bypass grafting (CABG)
* Cardiogenic shock at initial hospital presentation, consisting of persistent hypotension (systolic blood pressure \< 90 mm Hg for \> 20 minutes) and signs of end-organ dysfunction (oliguria, altered mental status, poor peripheral perfusion, and lactic acidosis)
* TIMI grade 2 or 3 flow in the left anterior descending artery documented on the initial diagnostic angiogram
* Culprit lesion in the left anterior descending artery that is not suitable for primary PCI
* Treatment with intravenous fibrinolytic therapy (i.e. alteplase, reteplase, tenecteplase, or streptokinase) within the 24 hours before presentation
* Pregnancy
* Know baseline creatinine \> 2.5 mg/dL without renal dialysis/renal replacement therapy within the 30 days before presentation
* Inability to comply with study procedures, inability to undergo cardiac catheterization or primary percutaneous coronary intervention (PCI)
* Participation in a study of experimental therapy (drug or device) within 30 days of presentation, or prior participation in this study","KAI-9803 for Injection, KAI-9803 for Injection, KAI-9803 for Injection, KAI-9803 for Injection, Placebo",INTERVENTIONAL,COMPLETED
NCT03985397,Patients With Acute Myocardial Infarction,Cardiovascular Diseases,"* Acute myocardial infarction
* Discharge planned
* Minimal literacy
* 18-75 years of age
* No cancer or psychiatric diagnosis
* Not previously trained
* Being willing to participate in research","* Patients who had myocardial infarction,
* İntubated, who had been intubated,
* were treated in other services due to additional diseases such as GIS bleeding, pneumonia, etc. after myocardial infarction,
* patients who had myocardial infarction and returned to their own services after treatment,
* who wanted to be transferred to another hospital while they were receiving treatment after myocardial infarction,
* who wanted to go to another hospital for an outpatient appointment,
* who did not want to come to polyclinic control from another city caused data loss.",discharge training,INTERVENTIONAL,COMPLETED
NCT02828683,Safety and Efficacy of TCD-10023 (Ultimaster) Drug-eluting Stent in STEMI Patients - MASTER Study,Acute ST Segment Elevation Myocardial Infarction,"* Age equal or more than 18 years
* Chest pain \> 20 minutes
* Primary PCI \<24h from symptoms onset
* ST-segment elevation of \> 1 mm in \> 2 contiguous leads, or (presumably new) left bundle branch block, or true posterior MI with ST depression of \> 1 mm in \> 2 contiguous anterior leads
* Presence of at least one acute infarct artery target vessel with one or more coronary artery stenoses in a native coronary artery from 2.5-4.0 mm in diameter that can be covered with one or multiple stents
* Signed informed consent","* Female of childbearing potential (age \< 50 and last menstruation within the last 12 months), who did not underwent tubal ligation, ovariectomy or hysterectomy
* Known intolerance to aspirin, clopidogrel, heparin, bivalirudin, cobalt, chromium, nickel, sirolimus or contrast material
* Currently participating in another trial before reaching primary endpoint
* Mechanical complication of acute myocardial infarction (e.g. cardiogenic shock...)
* Acute myocardial infarction secondary to stent thrombosis
* Previously stented infarction related artery (IRA)
* Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained throughout the peri-surgical period
* Patients with non-cardiac comorbid conditions with life expectancy\< 1 year or that may result in protocol non-compliance
* History of bleeding diathesis or known coagulopathy
* Use of oral anticoagulants","PCI in patients with ST-elevation myocardial infarction, PCI in patients with ST-elevation myocardial infarction",INTERVENTIONAL,COMPLETED
NCT01392105,Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction,Acute Myocardial Infarction,"* aged 18-70 years
* ischemic chest pain for \>30 min
* admitted to hospital \<24 h after the onset of chest pain
* electrocardiography showed ST segment elevation \>1 mm in two consecutive leads in the limb leads or \>2 mm in the precordial leads
* they could be enrolled in the study \<72 h after successful revascularization","* cardiogenic shock (defined as systolic blood pressure \<90 mmHg requiring intravenous pressors or intra-aortic balloon counterpulsation)
* life-threatening arrhythmia
* impossible conditions for cardiac catheterization
* advanced renal or hepatic dysfunction
* history of previous coronary artery bypass graft
* history of hematologic disease
* history of malignancy
* major bleeding requiring blood transfusion
* stroke or transient ischemic attack in the previous 6 months
* structural abnormalities of the central nervous system (brain tumor, aneurysm, history of surgery)
* traumatic injury after myocardial infarction
* use of corticosteroids or antibiotics during the previous month
* major surgical procedure in the previous 3 months
* cardiopulmonary resuscitation for \>10 min within the previous 2 weeks
* positive skin test for penicillin
* positive result for viral markers (human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) and Venereal Disease Research Laboratory (VDRL) test)
* pregnancy, possible candidate for pregnancy or breastfeeding females
* drug abusers
* inappropriate patients to participate in the study according to the chief investigator","Mesenchymal stem cell, Control group",INTERVENTIONAL,COMPLETED
NCT00905905,Additive Effect of Ezetimibe Upon Simvastatin During Myocardial Infarction,Myocardial Infarction,"* less than 24 hours after the onset of myocardial infarction symptoms
* ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads
* myocardial necrosis, as evidenced by increased CK-MB and troponin levels",* use of statins for the last 6 months before myocardial infarction,"Simvastatin, Ezetimibe-Simvastatin",INTERVENTIONAL,COMPLETED
NCT03637205,Extracorporeal Life Support in Cardiogenic Shock,"Acute Myocardial Infarction, Cardiogenic Shock","* Cardiogenic shock complicating AMI (STEMI or NSTEMI) plus obligatory:
* Planned revascularization (PCI or alternatively CABG)
* Systolic blood pressure \<90 mmHg \>30 min or catecholamines required to maintain pressure \>90 mmHg during Systole
* Signs of impaired organ perfusion with at least one of the following criteria a) Altered mental Status, b) Cold, clammy skin and extremities, c) Oliguria with urine output \<30 ml/h
* Arterial lactate \>3 mmol/l
* Informed consent","* Resuscitation \>45 minutes
* Mechanical cause of cardiogenic shock
* Onset of shock \>12 h
* Severe peripheral artery disease with impossibility to insert ECLS cannulae
* Age \<18 years or age \>75 years
* Shock of other cause (bradycardia, sepsis, hypovolemia, etc.)
* Other severe concomitant disease with limited life expectancy \<6 months
* Pregnancy
* Participation in another trial","ECLS insertion, Revascularisation and optimal medical treatment",INTERVENTIONAL,COMPLETED
NCT02376283,P3AMI Antiplatelet Trial,Heart Attack,"1. Patients presenting with STEMI for PCI (characterized by chest discomfort, and prominent STsegment elevation)
2. Patients presenting with NSTEMI (characterized by chest discomfort, raised levels of myocardial enzymes and/or STsegment depression or prominent T wave inversion)
3. Able to give verbal consent (STEMI patients pre procedure) and/or written consent (STEMI after procedure and NSTEMI patients prior to enrolment).
4. Age\>18 years of age
5. Able to take Aspirin and either prasugrel or ticagrelor.
6. Have no concurrent septic or inflammatory illness
7. Thienopyridine naive","1. Be unable to provide verbal and written consent
2. Allergic to aspirin or any of the P2Y12 antagonists in the trial
3. Have preexisting cardiogenic shock
4. Have a concurrent septic or inflammatory disease e.g. rheumatoid arthritis, lupus, pneumonia.
5. Already taking a P2Y12 inhibitor
6. Known bleeding diathesis
7. Patients under 75 years of age or under 60 kg or those who have had a previous stroke/transient ischaemic attack, will not be eligible for prasugrel but rather ticagrelor.
8. Patients with a history of intracranial haemorrhage will not receive prasugrel or ticagrelor but rather will receive treatment with clopidogrel.","Prasugrel, Clopidogrel, ticagrelor",INTERVENTIONAL,COMPLETED
NCT06564597,Activity-based Training After Myocardial Infarction,"Myocardial Ischemia, Activities of Daily Living","* Diagnosis of myocardial infarction (ST elevation or non-ST elevation)
* Ejection fraction \> 40%","* Ejection fraction \< 40%
* Presence of exercise-induced ischemia
* Presence of orthopedic or neurological disorder that will affect the current study
* Presence of pulmonary disease that will affect the current study (COPD, Asthma)
* Presence of visual impairment
* Presence of malignancy",Patient education,INTERVENTIONAL,COMPLETED
NCT01327183,A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention,Myocardial Infarction,"* Adult patients, \>18 to \<75 years of age
* Non ST-elevation myocardial infarction
* Woman of childbearing potential will be allowed only if using two acceptable methods of contraception
* Body mass index (BMI) \</= 40 kg/m2","* Acute ST-elevation myocardial infarction (STEMI)
* Culprit coronary lesion with a total thrombotic occlusion or a lesion requiring the use of distal embolization protection or thrombectomy devices
* Percutaneous coronary intervention (PCI) within the past 72 hours
* Thrombolytic therapy within the past 7 days
* Major surgery within the past 3 months
* History of cerebral vascular disease or stroke in the past 3 months
* Bleeding disorders
* Inadequately controlled severe hypertension
* Prior coronary artery bypass graft (CABG) surgery
* Decompensated heart failure (oedema and/or rale)
* Acute infection at screening or active chronic infection within 3 months prior to PCI
* Patients known to be HIV positive, patients receiving antiretroviral drugs, or immuno-suppressed patients
* Uncontrolled diabetes mellitus (HbA1C \>10%) at baseline","Percutaneous Coronary Intervention (PCI), RO4905417, RO4905417, placebo",INTERVENTIONAL,COMPLETED
NCT00132093,Effects of Eplerenone on Left Ventricular Remodelling Following Heart Attack,Myocardial Infarction,"1. Age 18 or above
2. Acute myocardial infarction within last 1-14 days (defined by typical electrocardiogram \[ECG\] changes and/or elevated cardiac enzymes to at least twice the upper limit of normal)
3. Left ventricular systolic dysfunction (LVSD) based on echocardiographic wall motion score index (WMSI) and left ventricular ejection fraction (LVEF) \< 40%
4. Ability to give written informed consent","1. Clinical or radiological heart failure
2. Established diabetes mellitus
3. Current use of potassium (K)-sparing diuretics, clarithromycin, nefazodone, itraconazole, ketoconazole, ritonavir, nelfinavir, tacrolimus, cyclosporin.
4. Serum creatinine \> 220 µmol/l
5. Serum potassium \> 5.0 mmol/l
6. Pregnancy
7. Addison's disease
8. MRI-incompatible (ferrous) sulphate prosthesis
9. Claustrophobia (unable to tolerate MR environment)
10. Concurrent use of phenytoin, carbamazepine, rifampicin or St. John's Wort (reduce efficacy of eplerenone).",Eplerenone,INTERVENTIONAL,COMPLETED
NCT02182011,"A Study to Investigate the Procoagulant Effect of Tenecteplase (TNK-tPA), Alteplase (Rt-PA) and Streptokinase (SK) Administered to Patients With Acute Myocardial Infarction (AMI)",Myocardial Infarction,"* Onset of symptoms of AMI within 6 hours from randomisation
* A twelve-lead electrocardiogram (ECG) showing ST-segment elevation ≥ 0.1 millivolt (mV) in two or more limb leads, or ≥ 0.2 mV in two or more contiguous precordial leads indicative of AMI, or new left bundle-branch block
* Age ≥ 18","* Hypertension defined as blood pressure \> 180/110 mmHg (systolic BP \> 180 mmHg and/or diastolic BP \> 110 mmHg) on repeated measurements during current admission prior to randomisation
* Use of abciximab (ReoPro®) within the preceding 7 days or eptifibatide (Integrilin®) or tirofiban (aggrastat®) within the past 48 hours
* Use of heparin within the preceding 12 hours
* Current therapeutic oral anticoagulation
* Major surgery, biopsy of a parenchymal organ, or significant trauma within 2 months
* Any minor head trauma and any other trauma occurring after the onset of the current myocardial infarction
* Any known history of stroke or transient ischemic attack or dementia
* Any known structural damage of the central nervous system
* Ruptured aortic aneurism
* Active bleeding
* Prolonged cardiopulmonary resuscitation (\> 10 minutes) in the previous two weeks
* Pregnancy or lactation, parturition within the previous 30 days. Women of childbearing potential must have a negative pregnancy test
* Any known active participation in another investigative drug study or device protocol in the past 30 days
* Previous enrolment in this study
* Any other condition that the investigator feels would place the patient at increased risk if the investigational therapy were initiated
* Inability to follow the protocol and comply with follow-up requirements","Tenecteplase, Alteplase, Streptokinase",INTERVENTIONAL,COMPLETED
NCT00502528,Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction,ST-Elevation Myocardial Infarction,"* STEMI patients (defined as: Evidence of ischemic chest pain for \>30 minutes within \<12 hours and new ST-segment elevation for ≥2 mm in two or more contiguous electrocardiographic leads or in case of a true posterior infarction reciprocal ST-segment depressions in in V1 and V2 \>1mm and/or elevated serum creatine phosphokinase or twofold elevation of troponin-T), aged 18 years and above, who undergo primary percutaneous revascularization (PCI) and have confirmed initial TIMI 0 or 1 in the infarct related coronary artery.","* Significant liver disease
* Thrombolytic therapy
* History of prior myocardial infarction
* Current atrial fibrillation
* History of congestive heart failure
* History of migraine headache
* Significant valvular heart disease, primary myocardial disease
* Cardiogenic shock (sRR \<90mmHg or need for inotropic support)
* Child-bearing potential
* Inability to read, understand and sign the informed consent
* Life expectancy \<3y
* Prior organ transplantation
* Medication with konazoles, ritonavir, rifampicin and sulfonyl-urea derivatives
* Participation in another clinical study
* Metal implants contraindicating CMR","Placebo, BQ-123",INTERVENTIONAL,COMPLETED
NCT00135928,Stem Cells in Myocardial Infarction,Acute Myocardial Infarction,"* Patients between 20 and 70 years with STEMI were eligible if they had a successful PCI within 12 hours after onset of symptoms.
* The target lesion had to be located in the proximal section of the left anterior descending (LAD), left circumflex (LCX) or right coronary artery (RCA).
* Only patients with creatine kinase \[CK\]-MB \>100 microgram/L or development of Q waves in the electrocardiogram were included.","* Ventricular arrhythmia after PCI requiring treatment
* Pregnancy
* Unprotected left main stem lesion
* History of prior myocardial infarction
* Diagnosed or suspected cancer
* New York Heart Association (NYHA) class 3-4
* Known severe claustrophobia
* Significant stenosis in another coronary vessel than the acutely treated vessel, that might demand treatment with PCI or coronary artery bypass graft surgery (CABG) prior to the last follow-up exam.",Granulocyte Colony Stimulating Factor G-CSF (Neupogen®),INTERVENTIONAL,COMPLETED
NCT00064428,OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction,Thromboembolism,"* Subjects who presented or were admitted to hospital with:

  1. Signs and symptoms of AMI
  2. Were able to randomize within 12 hours of symptom onset; and-
  3. Had definite ECG changes indicating STEMI: persistent ST-elevation (≥0.2mV in two contiguous precordial leads, or ≥0.1mV in at least two limb leads), or new left bundle branch block, or ECG changes indicating true posterior MI.
* Written informed consent
* Able to be randomized within 24 hours of symptom onset","* Age \<21 years.
* Was currently receiving an oral anticoagulant agent with an INR \>1.8.
* Had any contraindication to anticoagulation therapy such as high risk of bleeding or active bleeding.
* Had hemorrhagic stroke within the last 12 months.
* Had an indication for anticoagulation other than ACS.
* Pregnant women or women of child-bearing potential who were not using an effective method of contraception.
* Had a co-morbid condition with a life-expectancy \<6 months.
* Previous enrollment in one of the fondaparinux ACS trials.
* Participation in another pharmacotherapeutic study within the prior 30 days or was currently receiving an experimental pharmacological agent.
* Had a known allergy to heparin or fondaparinux.
* Had severe renal insufficiency (i.e. serum creatinine ≥3mg/dL or ≥265μmol/L).
* Had \>5000IU UFH administered prior to randomization.
* Had LMWH administered prior to randomization.
* Subject had pre-randomization revascularization (PCI) for the index event.
* Subject had pre-randomization rescue PCI.","fondaparinux - UFH not indicated, Control - UFH not indicated, Fondaparinux - UFH indicated, Control - UFH",INTERVENTIONAL,COMPLETED
NCT04000893,Effect of Aerobic or Resistance Exercise on the Endothelial Response in Post-acute Myocardial Infarction Patients Submitted to Angioplasty,"Cardiac Rehabilitation, Aerobic Exercise, Resistance Exercise","* Post-acute myocardial infarction patients
* Ergometric test 30 days after the infarction
* Ejection fraction\> 40% (Simpson's method)
* Regular use of optimized drugs",* Unable to perform the randomized exercise,Resistance exercise session,INTERVENTIONAL,COMPLETED
NCT01664611,Daily REmote Ischaemic Conditioning Following Acute Myocardial Infarction,Post Myocardial Infarction,"* LVEF \< 45% on baseline ECHO
* First STEMI
* Successful revascularisation by PPCI
* Able to attend regional centre for follow-up appointment
* Competent to consent","* \< 18 of age
* ICD or CRTP/D in-situ
* Prior history of heart failure
* Haemoglobin \< 11.5 g/dl
* Creatinine \> 200 µmol/L (eGFR\<30ml/min/m2)
* Known malignancy/other comorbid condition which in the opinion of the investigator is likely to have significant negative influence on life expectancy
* Significant complications/illness following MI
* Unable to undergo cMRI
* Further planned coronary interventions
* Enrollment in another clinical trial","Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm, Sham conditioning",INTERVENTIONAL,COMPLETED
NCT01888211,Effect of Omega 3 Fatty Acids on Vascular Function,Previous Myocardial Infarction,• Myocardial infarction at least 3 months previously.,"* Dietary fish allergy or intolerance
* Women of child bearing potential
* Malignant arrhythmias
* Renal or hepatic failure
* Severe or significant co-morbidity
* Previous history of blood dyscrasia
* Unable to tolerate the supine position
* Lack of informed consent
* Blood donation within last 3 months","Omega 3 fatty acid supplementation, Olive Oil",INTERVENTIONAL,COMPLETED
NCT05419583,Targeting Investigation and Treatment in Patients With Type 2 Myocardial Infarction,Myocardial Infarction Type 2,"Adult patients with a clinical diagnosis of type 2 myocardial infarction, defined as:

i. Symptoms of myocardial ischaemia, or signs of myocardial ischaemia on 12-lead electrocardiogram (≥0.5mm ST segment depression in any two contiguous leads or new regional T wave inversion)

ii. A clinically significant change in high-sensitivity cardiac troponin concentration with at least one value above the 99th centile upper reference limit, or a single measurement if considered significantly elevated

iii. Documented evidence of myocardial oxygen supply (anaemia, hypoxia, hypotension, bradycardia, tachycardia, arrhythmia) or demand (hypertension, left ventricular hypertrophy, valvular heart disease) imbalance.","i. Patients under 30 years who are less likely to benefit from cardiac imaging

ii. Inability to give informed consent

iii. Patients on renal replacement therapy or with eGFR \<30ml/min

iv. Patients with advanced frailty (based on Clinical Frailty Score ≥7)

v. Patients who are pregnant or breast feeding

vi. Patients with ST-segment elevation on 12-lead electrocardiogram

vii. Patients with a clinical diagnosis of type 1 myocardial infarction

viii. Patients who have had diagnostic imaging confirming coronary vasospasm, embolism or spontaneous coronary artery dissection has caused type 2 myocardial infarction

ix. Previous randomization into TARGET-Type 2 pilot study","Coronary computed tomography angiography, Invasive coronary angiography, Transthoracic echocardiography, Cardiac MRI scan, Antiplatelet Drug (Aspirin or Statin), Anticoagulants (Apixaban, Edoxaban, Rivaroxoban, Warfarin), Guideline directed heart failure therapy, Statins (Cardiovascular Agents)",INTERVENTIONAL,COMPLETED
NCT00306228,Role of Tirofiban and the Paclitaxel Eluting Stent in Postfibrinolysis Angioplasty,Myocardial Infarction,"Patients with ST-segment elevation acute myocardial infarction with all of the following criteria will be eligible for enrollment:

1. Age \>18 years.
2. Chest discomfort \>30 minutes with no response to nitroglycerin.
3. Time from the onset of symptoms to randomization \< 12 hours.
4. ST segment elevation \> 1 mm in two or more limb leads or 2 mm in two or more contiguous precordial leads or non-diagnostic ECG (left bundle branch block or pacemaker rhythm) with classic symptoms.
5. Killip class \> 3.
6. Written informed consent will be obtained.","Patients presenting with any of the following will not be included in the study.

1. Cardiogenic shock defined as a systolic blood pressure \<90 mm Hg without response to fluid administration or \<100 mmHg in patients with supportive treatment and no bradycardia.
2. Suspected mechanical complications of acute myocardial infarction.
3. Previous CABG.
4. Non-cardiac disease that is likely to jeopardize the planned termination of the study.
5. Woman of childbearing potential unless a negative pregnant test.
6. Active bleeding and recent (within 2 weeks) surgery that contraindicate the use of heparin, tirofiban, or platelet aggregation inhibitors.
7. Contraindications for thrombolytic use.

   * previous hemorrhagic stroke at any time
   * history of prior non-hemorrhagic cerebrovascular accident within 12 months
   * intracerebral neoplasia
   * active internal bleeding
   * suspected aortic dissection
   * Uncontrolled hypertension \>180/110 in several measurements
   * any other known intracerebral pathology not covered in contraindications
   * Current use of anticoagulants or heparin use within 8 hours
   * known bleeding diathesis
   * recent trauma (\< 4 weeks), including head trauma or traumatic or prolonged (\>10 minutes) CPR or recent major surgery or biopsy (\<8 weeks)
   * noncompressible vascular punctures
   * recent (\< 4 weeks) internal bleeding
   * pregnancy
   * active peptic ulcer
8. History of hypersensitivity to aspirin, ticlopidine, clopidogrel, heparin, tirofiban and stainless steel.
9. Known renal failure, creatinine \>2,5 mg/dL.
10. Known impaired hepatic function that contraindicates the use of clopidogrel.
11. Known thrombocytopenia (100.000).
12. Participation in other trial.
13. Known multivessel disease identified as no suitable for revascularization.
14. Known peripheral vascular disease that difficult cardiac catheterization.","Postfibrinolysis percutaneous coronary intervention, Postfibrinolysis percutaneous coronary intervention, Postfibrinolysis percutaneous coronary intervention, Postfibrinolysis percutaneous coronary intervention",INTERVENTIONAL,COMPLETED
NCT02023983,Verification of the Safety of Early Discharge in Patients After Acute ST-segment Myocardial Infarction,"Coronary Artery Disease, Acute Myocardial Infarction With ST-segment Elevation, Primary Percutaneous Coronary Intervention, Early Discharge","* Signed informed consent
* Age ≥18 do ≤ 75 years
* Acute myocardial infarction with ST-segment elevation, treated with successful percutaneous coronary intervention within 12 hours from the onset of symptoms
* Left ventricle ejection fraction ≥ 45% by echocardiography
* Single- or two-vessel disease (stenosis of major epicardial artery ≥ 70%)
* Haemodynamic and rhythmic stability (Killip class I, no arrythmia requiring treatment occurring \> 2 hours after PCI)
* Assumed good cooperation and social background","* Symptoms of residual ischemia
* Significant comorbidities or abnormalities in paraclinical tests, requiring additional evaluation within continuing hospitalization
* Contraindication of dual antiplatelet therapy or need for anticoagulation therapy
* Hihg risk of bleeding complications
* Participation in other clinical study","Early discharge, Standard discharge",INTERVENTIONAL,COMPLETED
NCT00469261,Tetracycline (Doxycycline) and Post Myocardial Infarction Remodeling,"Myocardial Infarction, Left Ventricular Remodeling","* Acute myocardial infarction
* Left ventricular ejection fraction less than 40%","* No written consensus
* Allergy to tetracycline
* Mechanical complication of AMI
* Previous myocardial infarction
* Valvular and/or myocardiopathy known or suspected
* Renal failure (creatinine above 2 mg/dL)
* Connective tissue disease
* Pregnancy","Doxycycline, Current medical therapy for AMI",INTERVENTIONAL,COMPLETED
NCT02272283,Optical Coherence Tomography Guided Percutaneous Coronary Intervention With Stent Implantation,"Coronary Artery Disease, Myocardial Infarction","* A Non ST segment Elevation Myocardial Infarction (NSTEMI) had been diagnosed
* A de novo lesion (more than or equal to 50% dimater stenosis) had been visualized on coronary angiography
* A Percutaneous Coronary Intervention with Drug-Eluting Stent (DES) implantation was indicated","* Patients included in other randomized trials
* Lifeexpectancy \<1 year
* Allergy to aspirin, clopidogrel, ticagrelor and prasugrel
* Allergy to limus-agents
* Ostial lesions (not possible to flush by OCT)
* S-creatinin \>170 micrograms/l
* Tortuous and extremely calcified lesions where intravascular imaging is deemed associated with an increased risk for the patient
* Very long lesions (due to the limited pullback length of the OCT system)",Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation,INTERVENTIONAL,COMPLETED
NCT00046228,A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse),Myocardial Infarction,"* Patients who have prolonged, continuous (lasting at least 20 minutes) signs and symptoms of A heart attack not eliminated with nitrates and onset within 6 hours of randomization,and confirmation by Electrocardiogram","* Low risk clinical presentation
* patients who will not be undergoing a catherization within 4 hours of the qualifying Electrocardiogram","abciximab placebo; reteplase placebo, abciximab, abciximab, Abciximab; reteplase; abciximab placebo; abciximab, abciximab; reteplase placebo; abciximab placebo; abciximab, abciximab placebo; reteplase placebo, abciximab, abciximab, abciximab; reteplase placebo; abciximab placebo; abciximab, Abciximab; reteplase; abciximab placebo; abciximab",INTERVENTIONAL,COMPLETED
NCT02313961,Remote Ischemic Conditioning in ST-elevation Myocardial Infarction as Adjuvant to Primary Angioplasty,ST Elevation Myocardial Infarction,"* STEMI defined as chest pain (or epigastric pain) for more than 30 minutes and either: (i) new ST elevation at the J point in two contiguous leads with the cut-off points of ≥0.2 mV in men or ≥0.15 mV in women in leads V2-V3 or ≥0.1 mV in all other leads, (ii) or new or presumed new left bundle branch block (LBBB)
* Symptom onset not more than 12 h before presentation
* Willingness and capability to provide informed consent","* Cardiogenic shock as defined by systemic hypotension (systolic arterial pressure - SAP - below 90 mmHg) and evidence of tissue hypoperfusion
* Post-cardiac arrest status
* Need for mechanical ventilation
* Known peripheral artery disease or evidence of lower limb ischemia
* Recent myocardial infarction (within 30 days)",Remote ischaemic conditioning,INTERVENTIONAL,COMPLETED
NCT02709798,ShenFu Injection for Myocardial Protection in Patients With Acute ST Segment Elevation Myocardial Infarction,Myocardial Infarction,"1. Age ≥18 and \<75 years;
2. First-time acute anterior STEMI;
3. The time from onset of ischemic symptom to the time of initial PCI balloon inflation ≤6 hours;
4. \>0.1 mV ST segment elevation in at least two contiguous precordial leads according to electrocardiogram;
5. Scheduled for primary PCI;
6. The presence of left anterior descending branch (LAD) occlusion in proximal or middle segment with pre-PCI TIMI flow 0 or 1 according to baseline coronary angiogram;
7. Written informed consent.","1. Hypertrophic cardiomyopathy, aortic valve stenosis and/or regurgitation, pericarditis, or myocarditis;
2. Cardiogenic shock, severe ventricular arrhythmia, serious heart failure (Killip class III and above) or mechanical complications;
3. Patients after cardiopulmonary resuscitation (CPR) (including cardioversion);
4. Patients who have already received thrombolytic therapy;
5. Prior myocardial infarction or coronary artery bypass surgery;
6. Known serious hepatic, renal, blood, respiratory, or neuropsychiatric diseases;
7. Malignant tumor, lymphoma, HIV-positive, or hepatitis;
8. Uncontrolled hypertension (systolic BP \>160 mm Hg or a diastolic BP \>100 mmHg on at least two consecutive readings);
9. Patients with active bleeding, major surgery or trauma within 3 months and cerebrovascular accident within 6 months;
10. History of anemia (hemoglobin\<90g/L) or thrombocytopenia (thrombocyte\<90×109/L);
11. Multi-vessel disease with non-culprit vessel intervention;
12. Breastfeeding, pregnant, or potentially fertile women;
13. Patients who have known to be allergic to Shenfu Injection or its components or patients with serious adverse effect;
14. Patients with potential contraindication to CMR;
15. Participation in other clinical trial in recent 3 months;
16. Patients who cannot complete this trial or comply with the protocol.","Shenfu Injection, 5% Glucose Injection",INTERVENTIONAL,COMPLETED
NCT01379261,Efficacy of Endovascular Catheter Cooling Combined With Cold Saline for the Treatment of Acute Myocardial Infarction,"Myocardial Infarction, Myocardial Reperfusion Injury, Anterior Wall Myocardial Infarction, Inferior Wall Myocardial Infarction","1. Clinical symptoms and signs of myocardial infarction and have a 12-lead ECG providing evidence of an ongoing acute myocardial infarction, involving a large area of myocardium, as defined by the following ECG criteria. The ECG changes should be present upon arrival to the cath lab:

   1. Anterior infarct: ST-segment elevation \>0.2mV measured 0.08 sec after the J point in 2 or more anatomically contiguous precordial leads, V1 through V4; and/or \>0.2mV in lead V5 V6.
   2. Inferior infarct: ST elevation \>0.2mV measured 0.08 sec after the J point in 2 or more anatomically contiguous inferior leads, coupled with ST depression in 2 contiguous anterior leads for a total ST deviation (inferior ST elevation plus anterior ST depression) of \>0.8mV.
2. Present to the study PCI lab within six (6) hours of the onset of acute cardiac ischemic signs or symptoms (such as chest pain or pressure, arm or jaw pain, dyspnea, nausea/vomiting, or syncope).
3. Be a candidate for PCI and have PCI planned as the immediate intervention.
4. Be willing and able to comply with study procedures, including returning for the MRI scan at 4 ±2 days and be available for additional follow up Subject understands study procedures and agrees to participate in the study by giving written informed consent.
5. Be in Killips Class I.","1. Age less than eighteen (\<18) years of age
2. Age greater than or equal to eighty (80) years of age
3. Are pregnant.
4. Having an aortic dissection
5. History of a prior large myocardial infarct or an infarct in the same segment that is currently affected.
6. Acute administration of a thrombolytic agent for the qualifying MI
7. Clinical suspicion of a non-thrombotic (e.g., pericarditis, vasospasm, takotsubo, illicit drug use) cause for ST-segment elevation as determined by the investigator
8. If (during the screening process) the determination is made by site-study personnel that initiation of cooling prior to diagnostic coronary angiography is technically not feasible for any reason (should the patient be randomized to the Hypothermia Arm), the prospective subject should not be enrolled.
9. Known risk for heparin induced thrombocytopenia (HIT)
10. Require an immediate surgical or procedural intervention other than PCI (e.g. CABG)
11. Present in cardiogenic shock or with end-stage cardiomyopathy
12. Have undergone at least ten (10) minutes of cardiopulmonary resuscitation (CPR) prior to presentation to the PCI facility
13. History of surgical coronary artery revascularization (e.g. CABG)
14. Active bleeding, coagulopathy, or other contraindication to the placement of a heparin-coated 14F central venous catheter via a 14F femoral venous introducer sheath (e.g., known history of heparin induced thrombocytopenia, or IVC filter)
15. Contraindications to hypothermia
16. Personal or familial history of malignant hyperthermia
17. Known end-stage renal disease (ESRD; e.g., on dialysis, or status-post renal transplant), known severe hepatic failure (e.g., cirrhosis, or acute hepatitis), or any other contraindication to receiving meperidine (such as use of MAO inhibitors within previous 14 days, history of seizures, history of hypersensitivity to meperidine, etc.).
18. Serious concurrant medical condition likely to result in death during the next 12 months. Any other acute or chronic condition which the Investigator believes will unacceptably increase the risk of study participation or interfere with study procedures and assessments.
19. Contraindication to MRI (e.g., cardiac pacemaker, ICD, nerve stimulator, brain aneurysm clips, cochlear implants, claustrophobia)
20. Deemed unsuitable by the investigators to participate in the study.
21. Active or recent (within 1 month prior to study enrollment) participation in another investigational clinical research study.
22. Enrollment in or planned to be enrolled in another study of AMI therapy",Cooling,INTERVENTIONAL,COMPLETED
NCT05077683,Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF,"Myocardial Infarction, Acute, Left Ventricular Thrombus","* Age ≥ 18 years;
* Anterior STEMI (e.g., ST elevation above the J-point of ≥0.1 millivolt in ≥two contiguous leads or left bundle branch block) or very high-risk NSTEMI (e.g., dynamic ECG changes or ongoing chest pain or acute heart failure or hemodynamic instability independent of ECG changes or life-threatening ventricular arrhythmias) with echographic evidence of anterior wall motion abnormalities and, with a culprit lesion of the proximal or mid portion of the left anterior descending (LAD) on the coronary angiography;
* No contraindication to CMR (e.g., claustrophobia, pacemaker or defibrillator not compatible);
* Ability to provide written informed consent and willing to participate in 1-month follow-up period.
* Affiliation of social security regime.","* Patients with cardiogenic shock (systolic blood pressure \<90 mmHg with clinical signs of low output or patients requiring inotropic agents);
* Patients referred to surgery for coronary artery bypass grafting (CABG) or treatment of acute complications (e.g. ventricular septal rupture);
* Patients treated with fibrinolytic therapy;
* LV thrombus diagnosed before randomization using a transthoracic echocardiography;
* Active major bleeding or major surgery within the last 30 days;High bleeding risk (patients considered at increased risk of bleeding during DAPT; e.g. PRECISE-DAPT score \>25; severe liver failure or Child Pugh class C);
* Known history of intracranial hemorrhagic stroke or intra-cranial aneurysm;
* Known history of peptic ulcer;
* Known stroke (any type) within the last 30 days;
* Known intolerance to aspirin, P2Y12 inhibitors, rivaroxaban and their excipients;
* Patients with presence of malignant neoplasms at high risk of bleeding
* Patients with hepatic impairment
* According to the SmPC any contraindication to rivaroxaban, aspirin, clopidogrel, ticagrelor
* Known intolerance to gadolinium chelates;
* Chronic kidney disease (creatinine clearance (ClCr) \<30 mL/min);
* Indication for anticoagulation (e.g. atrial fibrillation, mechanical valves, LV thrombus...);
* Life expectancy \<1 month;
* Known pregnancy at time of randomization (pregnancy test done) or breastfeeding women;
* Currently participating in another trial
* Protected adults (including individual under guardianship by court order)
* Persons deprived of their liberty by judicial or administrative decision","Rivaroxaban 2.5 MG [Xarelto], DAPT strategy",INTERVENTIONAL,COMPLETED
NCT00714961,Clopidogrel as Adjunctive Reperfusion Therapy - Thrombolysis in Myocardial Infarction,Acute Coronary Syndromes,"* STEMI within 12 hours of randomization
* Planned treatment with a fibrinolytic agent and aspirin","* Intention of performing coronary angiography within 48 hours of fibrinolysis
* Treatment with clopidogrel or ticlopidine within 7 days prior to enrollment, or planned treatment with clopidogrel or ticlopidine.
* Contraindication to fibrinolysis
* Planned use of a glycoprotein IIb/IIIa inhibitor
* Prior CABG
* Evidence of cardiogenic shock or acute pulmonary edema requiring intubation or an intraaortic balloon pump
* Known renal or hepatic insufficiency","Clopidogrel (SR25990), Placebo",INTERVENTIONAL,COMPLETED
NCT02181998,A Trial on Efficacy and Safety of Full Dose Tenecteplase Combined With Unfractionated Heparin (UFH) or Enoxaparin in Acute Myocardial Infarction (AMI) in the Prehospital Setting,Myocardial Infarction,"* Onset of symptoms of AMI within six hours prior to randomisation
* A 12-lead ECG with one of the following: ST-segment elevation ≥ 0.1 millivolt (mV) in two or more limb leads, or ≥ 0.2 mV in two or more contiguous precordial leads indicative of AMI, or left bundle-branch block
* Age ≥ 18
* Informed consent received","* Hypertension defined as blood pressure (BP) \> 180/110 mmHg (systolic blood pressure (SBP) 180 mmHg and/or diastolic blood pressure (DBP) \> 110 mmHg) on repeated measurements during current admission prior to randomisation
* Use of abciximab (ReoPro ®) or other glycoprotein-IIb/IIIa antagonists within the preceding seven days
* Major surgery, biopsy of a parenchymal organ, or significant trauma within two months
* Any minor head trauma and any other trauma occurring after onset of the current myocardial infarction (MI)
* Any known history of stroke or transient ischaemic attack or dementia
* Any known structural damage of the central nervous system
* Prolonged cardiopulmonary resuscitation (\> 10 min) in the previous two weeks
* Current oral anticoagulation
* Standard UFH (heparin sodium) \> 5000 international units (IU), or a subcutaneous (SC) therapeutic dose of any low molecular weight heparin (LMWH) within six hours of randomisation
* Known thrombocytopenia (prior platelet count below 100 000 cells/μL (100 x 10\*\*9/L))
* Known renal insufficiency (prior S-creatinine \> 2.5 mg % (\> 220 μmol/L) for men and 2.0 mg % (\> 175 μmol/L)) for women
* Pregnancy or lactation, parturition within the previous 30 days. Women of childbearing potential had to have a negative pregnancy test, or use a medically accepted method of birth control
* Treatment with an investigational drug under another study protocol in the past seven days
* Previous enrolment in this study
* Known sensitivity to tenecteplase, tissue plasminogen activator (tPA), abciximab, heparin or LMWH
* Any other condition that the investigator felt would place the patient at increased risk if the investigational therapy was initiated (e.g. known haemorrhagic diathesis, acute pericarditis and/or subacute bacterial endocarditis, acute pancreatitis, severe hepatic dysfunction, diabetic haemorrhagic retinopathy or other haemorrhagic ophthalmic conditions, active peptic ulceration, arterial aneurysm and known arterial/venous malformation, neoplasm with increased bleeding risk)
* Inability to follow protocol and comply with follow-up requirements","Full dose tenecteplase, Unfractioned heparin, Enoxaparin",INTERVENTIONAL,COMPLETED
NCT02318498,Stockholm Myocardial Infarction With Normal Coronaries (SMINC)-2 Study on Diagnosis Made by Cardiac MRI,Myocardial Infarction,"* 35-70 years
* Fullfill the diagnosic criteria of myocardial infarction
* Normal coronary angiography or minor atheromatosis
* Sinus rythm on ECG at admission","* Previous myocardial infarction
* Known cardiomyopathy
* Pacemaker or claustrophobia
* Severe chronic obstructive lung or kidney disease
* Pulmonary embolism",CMR,INTERVENTIONAL,COMPLETED
NCT03445728,China-Administration of Nicorandil Group（CHANGE）,"Myocardial Infarction, Percutaneous Coronary Intervention, Nicorandil","1. Acute ST-T elevation MI patients (\<12h)
2. undergoing emergency PCI；
3. Subject has read and signed a written, informed consent form.","1. SBP\<80mmHg；
2. LM stenosis
3. Aortic dissection；
4. AMI (\<6 month)
5. PCI或CABG (\<6 month)
6. Already under the treatment of Nicorandil；
7. Contraindicated or intolerable to Nicorandil
8. severe adverse effects to CMR or MRI；
9. Currently (or within one month) participating in another new drug trial.；
10. Pregnant or lactation period；
11. Severe somatic disease preventing the participant from completing the trial, or based on the discretion of the investigators, the patient is incapable of participating; Individuals with abnormal laboratory test results and/or clinical manifestations rendering them unsuitable to participate as judged by the investigators;","Nicorandil, Placebo",INTERVENTIONAL,COMPLETED
NCT02212028,Pharmacological Effects of Crushing Prasugrel in STEMI Patients,Coronary Artery Disease,"Inclusion criteria:

* Patients with ST-elevation myocardial infarction undergoing primary PCI
* Age between 18 and 75 years old",":

* Age \>75 years
* Weight \<60 Kg
* On treatment with a P2Y12 receptor antagonist (ticlopidine, clopidogrel, prasugrel, ticagrelor) in past 7 days
* Known allergies to aspirin or prasugrel
* Considered at high risk for bleeding
* History of ischemic or hemorrhagic stroke or transient ischemic attack
* On treatment with oral anticoagulant (Vitamin K antagonists, dabigatran, rivaroxaban, apixaban)
* Treatment with IIb/IIIa glycoprotein inhibitors
* Fibrinolytics within 24 hours
* Known blood dyscrasia or bleeding diathesis
* Known platelet count \<80x106/mL
* Known hemoglobin \<10 g/dL
* Active bleeding
* Hemodynamic instability
* Known creatinine clearance \<30 mL/minute
* Known severe hepatic dysfunction
* Pregnant females\*

  * Women of childbearing age must use reliable birth control (i.e. oral contraceptives) while participating in the study.",prasugrel,INTERVENTIONAL,COMPLETED
NCT01878487,Assessment of Lumen Expansion After Thrombus Extraction in Primary Percutaneous Coronary Intervention,Acute ST Elevation Myocardial Infarction,"1. patients 18-75 years old with myocardial infarction with ST-segment elevation
2. symptoms of myocardial ischemia lasting more than 30 minutes
3. onset of symptoms within 12 hours of hospital presentation
4. ST-segment elevation of more than 0.1 mV in two or more leads on the ECG","1. inability to obtain informed consent
2. use of fibrinolytic drug within 12 hours of presentation
3. comorbidity with anticipated life expectancy of \< 6 months
4. cardiogenic shock on presentation
5. major bleeding diathesis
6. history of aspirin and clopidogrel intolerance
7. critical left main stem lesions
8. severe calcfic disease precluding safe passage of the imaging catheter
9. culprit lesion within saphenous vein grafts

   -",Thrombus aspiration (Intravascular Ultrasound catheter (Boston)),INTERVENTIONAL,COMPLETED
NCT00125645,Left Ventricular Function After Acute Myocardial Infarction (AMI). Treatment With Angiotensin 2-Receptor Blockade (GLOBAL-Study),Myocardial Infarction,"* Documented AMI; MPI \> 0.55
* Randomized within 7 days of AMI
* Written informed consent","* Age \< 18 years
* Any contraindications to angiotensin 2-receptor blockade
* In patients with WMSI \> 1.3 treatment with ACE-inhibitor or angiotensin 2-receptor blockers
* In patients with WMSI \<= 1.3 no initiated or planned treatment with an ACE-inhibitor. Treatment with an ACE-inhibitor must be started within 7 days
* Pregnancy or women of childbearing potential who are not using an effective method of contraception
* Other comorbid conditions that could influence the study
* Currently receiving an experimental study drug",Irbesartan Oral Tablet,INTERVENTIONAL,COMPLETED
NCT00246545,Effect Evaluation of Early Exercise Training After Myocardial Infarction,Myocardial Infarction,"* Myocardiac infarction, 2 weeks ago
* over 18 years
* able to participate i exercise groups","* unstable angina
* heart failure
* failure to reach a maximal pretest
* drug abuse",exercise,INTERVENTIONAL,COMPLETED
NCT03073447,WAMIF : Young Women Presenting Acute Myocardial Infarction in France,"Acute Myocardial Infarction, Women Over 18 and Under 50 Years of Age","* Women over 18 and under 50 years of age
* Women admitted for MI defined by significant release of biological markers of myocardial necrosis associated with one of the following signs: chest pain and / or ECG abnormalities and / or loss of viable myocardium in imaging and / or thrombus to coronary angiography
* Coronary angiography performed
* Patient not objecting to the use of personal data.
* Beneficiary of a social protection (excluding AME)
* Signature of informed consentement form","* Iatrogenic MI and those of patients who died before hospitalization
* Other causes of chest pain syndrome with elevated troponin, including myocarditis, Tako Tsubo, sepsis will be excluded after performing an MRI.
* Participation in other biomedical research protocol excluding registers
* Linguistic or mental disability or refusal to sign the informed consent",Specific blood sample of women under 50 years with acute MI,INTERVENTIONAL,COMPLETED
NCT01186445,Morphine In Acute Myocardial Infarction,Acute Myocardial Infarction,"1. Acute Myocardial Infarction less than 6 hours defined by

   1. prolonged chest pain (\>15 min)
   2. in association with

      * ST elevation 1mm or more in two contiguous leads
      * or occurence of Q wave in three contiguous leads
      * or occurence of left bundle branch block
2. Culprit lesion eligible for percutaneous coronary intervention (PCI)
3. TIMI flow 0 before PCI","1. Fibrinolysis
2. Allergy to morphine
3. Active epilepsy
4. Brain injury or intracranial hypertension
5. Previous AMI, coronary artery bypass graft (CABG)
6. Cardiac arrest
7. Cardiogenic shock, significant mitral regurgitation or intraventricular communication at inclusion
8. Mechanical ventilation at inclusion
9. Significant ventricular arrhythmia or atrioventricular block type II or III at inclusion
10. Decompensated chronic obstructive pulmonary disease at inclusion
11. chronic hepatocellular failure
12. MRI contraindications
13. Gadolinium chelates injection contraindications
14. Current treatment with morphine chlorhydrate, buprenorphine, nalbuphine, pentazocine","morphine chlorhydrate, saline solution",INTERVENTIONAL,COMPLETED
NCT02406677,Affordability and Real-world Antiplatelet Treatment Effectiveness After Myocardial Infarction Study,"Cost Sharing, Acute Coronary Syndrome","Patients are eligible to be included in the study if they meet all of the following criteria:

* are ≥ 18 years of age
* have been diagnosed with STEMI or NSTEMI during the index hospitalization
* be treated with a P2Y12 receptor inhibitor at the time of enrollment
* have U.S. based health insurance coverage with prescription drug benefit
* have been fully informed and are able to provide written consent for longitudinal follow-up","Patients are excluded if they meet any of the following criteria:

* have a history of prior intracranial hemorrhage
* have any contraindications to P2Y12 receptor inhibitor therapy at discharge
* involvement in another research study that specifies the type and duration of P2Y12 receptor inhibitor use within the next 12 months.
* have a life expectancy of less than one year
* have plans to move outside the US in the next year",Study voucher card,INTERVENTIONAL,COMPLETED
NCT01167751,Autologous Bone Marrow Derived Stem Cells for Acute Myocardial Infarction,Myocardial Infarction,"* CABG candidate
* At least 4 akinetic segments
* First anterior heart attack within in 10 days to 3 month.
* St elevation MI defined by: Post Acute MI LVEF less than 45% as assessed by echocardiography.
* The target lesion had to be located in the left anterior descending (LAD) section.","* History of prior anterior myocardial infarction:
* History of prior CABG
* Poor echocardiography window.
* Active infection or history of recurrent infection or positive test for syphilis (RPR), hepatitis B and C (HBSAg/ Anti HBc Anti - Hcv) HIV and HTLV-l
* Documental terminal illness or malignancy.
* Previous bone marrow transplant
* Autoimmune disease (e. g Lupus, Multiple sclerosis)
* Any contraindication for bone - marrow aspiration.
* Positive pregnancy test (in women with child bearing potential)","MNC, AC 133, Control",INTERVENTIONAL,COMPLETED
NCT02783287,The Impact of Text Messaging on Medication Adherence and Exercise Regimen Among Post-myocardial Infarction Patients,Myocardial Infarction,"* Post-MI hospital discharge within 2 weeks
* Enrolled in cardiac rehabilitation
* Prescribed anti-platelets, beta-blockers, ACE-inhibitors or ARBs, and/or statins on 1x/day regimen (for medication adherence trial)
* Prescribed exercise regimen (for exercise trial)
* Ability to read and write English
* Possession of a cell phone with text messaging capability","* Age \< 18
* Incarcerated individuals
* Unable to read and write English
* Not in possession of a cell phone
* Patients prescribed medication regimen \> 1x/day","Text message reminder for medication adherence, Text message reminder for exercise regimen",INTERVENTIONAL,COMPLETED
NCT00906451,Simvastatin Effect on Inflammation and Endothelial Function After Myocardial Infarction,"Myocardial Infarction, Inflammation, Endothelial Dysfunction","* Less than 24 hours after the onset of MI symptoms
* ST-segment elevation of a least 1 mm (frontal plane) or 2 mm (horizontal plane) in two contiguous leads
* Myocardial necrosis, as evidenced by increased CK-MB and troponin levels",* Use of statins for at least 6 months prior the myocardial infarction,Simvastatin,INTERVENTIONAL,COMPLETED
NCT01213251,Post-Myocardial Infarction Remodeling Prevention Therapy,"Acute Myocardial Infarction, Pacing Therapy, Cardiac Remodeling, Heart Failure","* Myocardial Infarction (MI) within the past 10 days
* Peak Creatine Phosphokinase (CPK) greater than 3000 Units/Litre (U/L) at time of MI, or a troponin T (TnT) greater than 10 micrograms/Litre (mcg/L)
* At least 18 years old
* Willing to comply with the protocol","* Documented MI greater than 10 days
* Chronic renal disease, as defined by estimated glomerular filtration rate (eGFR) less than 30 milliliters/minute/1.73 square meter
* Life expectancy less than 18 months, as determined by a physician
* Existing pacemaker, Implantable Cardioverter Defibrillator (ICD), or Cardiac Resynchronization Therapy (CRT) device
* QRS duration greater than 120 milliseconds (ms)
* Coronary Artery Bypass Graft (CABG) within 30 days prior to MI, or CABG procedure planned
* Third degree atrioventricular (AV) block or symptomatic bradyarrhythmia
* Persistent atrial fibrillation (AF) that is not self terminating within 7 days or is terminated electrically or pharmacologically
* Permanent AF that is non self terminating, with cardioversion failed or not attempted within the past year
* New York Heart Association (NYHA) Class IV
* Non-ischemic cardiomyopathy
* Pregnant or planning to become pregnant during the study
* Enrolled or planning to participate in a concurrent drug and/or device study during the course of this clinical trial. Co-enrollment in concurrent trials is only allowed with documented pre-approval from Medtronic, documenting that there is not a concern that co-enrollment could confound the results of this trial.
* Breast feeding
* Of a vulnerable population as determined by local law or requirement, or a physician","Single Site Pacing, Dual Site Pacing",INTERVENTIONAL,COMPLETED
NCT01347554,Efficacy of Everolimus-Eluting Versus Zotarolimus-Eluting Sten for Coronary Lesions in Acute Myocardial Infarction,Myocardial Infarction,"* Age \> 18 years
* Chest pain duration more than 10 minutes
* At least on of the following criteria
* A. ECG change (T inversion, ST depression or ST elevation)
* B. Cardiac enzyme elevation more than upper normal limit
* Significant coronary artery stenosis (\>50% by visual estimate)
* The patient or guardian agrees to the study","* Stent thrombosis
* Left main disease
* Cardiogenic shock
* Cronic kidney disease or renal failure requiring hemodialysis
* History of bleeding diathesis or known coagulopathy
* Gastrointestinal or genitourinary bleeding within the prior 3 months
* History of major surgery within 2 months
* Planned surgery requiring cessation of clopidogrel within 12 months of percutaneous coronary intervention (PCI)
* Serious patients whose life expectancy \<1 year or severe infectious status","Everolimus eluting stent, Zotarolimus eluting stent",INTERVENTIONAL,COMPLETED
NCT00266487,The Norwegian Vitamin Trial (NORVIT),Acute Myocardial Infarction,"* Acute myocardial infarction within 7 days prior to randomization
* Men and women aged 30-85 years
* Written informed consent","* Coexisting disease that shortens expected survival to less than 4 years
* Ongoing treatment with B vitamins
* Expected poor compliance","Folic acid, Vitamin B12, Vitamin B6",INTERVENTIONAL,COMPLETED
